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ABSTRACT
ROLES OF SURFACTANT AND BINARY POLYMERS ON DISSOLUTION
ENHANCEMENT OF BCS II DRUGS FROM NANOCOMPOSITES AND
AMORPHOUS SOLID DISPERSIONS
by
Md Mahbubur Rahman
Drug nanocomposites and amorphous solid dispersions (ASDs) are two major
formulation platforms used for the bioavailability enhancement of BCS Class II drugs.
The major drawback of nanocomposites is their inability to attain high drug
supersaturation during in vitro (<50% relative supersaturation) and in vivo dissolution.
On the other hand, formulating an amorphous solid dispersion (ASD) with high drug
loading (>20%) that releases drug rapidly, while generating and maintaining high
supersaturation over at least three hours is challenging. The goal of this thesis is to
develop a fundamental understanding of the impact of anionic surfactants–polymers
on in vitro drug release from nanocomposites and ASDs, while addressing the above
challenges. To achieve this goal, the following objectives are set: (1) compare
griseofulvin (GF, drug) release from spray-dried nanocomposites and ASDs with
identical formulation that has low GF:polymer (HPC/Soluplus) mass ratio (1:1 to 1:5)
and an anionic surfactant (SDS), (2) examine the presence/absence of SDS on drug
release from nanocomposites, (3) develop rapidly supersaturating ternary ASDs of
GF with HPC/Sol and SDS as a minor component, (4) investigate GF release from
ternary ASDs of GF with a hydrophilic, wettability-enhancing polymer (HPC/PVPVA64) as a minor component and an amphiphilic polymer as drug precipitation
inhibitor (Soluplus), and (5) apply the fundamental knowledge generated for GF to
another BCS Class II drug, itraconazole (ITZ).
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Spray-drying of aqueous GF nanosuspensions with 1:5 GF:Sol–0.125% SDS
has led to formation of a novel class of nanocomposites, HyNASDs, which have
notable amorphous GF content (~5–20%). Their dissolution has generated 300%
supersaturation within 20 min that is largely maintained after 3 h (250%). Such
remarkable drug supersaturation is made possible by strong intermolecular
interactions/miscibility between GF–Soluplus at 1:5 ratio and ensuing fast kinetic
solubilization of GF nanoparticles upon contact of HyNASDs with water. While
HyNASDs do not generate as high saturation as ASDs (480%), they can be rendered
competitive to ASDs upon further optimization. The supersaturation generation by
HyNASDs is affected by presence of SDS either in the formulation or in the
dissolution medium, drug–polymer interactions/miscibility as well as the size of the
drug (nano)crystals in the polymeric matrix. Incorporating even 1.23% SDS in Solbased ASDs has led to dramatic increase in supersaturation (max. 570%), but it has
no notable improvement for HPC-based ASDs. SDS provides Sol-based ASDs with
enhanced wettability and augments Sol in solubilizing GF, without interfering with
Sol’s ability to inhibit GF recrystallization. Combination of Sol with HPC/VA64 has
led to a trade-off between rapid drug release and high supersaturation. A strong
synergistic effect exists for the ASD with 11:1 Sol:VA64. The inclusion of a
hydrophilic polymer as a minor component in an amphiphilic, precipitation-inhibiting
polymer of a ternary ASD exhibited optimal drug release. General findings from GF
regarding HyNASD formation and impact of SDS are applicable to ITZ as well.
Overall, this thesis has generated fundamental knowledge about the impact of SDS
and binary polymers on improved in vitro release of BCS Class II drugs.
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CHAPTER 1
INTRODUCTION

1.1 Motivation
It is estimated that approximately 40% of the marketed drugs and 75% of the new
drug candidates coming out of the drug discovery pipeline are poorly water soluble
(Di et al., 2009; Kipp, 2004; Lipinski, 2002). Due to their poor aqueous solubility,
intestinal absorption of these drugs turns out to be rate-limiting, which leads to low
bioavailability eventually (Fasano, 1998; Müllertz et al., 2010). Over the years,
significant number of research has been carried out and directed toward developing
various formulation/processing strategies to enhance the dissolution performance of
these drugs. These strategies include production of prodrug (Rumondor et al., 2016),
salt formation (Elder et al., 2013; Rahman et al., 2012), micelle formation (Letchford
and Burt, 2007), cyclodextrin complexes (Aleem et al., 2008; Srivalli and Mishra,
2016), lipid-based systems (Hauss et al., 1998; Humberstone and Charman, 1997),
drug nanocrystals (Li et al., 2016a; Merisko-Liversidge et al., 2003), amorphous solid
dispersions (ASDs) (Nakagami, 1991; Serajuddin, 1999) etc. Among all these
approaches, increasing the surface area by reducing drug particle size (drug
nanocrystals) and increasing saturation solubility of the drug through the formation of
ASD have achieved prevalence both in the academia and industry to enhance
dissolution rate/bioavailability of poorly-water soluble drugs.
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1.1.1 Background on Drug Nanocrystals and Their Production
In pharmaceutics literature, drug nanocrystals are defined as crystals with a size in the
nanometer range; usually ranging from 10 nanometers to 1000 nm (Keck and Müller,
2006). Since the nanoparticles have tremendously higher specific surface area
compared to the micron-sized particles, drug nanoparticles can provide significant
dissolution rate and bioavailability enhancement to a multitude of poorly watersoluble drugs (Singh et al., 2011; Tanaka et al., 2012). The classical Noyes–Whitney
equation (Noyes and Whitney, 1897b) could help to explain the improvement in drug
dissolution rate, dm/dt, due to the particle size reduction and ensuing increase in
surface area (Equation 1.1):
 dm  AD (Cs − C )

=
h
 dt 

(1.1)

where m is mass of drug dissolved at time t, A is the surface area of the particles, D is
the diffusion coefficient, h is the diffusion layer thickness, Cs is the saturation
solubility, and C is the instantaneous concentration in the bulk dissolution medium. In
addition to the significant enhancement of the particle surface area, the diffusion layer
thickness (h) also decreases significantly as particle size decreases (Galli, 2006).
Furthermore, the particle size of drugs could also influence their saturation solubility
in the bulk solution, which can be explained by the Ostwald–Freundlich equation
(Equation 1.2) (Shchekin and Rusanov, 2008).

C 
2 V
log  S  =
 C  2.303RT  r

(1.2)

where CS is saturation solubility, C∞ is solubility of large particles, σ is interfacial
tension, V is atomic volume, R is gas constant, T is absolute temperature, ρ is density
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of the solid, and r radius of the small particle. According to Equation (1.2), the
reduction of particle size especially to sizes below 100 nm increases the saturation
solubility CS (Shegokar and Müller, 2010). This indicates that not only do
nanoparticles affect the dissolution rate by higher specific surface area and reduced
diffusion layer thickness, but also they allow for higher saturation solubility CS.
(Kesisoglou et al., 2007) have also demonstrated 10–15% solubility increase with the
reduction of drug particle size down to 100 nm. Others reported similarly higher
solubility of the ultrasmall particles and nanoparticles (Junghanns and Müller, 2008b;
Shegokar and Müller, 2010).
Among various methods used for the production of drug nanoparticles (Li et
al., 2016a), wet stirred media milling (WSMM) has found the most common use in
the pharmaceutical industry owing to its unique advantages: WSMM is organic
solvent free, scalable, and environmentally benign. Moreover, WSMM allows for
production of nanosuspensions with high drug loading, which exhibit low excipient
side effects. Also, it has continuous processing capability and can be applied
universally to any poorly water-soluble drug (Afolabi et al., 2014; Bhakay et al.,
2018b; Kesisoglou et al., 2007; Li et al., 2016a; Merisko-Liversidge and Liversidge,
2008). Nanosuspensions also have the advantage of higher mass packing (higher
dose) per injection volume and improved physical stability owing to the use of
stabilizers such as polymers and/or surfactants (Müller and Peters, 1998; Rabinow,
2004). Several marketed products such as Rapamune® (Pfizer (Wyeth), New York
City, NY, USA), Emend® (Merck, Kenilworth, NJ, USA), Tricor® (AbbVie, North
Chicago, IL, USA), Megace® ES (PAR Pharmaceuticals, Woodcliff Lake, NJ, USA),
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and Invega® SustennaTM (Janssen, Beerse, Belgium) made use of wet media
milling.
In the common recirculating mode of WSMM operation, micron-sized drug
particles in an aqueous solution of stabilizers, usually polymers and/or surfactants,
circulates from a holding tank passing through the milling chamber, exiting through a
screen, and returning to the holding tank. During the milling operation, the milling
media (beads) are retained in the milling chamber by the screen. Due to high speed
rotation of the rotor/stirrer, turbulent motion is induced in the suspension, and the
mechanical power consumed is dissipated during frequent bead–bead collisions
(Eskin et al., 2005). The drug particles captured between the beads are subjected to
stress, which is concentrated on the cracks already present in the material and causes
crack propagation, ultimately leading to breakage of the particles (Schönert, 1988)
and eventually production of nanoparticles.
1.1.2 Typical Issues in the Production–Drying of Drug Nanosuspensions
Despite its advantages, WSMM is not devoid of any issues during the production of
drug nanoparticles. A major issue is the aggregation–growth tendency of the milled
drug particles in the aqueous suspensions during milling or storage (Li et al., 2016a).
Formation of aggregated particles negates the advantage associated with the large
surface area of the drug nanoparticles. Usually, two major competing mechanisms
operate during the milling of the drug particles: breakage of the drug particles due to
mechanical stresses and aggregation due to highly attractive inter-particle forces (van
der Waals, hydrophobic forces, etc.) (Bhakay et al., 2013b). Additionally, Ostwald
ripening may occur causing drug nanocrystals to grow (Bitterlich et al., 2014).
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Ostwald ripening can be defined as a process where differences in solubility, as a
function of particle sizes, leads to a transport of dissolved drug from small to larger
particles causing growth over time. Therefore, physical stability of the drug
nanosuspensions by various stabilizers (Cerdeira et al., 2010; Wu et al., 2011), also
known as dispersants, is required during milling and storage for proper downstream
processing and adequate shelf-life.
Selection of proper stabilizers with optimum concentration plays a major role
in formulating a stable drug nanosuspension. Inadequate concentration of stabilizers
may not be able to prevent aggregation of drug nanoparticles, while excess in
concentration may facilitate Ostwald ripening. Electrostatic interactions, steric forces,
entropic forces, and van der Waals forces among the nanoparticles usually determine
the physical stability of the drug nanosuspension (Wu et al., 2011). Drug particles
dispersed within a liquid continuous medium are stabilized by steric, electrostatic
mechanisms or combination of both i.e., electrosteric mechanism (see Figure 1.1),
owing to adsorption of polymers and/or surfactants on drug particle surfaces (Basa et
al., 2008; Bilgili et al., 2016; Merisko-Liversidge and Liversidge, 2011; Van
Eerdenbrugh et al., 2008c). Nonionic polymers or nonionic surfactants (e.g.,
poloxamers, cellulosic derivatives, polysorbates, and povidones etc.) usually provide
steric stability by preventing the particles from getting into the range of attractive van
der Waals forces. Electrostatic stabilization is usually imparted by ionic surfactants,
e.g., sodium dodecyl sulfate (SDS), dioctyl sulfosuccinate sodium salt (DOSS), and
benzethonium chloride (BKC). In electrosteric stabilization, nonionic polymers or
surfactants and ionic surfactants stabilize the particles, acting simultaneously.
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Figure 1.1 Schematic of physical stabilization mechanism in drug nanosuspensions:
(a) steric stabilization imparted by nonionic polymers; (b) electrostatic stabilization
imparted by anionic surfactants; and (c) electrosteric stabilization imparted by both
nonionic polymers and anionic surfactants.

Usually, solid dosage forms are preferred over suspensions due to
convenience and easiness of their use by patients. Therefore, nanosuspensions
produced via WSMM are dried and converted into nanocomposites microparticles or
simply nanocomposites, which are ultimately incorporated into standard dosage
forms such as tablet, capsule, sachets (Basa et al., 2008; Bhakay et al., 2014a; Van
Eerdenbrugh et al., 2008b), and polymeric strip films (Bhakay et al., 2016; Krull et
al., 2016; Krull et al., 2015; Sievens-Figueroa et al., 2012; Susarla et al., 2015).
Drying of nanosuspensions can be achieved via spray-freeze drying (Cheow et al.,
2011; Wang et al., 2012), freeze drying (De Waard et al., 2008; Layre et al., 2006),
spray drying (Azad et al., 2015b; Lee, 2003), vacuum drying (Choi et al., 2008; Kim
and Lee, 2010), as well as granulation with, or coating onto, inert excipient particles
(Basa et al., 2008; Bhakay et al., 2014b).

6

Unfortunately, drug nanoparticles tend to form aggregates during both milling
and drying of the drug suspensions (Bhakay et al., 2013a; Lee, 2003), causing the loss
of surface area of the drug. It must be noted that the same dispersants (soluble
polymers and surfactants) used to prevent nanoparticle aggregation also act as matrix
former in the dried nanocomposites and modulate drug release during
dissolution/redispersion (Bhakay et al., 2018b; Li et al., 2016b; Li et al., 2016c).
However, depending on the formulation, drug nanoparticles may not be fully
recovered from the dried composites during redispersion and dissolution, which will
slow down the drug dissolution and reduce the bioavailability from such nanoparticlebased formulations (Bhakay et al., 2013a; Bhakay et al., 2018b; Chaubal and
Popescu, 2008). Here, redispersion refers to the dispersion of the drug composites in
various physiologically relevant fluids like water, and preservation of the milled drug
particle size. Various redispersion methods were studied extensively by Bhakay et al.
(2013b, 2018a). Slow/incomplete recovery of drug nanoparticles from the
nanocomposites was observed when a steric stabilizer or ionic stabilizer was used
alone in the precursor griseofulvin (drug) suspension (Bhakay et al., 2013b; Lee,
2003). Drug particles were fully recovered only when steric stabilizer and ionic
stabilizer were used in combination (e.g., Basa et al., 2008; Bhakay et al., 2013b)) or
when swellable dispersants were co-milled along with the drug (Azad et al., 2015b;
Bhakay, 2014; Bhakay et al., 2018a).
In the production of drug nanosuspensions/nanocomposites, the most widely
used dispersants are the soluble polymers (Bhakay et al., 2018b; Li et al., 2016a).
Among different properties of the polymers, molecular weight (MW) has a great

7

impact on the steric stabilization of the drug suspensions. It also regulates the
suspension/solution viscosity (Adamson and Gast, 1997; Choi et al., 2008; Ploehn
and Russel, 1990), mechanical properties of films (Rowe, 1986), and drug release
from polymer-based dosages (Mittal et al., 2007). Similarly, use of different polymers
or polymers with different MW is expected to determine the extent of aggregation in
drug nanosuspensions and nanocomposites. Interestingly, only few studies examined
the impact of different polymers and different MW of the same polymer on drug
nanosuspension stabilization and dissolution enhancement systematically, which
requires further investigation. On the other hand, despite being an effective
dispersant, surfactants may pose several challenges such as aggregation of the drug
nanoparticles in suspensions during milling/storage (Cerdeira et al., 2010; Knieke et
al., 2013), micellar solubilization of the drug (Yalkowsky and Roseman, 1981) and
particle growth via Ostwald ripening during milling and/or storage (Ghosh et al.,
2011; Knieke et al., 2013; Verma et al., 2011). Additional challenges associated with
the use of anionic surfactants include incompatibilities with other ionic molecules,
sensitivity to pH, salt or temperature changes, GIT irritation (Gupta and Kompella,
2006; Liversidge and Cundy, 1995), and even toxicity when used in excess
(Liversidge and Cundy, 1995), especially for inhalation applications (Lebhardt et al.,
2011; Suzuki et al., 2000). In view of all the aforementioned issues, during
formulation development, surfactant usage should be minimized to mitigate all
potential negative impact.
Besides all the challenges mentioned above regarding the drug nanoparticlebased formulations, limited supersaturation capability of nanocomposites appears to
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be the greatest impediment to the bioavailability enhancement and their
competitiveness to ASDs. Throughout the thesis, supersaturation refers to relative
supersaturation defined as S = (C/Cs –1), where C is the drug concentration in a
dissolution medium and Cs refers to the thermodynamic aqueous solubility of the
crystalline drug at the same temperature. While in the prevalent pharmaceutical
terminology, particles with sizes less than 1 µm are considered nanoparticles
(nanocrystals); in most published work, the median/mean size is in the range of 100–
400 nm (see the review by Li et al., 2016a) and fewer publications reported true drug
nanoparticles with a median/mean size below 100 nm (e.g., Li et al., 2015). As
mentioned in Section 1.1.1, owing to their high curvature, nanocrystals with sizes
<~100 nm tend to show high saturation solubility, which also enhances the
dissolution rate, and this phenomenon can be explained via the Kelvin and the
Ostwald–Freundlich equation (Equation 1.2) (Muller et al., 1998). The higher
apparent solubility that originates from the greater curvature of <~100 nm
nanocrystals than that of the micron-sized crystals was estimated to be ~10–15%
(Kesisoglou and Wu, 2008); however, up to 50% increase in apparent solubility was
also reported (Muller and Peters, 1998). In general, the potential benefit of
nanocrystals in terms of supersaturation is mostly left without consideration in the
field of bioavailability enhancement (Peltonen et al., 2018), which requires more
investigation.
1.1.3 Amorphous Form of Drugs
Enhanced dissolution rate, improved bioavailability, safe dose escalation, elimination
of food effects, and improved safety, efficacy and tolerability profiles are some of the
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numerous advantages of drug nanocrystals (Junghanns and Müller, 2008a). However,
with all these advantages, nanocrystal formulations are severely limited in their
bioavailability enhancement capability due to low aqueous solubility of drug
nanocrystals. Often for drugs with very low aqueous solubility, the achieved increase
in dissolution rate via size reduction is limited and insufficient to provide significant
enhancement of bioavailability (Müller et al., 2011). Another platform approach for
bioavailability enhancement of poorly water-soluble drugs is the production of
amorphous form of the drug. Amorphous drugs lack distinct intermolecular
arrangement that leads to crystalline structure. They exhibit lower thermodynamic
stability and higher apparent solubility then their crystalline counterparts. The
solubility advantage of the pure amorphous compared with its crystalline form could
be theoretically estimated using Equation (1.3) (Hancock and Parks, 2000):

  amorphous
 crystal
 

G

RT
=e


(1.3)

where σamorphous/σcrystal is the ratio of the solubility of amorphous form to the stable
crystalline from, ΔG is the free energy difference between the amorphous and
crystalline forms, R is the universal gas constant, and T is the temperature in Kelvin.
The free energy difference can be determined from Hoffman equation (Equation 1.4)
(Hoffman, 1958).
G =

H f  T  T

(1.4)

2
m

T

where ΔHf is the enthalpy of fusion, T is the operating temperature, Tm is the melting
point temperature, and ΔT is the difference between Tm and T.
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Unfortunately, taking advantage of amorphous form of poorly water-soluble
drugs is challenging since pure amorphous drugs are inherently metastable: they can
simply convert to crystalline form during processing and storage (recrystallization in
the solid state) (Marsac et al., 2006; Shamblin et al., 1999; Wu and Yu, 2006; Yu,
2001) as well as during dissolution (recrystallization in the liquid dissolution
medium) (Alonzo et al., 2010). Usually, pure amorphous products are undesirable to
scale up due to their highly unstable nature and higher energy state. To resolve this
stability issue, drugs are dispersed molecularly in an amorphous polymeric matrix,
known as amorphous solid dispersions (ASDs), which imparts stability (prevention of
recrystallization) to amorphous form of the drug during storage and dissolution.
Polymers can provide stability through a number of mechanisms including reduction
in the drug molecules’ mobility, increase in the glass transition temperature (Tg) of
amorphous drug via ASD formation and anti-plasticization exerted by the glassy
polymer matrix (Crowley and Zografi, 2002; Cui, 2007; Shah et al., 2013; Van den
Mooter et al., 2001), and strong drug–polymer intermolecular interactions such as
hydrogen bonding, hydrophobic interactions, etc. (Kestur and Taylor, 2010; Kestur et
al., 2011). Since the apparent solubility of the amorphous form is higher than its
crystalline counterpart, ASDs can offer significant enhancement in the dissolution
rate and supersaturation generation under non-sink conditions resulting in
bioavailability enhancement of the drugs with very low aqueous solubility (Ambike
et al., 2005; Six et al., 2004; Yamashita et al., 2003). Usually, types of the carrier
matrix, molecular level interaction of drug–polymer, the extent of recrystallization
inhibition during storage and dissolution, drug:polymer ratio, and manufacturing
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process play important roles in the production and stabilization of ASDs (Li et al.,
2017a; Qian et al., 2010; Thakral and Thakral, 2013).
1.1.4 Production of Amorphous Solid Dispersions (ASDs)
Processes used for the production of ASDs can be broadly classified into two major
categories: solvent-based processes and fusion/melting-based processes (Brough and
Williams, 2013). In the fusion/melting-based processes, drug and polymeric carriers
are melted together at a temperature above their melting or glass transition
temperature, then the molten liquid is solidified by rapid cooling. Due to the rapid
cooling, drug molecules do not have sufficient time and molecular mobility to
crystallize while being trapped inside the highly viscous polymeric matrix (Brough
and Williams, 2013), which leads to molecular dispersion of the drug inside the
polymer or formation of a solid drug–polymer solid solution. The resultant solid is
then crushed or milled to obtain a desired particle size. The main advantage of the
fusion/melting-based processes is that they do not require any solvent. However, an
important prerequisite for ASD formation is the miscibility of the drug and polymer
in the molten state to obtain a homogenous mixture. Thus, for a successful
formulation, a polymeric carrier that shares similar physicochemical properties with
the drug would be more suitable (Vo et al., 2013). Despite having found significant
use in pharmaceutical industry, the most serious limitation of the fusion/meltingbased processes is that they can only process drugs and polymers that are not
thermally degradable at the elevated temperatures required for proper processing
(Vasconcelos et al., 2016). Another issue is that if the drug and polymer are not
miscible at the processing temperature; phase separation of the drug during cooling is
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highly likely. Hot melt extrusion (HME) has become the standard fusion-based
process to produce ASDs (Baghel et al., 2016).
Solvent-based processes entail preparing a solution of both drug and polymer
in a single solvent or solvent mixture followed by removal of the solvent(s) to yield a
solid dispersion. This technique enables molecular level mixing of the drug and
polymer, which could be beneficial to the drug–polymer miscibility and stability of
the product. It addresses the main issue associated with the melting method relating to
the decomposition of drugs and carriers at high temperature because solvent can be
removed at relatively low temperatures. An important prerequisite of the solventbased process is the solubilization of the drug and polymer in the same solvent
mixture (Leuner and Dressman, 2000). However, finding out a suitable non-toxic
solvent is not always an easy task because carriers are hydrophilic in nature, whereas
drugs are hydrophobic. Another disadvantage of this method is residual solvent after
evaporation, which often requires a secondary drying process such as oven drying,
microwave drying, etc. to achieve an acceptable solvent content required by
regulations and maintain physical stability by avoiding any plasticization effect of the
residual solvent (Brough and Williams, 2013; Janssens and Van den Mooter, 2009).
Spray drying (Langham et al., 2012; Paradkar et al., 2004) and freeze drying
(Kagotani et al., 2013; Schersch et al., 2010) are two widely used processes for the
production of ASDs in the solvent-based process. Freeze drying or lyophilization is a
process comprised of freezing the drug–polymer solution followed by the reduction
of surrounding pressure allowing sublimation of the frozen solvent (Brough and
Williams, 2013; Van Drooge et al., 2006). In the spray drying process, a drug–
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polymer solution is atomized into a hot gas chamber that causes fast evaporation of
the solvent, resulting in sudden increase in viscosity and encapsulation of the drug
molecules in amorphous form into the polymeric matrix (Vehring, 2008). The fast
drying and presence of the amorphous polymer matrix prevents nucleation and
growth of drug crystals, thus enabling molecular level dispersion of the amorphous
drug in the polymeric matrix.
1.1.5 Challenges Involved with Amorphous Solid Dispersions (ASDs)
Despite several advantages of ASDs, the number of commercially available products
is not as high as one would anticipate or desire (see Table 1.1). The most important
problem is the poor stability of the amorphous drug during production, storage, and
dissolution. In general, recrystallization of the amorphous drugs occurs in two stages:
nucleation followed by crystal growth via diffusion or rearrangement of the drug
molecules (Baird and Taylor, 2012). Thus, for the physical stability, molecular
mobility of the drug–polymer is an important factor for the stability of the amorphous
drug. Moisture acts as a plasticizer and often reduces the Tg of ASD and thus
increases molecular mobility (Duddu and Sokoloski, 1995; Hancock and Zografi,
1994). Since polymer absorb moisture during storage, the storage at high relative
humidity (RH) can accelerate drug recrystallization (Rumondor et al., 2009). High
storage temperature, especially closer to the glass transition temperature of the ASD,
could be another reason for accelerated recrystallization of the drug due to enhanced
molecular mobility (Alhalaweh et al., 2015; Shibata et al., 2014).
Besides storage instability, maintenance of supersaturation during the
dissolution of ASDs is another major challenge. During dissolution, drug may phase
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separate in the form of liquid–liquid phase-separated (LLPS) droplets, or may convert
to crystalline nanoparticles, which will lead to a significant reduction of the
supersaturation and inability to maintain high extent of drug dissolution (Ilevbare and
Taylor, 2013). Crystallization from amorphous formulations is complex and may
occur either directly from the solid matrix upon contact with the dissolution medium
or from a supersaturated solution generated during dissolution under non-sink
conditions (Alonzo et al., 2010). Polymers play a critical role in altering the
crystallization kinetics of the drug from both the matrix (Ewing et al., 2014) and
solution phase (Raghavan et al., 2001), enabling supersaturation generation and
maintenance when the polymer is judiciously selected in the formulation (Alonzo et
al., 2011; Alonzo et al., 2010; Suzuki and Sunada, 1998). Multiple factors such as
polymer type, drug–polymer miscibility and interactions, and physical stability of the
amorphous drug have significant effect on the dissolution performance of ASDs
(Craig, 2002; Serajuddin, 1999). Therefore, a number of complex factors needs to be
considered during the evaluation of dissolution performance of ASDs including the
drug:polymer ratio, the relative dissolution rate of the components, and the
crystallization behavior of the drug during dissolution. In order to understand the
mechanisms of drug release from ASDs and to optimize polymer selection, it is
essential to evaluate the relative impact of the polymer on crystal nucleation and
growth.
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Table 1.1 List of Commercially Available Medicines Manufactured by Amorphous
Solid Dispersion (ASD) Technique Containing Poorly Water-soluble Drugs
Trade Name

Generic Name

Cesamet®

Nabilone

Processing
Technologya
SE

ISOPTIN® SR

Verapamil

ME

Sporanox®

Itraconazole

Prograf®
Kaletra®
Intelence®
Modigraf®
Zortress®
Norvir®
Onmel®
INCIVEKTM

Tacrolimus
Etonogestrel/
Ethinyl Estradiol
Lopinavir/Ritonavir
Etravirin
Tacrolimus
Everolimus
Ritonavir
Intraconazole
Telaprevir

Zelboraf®

Vemurafenib

Kalydeco®
Noxafil®
Astagraf XL®
Belsomra®
Harvoni®

Ivacaftor
Posaconazole
Tacrolimus
Suvorexant
Ledipasvir/Sofosbuvir
Dasabuvir/Ombitasvir/
Paritaprevir/Ritonavir
Sofosbuvir/Velpatasvir
Lumacaftor/Ivacaftor
Venetoclax
Elbasvir/Grazoprevir
Glecaprevir/Pibrentasv
ir

NuvaRing®

Viekira XRTM
Epclusa®
Orkambi®
VenclextaTM
Zepatier®
MavyretTM

FB bead
layering
SD

Company
(Year of Approval)b
Meda Pharma (1985)
Ranbaxy Laboratories
(1987)
Janssen (1992)
Astellas Pharma (1994)

ME

Merck (2001)

ME
SD
SD
SD
ME
ME
SD
Solvent/
anti-solvent
precipitation
SD
ME
WG
ME
SD

AbbVie (2007)
Janssen (2008)
Astellas Pharma (2009)
Novartis (2010)
AbbVie (2010)
Merz Pharma (2010)
Vertex (2011)

ME

AbbVie (2014)

SD
SD
ME
SD

Gilead Sciences (2016)
Vertex (2016)
AbbVie (2016)
Merck (2016)

ME

AbbVie (2017)c

Roche (2011)
Vertex (2012)
Merck (2013)
Astellas Pharma (2013)
Merck (2014)
Gilead Sciences (2014)

a

FB: Fluidized Bed; ME: Melt Extrusion; SD: Spray Drying; SE: Solvent Evaporation; WG: Wet
Granulation.
b
Based on US Food & Drug Administration (FDA), 2016 (Huang and Williams, 2018; Jermain et al.,
2018).
c
Based on European Medicines Agency: Public Assessment reports, 2016 (Huang and Williams, 2018;
Jermain et al., 2018).

Although the higher free energy of the amorphous form may theoretically
achieve a solubility level that is order of magnitude higher than that of its crystalline

16

counterpart, this high free energy also works as the driving force for spontaneous
recrystallization from the solid state or supersaturated solution upon dissolution
(Marsac et al., 2006). Usually, in the conventional ASDs, drug is molecularly
dispersed or solubilized in a polymeric carrier (binary system) (Konno et al., 2008).
However, significant improvement in the performance of drug ASDs has been
reported recently for ternary ASDs consisting of drug–binary polymers (Xie and
Taylor, 2016) or drug–polymer–surfactant (Ghebremeskel et al., 2007). Several
reports have shown the improved dissolution performance and storage stability due to
the presence of surfactant in the ASD formulation over the formulation w/o
surfactants (Ghebremeskel et al., 2007; Goddeeris et al., 2008; Joshi et al., 2004; Li et
al., 2013; Sotthivirat et al., 2013, Feng et al., 2018). It is claimed that presence of
surfactant in the ASD formulation increases the drug wettability by reducing the
interfacial energy barrier between the drug particles and the dissolution medium and
it can inhibit drug precipitation in the aqueous medium (Jung et al., 2016). On the
other hand, detrimental effects of the surfactants have also been reported in literature
during dissolution of ASDs due to the competitive interaction between drug–
polymer–surfactant resulting in promoted recrystallization of the drug from
supersaturated solutions (Chen et al., 2016; Liu et al., 2016; Deshpande et al., 2018).
In fact, sometimes by increasing the solubility and reducing the surface tension of the
growing crystals, surfactants might promote precipitation in vivo negating the
supersaturation maintenance of the drug (Rodríguez‐hornedo and Murphy, 1999).
Therefore, to say the least, the roles/impact of surfactant in the dissolution of drug
ASDs are elusive, and the use of surfactants can be detrimental/beneficial depending
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on the specific drug–polymer–surfactant system and composition. Hence, further
investigation of the roles of surfactants in the wettability enhancement and
recrystallization inhibition of drugs along with polymers is warranted.
Conventionally, ASD has been regarded as a simple binary component system
in which the drug acts as a solute and the polymer acts as a solvent (Meng et al.,
2017). However, a successful ASD formulation must be resistant to recrystallization
during processing and storage. Moreover, ideally having a high drug load, it should
generate and maintain high supersaturation during in vivo dissolution (Davis, 2018).
Meeting all these criteria using a single polymer (binary ASD) could be very
challenging; hence, an upsurge of research into ternary ASDs in the recent years is
notable (Davis, 2018). Significant improvement in the performance of drug ASDs has
already been reported recently by using ternary systems such as drug–binary
polymers (e.g., Xie and Taylor, 2016a) and drug–polymer–surfactant (e.g.,
Ghebremeskel et al., 2007). The use of binary polymers in a ternary drug ASD has
been the focus of recent studies for further improvement of drug dissolution. In the
ternary ASD system (binary polymer), the dissolution profile is regulated by the
characteristics of individual polymers (Ohyagi et al., 2017). Some polymers enable
rapid drug release, while others can efficiently inhibit recrystallization in the
polymeric matrix and the dissolution medium during the in vitro or in vivo dissolution
(Zhang et al., 2018). However, in the ternary ADSs, various polymers with different
hydrophilicity/amphiphilicity and drug recrystallization inhibition capability have
been combined to improve the dissolution performance of ASDs (Prasad et al., 2016;
Xie and Taylor, 2016a; Yoshida et al., 2012). Another driver for ternary ASDs
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besides dissolution enhancement is improved storage stability and long-term drug
recrystallization inhibition (Albadarin et al., 2017; Davis et al., 2018).
In the rest of Chapter 1, the remaining challenges and knowledge gaps
regarding various aspects of drug nanocomposites and ASDs that are used in the
dissolution enhancement of poorly water-soluble drugs are presented and how each
chapter of this dissertation will address them will be indicated.

1.2 Remaining Challenges and Knowledge Gaps
1.2.1 Comparative Assessment of Various Dispersants and Their Molecular
Weight in Nanosuspension Stabilization and Dissolution Rate Enhancement
Particle size growth and aggregation occur in drug suspensions during wet media
milling, storage, and downstream processing, and the extent of such phenomena must
be reduced as they reduce drug surface area available for dissolution (Bilgili et al.,
2016; Knieke et al., 2014). To prevent gross physical instability, drug
nanosuspensions are usually dried into nanocomposites that are then incorporated into
standard solid dosage forms such as tablets and capsules (Basa et al., 2008; Bhakay et
al., 2018b; Van Eerdenbrugh et al., 2008c). This approach also helps to achieve
patient compliance because solid oral dosage forms incorporating drug nanoparticles
are preferred over drug nanosuspensions. Among different drying techniques, spraydrying is preferred over other techniques due to several advantages such as its
continuous and scalable nature, its ability to produce micron-sized particles with large
surface area (Kemp, 2011), and its potential in producing high drug-loaded
nanocomposites (Azad et al., 2015b; Bhakay et al., 2014a). Although high drug
loading in dried powders can be achieved by both freeze drying and spray drying
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(Azad et al., 2015b; Niwa and Danjo, 2013), spray drying is inherently continuous
having a one-step process, and is more energy and time efficient compared to freeze
drying (Chin et al., 2014). Hence, spray drying is selected here as the drying method
for converting drug nanosuspensions into nanocomposites.
Although preparation of drug nanoparticles in the form of wet-milled
suspensions and their drying into nanocomposites has been shown to be an effective
approach for enhancing the dissolution rate of various poorly water-soluble drugs
(Bhakay et al., 2018b; Li et al., 2016a), several challenges remain in formulation
design. To prevent aggregation during milling and ensure physical stability of the
suspensions, dispersants such as polymers, sugars, and surfactants are added to the
suspensions where they function as stabilizers (Bhakay et al., 2018b; Chin et al.,
2014; Kesisoglou et al., 2007). Unfortunately, depending on the concentration and
types of dispersants used in the formulation, drug nanoparticles may still form
aggregates in the wet-milled suspensions due to attractive inter-particle forces (van
der Waals, hydrophobic forces, etc.) (Li et al., 2016a; Malamatari et al., 2018);
further aggregation may occur during drying (Bhakay et al., 2014a; Kim and Lee,
2010; Li et al., 2016d). It must be noted that the same dispersants used to prevent
nanoparticle aggregation also act as matrix former in the dried nanocomposites and
modulate drug release during dissolution/redispersion (Bhakay et al., 2018b; Li et al.,
2016a; Li et al., 2016b). Overall, the anticipated advantage of producing drug
nanoparticles in terms of dissolution enhancement may not be achieved fully due to
the aggregation of the drug particles upon milling and drying (Bose et al., 2012; Choi
et al., 2008) and slow nanoparticle recovery from the nanocomposite matrix (Bhakay
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et al., 2014a; Li et al., 2016b).
Among various classes of dispersants, surfactants have been commonly used
because they enhance drug wettability, reduce surface tension, and provide
electrostatic stabilization (Bhakay et al., 2018b; Gupta et al., 2013; Li et al., 2018a).
However, there could be several issues with use of surfactants in drug
nanosuspensions such as aggregation of drug nanoparticles (Knieke et al., 2013; Li et
al., 2016d), particle size growth due to Ostwald ripening during milling and/or
storage (Ghosh et al., 2011; Knieke et al., 2013), and micellar solubilization of the
drug (Yalkowsky and Roseman, 1981). Additional challenges for anionic surfactants
include incompatibilities with other ionic molecules; sensitivity to pH, salt, and
temperature changes; GIT (gastro intestinal tract) irritation (Gupta and Kompella,
2006; Liversidge and Cundy, 1995); and toxicity when used in excess (Liversidge
and Cundy, 1995), especially for the inhalation applications (Lebhardt et al., 2011;
Suzuki et al., 2000). Various formulation strategies can be used to mitigate these
issues with surfactants. One strategy is to use a combination of a surfactant with a
water-soluble adsorbing polymer, thereby reducing surfactant usage (Bhakay et al.,
2018b; Bilgili and Afolabi, 2012; Bilgili et al., 2016; Niwa et al., 2011). Another
strategy is to develop surfactant-free formulations that contain other classes of
dispersants either alone or in combination (Bhakay et al., 2018b; Chin et al., 2014).
For example, water-soluble polymers such as hydroxypropyl cellulose (HPC),
hydroxypropyl methyl cellulose (HPMC), polyvinylpyrrolidone (PVP), and
polyethylene glycol (PEG) can be used alone or in combination with other watersoluble dispersants such as sugars (e.g., sucrose, lactose) and sugar alcohols (e.g.,

21

mannitol, sorbitol) (Abdelwahed et al., 2006; Chin et al., 2014; Kesisoglou et al.,
2007), water-insoluble dispersants such as microcrystalline cellulose, anhydrous
dicalcium phosphate, and montmorillonite (Van Eerdenbrugh et al., 2008a), and
swellable crosslinked polymers such as sodium starch glycolate and croscarmellose
sodium (Azad et al., 2015b; Bhakay et al., 2014b).
Polymers

are

the

most

widely

used

dispersants

in

drug

nanosuspensions/nanocomposites (Bhakay et al., 2018b; Li et al., 2016a). Polymer
molecular weight (MW) affects steric stabilization in drug suspensions and
suspension/solution viscosity (Adamson and Gast, 1997; Choi et al., 2008; Ploehn
and Russel, 1990), mechanical properties of films (Rowe, 1986), and drug release
from polymer-based dosages (Mittal et al., 2007). More specifically, use of different
polymers or polymers with different MW is expected to determine the extent of
aggregation in drug nanosuspensions and nanocomposites. Interestingly, only few
studies examined the impact of different polymers and different MW of the same
polymer on drug nanosuspension stability systematically. For example, ITZ was wet
ball-milled for 4 days in aqueous solution of HPC with MW in the range ~10–50
kg/mol inside a vial (Choi et al., 2008). This study concluded that lower MW HPC is
more effective for faster particle size reduction, while suspensions with all HPC
grades were stable. However, they did not study the impact of MW on drug
dissolution. Nabumetone and halofantrine suspensions with HPMC and PVP were
wet media milled for 6 h in a mixer mill (Sepassi et al., 2007); however, drying of the
suspensions and dissolution testing were not performed. Their study suggests that
only lower MW HPMC (<50 kg/mol) led to drug suspensions having mean particle
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sizes less than 1 µm. Unfortunately, studies like (Choi et al., 2008; Sepassi et al.,
2007) that used low-energy mills as opposed to high-energy (wet stirred media) mills
do not truly reflect the impact of different polymers or MW on steric stabilization and
reduction of drug aggregate formation. In wet media milling, breakage kinetics and
extent of drug particle breakage depend on the viscosity of the drug suspensions,
which is affected by the type/MW of the polymer (Li et al., 2016a). The use of higher
MW polymer and/or higher polymer concentration causes more pronounced viscous
dampening and slower breakage (Bilgili and Afolabi, 2012; Sepassi et al., 2007).
While viscous dampening occurs in any wet media mill, low-energy mills are
particularly sensitive to viscous dampening; drug nanoparticles may not even be
produced with high MW polymers even after prolonged milling (see e.g., Sepassi et
al., 2007). Hence, such studies drew somewhat confounded conclusions about the
impact of polymer MW due to significant impact of viscous dampening. In the study
presented in Chapter 2, a wet stirred media mill was used instead, which reduces the
sensitivity to viscous dampening and helps to better elucidate the roles of polymer
MW.
Itraconazole (ITZ), an antifungal drug, has been used for the treatment of
local and systemic mycoses. As it is a hydrophobic model BCS Class II drug with
high permeability and poor water solubility (<1 ng/mL) (Peeters et al., 2002), several
research groups (Azad et al., 2016; De Smet et al., 2014; Parmentier et al., 2017;
Sarnes et al., 2014; Van Eerdenbrugh et al., 2008d) produced ITZ-loaded
nanocomposites to improve its dissolution rate. These studies used surfactants along
with other dispersants in the nanocomposite formulations; the highest drug loading
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that achieved immediate drug release (>80% in 20 min) was 63% (Van Eerdenbrugh
et al., 2008d). Therefore, in Chapter 2, the impact of various polymers/MW on ITZ
nanosuspension stabilization and ITZ release from spray-dried ITZ nanosuspensions
is investigated. This investigation could yield significant insight into the roles of
polymers and allow for design of high-drug loaded, fast-dissolving, surfactant-free
nanocomposites.
1.2.2 Drug Nanocomposites With High Supersaturation Capability and Their
Comparison to ASDs in Dissolution Enhancement
As mentioned in Section 1.1.2, hydrophilic/amphiphilic polymers and/or surfactants
are added to the suspensions as stabilizers to suppress the aggregation during and
after WSMM (Li et al., 2016b; Wang et al., 2013). In general, drug:stabilizer mass
ratio has been optimized based on several considerations. At low concentration of
stabilizers, drug nanoparticle aggregation cannot be suppressed (Knieke et al., 2013;
Li et al., 2016c); while if used in excess, stabilizers especially surfactants may
promote Ostwald ripening (Ghosh et al., 2011; Verma et al., 2011). Also depending
on the molecular weight of the polymer, too high concentration of the polymer can
cause significant viscous dampening, leading to slower breakage kinetics during
milling (Bilgili and Afolabi, 2012; Knieke et al., 2013) as well as downstream
processing issues (Bhakay et al., 2018). Finally, stabilizer concentration should be
minimized to achieve high drug loading in the final solid dosages, while still
achieving physical stability in the milled suspensions (Bhakay et al., 2018b; Li et al.,
2016b). In view of these considerations, it is no surprise to find that a drug:polymer
mass ratio much higher than 1 has been widely reported in several papers: 1:0.5 to
1:0.05 (Kesisoglou et al., 2007; Wang et al., 2013), 1:0.8 to 1:0.02 (Chang et al.,
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2015), and 1:1 to 1:0.02 (Van Eerdenbrugh et al., 2008c). A quick review of recent
literature (see Table 1.2) also suggests a similarly high drug:polymer mass ratio, i.e.,
1:1 to 1:0.01, in drug nanosuspensions used in the preparation of spray-dried
nanocomposites.
As mentioned in Section 1.1.2, drug nanosuspensions prepared via WSMM
are usually dried and converted into nanocomposite microparticles or shortly
nanocomposites. Pharmaceutical formulators need to resolve two major issues
regarding the drug release from nanocomposites. First, depending on the stabilizer
formulation in the precursor nanosuspensions, primary drug nanoparticles may not be
effectively recovered from the nanocomposites during the dissolution (Azad et al.,
2015b; Bilgili et al., 2018). This may be attributed to the poor physical stability of the
drug nanosuspensions (extensive aggregation) prepared by WSMM and/or inability of
the nanocomposite matrix to release drug nanoparticles fast enough (Azad et al.,
2015b; Bhakay et al., 2013a; Bilgili et al., 2018; Li et al., 2016c). These issues have
been largely addressed (see Bhakay et al., 2018b and the references cited therein),
e.g., by using strongly adsorbing/interacting polymers (Bilgili et al., 2018), soluble
excipients like sugars and sugar-alcohols (Iurian et al., 2017; Medarević et al., 2018),
combination of a polymer with a surfactant (Bhakay et al., 2014a; Li et al., 2016b),
and combining an adsorbing polymer with colloidal superdisintegrants (Azad et al.,
2015b; Li et al., 2018b).
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Table 1.2 Formulations and Drug–Polymer Content of Nanosuspensions Used for the Preparation of Spray-Dried
Nanocomposites in Recent Studies
Drug
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Naproxen
Lovastatin
Griseofulvin
Naproxen
Griseofulvin
Allisartan Isoproxil
Mefenamic Acid
Aprepitant
Carvedilol
Fenofibrate
Itraconazole
Itraconazole

Drug content
(% w/v)
1.0
0.5a
10a
1.0, 3.0, and 5.0
5.0
5.0
5.0a
2.5
8.3
10.0a
10.0a
10.0a

Polymeric stabilizerb
HPMC
PVP K12, K30, K17, and PVA
HPC SL
HPMC E15
HPC SL
PVP K30
HPC SSL
Pharmacoat 603 and HPC SSL
HPC SL
HPC
HPC SL
HPC L and HPC SL

a

Drug:polymer mass
ratio
1:0.5
1:0.2
1:0.25
1:0.2–1:0.6
1:0.25
1:0.01–1:0.03
1:0.15
1:0.5, 1:1
1:0.1–1:0.4
1:0.25
1:0.25–1:0.65
1:0.45

References
Kumar et al. (2014)
Zhang et al. (2014)
Azad et al. (2015)
Kumar et al. (2015)
Shah et al. (2016)
Hou et al. (2017)
Konnerth et al. (2017)
Toziopoulou et al. (2017)
Medarevic et al. (2018)
Aleandri et al. (2018)
Li et al. (2018)
Bilgili et al. (2018)

With respect to the total weight of the suspension liquid (% w/w); bHPMC: hydroxypropyl methylcellulose, HPC: hydroxypropyl cellulose, PVA: polyvinyl
alcohol, PVP: polyvinylpyrrolidone.
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Unfortunately, the second major challenge, i.e., the low supersaturation
generation capability of drug nanocomposites in in vitro and in vivo dissolution has
not been resolved. Interestingly, even though all studies mentioned in Table 1.2
reported significant increase in drug release from the spray-dried nanocomposites as
compared with as-received drug micro-crystals and their physical mixtures with the
excipients, none of these studies investigated or reported any supersaturation
generation in the dissolution tests. In fact, the low drug supersaturation from
nanocomposites is the primary reason for pharmaceutical formulators to opt for ASDs
for bioavailability enhancement of high-dose poorly soluble drugs. As mentioned in
Section 1.1.3, as the apparent solubility of the amorphous form is much greater than
its crystalline counterpart, ASDs provide high extent of drug release above
thermodynamic solubility and significant supersaturation (Ambike et al., 2005; Six et
al., 2004; Yamashita et al., 2003) unlike drug nanocomposites.
Surprisingly, although both drug nanocomposites and ASDs have been used
as two major platforms for dissolution enhancement, a head-to-head comparison of in
vitro drug release from these two solid dosage forms having identical formulation is
not available in the literature. Typically, to establish the dissolution enhancement
owing to the use of nanocrystals, nanocomposites were compared with the asreceived crystalline drug as well as physical mixtures of the as-received drug with the
same formulation of the nanocomposites (Bhakay et al., 2014a; Hecq et al., 2005).
Likewise, ASDs were compared to the as-received drug microparticles and/or drug
microparticles in tablets/capsules in terms of dissolution enhancement (Jung et al.,
1999; Six et al., 2004). In some cases, nanosuspensions, not dried nanocomposites,
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were compared with ASDs, but not in a head-to-head manner. For instance, Fakes et
al. (2009) investigated the bioavailability enhancement of a BCS class II drug, BMS488043, using a 10% (w/w) drug nanosuspension with 2% (w/w) hydroxypropyl
cellulose (HPC-SL) and 0.1% (w/w) sodium lauryl sulfate (SLS). They also prepared
the drug ASD by spray drying and flash evaporation techniques at different
drug:polymer (polyvinyl pyrrolidone, PVP) ratios. In the case of spray drying, 40:60
drug:PVP was used for the formulation development and further characterization,
whereas 90:10 drug:PVP ratio was selected in the case of flash evaporation. The
nanosuspension and two amorphous formulations containing 20% and 40% drug were
compared to a wet-milled crystalline drug in a capsule in a crossover beagle dog
study. While having different formulations, the ASDs showed superior bioavailability
enhancement compared with the nanosuspension, as expected from the relatively high
drug supersaturation capability of the ASDs with respect to the nanosuspension. In a
recent study (Li et al., 2017), a nanoextrusion process was used to compare
griseofulvin (GF) nanocomposites with ASDs. GF nanosuspensions prepared via
WSMM were extruded with additional polymers and simultaneously dried in a twinscrew extruder. This nanoextrusion process with two different polymers, i.e., HPC
(partially miscible with GF) and Soluplus (Sol, miscible with GF), led to the
formation of GF nanocomposite and GF ASD, respectively. The researchers
demonstrated that for 100 mg GF dose, GF–Sol ASD led to 340% (relative)
supersaturation whereas GF–HPC nanocomposite only achieved 60% supersaturation.
While this finding corroborates the well-known shortcoming of nanocomposites vs.
ASDs in drug supersaturation generation, a direct and scientifically fair head-to-head
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comparison of drug release from nanocomposites vs. ASDs having identical
polymer/formulation is still lacking in the literature. Finally, none of the previous
studies on spray-dried GF nanocomposites (Azad et al., 2015b; Bhakay et al., 2014a;
Shah et al., 2016) reported or investigated GF supersaturation in the dissolution
medium.
Chapter 3 presents how drug nanocomposites and ASDs with identical
formulation can be prepared using the spray drying process, which enables us to
compare their drug release in a head-to-head manner, unlike all previously mentioned
studies. The main objective is to improve the supersaturation capability of drug
nanocomposites in dissolution tests significantly using a relatively low drug:polymer
mass ratio (high polymer loading), i.e., 1:1 and 1:3, as compared with high
drug:polymer mass ratio like 3:1 in typical nanosuspension formulations (Table 1.1),
and compare their dissolution performances to those of the ASDs.
1.2.3 Roles of Surfactant in Drug Release from Spray-Dried Nanocomposites
A quick review of recent literature on spray-dried drug nanosuspensions that contain
polymer–anionic surfactants as stabilizers (see Table 1.3) suggests a high
drug:polymer mass ratio, i.e., 1:0.5 to 1:0.1, with minimal use of anionic surfactants
with respect to drug (1:0.1 to 1:0.0025). Selection of such low concentrations of
anionic surfactants, usually below their critical micelle concentration (CMC), has
been mostly driven by two considerations: (i) significant growth of drug nanoparticles
could occur due to Ostwald ripening above CMC (Ghosh et al., 2011; Verma et al.,
2011) and (ii) anionic surfactants are relatively toxic and can cause gastrointestinal
tract irritation, if used at high concentrations (Gupta and Kompella, 2006; Liversidge
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and Cundy, 1995).
As discussed in Section 1.2.2, the low supersaturation generation capability in
dissolution tests has not been resolved or addressed adequately. For example, even
though all studies reported in Table 1.3 indicated significant increase in drug release
from the spray-dried nanocomposites with surfactants as compared with as-received
drug micro-crystals and/or their physical mixtures with the excipients, they, except
Zuo et al. (2013), did not investigate or report any supersaturation generation in the
dissolution tests. The dissolution data in Zuo et al. (2013) suggest up to ~50%
(relative) supersaturation of fenofibrate from spray-dried nanocomposites in 0.15%
sodium dodecyl sulfate (SDS) solution, which is in line with supersaturation levels
from traditional nanocomposites (Li et al., 2017b; Müller and Peters, 1998). It is fair
to assert that low drug supersaturation from nanocomposites is still the primary
reason for pharmaceutical formulators to opt for ASDs for bioavailability
enhancement of poorly soluble drugs. Hence, a new approach for boosting the
supersaturation capability of nanocomposites to make them competitive to ASDs is
warranted.
Being motivated by the use of low drug:polymer mass ratios from 1:1 to 1:9 in
drug ASDs (Baghel et al., 2016; Singh and Van den Mooter, 2016) unlike the high
drug:polymer ratios (1:0.8 to 1:0.02) in traditional drug nanocomposites (Chang et al.,
2015; Kesisoglou et al., 2007; Van Eerdenbrugh et al., 2008c; Wang et al., 2013), as
also depicted in Table 1.3, in Chapter 4, drug nanocomposites with relatively high
polymer loading are presented. Judicious choice of polymers that have relatively low
aqueous viscosities even at high concentrations allowed for preparation of drug
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nanosuspensions and their spray-drying without processing issues. To avoid potential
toxicity issues associated with anionic surfactants, SDS, the most common anionic
surfactant, was used at 0.125% w/v in the drug suspensions, below its CMC (0.24%
w/v (Moroi et al., 1974)). Chapter 4 also presents the impact of SDS during in vitro
drug release from the nanocomposites.

31

Table 1.3 Formulations and Drug–Polymer–Anionic Surfactant Content of Aqueous Drug Nanosuspensions Used for the
Preparation of Spray-Dried Nanocomposites in Recent Studies
Drug
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Miconazole
Itraconazole
Fenofibrate
Griseofulvin
Azodicarbonamide
Lovastatin
Griseofulvin
Itraconazole
Griseofulvin
Hesperetin
Glibenclamide
Resveratrol
Rutin
Quercetin
Aprepitant
Carvedilol
Fenofibrate
Itraconazole

Drug
content
(% w/w)
20
20
10a
10
10
0.5
10
1a
5a
1
1
1
1
1
2.5a
8.3a
10
10

Polymeric stabilizer and
gradeb

Surfactantb

HPC LF, HPMC E15
HPC LF, HPMC E15
HPMC E5
HPC SL
HPC SL
PVP K12/K17/K30, PVA
HPC SL
PVP K40
HPC SL
HPMC
HPMC
HPMC
HPMC
HPMC
HPMC E15, HPC SSL
HPC SL
HPC
HPC L, HPC SL

SDS
SDS
SDS
SDS
SDS
SDS
SDS
SDS
DS
SC
SC
SC
SC
SC
SDS
SDS
SDS
SDS

a

Drug:polymer:
surfactant mass
ratio (–)
1:0.25:0.0025
1:0.25:0.0025
1:0.2:0.003
1:0.25:0.05
1:0.25:0.05
1:0.2:0.05
1:0.25:0.05
1:0.1:0.01–1:0.3:0.05
1:0.25:0.01
1:0.5:0.1
1:0.5:0.1
1:0.5:0.1
1:0.5:0.1
1:0.5:0.1
1:0.5:0.1, 1:1:0.04
1:0.1:0.01–1:0.4:0.01
1:0.25:0.05
1:0.25:0.02

References

Cerdeira et al. (2013)
Cerdeira et al. (2013)
Zuo et al. (2013)
Bhakay et al. (2014)
Bhakay et al. (2014)
Zhang et al. (2014)
Azad et al. (2015)
Kumar et al. (2015)
Shah et al. (2016)
Liu et al. (2018)
Liu et al. (2018)
Liu et al. (2018)
Liu et al. (2018)
Liu et al. (2018)
Toziopoulou et al. (2017)
Medarevic et al. (2018)
Aleandri et al. (2018)
Bilgili et al. (2018)

With respect to the total volume of the suspension liquid (% w/v); bDS: docusate sodium; HPMC: hydroxypropyl methylcellulose, HPC: hydroxypropyl
cellulose, PVA: polyvinyl alcohol, PVP: polyvinylpyrrolidone; SC: sodium cholate; SDS: sodium dodecyl sulfate.
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1.2.4 Roles of an Anionic Surfactant in Drug Release from Spray-Dried ASDs
In most of the recent studies (see Table 1.4), anionic surfactants like sodium dodecyl
sulfate (SDS) have been used as a carrier along with polymers in ASDs so as to
solubilize the drug; hence, surfactants form a high mass fraction of the ASDs. This is
not surprising as the use of surfactants and surfactants–polymers as carriers has been
an emerging trend in the last two decades (Vasconcelos et al., 2007). When polymers
alone cannot achieve high kinetic solubilization, they are augmented with copious
amounts of surfactants which can solubilize drugs through micellar solubilization and
surfactant–polymer complex formation (Jung et al., 2016; Liu et al., 2016; Xia et al.,
2016). Although the role of anionic surfactants in wettability enhancement of drugs is
commonly accepted and mentioned, Table 1.4 suggests that this aspect either for
anionic surfactants like SDS alone or along with polymers has been rarely examined
and quantified, especially in relation to the drug release from ASDs. For example,
(Lu et al., 2014) investigated the impact SDS, the most commonly used anionic
surfactant, in the wettability enhancement of simvastatin (SV) and its relation to the
dissolution rate of the SV–polyvinyl pyrrolidone (PVP) solid dispersion via separate
measurements of contact angle and water absorption into a packed powder bed.
While they reported the positive impact of SDS inclusion on drug wettability and
drug release form the solid dispersions, they did not investigate the impact of SDS on
the supersaturation maintenance/recrystallization kinetics. Similarly, the impact of
anionic surfactants on drug supersaturation maintenance has not been routinely
studied in separate desupersaturation–recrystallization kinetic studies unlike in Chen
et al. (2018), Deshpande et al. (2018) and Feng et al. (2018). Moreover, several
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studies have indicated that SDS had deleterious impact on drug supersaturation
maintenance as it promoted drug recrystallization in the presence of polyvinyl
pyrrolidone-vinyl acetate (PVP-VA) (Liu et al., 2016) and crystal growth in the
presence of PVP (Mosquera-Giraldo et al., 2014).
As SDS was intended as a carrier/solubilizer in most of the studies in Table
1.4, the drug:SDS mass ratios in ASDs are typically in the range of 1:0.2 to 1:3,
except in few studies (Dave et al., 2013; Kim et al., 2018; Lu et al., 2014; Truong et
al., 2015; Yan et al., 2012) that did not investigate the impact of SDS on drug
wettability and recrystallization kinetics. In other words, SDS has been rarely used as
a minor component, e.g., 1:0.05 or 20:1 drug:polymer mass ratio. In view of the
existing literature, it is fair to state that the impact of SDS, as a minor component of
the ASD, on both drug wettability enhancement and drug crystallization
inhibition/supersaturation maintenance in the presence of polymers, specifically
hydroxypropyl cellulose (HPC) and Soluplus (Sol), has not been systematically
examined. It is hypothesized that the use of SDS as a minor component along with a
drug-miscible polymer, which can provide solubilization and supersaturation
maintenance, could boost supersaturation from the ASDs via mainly wettability
enhancement and some additional drug solubilization, without having any deleterious
effect on drug recrystallization. Another driver for the use of SDS as a minor
component of ASDs is that anionic surfactants are relatively toxic and can cause
gastrointestinal tract irritation (Gupta and Kompella, 2006; Kim et al., 2016),
especially if used at high concentrations in ASDs with high drug doses.
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Table 1.4 The Formulation Composition of Drug ASDs with Sodium Dodecyl Sulfate (SDS) in Recent Studies and Survey of the
Use of Wettability and Desupersaturation Tests
Drug
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Ketoprofen
Tacrolimus
Docetaxel
Valsartan
Sulfathiazole
Simvastatin
Sorafenib
Tacrolimus
Felodipine
Itraconazole
Itraconazole
Sirolimus
Nifedipine

Drug
loadinga
(% w/w)
10%
10%
5–9%
50–67%
33–50%
33%
20–50%
20–33%
23%
50%
20%
16–48%
14–40%

Polymerb

Drug:Polymer:SDS

Wettability
testing

DeS
testingc

References

PEG
CMC-Na
PVP K30
HPMC
PVP K29/32
PVP K29/32
Soluplus
HPMC
Soluplus
Soluplus, PVP VA64
HPMC-AS
HPMC
Kolliphor, Soluplus

1:8:1
3:24:3
1:9:1–1:19:1
3:1.25:0.25–3:2:1
1:1:0.1–1:1:1
1:3:0.02–1:3:0.06
1:0.9:0.1–1:4.5:0.5
1:1:1–1:1:3
1:3:0.2–1:3:0.4
2:1:1
1:3.75:0.25–1:2.75:1.25
1:1:0.05–1:5:0.1
1:1:0.5–1:4:2

No
No
No
No
No
Yes
No
No
No
No
No
No
No

No
No
No
No
No
No
No
No
Yes
Yes
Yes
No
No

Mura et al. (2005)
Park et al. (2009)
Moes et al. (2011)
Yan et al. (2012)
Dave et al. (2013)
Lu et al. (2014)
Truong et al. (2015)
Jung et al. (2016)
Chen et al. (2018)
Deshpande et al. (2018)
Feng et al. (2018)
Kim et al. (2018)
Muralichand and
Bhikshapathi, (2018)

a

% w/w with respect to the total weight of the total solid content.
CMC-Na: Carboxymethylcellulose-sodium; HPMC: hydroxypropyl methylcellulose; HPMC-AS: hydroxypropyl methylcellulose-acetyl succinate; PEG:
polyethylene glycol; PVP: polyvinyl pyrrolidone; PVP-VA: polyvinyl pyrrolidone-vinyl acetate.
c
DeS testing: Desupersaturation testing
b
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Unlike all previous studies, the study presented in Chapter 5 aims to examine
the impact of a common anionic surfactant, SDS, as a minor component of a drug–
polymer–SDS ASD, on in vitro drug release while elucidating its roles in wettability
enhancement and recrystallization inhibition in the presence of HPC/Sol.
1.2.5 Synergistic Effects of Binary Polymers in ASDs in Drug Supersaturation
Several recent reports (see Table 1.5) have shown improved dissolution performance
and storage stability of the ternary ASDs (binary polymers with drug) over binary
ASDs (single polymer with drug). Al-Obaidi and Buckton (2009) studied the
dissolution performance and storage stability of binary and ternary griseofulvin (GF)
ASDs produced by hydroxypropyl methylcellulose acetate succinate (HPMCAS) and
poly[N-(2-hydroxypropyl) methacrylamide] (PHPMA) in the dissolution performance
and storage stability. Although the ternary ASD provided significant storage stability
due to the stronger GF interactions with both HPMCAS and PHPMA via hydrogen
bonding, there was no improvement observed during dissolution compared to the
binary ASDs. Xie and Taylor (2016b) optimized the dissolution performance of a
high drug loaded ASD containing celecoxib (CXB) by using binary polymers.
Polyacrylic acid (PAA), a hydrophilic polymer, was used to achieve rapid drug
release, while hydroxypropyl methylcellulose (HPMC) or HPMCAS were used to
inhibit CXB recrystallization, thus maintaining the supersaturation during dissolution.
The ternary ASDs with certain ratios of HPMC and PAA achieved rapid release as
well as crystallization inhibition at 30% CXB loading. The optimum formulation was
reported to have 3:6:1 mass ratio for both CXB–PAA–HPMCAS and CXB–PAA–
HPMC, which achieved fast CXB release and high supersaturation generation–
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maintenance. Xie and Taylor (2016a) also investigated the effectiveness of polyvinyl
pyrrolidone (PVP) K12, PVP K29/32, HPMC, and HPMCAS in inhibiting CXB
crystallization via desupersaturation experiments and compared the CXB release rate
and crystallization tendency of CXB in various binary and ternary ASDs. HPMC and
HPMCAS were more effective than PVP K12 or PVP K29/32 in maintaining
supersaturation. The dissolution results from binary ASDs suggest that the CXB
release was substantially faster from PVP-based ASDs than HPMC/HPMCAS-based
ASDs. However, poor crystallization inhibition ability of PVP K12 and PVP K29/32
resulted in faster desupersaturation compared to HPCM/HPMCAS. Ternary ASD
with 4:1 PVP:HPMCAS/HPMC exhibited slower CXB release than PVP-based
binary ASD, but no desupersaturation was observed during dissolution time period
(16 h).
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Table 1.5 Binary Polymers Used in the Preparation of Ternary Drug ASDs via Solvent Evaporation Techniques
Drug

38

Drug
loadinga
(% w/w)
Griseofulvin 50
Cilostazol
20
API
30
Celecoxib
50
Celecoxib
50
Celecoxib
10–50
Celecoxib
30–50
Itraconazole 10–30
Griseofulvin 20
Ibuprofen
20
Itraconazole 30
Lovastatin
25
Lacidipine
16.7

Polymer1
(P1)b

Polymer2
(P2)b

Drug:P1:P2
Mass Ratio (–)c

Wettability
study

DeS
testd

References

HPMCAS
HPMC
PVP
PVP
PVP
PAA
PAA
Soluplus
HPMC
PVP VA64
Soluplus
Soluplus
Soluplus

PHPMA
PVP
PLGA
HPMCAS
HPMC
HPMCAS
HPMC
HPMCP
EUD
HPMCP
HPMCP
HA
GA

1:0.5:0.5
1:2:2–1:3:1
1:1.5:0.8
1:0.8:0.2
1:0.8:0.2
1:0.4:0.6–1:8:1
1:0.5:0.5–1:2:0.3
1:4.5:4.5–1:1.3:1
1:2:2
1:2:2
1:1.3:1
1:1.5:1.5
1:3.75:1.25

No
No
No
No
No
No
No
No
No
No
No
No
No

No
No
No
Yes
Yes
Yes
Yes
No
Yes
No
No
Yes
Yes

Al-Obaidi and Buckton, (2009)
Park et al. (2013)
Meeus et al. (2015)
Xie and Taylor, (2016a)
Xie and Taylor, (2016a)
Xie and Taylor, (2016b)
Xie and Taylor, (2016b)
Davis et al. (2017)
Ohyagi et al. (2017)
Ziaee et al. (2017)
Davis et al. (2018)
Guan et al. (2019b)
Guan et al. (2019a)

a

% w/w with respect to the total weight of the solid content.
EUD: Eudragit, GA: gum Arabic, HA: hyaluronic acid; HPMC, hydroxypropyl methylcellulose, HPMCAS: hydroxypropyl methyl cellulose acetate
succinate, HPMCP: hydroxypropyl methyl cellulose phthalate, PEG: polyethylene glycol, PHPMA: poly [N-(2-hydroxypropyl)methacrylate], PLGA:
Poly(lactic-co-glycolic acid), PAA: polyacrylic acid, PVP: polyvinyl pyrrolidone, PVP VA: polyvinyl pyrrolidone-vinyl acetate.
c
The ratios refer to the polymer1:polymer2 mass ratio. All formulations had 1:3 drug:total polymer mass ratio whether a single polymer or binary polymers
were used.
d
DeS test: desupersaturation test.
b
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Guan et al. (2019b) investigated the synergistic effect of Soluplus (Sol) and
hyaluronic acid (HA) on the in vivo and in vitro dissolution and supersaturation
maintenance of lovastatin (LOV). In their study, HA was used as a crystal growth
inhibitor and the Sol was used as a nucleation inhibitor. Desupersaturation test
confirmed the synergistic effect of HA–Sol combination on the supersaturation
maintenance of LOV. Significant enhancement in the dissolution performance was
achieved by the ASD with binary polymers (Sol–HA) than the ASDs with single
polymer. The possible reason for the synergistic effect of the binary polymer was
explained by the Sol–HA complex formation where HA could insert into the Sol
micelles and interact with Sol via hydrogen bonds providing both electrostatic and
steric stabilization against nucleation and crystal growth from the supersaturated drug
solutions. Guan et al. (2019a) investigated the synergistic effect of a nucleation
inhibitor (Sol) and a crystal growth inhibitor (gum arabic, GA) on the in vitro–in vivo
performance of lacidipine from ASD formulation. Although significant improvement
in supersaturation maintenance was not observed, synergistic effect in equilibrium
solubility enhancement and dissolution performance was observed with Sol–GA mass
ratio 3:1 even after 3 months of accelerated storage condition. The authors explained
that the complex micelle of Sol–GA could provide a softer core with improved
solubilizing ability, resulting in improved equilibrium solubility of the drug. Davis et
al. (2017) produced ternary ASDs of ITZ–Sol–HPMCP and studied the storage
stability and dissolution performance by varying the drug–polymer compositions.
After one year of storage at accelerated condition, all the ternary formulations had
amorphous ITZ confirming storage stability. Dissolution studies indicated that the
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formulations with higher Sol content exhibited faster dissolution and higher extent of
ITZ supersaturation. Ohyagi et al. (2017) investigated the synergistic role of polymer
blending on dissolution performance of GF ASDs. The ternary ASD of GF–HPMC–
Eudragit (EUD) showed faster drug release with a significantly higher supersaturation
than the GF–HPMC and GF–EUD ASDs. In their study, to produce a ternary ASD,
first a polymer blend was produced by spray drying of HPMC and EUD, and then this
spray-dried polymer blend was spray-dried again with GF to produce ternary ASD.
The authors reasoned that the hydrogen bond formation due to the intermolecular
interactions between HPMC and EUD likely helped to improve the dissolution
performance of ternary ASDs over binary ASDs.
The recent studies overall suggest that ternary ASDs that make judicious use
of binary polymers can outperform binary ASDs with a single polymer in one or more
of the following performance metrics: storage stability, rapid drug release, and high
supersaturation generation with prolonged maintenance. Among all studies, the work
of Xie and Taylor, (2016a, b) is quite intriguing and has offered a new strategy for
ternary ASDs. The inclusion of an effective crystallization inhibitor (HPMC,
HPMCAS) as a minor component in a hydrophilic polymer (PVP, PAA), which
enables rapid drug release, of a ternary drug ASD can achieve both rapid drug release
and high, sustained drug supersaturation during in vitro dissolution. The study
presented in Chapter 6 explores if this strategy works for ternary griseofulvin (GF)
ASDs with binary polymer combination of HPC/PVP-VA64 (hydrophilic polymer)
and Sol (amphiphilic polymer, possible crystallization inhibitor).
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1.3 Dissertation Outline
This dissertation has been organized into various chapters as follows:
1) Chapter 2 assesses the impact of polymers on the aggregation of wet-milled
itraconazole and their dissolution from spray-dried nanocomposites. The aim is to
understand the impact of polymer type and molecular weight on nanoparticle
stabilization and drug release from the nanocomposites. The fundamental
knowledge generated could help formulators guide the rational formulation design
of surfactant-free, stable nanosuspensions and fast dissolving spray-dried
nanocomposites.
2) Chapter 3 examines drug supersaturation generation during the dissolution of
spray-dried griseofulvin nanocomposites vs. ASDs, which contain a low
drug:polymer mass ration (high polymer loading). The characterization of the
nanocomposites suggests the formation of molecularly dispersed drug
surrounding the drug nanocrystals, a special class of nanocomposites we called
hybrid nanocrystal–ASD (HyNASD).
3) Impact of an anionic surfactant (SDS) in the formation and dissolution
performance of HyNASDs with various drug:polymer mass ratios and different
drug doses has been investigated and results/discussion are presented in Chapter
4. The criticality of the anionic surfactant in high supersaturating HyNASDs has
been indicated.
4) In Chapter 5, impact of surfactant as a minor component of ASDs on drug release
has been systematically investigated for various drug:polymer ratios and different
drug doses. Despite being a minor component, anionic surfactant played a major

41

role in supersaturation from ASDs.
5) In Chapter 6, synergistic effect of binary polymer combination in the drug
supersaturation generation and maintenance from ASDs has been examined using
combinations of two hydrophilic polymers that provide rapid drug release and an
amphiphilic

polymer

that

generates

supersaturation

and

inhibits

drug

recrystallization.
6) To generalize the observations and understanding from Chapters 3–5 that focused
on griseofulvin, in Chapter 7, another poorly water-soluble drug, itraconazole
(ITZ), has been used in HyNASDs and ASDs. HyNASD formation and its
significant supersaturation effect as well as positive impact of SDS as a minor
component of HyNASDs/ASDs has been corroborated.
7) Finally, Chapter 8 provides the conclusions and recommendations for future work
that originate from interesting research questions/issues identified during the
course of this investigation.
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CHAPTER 2
IMPACT OF POLYMERS ON THE AGGREGATION OF WET-MILLED
ITRACONAZOLE AND THEIR DISSOLUTION FROM SPRAY-DRIED
NANOCOMPOSITES

We explore the impact of various polymers and their molecular weight on the
stabilization of wet-milled suspensions of itraconazole (ITZ), a poorly soluble drug,
and its dissolution from spray-dried suspensions. To this end, ITZ suspensions with
SSL, SL, and L grades of hydroxypropyl cellulose (HPC) having molecular weights
(MWs) of 40, 100, and 140 kg/mol, respectively, hydroxypropyl methyl cellulose
(HPMC E3 with 10 kg/mol), polyvinylpyrrolidone (PVP K30 with 50 kg/mol),
sodium dodecyl sulfate (SDS, surfactant), and HPC SL–SDS were wet media milled
and spray-dried. Laser diffraction results show that 2.5% HPC SL–0.2% SDS led to
the finest ITZ nanosuspension, whereas without SDS, only 4.5% HPC with SL/L
grades ensured minimal aggregation. Rheological characterization reveals that
aggregated suspensions exhibited pronounced pseudoplasticity, whereas stable
suspensions

exhibited

near

Newtonian

behavior.

Spray-drying

yielded

nanocomposites with 60–78% mean ITZ loading and acceptable content uniformity.
Severe aggregation occurred during milling/drying when 4.5% polymers with MW 
50 kg/mol were used; their nanocomposites exhibited incomplete redispersion due to
slow matrix erosion and released ITZ slowly during dissolution test. Overall, high
drug-loaded, surfactant-free ITZ nanocomposites that exhibited immediate release
(>80% dissolved in 20 min) were prepared via spray-drying of wet-milled ITZ with
4.5% HPC SL/L.
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2.1 Materials and Methods
2.1.1 Materials
ITZ was purchased from Jai Radhe Sales (Ahmedabad, India). HPC, HPMC, and
PVP are commonly used hydrophilic, water-soluble polymers that serve as steric
stabilizers and dispersants in the preparation of drug nanosuspensions and
nanocomposites (Bhakay et al., 2018b; Li et al., 2016a). SSL, SL, and L grades of
HPC with MW of 40, 100, and 140 kg/mol, respectively, donated by Nisso America
Inc. (New York, NY, USA), were used to examine the impact of MW. HPMC
(Methocel E3 grade with 10 kg/mol MW) and PVP (Kollidon K30 grade with 50
kg/mol MW) were donated by Dow Chemical (Midland, MI, USA) and BASF
Corporation (Florham Park, NJ, USA), respectively. PVP K30 was selected because
it has slightly higher MW than HPC SSL, while E3 grade of HPMC was used because
such low MW HPMC (E3/E5) was commonly used in prior studies (e.g., (Bhakay et
al., 2018b; Tuomela et al., 2014)). SDS, purchased from Sigma Aldrich (Milwaukee,
WI, USA), is a commonly used anionic surfactant. Zirmil Y grade wear-resistant
yttrium-stabilized zirconia (YSZ) with a median size of 430 µm (400 µm nominal
size) was used as the milling media and purchased from Saint Gobain ZirPro
(Mountainside, NJ, USA).
2.1.2 Rational for Formulation Design and Wet Stirred Media Milling Process
The formulations used in the preparation of drug suspensions are provided in Table
2.1. Unless otherwise indicated, suspensions and nanocomposites are labeled with the
concentration‒type of the dispersants in the suspensions. All percentages (%) refer to
w/w with respect to the total weight of deionized water (200 g). ITZ concentration
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was kept constant at 10%. Formulations F1–F3 allow us to examine the impact of
HPC SL–SDS combination, which is known to be effective for stabilizing multiple
drug nanosuspensions due to its synergistic effect (e.g., (Bilgili et al., 2016)), with the
respective controls (SDS alone and HPC SL alone). Various surfactant-free
suspensions with different polymers/grades having 4.5% concentration were also
prepared (F4–F8). A higher polymer concentration (>4.5%) would reduce drug
loading in the nanocomposites below 50%; hence, it was not considered.

Table 2.1 Formulation of the Milled Suspensions and Drug Content in the
Nanocomposites

ID

Polymer
MWb
type/grade (kg/mol)

F1
F2
F3
F4
F5
F6
F7
F8

HPC SL
HPC SL
HPC SL
HPC SSL
HPC L
HPMC E3
PVP K30

a

100
100
100
40
140
10
50

Suspension contenta Theoretical
Polymer SDS
drug content
(% w/w) c (% w/w) c (% w/w) d
0
0.2
98.0
2.5
0
80.0
2.5
0.2
78.7
4.5
0
69.0
4.5
0
69.0
4.5
0
69.0
4.5
0
69.0
4.5
0
69.0

Actual drug
content, RSD
(% w/w, %) d
NMe
77.8, 3.6
78.3, 4.7
68.3, 2.9
61.0, 4.8
67.4, 4.4
59.5, 2.5
62.9, 5.1

a

ID is formulation identity
MW is Molecular Weight of the polymers
c
All suspensions have 10% ITZ. %w/w is with respect to the weight of deionized water (200g).
d
%w/w is the weight of ITZ with respect to the weight of nanocomposites;
e
Not measured.
b

A shear mixer (Fisher Scientific Laboratory Stirrer, Catalog No. 14-503,
Pittsburgh, PA) was used to disperse ITZ particles in aqueous dispersant solution.
The resultant ITZ pre-suspensions were transferred to the holding tank of a Netzsch
wet stirred media mill (Microcer, Fine Particle Technology LLC, Exton, PA, USA)
(Figure 2.1a). Selection of the milling conditions was guided by our prior studies on
wet media milling (Afolabi et al., 2014; Bilgili et al., 2016). 50 mL of the chamber
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was filled with zirconia beads, and a screen with 200 µm opening was used to hold
the beads in the chamber. The suspension was recirculated through the chamber at a
rate of 126 mL/min via a peristaltic pump and was milled at a rotor speed of 4000
rpm for 65 min. The milling chamber and holding tank were cooled by a chiller
(Advantage Engineering Greenwood, IN, USA). Particle sizes of samples taken at the
exit of the mill chamber were measured at different time intervals. A portion of each
suspension was separated in a vial and stored for 7 days at 8 °C to assess the shortterm physical stability.
2.1.3 Preparation of Nanocomposites via Spray Drying
The milled ITZ suspensions were dried following one-day storage using a spray dryer
(4M8-Trix, Procept, Zelzate, Belgium) running in a co-current flow set up (Figure
2.1b). The length and the diameter of the spray dryer are 1.59 m and 0.15 m,
respectively. The operating conditions were adapted from Azad et al. (2015b). The
suspensions were atomized at 2 bar atomizing pressure using a bi-fluid nozzle having
0.6 mm tip diameter. In each run, ~120 g milled suspensions were sprayed at 1.3–1.6
g/min spray rate using a peristaltic pump (Makeit-EZ, Creates, Zelzate, Belgium).
Drying air at 120 °C was fed co-currently at the top of the column at a rate of 0.37–
0.40 m3/min. The residence time was calculated to be ~4 s. After attainment of
steady-state in about 15 min, the outlet temperature was measured to be 35–38 °C in
different runs due to variable solids loading in different formulations (refer to Table
2.1). A cyclone separator was used at 54–70 mbar differential pressure to separate the
particles from the outlet air stream and divert them into a glass jar. The dried
powders, i.e., the nanocomposites, were used for further characterization.
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Figure 2.1 (a) Schematic of a wet stirred media mill in recirculation mode of
operation and (b) schematic of a co-current spray dryer. (Figures are not drawn to
scale.).
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2.1.4 Particle Sizing and Imaging
Particle size distributions (PSDs) of the suspensions were measured at various times
during milling as well as after 1-day and 7-day refrigerated storage by laser
diffraction using Coulter LS 13 320 (Beckman Coulter, Miami, FL). The steps
involved in measuring PSDs of the suspensions were adopted from ref. (Bilgili et al.,
2016). During sample addition, intensity was maintained between 40–45%, while
obscuration was below 8%. Mie scattering theory was used to compute the volumebased PSDs in the software with refractive index value 1.68 for ITZ and 1.33 for
deionized water (medium). Before each measurement, 2 mL suspension sample was
diluted with 5 mL of the respective stabilizer solution using a vortex mixer (Fisher
Scientific Digital Vortex Mixer, Model No: 945415, Pittsburgh, PA) at 1500 rpm for
1 min.
PSDs of the nanocomposites were measured by Rodos/Helos laser diffraction
(LD) system (Sympatec, NJ, USA) based on Fraunhofer theory using the dry powder
dispersion module. About 1 g of the sample was placed on the sample chute of the
Rodos dispersing system. The chute was vibrated at 100% setting to feed the sample,
and 1.0 bar dispersion pressure was imposed to suck in the falling powder through the
sample cell of the laser diffraction system. In addition, nanocomposite particles were
placed on a glass slide and visualized by Axio Scope.A1 polarized light microscope
(Carl Zeiss Microscopy GmbH, Göttingen, Germany).
Images of as-received ITZ and milled F3 suspension were taken using a LEO
1530 SVMP (Carl Zeiss, Inc., Peabody, MA, USA) SEM. For dry as-received ITZ
particles, a carbon tape was placed on an SEM stub and then the particles were placed
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on top of the carbon tape. For F3 suspension, approximately 1.0 mL aliquot of the
suspension sample was diluted to 30 mL with deionized water, mixed for 30 s with a
vortex mixer, mounted on top of a silicon chip (Ted Pella Inc., Redding, CA, USA),
and then placed on a carbon specimen holder (Li et al., 2016c). This sample was
placed into a desiccator for overnight drying under vacuum condition. The final
samples were then sputter coated with carbon using BAL-TEC MED020 (BAL-TEC,
Balzers, Switzerland) to reduce possible charging during imaging.
2.1.5 Apparent Shear Viscosity, Density, and Zeta Potential of the Suspensions
The apparent shear viscosity of the milled suspensions was measured using R/S plus
rheometer (Brookfield Engineering, Middleboro, MS, USA) with a water jacket
assembly Lauda Eco (Lauda-Brinkmann LP, Delran, NJ, USA) (Afolabi et al., 2014).
A coaxial cylinder with jacketed setup was used to impart a controlled shear rate on
the samples from 0 to 1000 1/s in 60 s. The jacket temperature was kept constant at
25 ± 0.5 °C. The raw data were analyzed using the Rheo3000 software (Brookfield
Engineering, Middleboro, MA, USA). The viscosities of selected dispersant
(stabilizer) solutions were also measured as they are needed in wettability study. For
the 2.5% HPC SL–0.2% SDS sample with viscosity <10 cP, a rheometer with higher
sensitivity/accuracy (Kinexus Ultra Plus Rotational Rheometer, Malvern Panalytical,
Southborough, MA, USA) was used. 40 mm rotational parallel plates with 0.75 mm
gap were used to provide a controlled shear rate on the sample from 0 to 1000 1/s.
The simple power-law model was fitted to measured viscosity profiles of all
suspensions (Equation 2.1):
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 =  ( ) = a n−1

(2.1)

where η and  are the apparent shear viscosity and shear rate, respectively, while a
and n are the consistency index and power-law index, respectively. This model shows
that n = 1 represents Newtonian flow behavior, n ˂ 1 represents shear-thinning
(pseudoplastic) behavior, and n ˃ 1 represents shear-thickening (dilatant) behavior.
The density () was measured thrice by weighing a 60 mL glass cylinder filled with
the suspension and dividing by the volume.
Using a Delsa Nano C zeta potential analyzer (Delsa Nano C,
BeckmanCoulter, USA), zeta potentials of wet-milled ITZ particles and the milled
suspensions with 2.5% HPC SL, 2.5% HPC SL–0.2% SDS, and 4.5% HPC SL were
measured. The Delsa Nano C uses electrophoretic light scattering (ELS) for zeta
potential determination; electrophoretic movement of charged particles was
determined from the Doppler shift of scattered light under an applied electric field.
2.1.6 X-Ray Powder Diffraction (XRPD)
The crystallinity of as-received ITZ, physical mixture corresponding to F4
formulation, and F4–F8 nanocomposites was analyzed using PXRD (PANalytical,
Westborough, MA, USA), equipped with Cu Kα radiation (λ = 1.5406 Å). The
samples were scanned at a rate 0.165 s-1 for 2θ ranging from 5 to 40°. To detect
characteristic peaks more distinctly, another set of samples were prepared: wet-milled
suspensions were centrifuged (Compact II centrifuge, Clay Adams® Brand, Sparks,
MD, USA) at 3200 rpm for 90 min to separate the drug from the aqueous phase with
excess polymer. The resultant solid phase was redispersed in deionized water
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followed by another centrifugation. The final solid phase was overnight-dried in a
vacuum hood before XRPD analysis.
2.1.7 Thermal Characterization
Thermograms of a physical mixture corresponding to F4 formulation as well as F2
and F4–F8 nanocomposites were obtained by a Mettler–Toledo differential scanning
calorimeter (DSC) (PolyDSC, Columbus, OH, USA). About 6 mg sample was placed
in a sealed aluminum pan and loaded into the DSC. The samples were heated at a rate
of 10 °C/min from 25 °C to 220 °C. Nitrogen gas was used as the purge gas and
protective gas at a flow rate of 50 mL/min and 150 mL/min, respectively. Using the
integrated software (STARe 10), peak melting point temperature Tm and fusion
enthalpy ΔHm were determined. For the characterization of the residual water in the
spray-dried nanocomposites, thermogravimetric analysis (TGA) was performed using
a TGA/DSC1/SF Stare system (Mettler Toledo, Inc., Columbus, OH). About 6 mg of
F4/F8 nanocomposites was placed in a ceramic crucible and heated from 25 °C to
150 °C at a constant rate of 10 °C/min under nitrogen flow.
2.1.8 Drug Wettability
Drug wettability was investigated by analyzing the penetration rate of dispersant
solutions into a packed bed of ITZ particles inside a cylindrical column according to
the Washburn method (Hołownia et al., 2008; Washburn, 1921). An Attension Sigma
700 (Biolin Scientific, Linthicum, MD, USA) set-up was used. Experimental method
was adapted from Li et al. (2017), and readers are referred to Appendix A for details.
Dispersant concentrations in the solutions were identical to those in the respective
wet-milled suspensions in Table 2.1. The apparent shear viscosity η and surface
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tension γ of the liquids were measured using R/S Plus Rheometer (Brookfield
Engineering, Middleboro, MA, USA) and Attension Sigma 700 (Biolin Scientific,
Linthicum, MD, USA), respectively. Only for the solutions having viscosity <10 cP
(2.5% HPC SL, 4.5% HPC SSL and 4.5% PVP K30), η was measured using a
Kinexus Ultra Plus Rotational Rheometer (Malvern Panalytical, Southborough, MA,
USA). The ratio of the cosine of contact angles cosθds/cosθw that does not require a
separate measurement of the constant C was calculated using the modified Washburn
equation (Li et al., 2017). Here, θds and θw are the contact angles between ITZ and the
dispersant solutions and between ITZ and deionized water, respectively. This ratio or
its logarithmic value provides a rough measure of the drug wettability enhancement
upon use of various dispersants in water.
2.1.9 Redispersion of the Drug Nanocomposites
The redispersion of the spray-dried powders was performed following the method in
refs. (Bhakay et al., 2014a; Li et al., 2016b). About 0.5 g of nanocomposites was
weighed and dispersed in a 60 mL beaker containing 30 mL of 3 g/L aqueous SDS
solution (the same concentration as that of the dissolution medium) and stirred with a
paddle-stirrer (CAT R18, Scientific Instrument Center Limited, Winchester, UK) at
400 rpm for 60 min. ~0.5 mL aliquot of redispersed sample was taken at 2, 10 and 60
min while stirring, and particle size was measured using laser diffraction. A droplet
of each redispersion sample was dropped on a glass slide and dried immediately
using a hot air gun. The Zeiss Axio Scope.A1 polarizing microscope was used to
capture the image of the dried samples. 30 mL medium was selected purposefully so
that the dispersants can fully dissolve, while releasing the ITZ nanoparticles/clusters
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with minimal dissolution. Indeed, the maximum amount of ITZ that can dissolve is
small (e.g., 0.11% of ITZ in F3 nanocomposites).
2.1.10 Drug Content and Dissolution Performance of the Nanocomposites
Actual drug content of the nanocomposite powders was measured by assay testing.
100 mg of the spray-dried powders was dissolved in 20 mL dichloromethane (DCM),
sonicated for 50 min to ensure complete dissolution of ITZ, and then stored overnight
to settle any undissolved particles. An aliquot of 100 µl was taken from the
supernatant and diluted to 10 mL with DCM. The absorbance of all the samples was
measured at 260 nm wavelength via Ultraviolet (UV)-spectrophotometer (Agilent,
Santa Clara, CA, USA). Six replicates were tested for each formulation to calculate
mean drug content and percent relative standard deviation (RSD).
Dissolution of as-received ITZ and spray-dried ITZ nanocomposites was
performed via a Distek 2100C dissolution tester (North Brunswick, NJ, USA)
according to the USP II paddle method. The dissolution medium was 1000 mL SDS
buffer with 3.0 g/L concentration. This solution was selected because it provides a
good discrimination of ITZ release among the nanocomposite formulations (Azad et
al., 2016). The medium was maintained at 37 °C and stirred by a paddle at 50 rpm.
Nanocomposites, equivalent to a dose of 20 mg of ITZ, were added to the medium,
and 4 mL samples were taken manually at 1, 2, 5, 10, 20, 30, and 60 min. The
absorbance of dissolved ITZ was measured via UV-spectroscopy (Agilent, Santa
Clara, CA, USA) at 260 nm wavelength. Aliquots of the samples were filtered using a
0.1 µm PVDF membrane type syringe filter to avoid any effect of undissolved drug
during UV-spectroscopy. The medium solution without drug was used as the blank.
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The amount of drug dissolved was measured using a calibration curve generated from
drug concentration vs. absorbance (R2 = 0.9995 with p < 0.0001). ITZ release was
reported as a function of dissolution time for an average of six replicates. >80% drug
release in 20 min was regarded as a stringent criterion for immediate drug release
(Azad et al., 2016; Bhakay et al., 2014b).
ITZ dissolution data was fitted by Korsmeyer‒Peppas model (Ritger and
Peppas, 1987a, b):

M t M  = kt n

(2.2)

where k is a constant incorporating structural and geometric characteristics of the
drug dosage form, n is the release exponent, indicative of the drug release
mechanism, and Mt/M∞ is fractional drug release. While this model has been used to
assess drug release mechanisms, it was simply used as an empirical kinetic model
here because some of the assumptions behind the mechanistic model were not
satisfied, which may potentially confound the interpretation of the release
mechanisms. Since the drug release rate (d(Mt/M∞)/dt) is proportional to kn (Peppas,
1985), kn provides a quantitative measure for comparing initial release rates from
different dispersant formulations.
Dissolution profiles of all nanocomposites were compared to those of F3 and
F4 nanocomposites, separately, using difference (ƒ1) and similarity (ƒ2) factors
(Boateng et al., 2009; Costa and Lobo, 2001). ƒ1 values up to 15 (0‒15) and ƒ2 values
greater than 50 (50‒100) suggest statistical similarity of two profiles.
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2.2 Results and Discussion
2.2.1 Apparent Breakage Kinetics During Wet Media Milling
The ITZ suspensions with various dispersants listed in Table 2.1 were wet milled in a
stirred media mill. Figure 2.2 presents the temporal evolution of median particle size
d50 and 90% passing size d90 of the milled suspensions, while Table 2.2 presents d50
and d90 of the final (65 min) milled suspensions and their sizes after 7-day
refrigerated storage.

Figure 2.2 Temporal evolution of (a) median size d50 and (b) 90% cumulative
passing size d90 during the milling of ITZ suspensions with 0.2% SDS (F1), 2.5%
HPC SL (F2), 2.5% HPC SL–0.2% SDS (F3), 4.5% HPC SL (F4), 4.5% HPC SSL
(F5), 4.5% HPC L (F6), 4.5% HPMC E3 (F7), and 4.5% PVP K30 (F8), respectively.
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As-received ITZ particles (Figure 2.3) had d50: 15.5 µm and d90: 45.8 µm,
measured via Rodos/Helos laser diffraction system. When milled with 2.5% HPC
SL–0.2% SDS, the best stabilizing formulation in this study, d50 and d90 of ITZ
particles monotonically decreased and attained a limiting, plateau size at 0.17 and
0.24 µm, respectively (Figure 2.2). Figure 2.3a and 2.3b visually confirms the
dramatic size reduction during high energy wet stirred media milling, which allows
us to prepare ~230 g ITZ nanosuspension within 65 min vs. ~8 g ITZ suspension in
several days by ball milling in a vial (Choi et al., 2008). Qualitative similarity
between the particle sizes observed in Figure 2.3b and laser diffraction measurement
signifies minimal aggregation in this suspension due to effective stabilization.
During wet media milling, two mechanisms act simultaneously: breakage of
the drug particles, fragments of already broken particles as well as aggregates
(deaggregation) and aggregation of the particles (Bilgili et al., 2004; Choi et al.,
2008; Sommer et al., 2006). The PSD and characteristic particle sizes like d50 and d90
evolve in accordance with the competition between the rates of these two opposing
mechanisms, i.e., breakage and aggregation. The monotonic decrease in particle size
for 2.5% HPC SL–0.2% SDS suggests that breakage was the dominant mechanism
during the milling owing to efficient stabilization. On the contrary, aggregation of
ITZ particles was the dominant mechanism during the milling with 0.2% SDS and
4.5% PVP, and d50 and d90 either changed in a non-monotone fashion or even
increased (Figure 2.2). Such interesting size increase and non-monotone behavior
were also observed in previous wet media milling studies where either poor
stabilization with dispersants occurred or no stabilizers were used (Bhakay et al.,
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2011; Bilgili and Afolabi, 2012). Previous studies (Bhakay et al., 2011; Monteiro et
al., 2013) reported that primary drug nanoparticles, which were examined by SEM
imaging, were produced by wet media milling even in the absence of dispersants,
while large aggregates formed in the suspensions were measured by laser diffraction.
For suspensions with other dispersants, the aggregation appeared to be slower than
the breakage, and d50 and d90 decreased in time, but all suspensions showed varying
extent of aggregation depending on the dispersant used (Figure 2.2). Without SDS,
only 4.5% HPC (any grade) could ensure a d90 below 1 m. It should be noted that
suspensions may undergo additional aggregation during the storage, which is
discussed below.

Figure 2.3 SEM images of ITZ particles: (a) before milling (marker size: 2 µm, 2
K× magnification) and (b) after milling (F3, 2.5% HPC SL–0.2% SDS) (marker size:
200 nm, 30 K× magnification).
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2.2.2 Stabilization Mechanisms
Let us now examine the impact of dispersants on the final milled particle sizes and
their 7-day stability (Table 2.2). When 0.2% SDS (an anionic surfactant) was used as
a stabilizer, an aggregated, coarse suspension with d50: 11.4 µm was formed.
Apparently 0.2% SDS was not sufficient to provide strong electrostatic stabilization,
and it also imparted lowest wettability enhancement among all the dispersants studied
(Table 2.3). The use of 2.5% HPC SL led to submicron median size in the final
suspension with d90: 1.82 µm, which could be explained by the adsorption of HPC on
ITZ particles and ensuing steric stabilization (Choi et al., 2008) and slow-down of
aggregation during milling. However, 2.5% HPC SL was not sufficient to prevent
further aggregation that results from Brownian motion during the storage, and ITZ
particle size dramatically increased over 7-day storage (Figure 2.4). Other
suspensions did not exhibit such a drastic change in particle size upon 7-day storage.
Zeta potentials of the wet-milled ITZ particles, the milled ITZ suspensions with 2.5%
HPC SL and 4.5% SL were measured to be 0.25, –2.2, and 0.34 mV, respectively.
Overall, the electrostatic charge of the ITZ particles in the milled suspensions was
very low: nearly neutral particles within experimental accuracy. Considering that
even short-term stability requires an absolute value of zeta potential greater than 20
mV (Lakshmi and Kumar, 2010; Riddick, 1968), steric stabilization appears to be the
dominant stabilization mechanism upon use of the polymeric dispersants in this study.
An increase in HPC SL concentration from 2.5% to 4.5% likely allowed for greater
HPC adsorption and formation of a thicker polymer layer on ITZ particles, which
reduced aggregation potential of colliding particles. Adsorption of cellulosic
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polymers (HPMC and HPC) onto drug nanoparticles are known to follow Langmuir
or Freundlich adsorption isotherms (Bilgili and Afolabi, 2012; Knieke et al., 2013),
which display greater adsorption at higher polymer concentration in the bulk solution.
In addition, significant wettability enhancement upon use of HPC SL (Table 2.3)
could have facilitated deaggregation during the milling. Overall, the use of 4.5% HPC
SL largely mitigated aggregation and led to formation of a relatively stable
suspension over 7 days (Figure 2.4).
As compared with 4.5% HPC SL suspension, 4.5% HPMC E3 and 4.5% PVP
K30 suspensions had larger ITZ aggregates, which could be explained by lower
extent of polymer adsorption onto ITZ particles and ensuing poorer steric stabilizing
action by the respective polymers. In fact, adequate stabilization of wet-milled ITZ
suspensions required the use of 0.05%–0.2% SDS when HPMC E3 was used (Azad et
al., 2016). Besides, while 4.5% PVP K30 has slightly higher MW (50 kg/mol) than
4.5% HPC SSL (40 kg/mol), its stabilizing capability was inferior to HPC SSL,
which suggests that the ITZ–specific polymer interaction through their functional
groups determine the extent of polymer adsorption and modulate steric stabilization
(Choi et al., 2008). While polymer adsorption on ITZ particles was not studied here,
our results suggest that HPC appears to be a better steric stabilizer than PVP and
HPMC.
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Figure 2.4 Volume-based particle size statistics of the ITZ suspensions with 0.2%
SDS (F1), 2.5% HPC SL (F2), 2.5% HPC SL–0.2% SDS (F3), 4.5% HPC SL (F4),
4.5% HPC SSL (F5), 4.5% HPC L (F6), 4.5% HPMC E3 (F7), and 4.5% PVP K30
(F8) after milling (65 min) and 7-day storage at 8 °C: (a) Median particle size d50 and
(b) 90% cumulative passing size d90.
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Table 2.2 Particle Size Statistics of the Drug Suspensions After Milling and 7-day Storage and Those of the Spray-dried
Nanocomposites
Formulation Suspension
ID
composition a

F1
F2
F3
F4
F5
F6
F7
F8
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a

0.2% SDS
2.5% HPC SL
2.5% HPC SL–0.2% SDS
4.5% HPC SL
4.5% HPC SSL
4.5% HPC L
4.5% HPMC E3
4.5% PVP K30

Particle size of the
suspensions after milling
(µm)
d50±SD
d90±SD
11.4±0.44 28.5±0.57
0.27±0.02 1.82±0.04
0.17±0.00 0.24±0.00
0.20±0.00 0.32±0.00
0.24±0.01 0.44±0.02
0.19±0.00 0.25±0.00
0.32±0.02 1.73±0.09
3.25±0.47 11.1±3.92

Particle size of the
suspensions after 7 days
(µm)
d50±SD
d90±SD
5.32±0.10
17.4±0.41
8.23±0.02
53.5±2.40
0.17±0.00
0.24±0.00
0.21±0.00
0.34±0.01
0.26±0.00
0.50±0.02
0.20±0.01
0.31±0.00
0.35±0.00
1.64±0.02
3.33±0.20
8.24±1.08

All suspensions have 10% ITZ. %w/w is with respect to the weight of deionized water (200g).
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Nanocomposite particle
size (µm)
d50±SD
8.43±1.18
13.9±0.04
11.3±0.26
16.2±0.01
14.0±0.11
23.5±0.18
17.7±0.10
15.2±0.11

d90±SD
18.7±1.80
26.4±0.11
21.2±0.33
32.3±0.17
29.4±0.06
49.2±0.67
39.8±0.12
27.9±0.21

Table 2.3 Wetting Effectiveness Factor Calculated Using the Modified Washburn Method for Various ITZ–stabilizer Solution
Pairs
Formulation of the
stabilizer solutiona
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Water
0.2% SDS
2.5% HPC SL
2.5% HPC SL–0.2% SDS
4.5% HPC SL
4.5% HPC SSL
4.5% HPC L
4.5% HPMC E3
4.5% PVP K30

R2

Slope
(g2/s)
-06

6.47×10
1.20×10-03
5.00×10-04
8.00×10-04
2.20×10-03
5.10×10-03
1.40×10-03
3.40×10-03
3.20×10-03

(-)
0.995
0.999
0.999
0.999
0.999
0.999
0.998
0.999
0.998

Viscosity
η(cP)
0.89b
0.94c
4.59
17.4
13.4
4.13
24.3
6.10
1.66

a

%w/w is with respect to the weight of deionized water.
Taken from ref. (Korson et al., 1969).
c
Taken from ref. (Kushner et al., 1952).
b
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Density
ρ (g/mL)
1.00
1.00
1.01
1.03
1.01
1.00
1.02
1.01
1.01

Surface
tension
γ (mN/m)
70.8
32.8
42.4
38.2
42.3
43.0
41.8
42.8
50.7

log
(cosθds/cosθw)
(-)
0
2.69
2.81
3.63
3.92
3.78
3.98
3.77
3.10

The combination of 2.5% HPC SL and 0.2% SDS led to the finest ITZ
particles and a 7-day stable suspension. HPC–SDS provides synergistic stabilization
during milling and storage for a multitude of BCS Class II drugs due to combined
electrostatic stabilization (zeta potential of –9.7 mV) by negatively charged SDS and
steric stabilization by adsorbed HPC, i.e., electrosteric stabilization (Bilgili and
Afolabi, 2012; Bilgili et al., 2016; Peltonen and Hirvonen, 2010; Shete et al., 2016)
besides wettability enhancement of the lipophilic drug (see Table 2.3) and associated
deaggregation effectiveness provided by the combination (Li et al., 2018a). The
significantly higher wetting enhancement ratio for 2.5% HPC SL–0.2% SDS as
compared with 0.2% SDS and 2.5% HPC SL (Table 2.3) corroborates the synergy.
Such synergistic effects have been reported previously (Basa et al., 2008; Lee et al.,
2008; Ryde and Ruddy, 2002). HPC and SDS interact, forming aggregates or micellelike SDS clusters bound to HPC (Winnik and Winnik, 1990). The formation of such
clusters could be deduced from the higher viscosity of 2.5% HPC SL–0.2% SDS
aqueous solution than those of 0.2% SDS and 2.5% HPC SL aqueous solutions
(Table 2.3). These clusters can co-adsorb on particle surfaces (Berglund et al., 2003a,
b; Evertsson and Nilsson, 1997), potentially facilitating adsorption of HPC (Cerdeira
et al., 2010) and enabling electrosteric stabilization. It should be noted that in the
absence of SDS, only HPC SL/L led to stable particle sizes close to those of the
HPC–SDS combination (Figure 2.4).
A comparison of the final milled particle sizes (Table 2.2) for suspensions
with SSL, SL, and L grades of 4.5% HPC with 40, 100, and 140 kg/mol MW,
respectively, suggests that higher MW HPC led to finer and more stable ITZ
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suspensions. The apparent breakage was faster for the higher MW HPC than lower
MW (Figure 2.2) because the rate of aggregation was slower in higher MW HPC.
These findings suggest higher MW HPC is more effective for the stabilization of ITZ,
which is in contrast with ref. (Choi et al., 2008). The authors of ref. (Choi et al.,
2008) highlight a thermodynamic consideration that polymers of higher MW have
less entropy loss related to their freedom of motion, which results in a higher affinity
to the drug surface and thus stronger adsorption and slower desorption (Morrison and
Ross, 2002; Ploehn and Russel, 1990). Therefore, according to this thermodynamic
consideration, a polymer with higher MW should provide better stabilization, which
is contrary to the findings in ref. (Choi et al., 2008), but in line with our study. As
argued in Introduction, unfortunately, studies like (Choi et al., 2008; Sepassi et al.,
2007) that used low-energy mills do not truly reflect the impact of different polymers
or MW on steric stabilization and reduction of drug aggregate formation. The use of
higher MW polymer and/or higher polymer concentration causes more pronounced
viscous dampening (Bilgili and Afolabi, 2012), which slows down the breakage in
low-energy mills more profoundly than in high-energy mills. Hence, such studies
drew somewhat confounded conclusions about the impact of polymer MW due to
pronounced impact of viscous dampening. Not only did high-energy, wet stirred
media milling enabled faster production of ITZ nanoparticles than low energy mills
used in ref. (Choi et al., 2008) for ITZ–HPC, but also it allowed us to elucidate the
role of polymer MW in stabilization of drug nanoparticles, which in line with the
thermodynamic consideration of polymer adsorption.
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2.2.3 Rheology of the Milled Suspensions
To further assess the aggregation state of the precursor suspensions, rheological
characterization of the ITZ suspensions was performed as an orthogonal
characterization method, similar to (Azad et al., 2015a; Li et al., 2018a). Figure 2.5
illustrates the apparent shear viscosity profiles of the milled suspensions. The powerlaw model was fitted to the apparent shear viscosity profiles, and the fitted
consistency index a, power-law index (n), and R2 values are reported in Table 2.4.
The p-values for the model fit and the estimated parameters are less than 0.05 and R2
values are in the range of 0.94–0.99, which suggest that overall the power-law model
fitted the data fairly well and both the model and its parameters were statistically
significant. Milled ITZ suspensions that had high extent of aggregation, as revealed
by laser diffraction measurement results (see Table 2.2), exhibited pronounced
pseudoplastic behavior, as shown by the sharp decrease in viscosity with an increase
in shear rate (Figure 2.5), n < 1 (~0.2–0.3), and high a values (Azad et al., 2015a; Li
et al., 2018a). The milled suspensions with smaller aggregates (HPC SL/L) exhibited
slight pseudoplasticity, tending toward near-Newtonian behavior (n ~0.9–1).
Suspensions with higher HPC MW had smaller aggregates and displayed less
pseudoplasticity (higher n and lower a). During the rheological characterization,
suspension samples were subjected to increasing shear rate, and any aggregates
present were deaggregated upon an increase in shear rate (Barthelmes et al., 2003;
Bernhardt et al., 1999). Usually, aggregates occlude liquid in their void spaces, which
raises the effective volume fraction of the solid in a suspension with fixed solids
amount. Hence, deaggregation during the characterization upon an increase in shear
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rate reduces the apparent shear viscosity (pseudoplasticity), and this effect was more
pronounced for suspensions that exhibited a higher extent of aggregation. Overall, the
rheological characterization supports our earlier finding that higher MW HPC is more
favorable for ITZ stabilization because smaller aggregates formed during the milling,
which led to less remarkable pseudoplasticity for the respective suspensions.

Figure 2.5 Semi-log plots for apparent shear viscosity vs. shear rate of the milled
ITZ suspensions with 0.2% SDS (F1), 2.5% HPC SL (F2), 2.5% HPC SL–0.2% SDS
(F3), 4.5% HPC SL (F4), 4.5% HPC SSL (F5), 4.5% HPC L (F6), 4.5% HPMC E3
(F7), and 4.5% PVP K30 (F8), respectively.
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Table 2.4 Power-law Model Parameters Obtained from Fitting the Apparent Shear
Viscosity Profiles of Various Milled ITZ Suspensions
Formulation
ID
F1
F2
F3
F4
F5
F6
F7
F8
a

Suspension composition a

n (-)

a (cP.sn)

R2 (-)

0.2% SDS
2.5% HPC SL
2.5% HPC SL–0.2% SDS
4.5% HPC SL
4.5% HPC SSL
4.5% HPC L
4.5% HPMC E3
4.5% PVP K30

0.33
0.30
0.90
0.91
0.84
1.05
0.24
0.30

2230
3180
9.80
41.1
44.0
14.4
6620
2960

0.974
0.989
0.950
0.954
0.984
0.940
0.994
0.988

All suspensions have 10% ITZ. %w/w is with respect to the weight of deionized water (200g).

2.2.4 Properties of the ITZ Nanocomposites
The milled ITZ suspensions were spray-dried to prepare nanocomposites using a cocurrent spray dryer. High ITZ loaded nanocomposites (60–78%) were produced via
spray-drying (Table 2.1), and most of the nanocomposites had higher ITZ loading
than those reported earlier (Azad et al., 2016; De Smet et al., 2014; Parmentier et al.,
2017; Sarnes et al., 2014; Van Eerdenbrugh et al., 2008d). All nanocomposites had
RSDs less than 6.0%, suggesting pharmaceutically acceptable content uniformity.
There was a slight variation in the theoretical and actual drug content, which can be
attributed to preferential drug loss during handling/transfer after milling, poor
separation of finer particles in the cyclone of the spray drier, and presence of some
residual moisture after drying (Azad et al., 2015b). By measuring weight loss of the
selected nanocomposites (F4 and F8) via TGA, mean moisture contents were
determined. F4 and F8 nanocomposites had a residual moisture content of 2.1 ± 0.2%
w/w and 1.8 ± 0.3% w/w, respectively, which confirms removal of most of the water
from the milled suspensions during spray drying.
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The optical microscope images (Figure 2.6) illustrate that rounded and nearly
spherical nanocomposite particles were formed upon spray drying. The characteristic
sizes of the nanocomposite particles, as measured by laser diffraction, display few
trends (see Table 2.2). First, a comparison of F1–F3 nanocomposites to F4–F8
nanocomposites suggests that the lower dispersant loading led to smaller
nanocomposites. Formation of coarser nanocomposites upon use of higher dispersant
loading was also observed in previous spray drying studies (Sun et al., 2015;
Vatanara, 2015). For different grades of 4.5% HPC, the nanocomposites with a higher
MW HPC had larger particles, especially for HPC L grade. Among F4–F8
nanocomposites with 4.5% polymer (identical dispersant and total solids loading), the
median sizes did not vary greatly (14–18 µm), with the exception for HPC L having
the highest MW (24 µm).
In DSC thermograms, the physical mixture with F4 formulation (10% ITZ–
4.5% HPC SL) and the nanocomposites exhibited a distinguished endothermic peak
correspond to the melting of ITZ (Figure 2.7). The melting point temperature Tm and
the fusion enthalpy ΔHm were lower for the nanocomposites than for the physical
mixture. The observed reduction in Tm and ΔHm is most likely due to defect
formation and accumulation during milling (Azad et al., 2015b; Monteiro et al.,
2013). Moreover, according to Gibbs‒Thomson equation (Wu and Nancollas, 1998),
the melting temperature of a material is proportional to its cohesive energy, which
indicates that nanoparticles with reduced cohesive energy require less energy for
melting, thus, exhibiting lower Tm and ΔHm as compared to as-received
microparticles. The reduction in Tm and ΔHm was more pronounced for HPMC E3
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and PVP K30, which might be due to some amorphization on the surface of the drug
particles and suppressed recrystallization during drying in the presence of these
polymers. Kayaert and Mooter (Kayaert and Van den Mooter, 2012) also reported
similar amorphization on the surface of drug nanoparticles during drying, depending
on the drug–polymer interaction.

Figure 2.6 Optical microscope images of the nanocomposites prepared from the
milled ITZ suspensions with (a) 2.5% HPC SL (F2), (b) 2.5% HPC SL–0.2% SDS
(F3), (c) 4.5% HPC SL (F4), (d) 4.5% HPC SSL (F5), (e) 4.5% HPC L (F6), (f) 4.5%
HPMC E3 (F7), and (g) 4.5% PVP K30 (F8), respectively. The marker size is 20 µm
in all images.
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In DSC thermograms, the physical mixture with F4 formulation (10% ITZ–
4.5% HPC SL) and the nanocomposites exhibited a distinguished endothermic peak
correspond to the melting of ITZ (Figure 2.7). The melting point temperature Tm and
the fusion enthalpy ΔHm were lower for the nanocomposites than for the physical
mixture. The observed reduction in Tm and ΔHm is most likely due to defect
formation and accumulation during milling (Azad et al., 2015b; Monteiro et al.,
2013). Moreover, according to Gibbs‒Thomson equation (Wu and Nancollas, 1998),
the melting temperature of a material is proportional to its cohesive energy, which
indicates that nanoparticles with reduced cohesive energy require less energy for
melting, thus, exhibiting lower Tm and ΔHm as compared to as-received
microparticles. The reduction in Tm and ΔHm was more pronounced for HPMC E3
and PVP K30, which might be due to some amorphization on the surface of the drug
particles and suppressed recrystallization during drying in the presence of these
polymers. Kayaert and Mooter (2012) also reported similar amorphization on the
surface of drug nanoparticles during drying, depending on the drug–polymer
interaction.
XRPD diffractograms (Figure 2.8a) illustrate distinct, sharp peaks for asreceived crystalline ITZ vs. lack of peaks for the (amorphous) polymers. Regardless
of the preparation procedure, milled ITZ suspensions after drying exhibited the same
peaks as those of the as-received ITZ and the physical mixture with F4 formulation
(10% ITZ–4.5% HPC SL) (Figure 2.8b and 2.8c). However, the peak intensities were
reduced along with broadening after milling–drying, which could be attributed to the
smaller drug particle sizes and high stresses imparted by the milling process (Van
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Eerdenbrugh et al., 2008d) and coverage of ITZ by the polymeric matrix. Similar
observations were reported for loviride nanoparticles (Van Eerdenbrugh et al., 2007).
Removal of excess polymer in the milled suspensions by centrifugation followed by
drying led to slightly sharper peaks with higher intensity, signifying the role of the
excess polymer (Figure 2.8c vs. Figure 2.8b). Overall, XRPD and DSC results
together suggest that the crystalline nature of ITZ was preserved after milling and
drying despite the formation of defects and potentially small fraction of amorphous
drug.

Figure 2.7 DSC thermograms of as-received ITZ, physical mixture of F4 (blend of
10% ITZ–4.5% HPC SL), as well as the nanocomposites prepared via spray-drying of
the milled ITZ suspensions with 2.5% HPC SL (F2), 4.5% HPC SL (F4), 4.5% HPC
SSL (F5), 4.5% HPC L (F6), 4.5% HPMC E3 (F7), and 4.5% PVP K30 (F8),
respectively.
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Figure 2.8 XRD diffractograms of (a) as-received ITZ, HPC SL, HPMC E3, and
PVP K30; (b) physical mixture of F4 (blend of 10% ITZ–4.5% HPC SL) and spraydried milled ITZ suspensions with 4.5% HPC SL (F4), 4.5% HPC SSL (F5), 4.5%
HPC L (F6), 4.5% HPMC E3 (F7), and 4.5% PVP K30 (F8); and (c) physical mixture
of F4 (blend of 10% ITZ–4.5% HPC SL) and centrifuged–oven-dried milled ITZ
suspensions with 4.5% HPC SL (F4), 4.5% HPC SSL (F5), 4.5% HPC L (F6), 4.5%
HPMC E3 (F7), and 4.5% PVP K30 (F8).
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2.2.5 Redispersibility of the Nanocomposites
Figure 2.9 presents the characteristic particle sizes after 2 min, 10 min, and 60 min
redispersion of the nanocomposites in the redispersion medium as well as the particle
sizes of the ITZ suspensions after milling and one-day storage (prior to spray-drying).
Figure A3 of Appendix A presents the optical microscope images of the abovementioned redispersed samples. Ideally, during the redispersion test, the dispersant
(polymeric) matrix should erode fast while dissolving in water and release the ITZ
particles/clusters. Note that the dissolution of ITZ particles was negligible during the
redispersion test by design, unlike that in dissolution testing. The nanocomposite
particles with 2.5% HPC SL, 4.5% HPC SSL, 4.5% HPMC E3, and 4.5% PVP K30
did not erode at all or eroded extremely slowly, keeping their large size and
morphology intact during the 60 min redispersion (Figure 2.9 and Figure A3). These
dispersants all had MW  50 kg/mol. Only the nanocomposites with 4.5% HPC (SL/L
grades with 100/140 kg/mol MW) and 2.5% HPC–0.2% SDS exhibited fast erosion
and recovered ITZ nanoparticles/clusters. The optical microscope images in Figure
A3 qualitatively support the redispersion behavior quantified by the laser diffraction
results. When redispersion was slow and incomplete, the rounded/spherical
nanocomposite particles appeared in the images even after 60 min, whereas fast
redispersion was associated with complete erosion of the nanocomposite matrix,
leading to disappearance of the nanocomposite particles in the images.
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Figure 2.9 Volume-based particle size statistics of the ITZ suspensions after milling
(65 min), before spray drying (after 1 day of milling), and the nanocomposites
redispersed in 3 g/L SDS solution for 2 min, 10 min, and 60 min: (a) Median particle
size d50 and (b) 90% passing size d90. Suspension formulations contain 2.5% HPC
SL(F2), 2.5% HPC SL–0.2% SDS (F3), 4.5% HPC SL (F4), 4.5% HPC SSL (F5),
4.5% HPC L (F6), 4.5% HPMC E3 (F7), and 4.5% PVP K30 (F8).

An interesting question arises as to how hydrophilic and freely water-soluble
dispersants used in this study could not achieve fast redispersion for all
nanocomposite formulations. Indeed, according to the modified Washburn
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experiments (see Figure A1 of Appendix A), the polymeric dispersant solutions
penetrated into pores of a packed ITZ bed much faster than water and improved ITZ
wettability drastically as per higher values of the wetting effectiveness factor, i.e.,
log(cosθds/cosθw) (Table 2.3). Accordingly, upon use of dispersants in the
nanocomposites, one would expect that (i) the redispersion/dissolution medium could
penetrate into the pores of the nanocomposite particles generated upon dissolution of
the water-soluble dispersants fast and (ii) any ITZ aggregates released from the
nanocomposites could redisperse/dissolve in the redispersion/dissolution medium.
However, the redispersion tests (see Figure 2.9) suggest that the significant
wettability enhancement upon use of dispersants observed in the modified Washburn
experiments (Table 2.3) did not translate into fast redispersion of the nanocomposites
and fast recovery of the ITZ nanoparticles for some dispersants. For example, while
the use of dispersants with high log(cosθds/cosθw) in the nanocomposites led to
recovery of ultrafine particles during the redispersion (e.g., 2.5% HPC SL–0.2%
SDS), this was not the case for 4.5% HPC SSL.
In the Washburn method, a polymeric dispersant solution penetrated through
the void space of packed ITZ particles, whereas in the redispersion test, the polymeric
solution is expected to locally form around the nanocomposite upon dissolution of the
polymeric matrix. It is likely that the polymer at the surfaces of the nanocomposite
particles with 2.5% HPC SL, 4.5% HPC SSL, 4.5% HPMC E3, and 4.5% PVP K30
did not locally dissolve to provide the “theoretical” wettability enhancement. Since
ITZ is a highly hydrophobic drug, which is indicated by the log-partition coefficient
(logP) value of 8.5 (Van Eerdenbrugh et al., 2008b), and it comprises 60%–78% of
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the nanocomposites, the nanocomposite surface could be hydrophobic despite the
presence of hydrophilic dispersants especially if the drug nanoparticles are not welldispersed in the polymeric dispersant matrix due to formation of aggregates. Note that
the aforementioned nanocomposites had aggregated ITZ particles that were already
formed in the precursor suspensions during milling–storage (Figure 2.9) and that were
likely formed during the drying (for 4.5% HPC SSL). Aggregation of drug
nanoparticles during drying have been reported by other researchers (Li et al., 2016c;
Van Eerdenbrugh et al., 2008b): when used at insufficiently low concentration,
dispersants (e.g., 2.5% HPC SL) could not provide a sufficient physical barrier
between drug nanoparticles and their existing aggregates, and larger clusters,
sometimes called agglomerates or hard aggregates, can form (Li et al., 2016c; Van
Eerdenbrugh et al., 2008b). Although the exact mechanism leading to nanoparticle
aggregation during drying is unknown (Van Eerdenbrugh et al., 2008b), the capillary
pressure theory suggests that aggregation is due to the capillary forces encountered
during the drying process (Wang et al., 2005); others attributed aggregation to
polymer chain entanglement and/or potential micro-phase separation of polymeric
stabilizer from particles upon increase in particle concentration with reduced water
content (Kim and Lee, 2010; Lee et al., 2009; Vehring, 2008). In summary, the
aggregates of hydrophobic ITZ particles on the surface of the nanocomposites appear
to have prevented solubilization of the polymer, thus negating any potential
wettability improvement thereupon, and leading to negligible/slow erosion. The
nanocomposites with 4.5% HPC (SL/L grades with 100/140 kg/mol MW) and 2.5%
HPC–0.2% SDS did not have small aggregates in the precursor suspensions; hence, it
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is expected that the hydrophobic ITZ nanoparticles/aggregates were well-dispersed in
the hydrophilic polymeric matrix, and the matrix wetted and eroded fast upon contact
with the aqueous media, thus releasing the ITZ nanoparticles fast.
2.2.6 ITZ Dissolution Enhancement
The dissolution profiles of the as-received ITZ, the physical mixture of formulation
F4, and the nanocomposites with various dispersants are presented in Figures 2.10
and 2.11. The p-values for the Korsmeyer–Peppas model fit and the estimated
parameters are less than 0.05, and R2 values are in the range of 0.92–0.99 (Table 2.5),
both of which suggest that overall the model fitted the data fairly well and both the
model and its parameters were statistically significant. The kn value was used to
compare initial dissolution rates of various nanocomposites, while >80% ITZ release
in 20 min was used as the main discriminating criterion for immediate release. The
f1–f2 statistics suggest that the dissolution profiles of F3 and F4 nanocomposites were
similar; all dissolution profiles were statistically different from those of F3 and F4
nanocomposites (Section A.4 of Appendix A).
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Table 2.5 Korsmeyer‒Peppas Model Parameters Obtained From Fitting the
Dissolution Data

a

Formulation Formulation
ID a
composition b

Korsmeyer‒Peppas model

F1
F2
F3
F4
F5
F6
F7
F8

0.47
0.50
0.30
0.23
0.42
0.35
0.37
0.54

n
(-)

0.2% SDS
2.5% HPC SL
2.5% HPC SL–0.2% SDS
4.5% HPC SL
4.5% HPC SSL
4.5% HPC L
4.5% HPMC E3
4.5% PVP K30

k
-n
(%min )
7.67
6.15
48.2
49.1
14.2
30.4
17.6
10.7

R2
(-)
0.963
0.992
0.929
0.942
0.978
0.923
0.982
0.952

kn
-n
(%min )
3.59
3.08
14.4
11.1
5.96
10.6
6.55
5.71

Formulation is labeled based on the composition of the respective milled ITZ suspension formulation.
All precursor suspensions have 10% ITZ. w/w is w.r.t. the weight of deionized water (200 g).

b

2.2.6.1 General Trends.

Figure 2.10 shows that only 7.3% of as-received ITZ

was released (dissolved) after 60 min. The slow ITZ dissolution was due to low
surface area of as-received, coarse ITZ crystals (d50: 15.5 µm) and lipophilic nature of
ITZ. The nanocomposites produced by spray drying of wet-milled ITZ suspensions
led to significantly higher ITZ dissolution for any dispersant used as compared with
as-received ITZ (Figures 2.10 and 2.11). Considering that only limited dissolution
improvement was observed for a physical mixture of as-received, coarse ITZ
particles–4.5% HPC SL, it is evident that ultrafine ITZ particles in the form of
nanoparticles and, to some extent, their aggregates (refer to Table 2.2) present in a
hydrophilic nanocomposite matrix, account for the significant dissolution rate
enhancement. In general, the nanocomposites that exhibited fast erosion and
redispersion (Figure 2.9) of the polymeric matrix released ITZ faster as compared
with those that exhibited slow redispersion (Figures 2.10 and 2.11), which originated
from the presence of aggregates in the respective nanocomposites. It is also important
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to note that the redispersion of the nanocomposites with any dispersant formulation is
expected to be faster in the dissolution test than in the redispersion test because the
ITZ particles on the surface of the nanocomposites can dissolve in the dissolution test
with 1000 mL medium, thus facilitating the redispersion. This explains why >75% of
ITZ dissolved from the nanocomposites with 4.5% HPC SSL/HPMC E3/PVP K30 at
60 min (Figure 2.11) despite their slow erosion during 60 min redispersion test
(Figure 2.9).

Figure 2.10 Drug dissolution from the nanocomposites prepared via spray-drying of
the milled ITZ suspensions with 0.2% SDS (F1), 2.5% HPC SL (F2), 2.5% HPC SL–
0.2% SDS (F3), and 4.5% HPC SL (F4) as well as from physical mixture of
formulation F4 (blend of 10% ITZ–4.5% HPC SL) and as-received ITZ.
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Figure 2.11 Drug dissolution from the nanocomposites prepared via spray-drying of
the milled ITZ suspensions with 4.5% concentration of HPC SL (F4), HPC SSL (F5),
HPC L (F6), HPMC E3 (F7), and PVP K30 (F8) as well as from as-received ITZ.

While the ITZ particle size in the nanocomposites is clearly a dominant factor
in ITZ dissolution enhancement, a question arises as to whether nanocomposite
particle size (refer to Table 2.2) can significantly affect the dissolution results. Note
that 0.2% SDS nanocomposites (smallest nanocomposites) and 4.5% HPC L (biggest
nanocomposites) exhibited one of the slowest (kn = 3.59 %min-0.47) and the fastest
ITZ release (kn = 10.6 %min-0.35), respectively, among all nanocomposites, contrary
to what one would expect if the nanocomposite particle size itself is a dominant factor
for ITZ release. To answer this question more precisely, we also spray-dried the
milled 4.5% HPC SL suspension (F4) using a larger nozzle tip opening (1.2 mm vs.
0.6 mm) at lower atomization pressure (1.5 bar vs. 2.0 bar) as compared with the
baseline drying conditions. The so-formed nanocomposite particles were coarser (d50:
20.7 µm and d90: 40.6 µm) than the baseline 4.5% HPC SL nanocomposites (d50: 16.2
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µm and d90: 32.3 µm), both having identical dispersant formulation. The dissolution
profiles (see Figure A.2 of Appendix A) indicate that despite ~30% increase in d50
and d90, there is no statistically significant impact of the nanocomposite particle size
on ITZ release (ƒ1 = 0.93 and ƒ2 = 91.8) within the particle size range studied. Hence,
while there may be some confounding effect of the nanocomposite particle size, it is
expected

that

the

milled

ITZ

(aggregate)

particle

size

and

dispersant

type/concentration have more dominant effects on the drug release.
2.2.6.2

Impact of Various Dispersants.

Figure 2.10 shows that the

nanocomposites with 0.2% SDS and 2.5% HPC SL released 48.1% and 49.2% of ITZ
at 60 min, respectively. However, the drug release from both nanocomposites was
still slow and immediate release (>80% in 20 min) was not achieved. On the other
hand, immediate release was achieved when combination of HPC and SDS (F3) or
higher concentration of HPC SL (F4) was used. In fact, the dissolution profile of
4.5% HPC SL formulation is statistically similar to that of 2.5% HPC–0.2% SDS,
which suggests the feasibility of preparing an equivalent surfactant-free
nanocomposite. The dispersants were ranked-ordered based on the initial ITZ release
rates, quantified by kn, as follows: 2.5% HPC–0.2% SDS > 4.5% HPC SL > 0.2%
SDS > 2.5% HPC SL. These results can be explained by the faster redispersion
behavior of the 4.5% HPC SL and 2.5% HPC–0.2% SDS nanocomposites and the
smaller aggregate sizes in the respective milled/stored precursor suspensions.
Figure 2.11 compares the ITZ release from the nanocomposites prepared with
4.5% polymer alone in the milled suspensions. The nanocomposites were rankedordered based on ITZ release in 20 min as follows: HPC SL  HPC L > PVP K30 >
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HPMC E3 > HPC SSL. Only HPC SL/L grades with 100 kg/mol and 140 kg/mol
MW, respectively, achieved immediate release because they had small aggregates in
their precursor suspensions and exhibited faster redispersion than the other polymers
and HPC SSL (Figure 2.9). These observations for HPC were also confirmed by the
kn values of the respective nanocomposites: HPC SL > HPC L > HPMC E3 > HPC
SSL > PVP K30. It appears that there is an optimum HPC MW for the fastest ITZ
release. Although the precursor suspension with HPC L had slightly smaller
aggregates than that with HPC SL, the former exhibited slower ITZ release perhaps
due to slower redispersion (see Figure 2.9). This may also be partly explained by the
confounding effect of the nanocomposite particle size as HPC L nanocomposites
were the biggest among all. The nanocomposites with low MW polymers, i.e., HPC
SSL (40 kg/mol), PVP K30 (50 kg/mol), and HPMC E3 (10 kg/mol) exhibited slower
ITZ release than HPC SL/L because of the large aggregates formed during milling,
storage, and drying and the ensuing slower redispersion (Figure 2.9). Finally, the
lowest extent of ITZ release at 20 and 60 min with HPC SSL could be related to
formation of hard aggregates during drying, slow redispersion of the nanocomposites,
and slow deaggregation of the hard ITZ aggregates in the dissolution medium (Li et
al., 2016c). While the precursor suspension with PVP K30 had large ITZ aggregates,
it appears that the aggregates emanating from the nanocomposites were dispersed in
the dissolution test, leading to higher ITZ release in 20 and 60 min as compared with
HPC SSL.

82

2.3 Conclusions
This study has demonstrated that wet-milled stable 10% ITZ nanosuspensions
showing near-Newtonian flow behavior can be prepared with 4.5% HPC SL/L (100
and 140 kg/mol MW, respectively). At 4.5% concentration, HPC SSL (40 kg/mol),
HPMC E3 (10 kg/mol), and PVP K30 (50 kg/mol) could not suppress ITZ
nanoparticle aggregation, leading to significant pseudoplastic behavior. Contrary to
previous studies that highlight the favorability of low MW polymers (Choi et al.,
2008; Sepassi et al., 2007) (specifically <50 kg/mol for ITZ–HPC (Choi et al.,
2008)), our study demonstrated that higher MW HPC (100 and 140 kg/mol) is more
favorable for ITZ nanosuspension stabilization, which in line with the
thermodynamic considerations of polymer adsorption. Spray drying of the ITZ
suspensions yielded nanocomposites with 60–78% mean ITZ loading, which is higher
than that in the ITZ nanocomposites produced in prior studies, and acceptable content
uniformity. Severe aggregation occurred during the milling/drying when 4.5%
polymers with MW  50 kg/mol were used. Their nanocomposites did not redisperse
into ITZ nanoparticles/aggregates due to negligible/slow matrix erosion in the
redispersion test; thus, they did not exhibit immediate release during the dissolution
test. While the use of higher MW HPC (100 and 140 kg/mol) was more favorable
from both nanosuspension stabilization and ITZ release perspectives, there exists an
optimal MW. The fastest ITZ dissolution among the nanocomposites with 4.5%
polymer was achieved by HPC SL (100 kg/mol). Moreover, the viscous dampening
effect even in a wet stirred media mill could detrimentally slow down the breakage
rate if polymers with higher MW (e.g., >150 kg/mol) were used. Overall, high drug-
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loaded, surfactant-free ITZ nanocomposites that exhibited fast redispersion and
immediate release were prepared via spray-drying of wet-milled ITZ with 4.5% HPC
SL/L. In a future study, higher MW grades (> 50 kg/mol) of HPMC and PVP will be
used to examine if they could improve nanosuspension stability and ITZ release
similar to HPC. Moreover, HPC with MW above 150 kg/mol will be used to examine
the limits of wet stirred media milling in producing drug nanosuspensions fast, as
such limiting conditions could occur due to pronounced viscous dampening.
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CHAPTER 3
DISSOLUTION ENHANCEMENT VIA DRUG HYBRID NANOCRYSTAL–
AMORPHOUS SOLID DISPERSION (HYNASD) VS. ASD

As has been indicated in Chapter 1, drug nanocomposites (nanoparticle-based dosage
form) and amorphous solid dispersions (ASDs) are two major approached to enhance
the bioavailability of the poorly water-soluble drugs, both approaches have some
advantages and disadvantages. A major shortcoming of drug nanocomposites as
compared with amorphous solid dispersions (ASDs) is their limited supersaturation
capability in the dissolution media. Chapter 3 aims to address this limitation of the
drug nanocomposites by introducing a new class of drug nanoparticles called hybrid
nanocrystal–amorphous

solid

dispersions

(HyNASDs)

and

compare

their

performance to ASDs. A wet-milled griseofulvin (GF, BCS II drug) nanosuspension
and a GF solution, both containing the same dissolved polymer–surfactant (SDS:
sodium dodecyl sulfate) with 1:1 and 1:3 GF:polymer mass ratios, were spray-dried.
Hydroxypropyl cellulose (HPC) and Soluplus (Sol) were used as matrix-forming
polymers. XRPD, DSC, and Raman spectroscopy reveal that ASDs were formed
upon

spray-drying

the

solution-based

feed,

whereas

nanocomposites

and

nanocomposites with >10% amorphous content, HyNASDs, were formed with the
nanosuspension-based feed. Sol provided higher GF relative supersaturation, up to
180% and 360% for HyNASDs and ASDs, respectively, in the dissolution tests than
HPC (up to 50% for both) owing to Sol’s stronger intermolecular interactions and
miscibility with GF and its recrystallization inhibition. Besides the higher kinetic
solubility of GF in Sol, presence of GF nanoparticles vs. micron-sized particles in the
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nanocomposites enabled fast supersaturation. This study demonstrates successful
preparation of fast supersaturating (190% within 20 min) HyNASDs, which renders
nanoparticle formulations competitive to ASDs in bioavailability enhancement of
poorly soluble drugs.

3.1 Materials and Methods
3.1.1 Materials
BP/EP grade micronized griseofulvin (GF) was purchased from Letco Medical
(Decatur, AL, USA) and used as a challenging Biopharmaceutics Classification
System (BCS) Class II drug because GF nanocrystals exhibit severe aggregation in
suspensions, if improperly stabilized (Bilgili and Afolabi, 2012), and it is known to
be a fast crystallizing drug (Baird et al., 2010). Its solubility in deionized (DI) water
is ~8.9 mg/L at 25 °C and ~14.2 mg/L at 37 °C; it has a melting point Tm of 220 °C
and a glass transition temperature Tg of 89 °C (Baird et al., 2010). Hydroxypropyl
cellulose (HPC, SSL grade, Nisso America Inc., New York, NY) is a semi-crystalline
polymer with low crystallinity and amorphous domains of very low Tg. It is widely
used as a stabilizer during milling and matrix former in the nanocomposites (Azad et
al., 2015b; Bhakay et al., 2014a). Soluplus (Sol, BASF, Tarrytown, NY)) is an
amphiphilic graft copolymer produced from polyvinyl caprolactam–polyvinyl
acetate–polyethylene glycol having a single glass transition temperature of 73 ± 2 °C
(Terife et al., 2012). Sol has been commonly used to produce ASDs of various poorly
water-soluble drugs (Ha et al., 2014). An anionic surfactant, sodium dodecyl sulfate
(SDS), purchased from GFS Chemicals, Inc. (Columbus, OH) was used as a wetting
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agent, which also helps to stabilize GF nanosuspensions. Acetone (ACS reagent, ≥
99.5%) was purchased from BDH Analytical chemicals, (VWR, GA) and used as a
solvent to prepare solution-based feed to the spray dryer. In WSMM, Yttrium
zirconia beads (Zirmil Y, Saint Gobain ZirPro, Mountainside, NJ, USA) with a
median size of 430 µm were used.
3.1.2 Preparation of Spray-Dried Powders
Aqueous suspension-based (W:water) feeds and organic solution-based (S:solvent)
feeds of GF were fed to the spray dryer for the preparation of drug nanocomposites
and ASDs, respectively (Figure 3.1). Table 3.1 presents the formulations used in the
precursor feeds. Drug concentration was kept constant at 2.5% (w/v). The GF
concentration was calculated w.r.t. the total volume of the water in the suspensionbased feeds and the total volume of the solvent mixture (acetone–water) in the
solution-based feeds, which was fixed at 240 mL. GF nanosuspensions were prepared
with two different polymers (HPC/Sol) at 1:1 and 1:3 drug:polymer mass ratios to
examine the impact of polymer type and polymer loading on GF release in dissolution
tests. To elucidate the role of Sol, a nanosuspension with 3:1 GF:Sol (W-Sol-3:1) and
a suspension of as-received (micronized) GF with 1:3 GF:Sol (W-M-Sol-1:3) were
also prepared. In all formulations, SDS concentration was kept constant below the
critical micelle concentration (CMC, 0.23%, w/v) at 0.125% (w/v) to minimize
Ostwald ripening (Knieke et al., 2013).
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Figure 3.1 Schematic illustration of the process setup: (a) wet-stirred media milling (WSMM) of drug in aqueous solution of
polymer–surfactant for the preparation of the drug nanosuspension-based (W) feed, (b) mixing of drug, polymer, and surfactant in
acetone–water mixture for the preparation of the drug solution-based (S) feed, and (c) co-current spray drying of each feed
separately. Diagrams are not drawn to scale.
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Table 3.1 Formulations of the Suspension-based (W) Feeds and Solution-based (S)
Feeds Used in Spray Drying
Formulationa
W-Sol-1:3
W-Sol-1:1
W-Sol-3:1
W-HPC-1:3
W-HPC-1:1
S-Sol-1:3
S-Sol-1:1
S-HPC-1:3
S-HPC-1:1

GF
(% w/v)b
2.5
2.5
2.5
2.5
2.5
2.5
2.5
2.5
2.5

Polymer
(% w/v)b
7.5
2.5
0.8
7.5
2.5
7.5
2.5
7.5
2.5

SDS
(% w/v)b
0.125
0.125
0.125
0.125
0.125
0.125
0.125
0.125
0.125

Water
(mL)
240
240
240
240
240
40
40
40
40

Acetone
(mL)
0
0
0
0
0
200
200
200
200

a

S denotes solution-based feed; W denotes nanosuspension-based feed; Sol denotes Soluplus; the
ratios refer to the drug:polymer mass ratios. All formulations have 0.125% w/v SDS.
b
% w/v with respect to the total volume (240 mL) of the liquid (water/solvent).

In the preparation of nanosuspension-based (W) feeds, a shear mixer (Fisher
Scientific Laboratory Stirrer, Catalog No. 14-503, Pittsburgh, PA) was used to
disperse as-received GF particles in the aqueous dispersant (HPC/Sol–SDS) solutions
first. The resultant GF pre-suspensions were transferred to the holding tank of a
Microcer wet stirred media mill (WSMM) (Netzsch Fine Particle Technology, LLC,
Exton, PA, USA) with 80 mL milling chamber (Figure 3.1a). Milling conditions were
adopted from our prior work on WSMM (Afolabi et al., 2014; Bilgili et al., 2016). 50
mL of the milling chamber was filled with zirconia beads, and to hold the beads in the
chamber a screen with 200 µm opening was used at the outlet of the chamber. The
pre-suspension was recirculated through the chamber at a rate of 126 mL/min via a
peristaltic pump and was milled at a rotor speed of 3200 rpm for 64 min. A portion of
each suspension was separated in a vial and stored for 7 days at 8 °C to assess the
short-term physical stability. Also, the milled suspensions were refrigerated at 8 °C
for overnight before spray drying.
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To prepare the solution-based (S) feeds, a mixture of acetone–water was
purposefully selected to dissolve all components of the formulation (Figure 3.1b). To
ensure a head-to-head comparison of the nanocomposites with ASDs, the
formulations of the solution-based (S) feeds are kept identical to those of the
suspension-based (W) feeds. 40 mL of deionized water was added to 200 mL acetone
to prepare a total of 240 mL solvent mixture. After dissolving the drug–polymer–
surfactant into the binary solvent mixture using a magnetic stirrer, the solutions were
sonicated for 30 min before feeding to the spray dryer.
Using a spray dryer (4M8-Trix, Procept, Zelzate, Belgium) having a cocurrent flow set-up (Figure 3.1c), GF suspensions and drug–polymer solutions were
dried. The total length and the diameter of the spray dryer are 1.59 m and 0.15 m,
respectively. To ensure complete drying, inlet temperature was selected above the
boiling temperature of the respective pure liquids. Drying air at 120 °C flowing at
0.37–0.40 m3/min and drying air at 75 °C flowing at rate of 0.27–0.30 m3/min were
fed co-currently at the top of the dryer column to dry W feeds and S feeds (see Table
2), respectively. 200 g suspension/solution of each formulation was sprayed at 2.0
g/min rate using a peristaltic pump (Make-it-EZ, Creates, Zelzate, Belgium). A
cyclone separator was used to separate the dried particles from the outlet stream into a
glass jar. Atomizing air pressure of 2.0 bar, a bi-fluidic nozzle with tip diameter of
0.6 mm, and cyclone pressure of 55–60 mbar were selected based on prior experience
(Azad et al., 2015b) and exploratory experiments. The dried particles obtained from
the collection jar were transferred into double plastic bags and stored in a vacuumdesiccator at room temperature for further characterization.
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3.2 Characterization Techniques
3.2.1 Particle Sizing
Drug particle size distributions (PSDs) in the suspensions were measured by laser
diffraction (LS 13 320, Beckman Coulter, Miami, FL) based on Mie scattering theory
following the procedure described in ref. (Bilgili et al., 2016) at various times: right
after milling, after 1-day and 7-day storage at 8 °C to in a refrigerator. The intensity
was maintained between 40–50% while the obscuration was maintained below 8.0%
for all measurements. Refractive index values are 1.65 for GF (drug) and 1.33 for
deionized water (medium). Before each measurement, a 2.0 mL suspension sample
was dispersed into 5.0 mL of the respective stabilizer solution using a vortex mixer
(Fisher Scientific Digital Vortex Mixer, Model No: 945415, Pittsburgh, PA) at 1500
rpm for one min prior to each measurement.
The particle sizes of the spray-dried powders were measured by a
Rodos/Helos laser diffraction system (Sympatec, NJ, USA) based on Fraunhofer
theory following the procedure described in ref. (Li et al., 2016b). About 1 g of the
powder sample was placed on top of the sample chute of the Rodos dispersing system
and the sample chute was vibrated at a 100% setting, and 0.1 bar dispersion pressure
was used to suck in the falling powder through the sample cell of the laser diffraction
system. For further confirmation of the particle sizes, spray-dried particles were
placed on a glass slide and observed by Axio Scope.A1 polarized light microscope
(PLM, Carl Zeiss Microscopy GmbH, Göttingen, Germany).
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3.2.2 Solid State Characterization and Drug–Polymer Interactions
To analyze the crystallinity of the as-received GF, HPC, Sol, spray-dried powders,
and physical mixtures of GF–polymer–SDS (same formulation as stated in Table 3.1),
X-ray powder diffraction (XRPD) (PANanalytical, Westborough, MA, USA),
provided with Cu Kα radiation (λ= 1.5406 Å) was used. The samples were scanned at
a rate of 0.165 s-1 for 2θ ranging from 5° to 40°. The total area under three distinct,
non-overlapping peaks of GF at characteristic diffraction angles of 13.2o, 14.6o, and
16.5o was calculated for both the physical mixtures and the spray-dried powders using
the equipment’s HighScore Plus software, which was then used to estimate the
crystallinity.
Differential scanning calorimetry (DSC) of the as-received GF, Sol, HPC,
physical mixtures of GF–polymer–SDS, and spray-dried powders was performed
using a Mettler-Toledo polymer analyzer (PolyDSC, Columbus, OH, USA) with
integrated STARe 10 software. ~6.0–7.0 mg powder sample was placed in an
aluminum pan with a hole in the lid and loaded into the DSC machine. As-received
GF was heated at a rate of 10 °C/min from 25 °C to 250 °C. All other samples were
heated from 25 °C to 70 °C and the temperature was held for 2 min at 70 °C, then
cooled back to 25 °C to remove any residual solvent in the sample. In the final step,
the samples were heated from 25 °C to 250 °C at 10 °C/min. Nitrogen gas was used
as the purge gas and protective gas at a flow rate of 50 mL/min and 150 mL/min,
respectively. Thermogravimetric analysis (TGA) was performed to measure the
residual water/solvent content using a TGA/DSC1/SF Stare system (Mettler Toledo,
Inc., Columbus, OH). ~6.0–7.0 mg of each spray-dried sample was placed in a
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ceramic crucible and heated from 25 °C to 150 °C at a heating rate of 10 °C/min
under nitrogen flow.
Raman spectroscopy was conducted using a Fergie Imaging Spectrometer
System (Princeton Instruments, Trenton, NJ) with a 500-mW external diode laser
processing at 785 nm wavelength. Data acquisition time for all spectra was 15 s per
scanned spectrum (100–1800 cm-1) and each spectrum acquired was averaged over
two scans. The data was presented for the range of 1550–1800 cm-1 wavenumber.
3.2.3 Characterization of Drug Recrystallization
To elucidate the role of drying rate on drug recrystallization during drying, a droplet
of 20 µL of the solution prepared for the solution-based (S) feed was put onto a hot
glass slide at 75 °C and kept for drying in quiescent air. After about one min drying,
the slides were placed under the polarized light microscope (PLM) to observe if any
drug recrystallization occurred. To elucidate GF recrystallization in the presence of
water, a small portion of the spray-dried powders prepared using the solution-based
(S) feed (S-HPC-1:3 and S-Sol-1:3) was gently pressed to form a loose compact,
which was then mounted onto a microscopic glass slide, and placed under the PLM.
20 µL of deionized water was added to the sample and the PLM images were
captured at 0, 1, 2, and 5 min from the moment of water addition.
3.2.4 Study of Nanoparticle Recovery From the Nanocomposites
Aqueous redispersion of the nanocomposites was performed following a previously
established method (Bilgili et al., 2018; Li et al., 2016b). About 0.5 g of the spraydried powders prepared using the nanosuspension-based (W) feeds was dispersed in
30 mL of deionized water inside a 60 mL beaker and stirred at 500 rpm for 60 min
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with a paddle-stirrer (CAT R18, Scientific Instrument Center Limited, Winchester,
UK). ~1.0 mL aliquot of redispersed sample was taken at 2, 10 and 60 min while
stirring, and particle size was measured using laser diffraction (LS 13 320, Beckman
Coulter, Miami, FL). At the same collection times, a droplet of each redispersed
sample was taken and dried immediately by dropping on a preheated glass slide on a
hot plate at 100 °C. After drying, the PLM was used to capture images of the
redispersed particles. The details of the experimental methods and results are
presented in Appendix B.
3.2.5 Drug Content and Dissolution Performance of the Spray-Dried Powders
The drug content in the dried powders varied based on the drug:polymer mass ratios.
To measure the actual drug content in the spray-dried powders, an assay testing was
performed by dissolving 100 mg of the sample powders in 20 mL methanol under 30
min of sonication, followed by overnight storage to ensure complete solubilization of
the GF particles. An aliquot of 100 µL was taken from the GF solution and diluted up
to 10 mL using methanol. The absorbance of the samples was measured at 292 nm
using UV spectrophotometer (Agilent, Santa Clara, CA, USA), and the drug
concentration was calculated from a pre-established calibration curve. Six replicates
were tested for each formulation to calculate mean drug content along with the
relative standard deviation (RSD).
Drug release from the spray-dried powders and various physical mixtures
(PMs) prepared by blending was determined via a Distek 2100C dissolution tester
(North Brunswick, NJ, USA), following the USP II paddle method. 1000 mL
deionized water at 37 °C was stirred at 50 rpm paddle speed. Spray-dried powder
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samples containing 100 mg GF (above the thermodynamic solubility of as-received
GF particles) were weighed and added to the dissolution medium and 4 mL samples
were taken out manually at 1, 2, 5, 10, 20, 30, 60, 120, 180, and 210 min. These
aliquots were filtered through 0.1 µm PVDF membrane-type syringe filter before
UV-spectroscopy measurements (similar to Bhakay et al. (2014a) and Li et al.
(2017)). The filtered samples were diluted with 37 °C deionized water at a ratio of 1
to 5 before UV measurement. Dissolved GF amount was measured by UV
spectroscopy at 296 nm wavelength and calculated using a pre-established calibration
curve. Deionized water was used as the blank before UV measurement and six
replicates of each sample were performed. In this paper, relative % supersaturation is
reported based on GF concentration at 210 min and thermodynamic solubility of asreceived GF particles, unless otherwise indicated.
3.2.6 Supersaturation Maintenance Ability of the Polymers
The supersaturation maintenance ability of HPC/Sol was examined in a separate
desupersaturation test (similar to ref. (Konno et al., 2008)). A concentrated solution
of GF in acetone was prepared by dissolving 100 mg of as-received GF in 20 mL
acetone. This solution was subsequently added to 1000 mL of pre-dissolved HPC–
SDS/Sol–SDS solution with 100 µg/mL and 300 µg/mL polymer concentration,
which maintained 1:1 and 1:3 drug:polymer mass ratio, respectively, in the USP II
paddle type dissolution tester. The addition resulted in 92–99 µg/mL supersaturated
solutions of GF initially, and any subsequent desupersaturation during the following
210 min was tracked via GF concentration measurements. The experimental
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conditions and concentration measurement were identical to those in the dissolution
test. All measurements were carried out in triplicate.

3.3 Results and Discussion
3.3.1 Properties of GF Nanosuspensions Prepared via Wet Stirred Media
Milling
Four different GF suspensions were wet media milled using HPC/Sol at 1:1 and 1:3
drug:polymer mass ratios in the presence of SDS. The median particle size d50 and
90% passing size d90 of the final milled suspensions (after 64 min), after 1-day and 7day storage are presented in Figure 3.2. Unless properly stabilized, GF nanoparticles
severely aggregate in aqueous suspensions, forming micron-sized particles (Bilgili
and Afolabi, 2012). The wet-milling of as-received (micronized) GF particles with
d50: 9.74 µm and d90: 27.4 µm yielded nanosuspensions with d50 in the range of 0.14–
0.19 µm. The small changes in d50 and d90 during the 7-day storage suggest that the
suspensions did not undergo drastic aggregation/growth during milling and storage.
On the other hand, an increase in HPC concentration led to smaller aggregates and
finer sizes. In a previous study, HPC–SDS was reported to have synergistic
stabilizing effect on GF suspensions during milling and storage (Bilgili and Afolabi,
2012) and stabilized multiple BCS Class II drug nanosuspensions (Bilgili et al.,
2016). HPC and Sol imparted steric stabilization by adsorbing on drug nanoparticles
(Bilgili and Afolabi, 2012; Yang et al., 2014), while the anionic surfactant (SDS)
enhanced

GF

wettability/deaggregation

and

helped

to

stabilize

the

GF

nanosuspensions via electrostatic repulsion (Bilgili and Afolabi, 2012; Bilgili et al.,
2016).
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Figure 3.2 Volume-based particle size statistics of the milled GF suspensions with
1:1 and 1:3 GF:polymer mass ratios after milling (64 min) as well as 1-day storage
and 7-day storage at 8 °C: (a) 10% cumulative passing size d10, (b) median particle
size d50 and (c) 90% cumulative passing size d90. All suspensions have 2.5% w/v GF
and 0.125% w/v SDS.

3.3.2 Size, Morphology, and Drug–Moisture Content of The Spray-Dried
Powders
Drug nanosuspension-based (W) feeds produced by WSMM and drug–polymer
solution-based (S) feeds with identical formulations were spray-dried separately. The
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residence time in the spray dryer was short, i.e., 4.0 s and 5.0 s, for W feeds and S
feeds, respectively.

Despite the relatively short residence time, the spray-dried

powders were completely dried, as indicated by the TGA, which shows weight loss of
~2.0% for the samples. The extremely large surface area generated by atomization of
the feed coupled with the fast-convective heat–mass transfer at high air temperature
enabled fast drying of the droplets. The mean (actual) drug content after spray-drying
was higher for feeds with higher drug:polymer mass ratio (Table 3.2). RSD values
were below 6%: 0.73–3.14%, which signifies pharmaceutically acceptable content
uniformity. The slightly lower drug content as compared with the theoretical value
can be attributed to preferential drug loss during handling/transfer after milling, poor
separation of finer particles in the cyclone separator of the spray dryer, and presence
of the residual moisture after drying (Azad et al., 2015b; Bilgili et al., 2018). The
median sizes of the spray-dried powders were measured to be in the range of 6.89–
19.0 µm and 11.0–15.8 µm (Table 3.2) for W feeds and S feeds, respectively. An
increase in polymer loading led to formation of coarser particles due to increase in
total solids loading and higher viscosity of the feed (Basa et al., 2008; Bilgili et al.,
2018; Li et al., 2018b). The microscopic images (Figure 3.3) illustrate that spraydried particles have rounded–donut shapes, and their sizes are in rough agreement
with the ranges mentioned in Table 3.2.
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Table 3.2
Content

Particle Size Statistics of the Spray-Dried Powders and Their Drug

Formulationa
W-Sol-1:3
W-Sol-1:1
W-Sol-3:1
W-HPC-1:3
W-HPC-1:1
S-Sol-1:3
S-Sol-1:1
S-HPC-1:3
S-HPC-1:1

Particle size statistics of the spraydried particles (µm)
d10±SD
d50±SD
d90±SD
9.29±0.1 19.0±0.1 33.6±0.1
4.48±0.1 10.1±0.1 21.9±0.2
1.66±0.1 6.89±0.3 15.3±0.4
6.37±0.1 16.5±0.6 40.0±0.1
5.24±0.1 12.9±0.1 34.2±0.1
4.11±0.0 12.3±0.0 33.2±0.1
5.03±0.1 11.0±0.1 20.2±0.0
6.48±0.0 15.8±0.6 31.3±1.0
7.05±0.2 13.0±0.9 26.9±0.8

Actual drug
content, RSD
(% w/w, %)
21.2, 1.50
42.0, 1.73
64.4, 0.51
22.3, 3.14
42.5, 2.83
21.5, 2.02
42.3, 2.21
24.4, 2.56
41.7, 0.73

Theoretical
drug content
(% w/w)
24.7
48.8
72.3
24.7
48.8
24.7
48.8
24.7
48.8

a

S denotes solution-based feed, W denotes nanosuspension-based feed, Sol denotes Soluplus; the
ratios refer to the drug:polymer mass ratios. All formulations have 0.125% w/v SDS.

Figure 3.3 Polarized light microscope images of the spray-dried particles prepared
using the GF nanosuspension-based (W) feed and the GF solution-based (S) feed with
1:3 GF:polymer mass ratios: (a) W-HPC-1:3, (b) S-HPC-1:3, (c) W-Sol-1:3, and (d)
S-Sol-1:3. All images were taken at 50X magnification (scale bar: 20 µm).
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3.3.3 Formation of Drug Nanocomposites/HyNASDs vs. ASDs Upon Spray
Drying
The solid state of GF in the spray-dried powders was investigated via XRPD (see
Figure 3.4) and DSC (see Figure 3.5). Table 3.3 presents the summary of DSC
thermal events and estimated crystallinity via XRPD. X-ray diffractograms depict that
as-received GF exhibited intense peak characteristics of a crystalline material,
whereas HPC/Sol exhibited halo pattern indicating amorphous structure (Figure 3.4a).
The physical mixtures (PMs), prepared by blending, exhibited peaks at the same
diffraction angles as those of as-received GF, albeit with reduced peak intensity
(Figure 3.4b and 3.4c), which can be attributed to the dilution and surface coverage of
GF microparticles with HPC/Sol, and the reduction is more discernible with
increasing polymer concentration. Similar XRPD diffractograms to those of the PMs
were observed for the spray-dried powders prepared using the suspension-based (W)
feeds confirming that spray-drying of W feeds led to formation of nanocomposites
that are mostly crystalline (Figure 3.4b and 3.4c). Interestingly, the diffractograms of
the spray-dried powders with W feeds especially those with higher polymer loading
(lower GF:polymer ratio) show clear peak broadening and peak intensity reduction as
compared with those of PMs, beyond the aforementioned dilution effect.
Surprisingly, wet milling followed by spray-drying led to reduction of crystallinity
and formation of notable (~5–20%) amorphous drug (see Table 3.3). To the best
knowledge of the authors, this level of amorphous content in drug nanocomposites is
not common. It is well-established that wet media milling does not cause any
detectable amorphization of as-received GF, in the absence of stabilizers, due to
plasticization effect of water (Monteiro et al., 2013). In the presence of high polymer
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loading in the nanosuspensions here, however, amorphization of GF took place
during the spray drying.

Figure 3.4 X-ray diffractograms of as-received GF, HPC, and Sol (a); physical
mixtures (PMs) of GF–polymer–SDS and the spray-dried powders prepared using the
GF nanosuspension-based (W) feed and GF solution-based (S) feed with various
GF:polymer mass ratios: (b) HPC as the polymer and (c) Sol as the polymer.
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Figure 3.5 DSC thermograms of as-received GF, HPC, and Sol (a); physical
mixtures (PMs) of GF–polymer–SDS and the spray-dried powders prepared using the
GF nanosuspension-based (W) feed and GF solution-based (S) feed with various
GF:polymer mass ratios: (b) HPC as the polymer and (c) Sol as the polymer.
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Table 3.3 Characteristic Temperatures–Enthalpy Values Obtained From DSC
Thermograms and Crystallinity Estimated From XRPD Diffractograms
Formulationa
S-HPC-1:1
W-HPC-1:1
S-HPC-1:3
W-HPC-1:3
W-Sol-3:1
S-Sol-1:1
W-Sol-1:1
S-Sol-1:3
W-Sol-1:3

Tg
(ºC)a,b
58.9
ND
57.7
ND
ND
74.6
ND
80.0
ND

Trc
(ºC)a,b
109
ND
124
ND
ND
127
ND
ND
ND

Hrc
(J/g)a,b
–20.0
ND
–1.71
ND
ND
–9.26
ND
ND
ND

Tm
(ºC)a,b
213
211
200
198
212
206
204
ND
186

Hf
(J/g)a,b
40.6
28.7
10.5
12.7
47.0
25.4
22.7
ND
7.37

Crystallinity
(%)b
6.5
95.5
ND
86.5
92.1
ND
86.3
ND
81.3

a

S denotes solution-based feed, W denotes nanosuspension-based feed, Sol denotes Soluplus; the ratios
refer to the drug:polymer mass ratios. All formulations have 0.125% w/v SDS. Other symbols: Tg, Trc,
and Tm stand for temperature for glass transition, recrystallization transition, and melting point,
respectively, while Hrc and Hf respectively stand for recrystallization enthalpy and fusion enthalpy.
b
ND: not detected.

Table 3.3 shows that despite being largely crystalline, the amorphous content
in the spray-dried powders prepared via nanosuspension-based (W) feeds increased
upon an increase in the polymer loading in the nanosuspensions. Moreover, higher
amorphous content was observed in the Sol formulations than in the HPC
formulations at the same drug:polymer mass ratio. These findings suggest that
amorphous GF was formed due to GF–polymer molecular interactions and/or
solubilization of the surface layer of nanoparticles by the polymer during the spraydrying. It is likely that presence of GF nanoparticles with large surface area could
have facilitated the formation of amorphous content around the GF nanoparticles. In
other words, the polymeric matrix of the spray-dried particles encapsulates drug
nanocrystals, surrounded by a layer of amorphous GF ASD in the polymeric matrix
(see Figure 3.6b). Formation of amorphous content upon drying of drug
nanosuspensions was first observed by (Kayaert and Van den Mooter, 2012), albeit to
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a much lower extent; however, the impact of such amorphous content on drug release
from the nanocomposites has not been studied at all. As the dissolution tests will
reveal below, despite being largely crystalline, these nanocomposites with high
polymer loading (low drug:polymer ratio) allow for much higher supersaturation than
traditional nanocomposites; hence, we refer to them as hybrid nanocrystal–ASD
(HyNASD). The higher amorphous content in the Sol than in the HPC formulations
could be related stronger molecular interactions of Sol with GF than HPC with GF
and GF–Sol miscibility. It is suggested that if the solubility parameter difference
between a drug and polymer is <7.0 MPa1/2, they are likely to be miscible; if the
difference is >10 MPa1/2, they are considered immiscible (Forster et al., 2001;
Greenhalgh et al., 1999). The solubility parameters of GF, HPC, and Sol are 12.2
(Thakral and Thakral, 2013), 24.0 (Choi et al., 1994), and 19.4 (Kolter et al., 2012)
MPa1/2, respectively. The solubility parameter differences between GF–Sol and GF–
HPC are 7.2 and 11.8 MPa1/2, respectively, which suggests that GF–Sol is borderline
miscible (or at least partially miscible), whereas GF–HPC is most likely immiscible.
While being useful, the solubility parameters do not account for all drug–polymer
interactions such as contributions from hydrogen bonding, hydrophobic interactions,
etc., and hence should be used with caution as rough estimates of drug–polymer
miscibility.
XRPD diffractograms (Figure 3.4b and Figure 3.4c) of the spray-dried
powders prepared using the solution-based (S) feeds showed halo pattern instead of
any characteristic diffraction peaks of GF (except S-HPC-1:1). These halo patterns
confirm that amorphous GF dispersed molecularly into the polymer matrix forming
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amorphous solid dispersions (ASDs). Despite the immiscibility of HPC with GF, fast
drying of acetone–water in 1:3 GF–HPC solution led to molecular dispersion and
arrested amorphous GF in the HPC matrix kinetically. On the other hand, the peaks in
the XRPD diffractogram of S-HPC-1:1 and 6.5% crystalline GF could be explained
by the insufficient HPC concentration to ensure complete dispersion of GF molecules
in the polymer matrix; hence, recrystallization of GF during spray-drying occurred.
The DSC thermograms in Figure 3.5a show an endothermic peak associated
with melting of as-received GF, with a Tm of 220.1 °C and ΔHf of 101.8 J/g; a glass
transition for Sol (amorphous) at 72.4 °C, and a slight endothermic event around
170–200 °C for HPC likely due to the melting of the small crystalline domain of
largely amorphous HPC (Sarode et al., 2013) (crystallinity was undetectable by
XRPD). The Tg of HPC could not be measured (in the range of –25 to 0 °C (Sarode et
al., 2013)) due to limitation of our equipment. For spray-dried powders prepared
using solution-based (S) feeds, a single Tg was observed for all the formulations
confirming the formation of molecular level dispersion (Luebbert et al., 2017;
Wlodarski et al., 2015) (see Table 3.3 and ASD schematic in Figure 3.6c). While SSol-1:3 exhibited only a glass transition, all other ASDs exhibited a glass transition
followed by an exothermic event due to re-crystallization of amorphous GF followed
by the melting of the recrystallized GF (Figure 3.5b and 3.5c). The (absolute value)
enthalpy of recrystallization was lower for Sol than for HPC formulations and was
lower when a higher polymer loading was used (in line with other studies e.g.,
(Wlodarski et al., 2015)). Recrystallization occurred during the heating step of DSC
scan because above Tg amorphous drug molecules and amorphous polymer had
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Figure 3.6 Schematic illustration of the solid state of the drug (GF) in (a) GF nanocomposite, (b) GF hybrid nanocrystal–
amorphous solid dispersion (HyNASD), and (c) GF amorphous solid dispersion (ASD). Figure is not drawn to scale.
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higher mobility, leading to GF recrystallization. Due to stronger molecular
interactions and miscibility of Sol with GF, S-Sol-1:3 with high Sol loading was able
to inhibit recrystallization even at high temperatures during the DSC scan.
The spray-dried powders prepared using the suspension-based (W) feeds, i.e.,
the nanocomposites including HyNASDs, exhibited a melting endotherm only
(Figure 3.5b and 3.5c). The Tm and fusion enthalpy ΔHf of these spray-dried powders
were lower than those of the respective physical mixtures (Table 3.3). Moreover,
higher polymer loading (1:3 vs. 1:1 W formulations) led to lower Tm and ΔHf, similar
to the lower peaks and crystallinity in XRPD. The observed reduction in Tm and ΔHf
of HyNASDs, as compared with the physical mixtures, may be partly attributed to
defect formation and accumulation during milling. However, only a slight reduction
in Tm and ΔHf occurred upon wet media milling of GF without stabilizers (Monteiro
et al., 2013). Hence, the reduction in Tm and ΔHf was mostly attributed to
amorphization of GF on the surface of the drug nanocrystals (Kayaert and Van den
Mooter, 2012) or its solubilization in the polymer upon spray-drying as well as the
solubilization during the DSC scan. Compared with the thermogram of as-received
GF, the thermograms of the physical mixtures also show a significant reduction of Tm
and ΔHf, which can be explained by the solubilization of GF in molten polymer at
high temperatures during the DSC scan. Finally, the lower Tm and ΔHf of the W-Sol
formulations than those for the W-HPC formulations could again be explained by the
higher miscibility and stronger molecular interaction of Sol with GF than HPC with
GF.
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The observed Raman lines in Figure 3.7a for as-received GF and PMs of GF
are largely in agreement with Fourier transform Raman data of ref. (Feng et al., 2008)
and Raman data of ref. (Żarów et al., 2011) for crystalline GF. The Raman spectra of
S-Sol-1:3 (Figure 3.7c) show that the GF line at 1606 cm–1 disappeared, and the lines
at other characteristic frequencies shifted to new positions that are characteristic of
amorphous GF, e.g., the line shift from 1712 to 1715 cm–1 (see Zarow et al. (Żarów et
al., 2011)), signifying formation of amorphous GF and strong molecular interactions
between GF and Sol in the ASD. While the GF line at 1606 cm–1 disappeared in the
Raman spectra of S-HPC-1:3 (Figure 3.7b), the shifts in other lines were subtler than
those for the Raman spectra of S-Sol-1:3, which could suggest stronger molecular
interactions between GF and Sol than GF and HPC. While the W-Sol-1:3 and WHPC-1:3 powders (HyNASDs) did not show disappearance of lines or line shifts,
unlike S-Sol-1:3 and S-HPC-1:3 powders (ASDs), their spectra clearly show
broadening of the characteristic GF lines and peak intensity reduction as compared
with the spectra of the respective PMs due to GF–polymer interactions and presence
of amorphous domains in these powders. In contrast, the spectra of W-Sol-3:1
(nanocomposite), having 1/9th of Sol content compared with W-Sol-1:3, did not show
as much line broadening compared to the spectra of its respective PM.
The XRPD, DSC, and Raman spectroscopy results overall suggest that spraydrying of GF–polymer solutions (S feeds) led to formation of ASDs, whereas spraydrying of GF–polymer nanosuspensions (W feeds) led to formation of drug
nanocomposites/HyNASDs. Although a hard and crisp distinction between traditional
nanocomposites and HyNASDs is not intended here, HyNASDs appear to have
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Figure 3.7 Raman spectra of as-received GF, physical mixtures (PMs) of GF–Sol–
SDS at 3:1 and 1:3 GF:Sol mass ratios and GF–HPC–SDS at 1:3 GF:HPC mass ratio
(a); physical mixtures of GF–polymer–SDS and the spray-dried powders prepared
using the GF nanosuspension-based (W) feed and GF solution-based (S) feed with 1:3
GF:polymer mass ratio: (b) HPC as the polymer and (c) Sol as the polymer. W-Sol3:1 stands for the spray-dried powder with 3:1 GF:Sol mass ratio.
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notable amorphous content (>%10 in XRPD) and/or exhibit significant Tm
depression–ΔHf reduction and GF Raman peak broadening as compared with the
respective physical mixtures. As a general observation, we note that spray-drying a
drug nanosuspension with a lower drug:polymer mass ratio (1:1, 1:3) than typically
used (see e.g., Table 1.2) and the use of a miscible polymer, i.e., Sol, that interacts
with the drug nanoparticles strongly and potentially solubilizes them during the spray
drying favor the formation of HyNASDs vs. nanocomposites (W-Sol-1:3 vs. W-Sol3:1). Moreover, as will be shown in Section 3.3.5, nanocomposites and HyNASDs
may behave quite differently in their functional responses such as drug release in
vitro.
3.3.4 Impact of Drying Rate and Drug–Polymer Interactions/Miscibility
In the solution-based (S) feeds, GF, polymer, and SDS were completely dissolved in
acetone–water mixture, which allowed molecular level interaction in the solution
before spray drying. Due to fast evaporation of the solvents in the spray dryer,
viscosity increases rapidly causing entrapment of the drug molecules in the polymer
matrices, which appears to have retarded phase separation even in the case of GF–
HPC (immiscible) and enables the ASD formation. In the nanosuspension-based (W)
feeds, GF exists as nanocrystalline particles while polymer and SDS were dissolved
in water. However, due to large surface area of GF nanocrystals and presence of
relatively high polymer loading (1:1 and 1:3 GF:polymer), GF was partially
solubilized or molecularly dispersed, especially in Sol, as the evaporation proceeds,
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leading to formation of GF molecularly dispersed in the polymer matrix surrounding
the GF nanocrystals (refer to Figure 3.6b).
To

demonstrate

the

criticality

of

drying

rate

and

drug–polymer

interactions/miscibility, we have devised a slower drying method: a single droplet of
GF–HPC–SDS solution on a heated glass slide at 75 ºC, same temperature as that of
hot air in the spray-drying. However, the droplet was dried in quiescent air, which
makes external mass transfer of solvent vapor in air controlling the evaporation rate,
making drying slower compared to spray drying. The drying took less than 40 s,
whereas the drying occurred less than ~5 s in the spray dryer. The PLM images in
Figure 3.8 illustrate that GF crystals formed during the slow drying of all solutions.
On the other hand, the drying of S-Sol-1:3 solution yielded few small crystals,
whereas that of S-Sol-1:1 solution yielded significant number of needle-shaped
crystals. The extent of recrystallization was much higher in HPC than in Sol. HPC
could not inhibit the nucleation/crystal growth of GF from the supersaturated solution
as evaporation proceeded during the spray-drying. Since only S-HPC-1:1 spray-dried
powder had 6.5% crystalline GF and others solution-based (S) spray-dried samples
did not have detectable GF crystals, it is concluded that the relatively fast evaporation
during the spray drying enabled ASD formation.
It is known that the phase separation and recrystallization involve diffusion
and nucleation of drug molecules, both of which require molecular mobility and can
be restricted by polymer molecules as inhibitor (Baghel et al., 2016). Strong drug–
polymer interactions can reduce the molecular mobility and delay crystallization
onset time and the extent of crystallization (Mistry et al., 2015). This is in line with
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earlier work, e.g., (Kothari et al., 2015), where the recrystallization time of nifedipine
increased with an increase in polymer (PVP) concentration. To gain additional
insights into the GF recrystallization inhibition capability of Sol/HPC in solutions,
desupersaturation experiments were performed. The GF desupersaturation curves
indicate the superior GF recrystallization inhibition and supersaturation maintenance
capability of Sol over HPC, and even at 1:1 drug:Sol mass ratio, Sol is an effective
inhibitor (Figure 3.9). Figure 3.9 also corroborates the fast recrystallization tendency
of GF (Baird et al., 2010) and establishes negligible role of SDS alone on
supersaturation maintenance. Again, these findings from the desupersaturation
experiments can be explained by adequate GF–Sol miscibility based on solubility
parameter differences and stronger GF–Sol molecular interactions than GF–HPC
interactions, based on Raman spectroscopy (Figure 3.7).

Figure 3.8 Polarized light microscope images of a droplet of GF solution-based (S)
feed, i.e., (a) S-Sol-1:3, (b) S-Sol-1:1, (c) S-HPC-1:3, and (d) S-HPC-1:1, dried on a
hot glass slide at 75 °C. All images were taken at 5X zoom (scale bar: 200 µm).
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Figure 3.9 GF desupersaturation curves for a supersaturated 20 mL GF–acetone
solution mixed with 1000 mL aqueous solution of 300 µg/mL and 100 µg/mL of
HPC/Sol–5 µg/mL SDS (equivalent to S-formulations with 1:3 and 1:1 drug:polymer
mass ratios, respectively), 5 µg/mL SDS only, and in the absence of any
recrystallization inhibitor. The initial GF concentration right after mixing ranged
from 92–99 µg/mL.
3.3.5 Dissolution Performance of the Spray-Dried Powders
The temporal evolution of GF release from the spray-dried powders and their
corresponding PMs containing 100 mg equivalent GF dose in 1000 mL deionized
water was investigated. We note from Figures 3.10 and 3.11 that the mere presence of
HPC/Sol–SDS could slightly increase the extent and rate of GF release without any
prior processing of the as-received micronized GF particles. This could be partly
explained by the wetting enhancement of the hydrophobic drug (GF) in the presence
of HPC/Sol–SDS and deaggregation of the large drug aggregates present in the asreceived drug (Li et al., 2017) and partly by the higher solubility in the dissolution
medium. The thermodynamic solubility of the GF microparticles at 37 °C was
measured to be 14.2 mg/L, 17.8 mg/L, and 18.3 mg/L in the deionized water, aqueous
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medium of Sol–SDS (1:3 drug:polymer ratio), and aqueous medium of HPC–SDS
(1:3 drug:polymer ratio), respectively.

Figure 3.10 Evolution of drug release from as-received GF, physical mixture (PM) of
GF–HPC–SDS, and spray-dried powders with two different GF:HPC mass ratios: (a)
1:1 GF:HPC and (b) 1:3 GF:HPC. Dissolution sample size is equivalent to 100 mg GF
dose.

114

Figure 3.11 Evolution of drug release from as-received GF, physical mixture (PM) of
GF–Sol–SDS, and spray-dried powders with two different GF:Sol mass ratios: (a) 1:1
GF:Sol and (b) 1:3 GF:Sol. Dissolution sample size is equivalent to 100 mg GF dose.

Figures 3.10 and 3.11 also show that both GF HyNASDs and ASDs prepared
via spray-drying of the suspension-based (W) and solution-based (S) feeds,
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respectively, enhanced the dissolution rate and the extent of GF release as compared
to the as-received GF and the physical mixtures (PM). However, even a cursory look
at the Figure 3.10 vs. Figure 3.11 reveals a drastic difference between HPC-based
formulations and Sol-based formulations: the former provided an order of magnitude
lower (relative) supersaturation than the latter, i.e., ~50% (for both HyNASDs and
ASDs) vs. 360% (S-Sol-1:3, ASD) and 180% (W-Sol-1:3, HyNASD). Another
interesting general observation is that there was little impact of polymer loading or
drug:polymer ratio on the supersaturation for HPC-based formulations, whereas
supersaturation significantly increased upon increase in polymer loading (lower
drug:polymer ratio) for Sol-based formulations.
HPC-based HyNASDs and ASDs performed equally poorly in enhancing
supersaturation (Figure 3.10), but for different reasons, as compared with Sol-based
HyNASDs and ASDs (Figure 3.11). S-HPC-1:1 and S-HPC-1:3 powders are ASDs
that have respectively 94% and 100% XRPD-amorphous GF, which has order of
magnitude higher apparent (kinetic) solubility than its crystalline counterpart.
Unfortunately, depending on the polymer–drug miscibility and interactions,
amorphous drugs may phase-separate and recrystallize upon contact of ASDs with
water in the dissolution medium (Alonzo et al., 2011; Chen et al., 2015) because once
imbibed into the ASD matrix, water acts as a plasticizing agent, reducing the Tg of the
ASD and enhancing the mobility of the drug molecules (Chen et al., 2015). HPC-SSL
has sub-ambient Tg (Sarode et al., 2013) (lower than Tg of Sol: 73 ± 2 °C) and its
ASDs have lower Tg than Sol-based ASDs (see Table 3.3). Moreover, due to HPC
immiscibility with GF, its relatively weak molecular interactions with GF as

116

compared with Sol (miscible with GF), as well as its poor GF nucleation/crystal
growth inhibition (refer to Figure 3.9), it is no surprise that the amorphous GF
recrystallized from HPC-based ASDs during the dissolution test, which also explains
the drastic differences between the HPC-based ASDs vs. Sol-based ASDs. PLM
images of a loose compact of the ASD particles in Figure 3.12 also corroborate the
formation of GF crystals from S-HPC-1:3 ASD upon its exposure to water, whereas
no recrystallization was observed for S-Sol-1:3. The HPC-based HyNASDs also
performed poorly. Although they released GF nanocrystals upon redispersion (see
Appendix B), these GF nanocrystals have limited supersaturation capability.
Moreover, the small amorphous content of the HyNASDs probably recrystallized in
water similar to amorphous GF in HPC-based ASDs. While HPC has been used in
both marketed drug nanocrystal products and in academia for preparation of drug
nanosuspensions and drug nanocomposites (Bhakay et al., 2018b; Li et al., 2016b),
we find here that it is not a suitable polymer for preventing GF recrystallization and
achieving high GF supersaturation.
What is remarkable about the dissolution results in Figure 3.11 is neither the
360% supersaturation obtained with the S-Sol-1:3 ASD nor the higher Sol loading
(1:3 vs. 1:1 GF:Sol ratio) achieving higher supersaturation. ASDs are well-known to
generate significant supersaturation (Alonzo et al., 2011; Jackson et al., 2015) due to
amorphous nature of the molecularly dispersed drug, and the polymer provides
solubilization of the drug within the swollen GF–Sol matrix and recrystallization
inhibition. Sol has a Tg of 73 ± 2 °C and strong molecular interactions with GF (GF
Raman line shifts in Figure 3.7); it is miscible with GF and is an excellent GF
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nucleation/crystal growth inhibitor, as evidenced by the small desupersaturation after
~3 h (Figure 3.9) and absence of crystals in the PLM image (Figure 3.12b). During
the PLM imaging of S-Sol-1:3 (see Figure 3.12b), the compact with the Sol matrix
got swollen after the addition of water while eroding slowly (not shown in the
images). Even after 5 min of water imbibition, no recrystallization of the amorphous
GF was observed, which supports how high supersaturation was reached in this ASD.
What we found surprising is that W-Sol-1:3 provides 180% GF
supersaturation (Figure 3.11). It is well-known that drug nanocomposites have limited
supersaturation capability, typically up to 10–15% (Kesisoglou and Wu, 2008), and
supersaturation capability of nanocomposites has not even been studied in depth
(Azad et al., 2015b; Bhakay et al., 2014a; Shah et al., 2016). Note that W-Sol-1:3 is
not a traditional nanocomposite: while largely composed of drug nanocrystals, it has
about 20% amorphous GF and in water it provided 180% supersaturation. In this
paper, we refer to such nanocomposites as HyNASDs (Figure 3.6b) to differentiate
them from nanocomposites (Figure 3.6a) and ASDs (Figure 3.6b). Another
remarkable finding is that W-Sol-1:3 (HyNASD) generated more supersaturation than
S-Sol-1:1 (ASD), i.e., 180% vs. 130%. Although this mainly resulted from the
HyNASD having more Sol than the ASD and this comparison is not head-to-head,
there is no similar result in literature where a formulation consisting of ~80%
nanocrystals outperforms an ASD with 100% amorphous drug. Clearly, HyNASDs
boost the supersaturating capabilities of traditional nanocomposites.
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Figure 3.12 Polarized light microscope images of a loose compact of the ASD particles (S-formulations) with (a) 1:3 GF:HPC
mass ratio and (b) 1:3 GF:Sol mass ratio in 20 µL deionized water. The images were taken at 0 (before adding water), 1, 2, and 5
min after the addition of deionized water addition. Except 0 min image (5X magnification, scale bar: 200 µm), which focused on
the compact, all other images focused on particles that emanated from the surface, which were captured at 20X magnification
(scale bar: 50 µm).
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Additional dissolution experiments were carried out with various spray-dried
powders prepared using suspension-based (W) feeds in order to elucidate the
significant functional performance difference between traditional nanocomposites
(e.g., W-Sol-3:1 with low Sol loading) and HyNASDs (W-Sol-1:1 and W-Sol-1:3
with high Sol loading) (see Figure 3.13). W-Sol-3:1, like any traditional
nanocomposite, provided low (30%) supersaturation, whereas the two HyNASDs,
i.e., W-Sol-1:1 and W-Sol-1:3, provided 100% and 180% supersaturation,
respectively. There is a clear trend: an increase in Sol loading led to higher
amorphous content and higher GF supersaturation/drug release. During dissolution of
the HyNASDs, the amorphous GF dissolves and diffuses through swollen Sol matrix
(Li et al., 2017), while additional GF could dissolve into the swollen Sol matrix and
supersaturate upon water imbibition. It is also likely that higher Sol loading helps the
solubilization in the dissolution medium. Not only did the higher Sol content lead to
HyNASDs having higher amorphous content upon spray drying (see Table 3.3), but
also the higher Sol loading enabled solubilization of additional GF within the swollen
Sol matrix and/or in the dissolution medium. Both mechanisms contributed to the
high supersaturation from HyNASDs. The contribution of amorphous GF and GF
solubilization by Sol within the swollen Sol matrix to supersaturation follows the
order: W-Sol-1:3 (180%) > W-Sol-1:1 (eq. 1:3) (130%) > W-Sol-1:1 (100%). Note
that W-Sol-1:1 (eq. 1:3) has the same total Sol content as in W-Sol-1:3, but 2/3rd of
Sol was pre-dissolved in the dissolution medium and it was not part of the W-Sol-1:1
matrix. Incorporating the whole Sol in the spray-dried matrix achieved higher
supersaturation than keeping 1/3rd of Sol in the matrix and pre-dissolving 2/3rd in the
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medium. Apparently, having all Sol in the spray-dried matrix allowed for more
amorphous GF generated during the spray-drying, while also helping the
solubilization of GF within the swollen Sol matrix. On the other hand, having
additional Sol in the dissolution medium generated more supersaturation, as inferred
from the dissolution of W-Sol-1:1 (eq. 1:3) vs. W-Sol-1:1.

Figure 3.13 Evolution of GF dissolution from physical mixture (PM) of GF–Sol–
SDS with 1:3 GF:Sol, spray-dried W-formulations with 1:1, 1:3, and 3:1 GF:Sol, as
well as W-Sol-1:1 (eq. 1:3), which has the same total Sol content as in W-Sol-1:3,
but 2/3rd of Sol was pre-dissolved in the dissolution medium and the remaining 1/3rd
was in W-Sol-1:1 (eq. 1:3). W-M-Sol-1:3 stands for the spray-dried powder prepared
using a suspension-based feed of as-received (micronized) GF. Dissolution sample
size is equivalent to 100 mg GF dose.

It may be argued that the higher supersaturation in HyNASDs as compared
with traditional nanocomposites is solely about GF–Sol interactions/miscibility and
GF solubilization by Sol. W-M-Sol-1:3 was prepared by spray-drying the aqueous
suspension of as-received (micronized, d50: 9.74 µm) GF microcrystals with Sol–
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SDS. W-Sol-1:3 (HyNASD), which contains drug nanocrystals with d50: 0.14 µm and
~20% amorphous GF, generated thrice as much supersaturation as W-M-Sol-1:3,
demonstrating the importance of crystal size in HyNASD for supersaturation
generation. The solubilization of GF particles (microparticles or nanoparticles) in the
Sol matrix and supersaturation generation during the dissolution is a kineticallydriven process, which is limited by the size of the particles: faster solubilization and
higher supersaturation occurred when GF nanoparticles were encapsulated by the Sol
matrix (HyNASD) as compared with the micronized GF particles owing to
approximately 70-times larger surface area of the nanoparticles.

3.4 Conclusions
Spray-drying of an aqueous GF nanosuspension with 1:1 and 1:3 GF:Sol/HPC mass
ratios in the presence of SDS led to formation HyNASDs, which have notable
amorphous GF content unlike traditional drug nanocomposites that typically have
1:0.8 to 1:0.02 drug:polymer mass ratio. To ensure a fair, head-to-head comparison of
HyNASDs to ASDs, ASDs with identical composition were prepared by spray-drying
the organic solution of GF–Sol/HPC–SDS in acetone–water mixture. All spray-dried
powders had acceptable content uniformity. XRPD–DSC–Raman spectroscopy shed
light on the nanocomposite/HyNASD and ASD formation. HPC-based HyNASDs
and ASDs performed equally poorly in enhancing GF supersaturation (50%) in
dissolution tests, whereas Sol-based ones achieved significant supersaturation: up to
360% for ASD and 180% for HyNASD. These results were explained by higher Tg of
Sol than that of HPC, GF–Sol miscibility, stronger molecular interactions between
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Sol–GF than HPC–GF, and excellent nucleation/crystal growth inhibition by Sol as
compared to HPC. The supersaturation generation capability of HyNASDs is largely
controlled by drug–polymer interactions/miscibility as well as the size of the drug
(nano)crystals in the polymeric matrix. Overall, the most striking finding from this
study is that despite having ~80% nanocrystals, HyNASDs provided fast drug
supersaturation (~190% within 20 min) unlike traditional nanocomposites (30%),
which could render nanoparticle formulations more attractive in bioavailability
enhancement of poorly soluble drugs. While HyNASDs did not generate as high
saturation as ASDs, they can be rendered competitive to ASDs upon further
formulation–process

optimization.

Future

research

efforts

will

include

(i) investigation of the storage stability of HyNASDs vs. ASDs under various
environmental conditions, (ii) preparation of HyNASDs with various drug–polymer
pairs and their comparative assessment, (iii) systematic examination of the impact of
various surfactants, and (iv) impact of various drug nanoparticle sizes in the range of
50–1000 nm on drug supersaturation.
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CHAPTER 4
DRUG RELEASE FROM SPRAY-DRIED HYBRID NANOCRYSTALS–
AMORPHOUS SOLID DISPERSIONS (HyNASDs): IMPACT OF SDS

As discussed in Chapter 1, limited supersaturation generation capability is a major
limitation of the drug nanocomposites compared to the ASD formulations. To address
this limitation, a new class of drug nanocomposites called HyNASDs has been
introduced in Chapter 3, which provided significant supersaturation generation in the
dissolution medium. In Chapter 4, we prepared hybrid nanocrystal–amorphous
solution dispersions (HyNASDs) in order to boost the drug release performance of
traditional nanocomposites while elucidating the impact of a common anionic
surfactant, sodium dodecyl sulfate (SDS), on drug release in dissolution tests. To this
end, 2.5% wet-milled griseofulvin (GF, BCS Class II drug) suspensions containing
1:1, 1:3, and 1:5 GF:polymer mass ratios, with 0.125% SDS (below CMC) and
without SDS, were spray-dried. Hydroxypropyl cellulose (HPC) and Soluplus (Sol)
were used as suspension stabilizers and matrix-forming polymers. Examination of
particle sizes in the milled suspensions revealed the criticality of SDS in the
synergistic stabilization of GF nanoparticles. XRPD and DSC results suggest that
nanocomposites and nanocomposites with notable amorphous GF (>10%),
HyNASDs, were formed upon spray-drying. Redispersion of the spray-dried powders
revealed

the

criticality

nanocomposites/HyNASDs,

of

SDS

which

in

could

nanoparticle
be

explained

recovery
by

GF

from

the

wettability

enhancement by SDS, as inferred from the modified Washburn experiment. Results
from in vitro dissolution tests with low (9 mg) GF dose suggest that enhanced
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wettability with SDS and smaller spray-dried particle sizes led to faster GF release.
For 100 mg GF dose (above thermodynamic solubility), Sol provided higher GF
relative supersaturation, e.g., 250% for the HyNASDs (1:5 GF:Sol with SDS) vs.
30% for the nanocomposites (3:1 GF:Sol with SDS), than HPC (up to 50%) owing to
Sol’s stronger intermolecular interactions–miscibility with GF and its kinetic
solubilization–recrystallization inhibition of GF. Higher polymer loading led to
higher supersaturation. SDS provided Sol-based HyNASDs with enhanced wettability
and augmented Sol in solubilizing SDS, leading to fast supersaturation (max. 300%
within 20 min). This study demonstrates how drug release from traditional
nanocomposites could be boosted upon incorporating a drug-miscible, solubilizing
polymer with a low GF:polymer mass ratio and an anionic surfactant.

4.1 Materials and Methods
4.1.1 Materials
BP/EP grade, micronized griseofulvin (GF) purchased from Letco Medical (Decatur,
AL, USA) was used as a challenging Biopharmaceutics Classification System (BCS)
Class II drug because GF nanocrystals exhibit severe aggregation in suspensions, if
improperly stabilized (Bilgili and Afolabi, 2012), and it is known to be a fast
crystallizing drug (Baird et al., 2010). Its solubility is ~8.9 mg/L at 25 °C and ~14.2
mg/L at 37 °C, melting point Tm 220 °C, and a glass transition temperature Tg of 89
°C (Baird et al., 2010). Hydroxypropyl cellulose (HPC, SSL grade, Nisso America
Inc., New York, NY) is a semi-crystalline polymer with low crystallinity and
amorphous domains of very low Tg. It is widely used as a stabilizer during milling

125

and matrix former in the nanocomposites (Azad et al., 2015b; Bhakay et al., 2014a).
Soluplus® (Sol) is an amphiphilic graft copolymer produced from polyvinyl
caprolactam–polyvinyl acetate–polyethylene glycol having a single glass transition
temperature of 73 ± 2 °C (Terife et al., 2012). Even 15% w/v aqueous solutions of
both polymers have less than 60 cP viscosity at 25 °C, which allowed us to perform
milling and spray drying without any processing issue. Sodium dodecyl sulfate
(SDS), an anionic surfactant with a CMC of 8.0 mM at ambient temperature,
purchased from GFS Chemicals, Inc. (Columbus, OH) was used as a wetting agent,
which also helps to stabilize GF nanosuspensions. Wear resistant yttrium zirconia
beads (Zirmil Y, Saint Gobain ZirPro, Mountainside, NJ, USA) with a median size of
430 µm was used as the milling media.
4.1.2 Milling and Spray Drying of Drug Suspensions
Aqueous suspension-based (W:water) feeds of GF prepared by wet milling were fed
to the spray dryer for the preparation of drug nanocomposites. Table 4.1 presents the
formulations used in the precursor feeds. The concentration of GF and SDS was kept
at 2.5% w/v and 0.125% w/v, respectively, in all suspensions. The concentration was
calculated with respect to the 240 mL suspension liquid (deionized water). GF
suspensions were prepared with two polymers (HPC and Sol) with three
drug:polymer mass ratios of 1:1, 1:3, and 1:5 to examine the impact of polymer type
and polymer loading on GF release in the dissolution tests. To prepare a traditional
nanocomposite, a GF nanosuspension with 3:1 GF:Sol (W-Sol-3:1, SDS) was also
prepared. Finally, to investigate the impact of SDS in the stabilization of the milled
GF suspensions and GF release during dissolution tests, surfactant-free suspensions
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having the same drug:polymer mass ratios were also prepared for comparative
analysis.

Table 4.1 Formulations and Compositions of the Aqueous (W) Suspension-Based
Feeds Used in Spray Drying Experiments
ID

Formulationa

W1
W2
W3
W4
W5
W6
W7
W8
W9
W10
W11
W12
W13

W-Sol-1:5
W-Sol-1:3
W-Sol-1:1
W-Sol-1:5, SDS
W-Sol-1:3, SDS
W-Sol-1:1, SDS
W-HPC-1:5
W-HPC-1:3
W-HPC-1:1
W-HPC-1:5, SDS
W-HPC-1:3, SDS
W-HPC-1:1, SDS
W-Sol-3:1, SDS

GF
(% w/v)b
2.5
2.5
2.5
2.5
2.5
2.5
2.5
2.5
2.5
2.5
2.5
2.5
2.5

Polymers
(% w/v)b
12.5
7.5
2.5
12.5
7.5
2.5
12.5
7.5
2.5
12.5
7.5
2.5
0.8

SDS
(% w/v)b
0
0
0
0.125
0.125
0.125
0
0
0
0.125
0.125
0.125
0.125

Water
(mL)
240
240
240
240
240
240
240
240
240
240
240
240
240

a

W denotes suspension-based feed; Sol denotes Soluplus; the ratios refer to the drug:polymer mass
ratios.
b
% w/v with respect to the volume (240 mL) of the deionized water.

In each milling experiment, a shear mixer (Fisher Scientific Laboratory
Stirrer, Catalog No. 14-503, Pittsburgh, PA) was used to disperse as-received GF
particles in aqueous stabilizer (HPC/Sol) solutions with and w/o SDS. The resultant
GF pre-suspensions were transferred to the holding tank of a Microcer wet stirred
media mill (WSMM) (Netzsch Fine Particle Technology, LLC, Exton, PA, USA)
having 80 mL chamber. Milling conditions were adapted from our prior work on wet
media milling (Afolabi et al., 2014; Bilgili et al., 2016). 50 mL of the milling
chamber was filled with zirconia beads, and a screen with 200 µm opening was used
in the outlet of the chamber to hold the beads in the chamber. A peristaltic pump was
used to recirculate the suspension through the chamber at a rate of 126 mL/min and
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the suspension was milled for 64 min at a rotor speed of 3200 rpm. A chiller
(Advantage Engineering Greenwood, IN, USA) was used to maintain the milling
chamber temperature below 35 °C throughout the milling. A portion of each
suspension was separated in a vial and stored for 7 days at 8 °C to assess the shortterm physical stability. Also, the milled suspensions were refrigerated at 8 °C
overnight before spray drying.
Milled GF suspensions were dried using a spray dryer (4M8-Trix, Procept,
Zelzate, Belgium) having a co-current flow set-up. The total length and the diameter
of the spray dryer are 1.59 and 0.15 m, respectively. To ensure complete drying, inlet
temperature was selected above the boiling temperature of the water. Drying air at
120 °C were fed at 0.37–0.40 m3/min at the top of the dryer column to dry the milled
GF nanosuspensions, while 200 g milled suspension of each formulation was fed at
2.0 g/min rate using a peristaltic pump (Make-it-EZ, Creates, Zelzate, Belgium) and
atomized by a bi-fluidic nozzle at the top of the column concurrently to air flow. A
cyclone separator was used to separate the dried particles from the outlet stream into a
glass jar. The residence time was calculated to be ~4.0 s for the feeds. Atomizing air
pressure of 2.0 bar, a bi-fluidic nozzle with tip diameter of 0.6 mm, and cyclone
pressure of 55–60 mbar were selected based on prior experience (Azad et al., 2015b)
and exploratory experiments. The dried particles obtained from the collection jar were
transferred into double plastic bag and stored into a vacuum-desiccator at room
temperature for further characterizations.
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4.2 Characterization Techniques
4.2.1 Particle Size Measurement
Drug particle size distributions (PSDs) in the suspensions were measured using a
laser diffraction (LS 13 320, Beckman Coulter, Miami, FL) based on Mie scattering
theory following the procedure described in Bilgili et al. (2016). Particle sizes were
measured at various time points: right after milling, after 1-day and 7-day storage at 8
°C to in a refrigerator. During the measurement, the intensity was maintained 40–
50% while the obscuration was maintained below 8.0%. Refractive index values are
1.65 for GF (drug) and 1.33 for deionized water (medium). For each measurement, a
2.0 mL suspension sample was diluted with 5.0 mL of the respective stabilizer
solution and mixed using a vortex mixer (Fisher Scientific Digital Vortex Mixer,
Model No: 945415, Pittsburgh, PA) at 1500 rpm for 1 min.
The particle sizes of the spray-dried powders were measured by a
Rodos/Helos laser diffraction system (Sympatec, NJ, USA) based on Fraunhofer
theory following the procedure described in Li et al. (2016b). About 1 g of the
powder sample was placed on top of the sample chute of the Rodos dispersing system
and the sample chute was vibrated at a 100% setting, and 0.1 bar dispersion pressure
was used to suck in the falling powder through the sample cell of the laser diffraction
system. For further confirmation of the particle sizes, spray-dried particles were
placed on a glass slide and observed by Axio Scope.A1 polarized light microscope
(PLM, Carl Zeiss Microscopy GmbH, Göttingen, Germany).
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4.2.2 Solid State Characterization and Drug–Polymer Interactions
To analyze the crystallinity of the as-received GF, HPC, Sol, spray-dried powders,
and physical mixtures of GF–polymer with or w/o SDS, X-ray powder diffraction
(XRPD) (PANanalytical, Westborough, MA, USA), provided with Cu Kα radiation
(λ= 1.5406 Å) was used. The samples were scanned at a rate of 0.165 s-1 for 2θ
ranging from 5° to 40°. The total area under three distinct, non-overlapping peaks of
GF at characteristic diffraction angles of 13.2, 14.6, and 16.5º was calculated for both
the physical mixtures and the spray-dried powders using the equipment’s HighScore
Plus software, which was then used to estimate the crystallinity.
Differential scanning calorimetry (DSC) of the as-received GF, Sol, HPC, and
spray-dried powders was performed using a Mettler-Toledo polymer analyzer
(PolyDSC, Columbus, OH, USA) with integrated STARe 10 software. ~6.0–7.0 mg
powder sample was placed in an aluminum pan with a hole in the lid and loaded into
the DSC machine. As-received GF was heated at a rate of 10 °C/min from 25 °C to
250 °C. All other samples were heated from 25 °C to 70 °C and the temperature was
held for 2 min at 70 °C, then cooled back to 25 °C to remove any residual solvent in
the sample. In the final step, the samples were heated from 25 °C to 250 °C at 10
°C/min. Nitrogen gas was used as the purge gas and protective gas at a flow rate of
50 mL/min and 150 mL/min, respectively. Thermogravimetric analysis (TGA) was
performed to measure the residual water/solvent content using a TGA/DSC1/SF Stare
system (Mettler Toledo, Inc., Columbus, OH). ~6.0–7.0 mg of each spray-dried
sample was placed in a ceramic crucible and heated from 25 °C to 150 °C at a heating
rate of 10 °C/min under nitrogen flow.

130

Raman spectroscopy was conducted using a Fergie Imaging Spectrometer
System (Princeton Instruments, Trenton, NJ) with a 500-mW external diode laser
processing at 785 nm wavelength. Data acquisition time for all spectra was 15 s per
scanned spectrum (100–1800 cm-1) and each spectrum acquired was averaged over
two scans. The data was presented for the range of 1550–1800 cm-1 wavenumber.
4.2.3 Nanoparticle Recovery From the Nanocomposites
Aqueous redispersion of the spray-dried powders was performed following the
method in refs. (Bhakay et al., 2014a; Li et al., 2016b). About 0.5 g of the spray-dried
powders produced from nanosuspension-based (W) feeds was dispersed in 30 mL of
deionized water inside a 60 mL beaker and stirred at 500 rpm for 60 min with a
paddle-stirrer (CAT R18, Scientific Instrument Center Limited, Winchester, UK).
~1.0 mL aliquot of redispersed sample was collected at 2, 10 and 60 min while
stirring, and particle size was measured using laser diffraction (LS 13 320, Beckman
Coulter, Miami, FL). At the same time, a droplet of each redispersed sample was
dried immediately by dropping on a preheated glass slide at 100 °C using a hot plate.
After drying, the polarized light microscope (PLM) was used to capture the images of
the redispersed particles. The details of the experimental methods and PLM images
are presented in Section C.2 of the Appendix C.
4.2.4 Drug Content in the Spray-Dried Powders and In Vitro Dissolution Tests
The drug content in the dried powders varied based on the drug:polymer mass ratios.
To measure the actual drug content, an assay testing was performed by dissolving 100
mg of the sample powders in 20 mL methanol under 30 min of sonication, followed
by overnight storage to ensure complete solubilization of the GF particles. An aliquot
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of 100 µL was taken from the GF solution and diluted up to 10 mL using methanol.
The absorbance of the samples was measured at 292 nm using UV spectrophotometer
(Agilent, Santa Clara, CA, USA), and the drug concentration was calculated from a
pre-established calibration curve. Six replicates were tested for each formulation to
calculate the mean drug content along with the relative standard deviation (RSD).
Drug release from the spray-dried powders and physical mixtures (PMs)
prepared by blending was determined via a Distek 2100C dissolution tester (North
Brunswick, NJ, USA), following the USP II paddle method. 1000 mL deionized
water at 37 °C was selected as the dissolution medium and stirred at 50 rpm paddle
speed. Considering the thermodynamic aqueous solubility of GF, i.e., 14.2 mg/L at 37
°C, a typical low (8.9 mg) dose and high dose (100 mg) of GF would allow for nonsupersaturating and supersaturating dissolution conditions. Although the low dose
may not arouse as much interest as the high dose, a low dose like 8.9 mg may
emulate potent poorly soluble drugs. The spray-dried powders were poured into the
dissolution medium and 4 mL samples were taken out manually at 1, 2, 5, 10, 20, 30,
and 60 min. These aliquots were filtered with a 0.1 µm PVDF membrane-type
syringe filter before UV-spectroscopy measurements to minimize any confounding
effect of the undissolved coarse drug aggregates (Bhakay et al., 2014a; Li et al.,
2016b). In separate dissolution tests, 100 mg equivalent GF was used to allow for
supersaturation in the bulk dissolution medium, which was conducted with additional
sampling at 120, 180, and 210 min. The filtered samples were diluted with deionized
water kept at 37 °C at a ratio of 1 to 5 before UV measurement. Dissolved GF
amount was measured by UV-vis spectroscopy at 296 nm wavelength and calculated
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using a pre-established calibration curve. Deionized water was used as blank before
UV measurement, and six replicates were performed for each sample. In this paper,
relative % supersaturation is reported based on GF concentration at 210 min and
thermodynamic solubility of as-received GF particles, unless otherwise indicated.
4.2.5 Drug Wettability Enhancement by Sol and HPC Solutions With or W/O
SDS
GF wettability was investigated by analyzing the penetration rate of stabilizer
solutions into a packed bed of GF particles inside a cylindrical column according to
the Washburn method (Hołownia et al., 2008; Washburn, 1921). Attension Sigma
700 (Biolin Scientific, Linthicum, MD, USA) set-up was used to measure the mass of
the liquid penetrated the GF powder bed as a function of time. Experimental methods
were adapted from Bilgili et al. (2018) and Li et al. (2017) and the details can be
found in Section C.1 of the Appendix C. In the current study, liquids and powder
refer to GF-saturated aqueous solutions of 15% Sol/HPC with 0.125% SDS or w/o
SDS and as-received GF, respectively. All percentages are (% w/w) with respective
to deionized water. The aqueous solution of the stabilizers and deionized water were
saturated with griseofulvin (GF) and stirred overnight. After overnight stirring, the
saturated solutions were used for further characterization. The apparent shear
viscosity and surface tension of the liquids were measured using R/S Plus Rheometer
(Brookfield Engineering, Middleboro, MA, USA) and Attension Sigma 700 (Biolin
Scientific, Linthicum, MD, USA), respectively. The ratio of the cosine of contact
angles cosθss/cosθw was calculated using the modified Washburn equation and used as
a wetting effectiveness factor. Here, θss is the contact angle between GF and the
stabilizer solutions and θw is the contact angle between GF and deionized water. The
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ratio was used as a rough measure of the drug wettability enhancement upon use of
different stabilizers (HPC/Sol and HPC/Sol–SDS) in water with respect to the GF–
water wettability.
4.2.6 Drug Supersaturation Maintenance Ability of the Polymers
Drug (GF) supersaturation maintenance ability of HPC/Sol with and w/o SDS was
examined in separate desupersaturation tests (similar to Konno et al. (2008)). A
concentrated solution of GF was prepared by dissolving 100 mg of as-received GF
into 20 mL of acetone via sonication for 40 min. This solution was subsequently
added to a 1000 mL of pre-dissolved HPC/Sol solution having 100 and 300 µg/mL
concentrations to maintain 1:1 and 1:3 drug:polymer ratios (similar to the
formulations in Table 4.1), respectively, with or w/o SDS in the USP II paddle type
dissolution tester. The addition resulted in 92–99 µg/mL supersaturated solution of
GF initially (target: 100 µg/mL, corresponding to complete dissolution of 100 mg
drug during dissolution testing). Any subsequent desupersaturation during the
following 210 min was tracked via GF concentration measurements. The
experimental conditions and concentration measurements were identical to those in
the dissolution test. All measurements were carried out in triplicate.

4.3 Results and Discussion
4.3.1 Properties of GF Suspensions Prepared via Wet Stirred Media Milling
Twelve GF suspensions with HPC/Sol at 1:1, 1:3, and 1:5 drug:polymer mass ratios
and 0.125% SDS and without SDS were wet media milled. Figure. 4.1 presents the
characteristic particle sizes of the 64 min milled suspensions and the suspensions after
134

1-day and 7-day storage. As-received GF (unmilled) particles had d50: 9.74 ± 0.23 µm
and d90: 27.4 ± 0.1 µm. After milling for 64 min, median particle sizes d50 were in the
range of 0.146–0.155 µm for W4–W6 (Sol–SDS) and 0.166–0.184 µm for W10–W12
(HPC–SDS) formulations. Unless properly stabilized, GF nanoparticles are known to
form micron-sized aggregates in aqueous suspensions (Bilgili and Afolabi, 2012).
Figure 4.1 suggests that only with SDS, GF nanosuspensions with median sizes d50
less than 200 nm were formed, and the small changes in their d50 and d90 during the 7day storage suggest that these suspensions were physically stable. With SDS, Solbased suspensions were insensitive to Sol loading, whereas finer aggregates were
formed with lower GF:HPC mass ratio (higher polymer loading). On the other hand,
without SDS, Sol-based suspensions with 1:1 and 1:3 GF:Sol exhibited severe
nanoparticle aggregation with a 4 µm median size, whereas submicron median sizes
were observed for HPC-based suspensions. These suspensions also exhibited notable
size increase upon 7-day storage. An increase in polymer concentration led to finer
aggregates.
Due to their relatively neutral charge, stabilizing capability of Sol/HPC solely
depends on their steric effects, which in turn is modulated by their adsorption onto
GF nanoparticle surfaces. The adsorption is dependent on free polymer concentration
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Figure 4.1 Volume-based particle size statistics of the milled GF suspensions with
1:1, 1:3, and 1:5 GF:polymer mass ratios and 0.125% SDS/without SDS after milling
(64 min) as well as 7-day storage at 8 °C: (a) 10% cumulative passing size d10, (b)
median particle size d50 and (c) 90% cumulative passing size d90.
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in the suspension, and usually increases as polymer concentration increases. The finer
aggregates and lower extent of aggregation can be explained by greater polymer
adsorption at higher polymer adsorption, which was already established in an earlier
HPC–GF adsorption study (Bilgili and Afolabi, 2012). Clearly, presence of 0.125%
in the suspensions had the most dramatic effect on the extent of nanoparticle
aggregation. HPC–SDS was reported to have synergistic stabilizing effect on GF
suspensions during milling and storage (Konno et al., 2008) and stabilized multiple
BCS Class II drug nanosuspensions (Bilgili et al., 2016). HPC and Sol imparted steric
stabilization by adsorbing on drug nanoparticles (Bilgili and Afolabi, 2012; Yang et
al., 2014), while the anionic surfactant (SDS) enhanced GF wettability/deaggregation
and helped to stabilize the GF nanosuspensions via electrostatic repulsion (Bilgili and
Afolabi, 2012; Bilgili et al., 2016). As can be seen from Table 4.2, both polymers and
polymer–SDS reduced the surface tension and enhanced the GF wettability by water.
As indicated by the higher wetting effectiveness factor, HPC (hydrophilic polymer)
rendered GF more wettable by water than Sol (amphiphilic polymer), and SDS
enhanced the wettability even further when used in combination with both polymers.
The wettability is important to the deaggregation of the aggregates formed during
milling, which allows for full exposure of GF particle surfaces for polymer
adsorption. The lower wettability of GF by Sol as compared with HPC could be one
reason for the large aggregates in Sol-based suspensions. On the other hand, with
SDS, finer suspensions were obtained with Sol than with HPC, which suggests
differing interactions between polymer–SDS.

137

Table 4.2 Properties of Drug-Saturated Deionized Water–Aqueous Stabilizer
Solutions and Wetting Effectiveness Factor Determined Using the Modified
Washburn Method
Formulation

η
(cP)

ρ
(g/mL)

γ
(mN/m)

Slope,
(g2/s)

R2

cosθss/cosθw

Water
Sol
Sol–SDS
HPC
HPC–SDS

0.89
8.76
13.5
53.2
58.3

1.00
1.01
1.01
1.01
1.01

66.5
41.4
40.5
39.9
34.8

7.0×10-3
1.2×10-3
1.5×10-3
1.5×10-3
2.4×10-3

0.990
0.989
0.991
0.998
0.999

1.00a
2.65
4.65
20.9
42.1

a

The slope of the water penetration data was used as reference for wettability enhancement by the
stabilizer solutions.

4.3.2 Size, Morphology, and Drug–Moisture Content of the Spray-Dried
Powders
Despite the relatively short residence time (4 s), the powders were completely dried,
as indicated by TGA, which shows weight loss of 2.0 ± 0.3% for the samples. The
extremely large surface area generated by atomization of the suspension feed coupled
with the convective heat–mass transfer at high air temperature enabled fast drying of
the droplets in the drying chamber. The mean (actual) drug content after spray-drying
was higher for feeds with higher drug:polymer mass ratio (Table 4.3). All RSD values
were below 6%: 0.51–4.71%, which signifies pharmaceutically acceptable content
uniformity. The lower drug content as compared with the theoretical value can be
attributed to preferential drug loss during handling/transfer of the suspensions after
milling, poor separation of finer particles in the cyclone separator of the spray dryer,
and presence of the residual moisture after drying (Azad et al., 2015b; Bilgili et al.,
2018). An increase in polymer loading (lower drug:polymer mass ratio) led to
formation of coarser particles due to increase in total solids loading and higher
viscosity of the precursor feed (Bilgili et al., 2018; Li et al., 2018b; Poozesh and
Bilgili, 2019). Compared to the significant impact of polymer loading on particle size,
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the impact of SDS was weak and did not exhibit a clear trend. The microscopic
images (Figure 4.2) illustrate that spray-dried particles are somewhat aggregated due
to their cohesive nature and individual particles have rounded–shriveled morphology.

Figure 4.2 Polarized light microscope images of the spray-dried particles prepared
using the GF suspension-based (W) feed with 1:3 GF:polymer mass ratios and
0.125% SDS/without SDS: (a) W-HPC-1:3 (b) W-HPC-1:3, SDS, (c) W-Sol-1:3, and
(d) W-Sol-1:3, SDS. All images were taken at 50X magnification (scale bar: 20 µm).

4.3.3 Formation of Drug Nanocomposites/HyNASDs
Figure 4.3 illustrates the XRPD diffractograms of the spray-dried powders, while
Table 4.4 presents their crystallinity. X-ray diffractograms depict that as-received GF
exhibited intense peak characteristics of a crystalline material, whereas HPC/Sol
exhibited halo pattern indicating amorphous structure. The physical mixtures (PMs),
prepared by blending of as-received GF with HPC/Sol or HPC/Sol–SDS powders,
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Table 4.3 Particle Size Statistics of the Spray-Dried Powders and Their Drug Content

ID
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W1
W2
W3
W4
W5
W6
W7
W8
W9
W10
W11
W12
W13
a

Formulationa

Particle size statistics of the spray-dried particles
(µm)

W-Sol-1:5
W-Sol-1:3
W-Sol-1:1
W-Sol-1:5, SDS
W-Sol-1:3, SDS
W-Sol-1:1, SDS
W-HPC-1:5
W-HPC-1:3
W-HPC-1:1
W-HPC-1:5, SDS
W-HPC-1:3, SDS
W-HPC-1:1, SDS
W-Sol-3:1, SDS

d10±SD
10.8±0.4
5.68±0.1
4.02±0.2
10.3±0.1
9.29±0.1
4.48±0.1
9.73±0.3
6.41±0.1
4.61±0.1
8.32±0.2
6.37±0.1
5.24±0.1
1.66±0.1

d50±SD
21.8±0.3
16.2±0.0
10.4±0.1
20.3±0.1
19.0±0.1
10.1±0.1
22.3±0.4
20.3±0.1
14.9±0.4
21.0±0.8
16.5±0.6
12.9±0.1
6.89±0.3

d90±SD
39.8±0.5
31.9±0.1
20.0±0.0
36.4±0.3
33.6±0.1
21.9±0.2
46.0±0.7
41.8±0.3
35.8±0.6
44.3±0.8
40.0±0.1
34.2±0.1
15.3±0.4

W denotes suspension-based feed; Sol denotes Soluplus; the ratios refer to the drug:polymer mass ratios.
% w/w with respect to the total weight of the spray-dried powder.

b
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Theoretical drug
content
(% w/w)b

Actual drug
content, RSD
(% w/w, %)b

16.7
25.0
50.0
16.5
24.7
48.8
16.7
25.0
50.0
16.5
24.7
48.8
72.3

15.4, 2.34
22.3, 4.47
44.1, 4.31
14.9, 3.47
21.2, 1.50
42.0, 1.73
14.9, 4.71
22.8, 4.60
45.4, 1.77
15.3, 1.48
22.3, 3.14
42.5, 2.83
64.4, 0.51

exhibited peaks at the same diffraction angles as those of as-received GF, albeit with
reduced intensity. The diffractograms of the spray-dried powders without SDS
(Figure 4.3a) and with SDS (Figure 4.3b) did not remarkably differ, except for peak
intensities; they exhibit a similar pattern regarding the impact of polymer loading.
The peak intensities of GF in the PMs were lower than those of the as-received GF
powder, which can be attributed to the dilution and surface coverage of GF
microparticles with HPC/Sol, and the reduction is more discernible with increasing
polymer concentration. Similar XRPD diffractograms to those of the PMs were
observed for the spray-dried powders confirming that spray-drying of the milled
suspensions led to formation of nanocomposites that are largely crystalline.
Interestingly, the diffractograms of the spray-dried powders displayed reduced peak
intensities as compared with their respective PMs, beyond the aforementioned
dilution effect of the polymer, which becomes more pronounced upon an increase in
polymer loading (lower drug:polymer mass ratio). Surprisingly, wet milling followed
by spray-drying led to reduction of crystallinity and formation of notable (up to 21%)
amorphous GF (see Table 4.4). To the best knowledge of the authors, this level of
amorphous content in drug nanocomposites is not common.
It is well-known that wet media milling does not cause any detectable
amorphization of as-received GF, in the absence of stabilizers, due to plasticization
effect of water (Monteiro et al., 2013; Żarów et al., 2011). XRPD diffractograms of
the wet-media milled GF and as-received GF were almost identical (Monteiro et al.,
2013) In the presence of high polymer loading in the suspensions here, however,

141

amorphization of GF took place during the spray drying. Table 4.4 shows that despite
being largely crystalline, the spray-dried powders had higher amorphous GF when

Figure 4.3 X-ray diffractograms of as-received GF, HPC, Sol, physical mixtures
(PMs) of GF–HPC/Sol and the spray-dried powders prepared using the GF
suspension-based (W) feed with 1:1, 1:3, and 1:5 drug:polymer mass ratios: (a)
without SDS and (b) with 0.125% SDS in the suspension. W-Sol-3:1, SDS and PMSol-3:1, SDS stand for the spray-dried powder prepared using a suspension-based
feed with 3:1 GF:Sol mass ratio and 0.125% SDS and its corresponding physical
mixture, respectively.
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Table 4.4 Melting Point Temperature and Fusion Enthalpy of the Spray-Dried
Powders Obtained From DSC Thermograms and Crystallinity Estimated From XRPD
Diffractograms
ID
W1
W2
W3
W4
W5
W6
W7
W8
W9
W10
W11
W12
W13

Formulationa
W-Sol-1:5
W-Sol-1:3
W-Sol-1:1
W-Sol-1:5, SDS
W-Sol-1:3, SDS
W-Sol-1:1, SDS
W-HPC-1:5
W-HPC-1:3
W-HPC-1:1
W-HPC-1:5, SDS
W-HPC-1:3, SDS
W-HPC-1:1, SDS
W-Sol-3:1, SDS

Tm (ºC)b
171
181
205
168
186
204
189
199
211
172
198
211
212

Hf (J/g)b
1.56
3.23
19.6
2.46
7.37
22.7
8.34
12.0
28.0
3.54
12.7
28.7
47.0

Tm (ºC)b
49.1
39.1
15.1
52.1
34.1
16.1
31.1
21.1
9.1
48.1
22.1
9.1
8.1

Crystallinity (%)
80.3
86.8
93.9
78.8
81.3
86.3
80.8
82.7
99.2
81.8
86.5
95.5
92.1

a

W denotes nanosuspension-based feed, Sol denotes Soluplus; the ratios refer to the drug:polymer mass
ratios.
b
Tm stands for melting point temperature, Tm stands for melting point depression, and Hf stands for
fusion enthalpy.

the polymer loading in the precursor suspension was higher. In general, more
amorphous GF formed in the Sol formulations than in the HPC formulations at the
same drug:polymer mass ratio with/without SDS except for 1:3 GF:polymer without
SDS. These findings imply that (i) amorphous GF formed due to GF–polymer
molecular interactions and/or solubilization of the surface layer of nanoparticles by
the polymer during the spray-drying and (ii) Sol appears to favor the amorphization
of

GF

more

than

HPC,

which

implies

stronger

Sol–GF

molecular

interactions/miscibility than HPC–GF. It is likely that presence of GF nanoparticles
and their aggregates with large surface area and higher polymer loading (more GF–
polymer interactions and higher GF solubilization in the polymer) could have favored
the formation of amorphous GF. Based on these findings and ref. (Kayaert and Van
den Mooter, 2012), it is proposed that the polymeric matrix of the spray-dried
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particles encapsulates drug nanocrystals/aggregates, surrounded by a layer of
amorphous GF molecularly dispersed in the polymer (see Figure 4.4b). Formation of
amorphous content upon drying of drug nanosuspensions was first noted in (Kayaert
and Van den Mooter, 2012), albeit to a lower extent, and was regarded as
“unfavorable”. Nonetheless, the impact of such amorphous content on drug release
from the nanocomposites has not been studied at all. As the dissolution tests will
reveal, despite being largely crystalline, these nanocomposites with relatively high
polymer loading (low drug:polymer ratio) allow for much higher supersaturation than
traditional nanocomposites, similar to the supersaturation levels observed for ASDs;
hence, we coin the term hybrid nanocrystal–ASD (HyNASD) for this special class of
nanocomposites.
The DSC thermograms in Figure 4.5 show an endothermic peak associated
with melting of as-received GF, with a melting point temperature Tm of 220.1 °C and
a fusion enthalpy ΔHf of 101.8 J/g; a glass transition for Sol (amorphous) at 72.4 °C;
and a slight endothermic event around 170–200 °C for HPC likely due to the melting
of the small crystalline domain of largely amorphous HPC (Sarode et al., 2013)
(crystallinity was undetectable by XRPD). The Tg of HPC could not be measured (in
the range of –25 to 0 °C (Sarode et al., 2013)) due to limitation of our equipment. The
spray-dried powders exhibited a melting endotherm only, corresponding to the fusion
of their GF crystals. The absence of any recrystallization event during the heating
could suggest that the amorphous GF in HyNASDs did not recrystallize due to GF–
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Figure 4.4 Schematic illustration of the solid state of the drug (GF) in (a) GF nanocomposite, (b) GF hybrid nanocrystal–
amorphous solid dispersion (HyNASD), and (c) GF amorphous solid dispersion (ASD). Figure is not drawn to scale.
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polymer molecular interactions as the small amorphous GF was in the ASD
surrounding the drug crystals (see Figure 4.4b).

Figure 4.5 DSC thermograms of as-received GF, HPC, Sol, and the spray-dried
powders prepared using the GF suspension-based (W) feed with 1:1, 1:3, and 1:5
drug:polymer mass ratios: (a) without SDS and (b) with 0.125% SDS in the
suspension. W-Sol-3:1, SDS stands for the spray-dried powder prepared using a
suspension-based feed with 3:1 GF:Sol mass ratio and 0.125% SDS.
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Wet media milling of as-received GF without any stabilizers depressed Tm by
less than 1 ºC (Monteiro et al., 2013). On the other hand, Figure 4.5 and Table 4.4
show that spray-drying of GF suspensions with polymers led to drastic melting point
depression (high ΔTm), up to 52 ºC, and reduction of ΔHf even if the ΔHf values were
corrected for dilution with polymer and reduced crystallinity (not shown for brevity).
The significant melting point depression in drug–polymer mixtures is indicator of
drug–polymer miscibility (Baird and Taylor, 2012; Newman et al., 2008). In general,
higher polymer loading (lower GF:polymer mass ratio) led to lower Tm as compared
with the as-received GF crystals, higher ΔTm, and lower ΔHf, regardless of the
presence/absence of SDS, which signifies significant GF–polymer molecular
interactions. Moreover,

without

exceptions,

having

identical

polymer/SDS

composition, the spray-dried powders with Sol had higher ΔTm and lower ΔHf than
those with HPC, which could be explained by (i) stronger GF–Sol interactions and
miscibility, (ii) higher initial amorphous content in the Sol-based spray-dried
powders, and (iii) higher extent of solubilization of GF in the polymer melt at high
temperatures due to the thermal treatment during the DSC scan. Compared with the
clear trends regarding the impact of polymer loading for formulations with/without
SDS, the trends for SDS impact were not as strong and as clear. For HPC-based
formulations, the impact of SDS was small and only notable for the highest HPC
loading (1:5), which exhibited higher ΔTm and lower ΔHf with SDS than without
SDS, implying increased solubilization of GF in the presence of SDS. For Sol-based
formulations, the impact of SDS was small at 1:1 GF:Sol loading. While lower ΔHf
without SDS than with SDS was noted for all GF:Sol powders, ΔTm did not follow a
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clear trend. The relatively low impact of SDS could be related to the small amount of
SDS in the formulations (1:0.05 GF:SDS).
4.3.4 Raman Spectroscopy and Drug–Polymer Miscibility
The observed Raman lines in Figure 4.6 for as-received GF and PMs of GF are
largely in agreement with Fourier transform Raman data of ref. (Feng et al., 2008)
and Raman data of ref. (Żarów et al., 2011) for crystalline GF. While the W-Sol-1:3
and W-HPC-1:3 powders did not show disappearance of any lines characteristic of
GF, their spectra clearly show broadening of the characteristic GF lines, peak
intensity reduction, and line shifts as compared with the spectra of the respective PMs
due to GF–polymer interactions (Meng et al., 2015) and presence of amorphous
domains in these powders (Baird et al., 2010). In contrast, the spectra of W-Sol-3:1
with SDS, having 1/9th of Sol content compared with W-Sol-1:3 with SDS, did not
show as much line broadening and line shift compared to the spectra of its respective
PM. Finally, the line at 1606 cm-1 does not exist in amorphous GF (Żarów et al.,
2011); hence, intensity reduction and line broadening/slight line shift at 1606 cm-1
could originate from the presence of amorphous GF content.
It is suggested that if the solubility parameter difference between a drug and
polymer is <7.0 MPa1/2, they are likely to be miscible; if the difference is >10 MPa1/2,
they are considered immiscible (Forster et al., 2001; Greenhalgh et al., 1999). The
solubility parameters of GF, HPC, and Sol are 12.2 (Thakral and Thakral, 2013), 24.0
(Choi et al., 1994), and 19.4 (Kolter et al., 2012) MPa1/2, respectively. The solubility
parameter differences between GF–Sol and GF–HPC are 7.2 and 11.8 MPa1/2,
respectively, which suggests that GF–Sol is borderline miscible, whereas GF–HPC is
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immiscible. Despite being useful, a caveat about the solubility parameters is worthnoting: the theoretical models of this approach are applicable for simple molecular

Figure 4.6 Raman spectra of as-received GF, physical mixtures (PMs) of GF–
HPC/Sol at 1:3 drug:polymer ratio, and the spray-dried powders prepared using the
GF suspension-based (W) feed with 1:3 GF:polymer mass ratio: (a) with SDS and (b)
without SDS in the suspensiom. W-Sol-3:1, SDS and PM-Sol-3:1, SDS stand for the
spray-dried powder prepared using a suspension-based feed with 3:1 GF:Sol mass
ratio and 0.125% SDS and its corresponding physical mixture, respectively.
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structures wherein van der Waals force plays a predominant role, while for drug–
polymer systems which are known to form highly directional interactions (e.g.,
hydrogen bonding) or long-range interactions (e.g., ionic interaction), this approach
can be erroneous (Baird et al., 2010; Meng et al., 2015). Indeed, the formation of
amorphous GF upon spray-drying with HPC-based suspensions, drastic melting point
depression and reduced ΔHf in the spray-dried powders (even after corrected for
crystallinity and GF loading) and the Raman spectroscopy results above suggest that
HPC molecularly interacts with GF, resulting in partial miscibility unlike the
prediction from the solubility parameters. However, the solubility parameters
correctly predicted the higher Sol–GF–miscibility than the HPC–GF miscibility,
which is in in line with the DSC and XRPD results.
The XRPD, DSC, and Raman spectroscopy results overall suggest that spraydrying of GF–polymer nanosuspensions with/without SDS led to formation of drug
nanocomposites/HyNASDs. Although a hard and crisp distinction between traditional
nanocomposites and HyNASDs is not intended here, HyNASDs appear to have
notable amorphous content (>%10 in XRPD) and/or exhibit significant Tm
depression–ΔHf reduction and GF Raman peak broadening as compared with the
respective physical mixtures. As a general observation, we note that spray-drying a
drug nanosuspension with a lower drug:polymer mass ratio (1:3 and 1:5) than
typically used (see e.g., Table 1.3) and the use of a strongly miscible polymer that
interacts with the drug nanoparticles and solubilizes them during the spray drying
favor the formation of HyNASDs vs. nanocomposites (W-Sol-1:3 vs. W-Sol-3:1).
Moreover, as will be shown in Section 4.3.7, nanocomposites and HyNASDs may
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behave quite differently in their functional responses such as in vitro drug release.
4.3.5 Redispersibility of the Spray-Dried Powders
Spray-dried powders were dispersed in 30 mL of deionized water inside a 60 mL
beaker and stirred at 500 rpm for 60 min, and particle sizes of the suspension samples
taken 2, 10, and 60 min into redispersion are presented in Figures 4.7 and 4.8 for
HPC-based and Sol-based formulations, respectively. Ideally, the redispersion of the
powders should yield particles with sizes similar to those in the milled suspensions. A
cursory look at these figures suggests that redispersion of the powders with SDS
achieved this ideal expectation: fast recovery of the drug nanoparticles that have
similar sizes to those in the precursor suspensions. The only exception was W-Sol1:1, SDS, which has the lowest Sol loading and had d90 above 1 µm. Without SDS,
most spray-dried powders exhibited slow or incomplete redispersion. Among Solbased powders only W-Sol-1:5 (with the highest Sol loading) exhibited complete
redispersion, whereas W-Sol-1:1 and W-Sol-1:3 redispersed extremely slowly
(incomplete redispersion). On the other hand, even without SDS, all HPC-based
powders were able to redisperse to different extents. Note that GF is a relatively
hydrophobic drug (Muster and Prestidge, 2005), while HPC is hydrophilic, and Sol is
amphiphilic. Based on modified Washburn method and results presented in Table 4.2,
we note (i) the higher wettability enhancement by HPC as compared with Sol in
aqueous solutions and (ii) higher wettability enhancement when SDS was present
along with the polymer in the aqueous solutions. Hence, the wettability of the spraydried powder largely controls the redispersion behavior. Although the spray-dried
powders encapsulate the drug crystals/amorphous GF, depending on the polymer
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loading, the surface will still have hydrophobic GF exposed to water. The dissolving
polymer/SDS in the microenvironment of the particles enhances wettability of the
hydrophobic drug and allows for faster imbibition/absorption of water in the particle,
which facilitates the redispersion.

Figure 4.7 Volume-based particle size statistics of the GF suspension-based (W)
feeds with 1:1, 1:3, and 1:5 GF:HPC mass ratios and 0.125% SDS/without SDS
before spray drying (SD) (after 1 day of milling), after spray drying (spray-dried
powders), and the spray-dried particles after redispersion in deionized water for 2
min, 10 min, and 60 min: (a) median particle size d50 and (b) 90% passing size d90.
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Figure 4.8 Volume-based particle size statistics of the GF suspension-based (W)
feeds with 1:1, 1:3, and 1:5 GF:Sol mass ratios and 0.125% SDS/without SDS before
spray drying (SD) (after 1 day of milling), after spray drying (spray-dried powders),
and the spray-dried particles after redispersion in deionized water for 2 min, 10 min,
and 60 min: (a) median particle size d50 and (b) 90% passing size d90.
4.3.6
Dissolution Performance of the Spray-Dried Powders in NonSupersaturating Condition
The temporal evolution of GF release from the spray-dried powders and the PM with
the highest polymer loading (1:5 GF:polymer) containing 8.9 mg equivalent GF dose
in 1000 mL deionized water at 37 ºC was investigated. The bulk dissolution medium
will not supersaturate for this low drug dose as the GF solubility is 14.2 mg/L. We
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note from Figure 4.9 that the mere presence of HPC/Sol (1:5 GF:polymer mass
ratio)/SDS could increase GF release rate without any wet-milling–spray drying of
the as-received (micronized) GF particles. This could be partly explained by the
wetting enhancement of the hydrophobic drug (GF) in the presence of HPC/Sol–SDS
(Table 4.2), deaggregation of the large drug aggregates present in the as-received
drug (Li et al., 2017b), and partly by the higher solubility of GF in the dissolution
medium due to dissolution of PM’s polymer/SDS in the dissolution medium. For
example, the thermodynamic solubility of the GF microparticles at 37 °C was
measured to be 14.2 mg/L, 17.8 mg/L, and 18.3 mg/L in the deionized water, aqueous

Figure 4.9 Evolution of drug release from as-received GF, physical mixture (PM)
with 1:5 GF:polymer mass ratio, and spray-dried powders prepared using GF
suspension-based (W) feeds with 1:1, 1:3, and 1:5 drug:polymer mass ratios: (a) HPC
without SDS, (b) HPC with SDS, (c) Sol without SDS, and (d) Sol with SDS.
Dissolution sample size equivalent to 8.9 mg GF dose (low dose, non-supersaturating
condition in the bulk dissolution medium).
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medium of 1:3 GF:Sol with SDS, and aqueous medium of 1:3 GF:HPC with SDS,
respectively. However, the spray-dried powders released GF faster than the PM
owing to the presence of GF nanoparticles/aggregates with larger surface area than
drug microcrystals and amorphous GF that has higher kinetic solubility than
crystalline GF.
A quick comparison of Figure 4.9b to 4.9a and Figure 4.9d to 4.9c reveals that
the spray-dried powders with SDS dissolved faster than those without SDS, which is
in accordance with the expectations from the redispersion results and the wetting
effectiveness factors presented in Table 4.2. The dissolution profiles of the powders
with SDS all exhibited fast, immediate drug release (>80% GF release in 20 min) and
their dissolution profiles are hard to differentiate. The presence of SDS imparted
wettability enhancement to the spray-dried powders, allowed for their faster
redispersion and recovery of the nanoparticles with small extent of aggregation, and
ultimately faster GF release. For powders with SDS, wettability may not be the ratelimiting process in drug dissolution; hence, other factors such as spray-dried particle
size might have played a role. For example, the fastest-dissolving powder, i.e., WHPC-1:1, SDS in Figure 4.9b had the smallest spray-dried particles. Without SDS,
the HPC-based powders exhibited faster GF release at higher HPC loading despite
larger size of the particles; whereas such monotonic behavior was not observed for
the Sol-based powders: 1:1 GF:Sol released GF faster than 1:3 GF:Sol, while 1:5
GF:Sol achieved the fastest drug release. These somewhat nuanced trends resulted
from differing spray-dried particle sizes, redispersibility, and drug particle sizes in the
precursor suspensions, and cannot be predicted by the redispersion results in Figure
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4.7 and Figure 4.8 also because of the different volume and microhydrodynamics in
the redispersion and dissolution tests. Owing to 1000 mL volume in the dissolution
test vs. 30 mL in the redispersion test, drug dissolution simultaneously occurred along
with erosion of the polymeric matrix in the dissolution test, which allowed
redispersion of 1:1 and 1:3 GF:Sol particles without SDS in the dissolution test,
whereas these powders did not redisperse much over 60 min in the redispersion test.
4.3.7 Dissolution Performance of the Spray-Dried Powders in Supersaturating
Condition
The temporal evolution of GF release from the spray-dried powders and the PM with
the highest polymer loading (1:5 GF:polymer) containing 100 mg equivalent GF dose
in 1000 mL deionized water at 37 ºC was investigated. The bulk dissolution medium
could supersaturate for this high drug dose as the GF solubility is 14.2 mg/L. Unless
otherwise specified, all supersaturation values are relative to aqueous thermodynamic
solubility of GF and calculated at 210 min. Considering that the major shortcoming of
traditional drug nanocomposites with low polymer loading (like W-Sol-3:1, SDS) as
compared with amorphous solid dispersions (ASDs) is their limited supersaturation
capability in dissolution media, the examination of drug dissolution under
supersaturating condition is critical. A cursory look at Figure 4.10 reveals
immediately various general trends: (i) the spray-dried powder could generate GF
superstation more than the corresponding PM for 1:5 GF:polymer, (ii) the GF
supersaturation was higher for spray-dried powders with SDS than those without
SDS, and (iii) Sol-based formulations generated much higher supersaturation than
HPC-based formulations especially when the formulation included SDS. These
results point to the criticality of the wet-media milling in preparing drug nanoparticles
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especially in the presence of SDS, wettability of the spray-dried powder, which was
enhanced by SDS (Table 4.2), GF–polymer miscibility (refer to Section 4.3.4), and
solubilization of the GF by the polymer/SDS.

Figure 4.10 Evolution of drug release from as-received GF, physical mixture (PM)
with 1:5 GF:polymer mass ratio, and spray-dried powders prepared using GF
suspension-based (W) feeds with 1:1, 1:3, and 1:5 drug:polymer mass ratios: (a) HPC
without SDS, (b) HPC with SDS, (c) Sol without SDS, and (d) Sol with SDS.
Dissolution sample size equivalent to 100 mg GF dose (high dose, supersaturating
condition in the bulk dissolution medium). W-Sol-3:1, SDS stands for the spray-dried
powder prepared using a suspension-based feed with 3:1 GF:Sol mass ratio with
0.125% SDS.

During the dissolution test, as water wets and imbibes into the spray-dried
particles, their polymer dissolves and the particles redisperse into smaller GF–
polymer/SDS clusters depending on the wettability, while their amorphous GF
fraction

contributes

to

the

dissolution
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fast.

In

the

polymer/SDS-rich

microenvironment of the particles and clusters released, GF could be solubilized by
the polymer/SDS, and the rate of this process depends on the cluster/particle size, GF
particle size inside these clusters as well as the drug:polymer mass ratio and
presence/absence of SDS. Unfortunately, depending on the polymer–drug miscibility
and interactions, amorphous content of the HyNASDs (see Table 4.4 for the
crystallinity) may phase-separate and recrystallize upon contact with water in the
dissolution medium (Alonzo et al., 2011; Chen et al., 2015) because water acts as a
plasticizing agent, reducing the glass transition of the ASD component of HyNASDs
and enhancing the mobility of the drug molecules (Chen et al., 2015). Finally, the
supersaturated GF in the dissolution medium and the released drug nanoparticles
form a metastable system, and GF could recrystallize on existing GF nanoparticles
and cause their growth, with ensuing GF desupersaturation in time. Strong drug–
polymer interactions can reduce the drug molecular mobility and delay
recrystallization onset time and the extent of recrystallization (Mistry et al., 2015).
Similarly, ref. (Kothari et al., 2015) found that the recrystallization time of nifedipine
increased with an increase in polymer (PVP) concentration. To gain additional
insights into the GF recrystallization inhibition capability of Sol/HPC–SDS in
solutions, independent desupersaturation experiments were performed. Figure 4.11
presents the GF desupersaturation curves. Supersaturation was attained fast upon
mixing a GF solution with deionized water and aqueous HPC/Sol/SDS solutions. The
supersaturation was largely maintained up to ~210 min with Sol and Sol–SDS,
signifying the superior inhibition capability of Sol. GF without any inhibitor and with
SDS alone recrystallized fast as GF is a fast recrystallizing compound (Baird et al.,
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2010). HPC and HPC–SDS could not maintain supersaturation long unlike Sol.

Figure 4.11 GF desupersaturation curves for a supersaturated 20 mL GF–acetone
solution mixed with 1000 mL aqueous solutions of 300 µg/mL and 100 µg/mL of
HPC/Sol–5 µg/mL SDS or w/o SDS (corresponding to 1:3 and 1:1 polymer:drug
formulations), 5 µg/mL SDS only, and deionized water (without any recrystallization
inhibitor). The initial concentration of GF right after mixing was targeted at 100
µg/mL.

A comparison of Figure 4.10a vs. 4.10b and wetting effectiveness factors in
Table 2.2 suggest that wetting enhancement with SDS helped to increase the GF
release, but even with SDS, the HPC-based spray-dried powders did not generate
more than ~50% supersaturation. HPC-SSL has sub-ambient glass transition
temperature Tg (Sarode et al., 2013) (much lower than Tg of Sol: 73 ± 2 °C) and the
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amorphous GF molecularly dispersed in HPC matrix of the HyNASDs may have
recrystallized due to plasticizing action of water. Moreover, due to HPC’s partial
miscibility with GF, its relatively weak molecular interactions with GF as compared
with Sol, as well as its poor GF nucleation/crystal growth inhibition (refer to Figure
4.11), HPC-based HyNASDs did not generate significant supersaturation even at 1:5
GF:HPC with SDS. While HPC has been used in both marketed drug nanocrystal
products and in academic research for preparation of drug nanosuspensions and drug
nanocomposites (Bhakay et al., 2018b; Li et al., 2016a), we find here that its SSL
grade is not effective in solubilizing GF, preventing GF recrystallization, and
achieving high GF supersaturation.
What is remarkable about the dissolution results in Figure 4.10c and 4.10d is
that Sol-based HyNASDs with SDS could generate high GF supersaturation fast (up
to 300% within 20 min), which is not common in pharmaceutical nanotechnology
literature. HyNASDs (1:5 GF:Sol with SDS) achieved 250% GF supersaturation vs.
30% achieved by the traditional nanocomposites with low polymer loading (3:1
GF:Sol with SDS). Traditional nanocomposites with drug:polymer mass ratios in the
1:0.8–1:0.02 range usually generate supersaturation up to 50% (see e.g., (Bhakay et
al., 2014a; Müller et al., 2011; Zuo et al., 2013)). The high supersaturation achieved
by HyNASDs was not possible without SDS because HyNASDs without SDS
exhibited retarded release of GF nanoparticles due to poor wettability (see Table 4.2)
and they had significant fraction of GF nanoparticle aggregates; both can be inferrred
from the poorer redispersibility (Figures 4.7 and 4.8) and the coarser GF particle sizes
in the precursor suspensions without SDS (Figure 4.1). Sol was responsible for the
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high supersaturation owing to its stronger intermolecular interactions–miscibility with
GF affording kinetic solubilization of GF and its inhibition of GF recrystallization
(refer to Figure 4.11). Finally, with a Tg of 73 ± 2 °C, Sol prevented recrystallization
of amorphous GF molecularly dispersed in the HyNASD during the dissolution test.
Another trend in Figure 4.10d was evident: an increase in Sol loading led to higher
GF supersaturation/drug release. One reason for this is the higher amorphous content
in HyNASDs at higher polymer loading (Table 4.4), which contributed to the faster
supersaturation generation, as in ASDs. Moreover, higher Sol loading with respect to
GF helped the solubilization of smaller GF nanocrystals within the Sol matrix of the
spray-dried particles and drug–Sol clusters emanating from them in the dissolution
medium.
Besides its drastic effect on wettability and drug particle size in Sol-based
formulations, SDS also helped to delay GF crystallization, despite the fact that SDS
alone could not suppress GF recrystallization (Figure 4.11). Presence of SDS might
have contributed to the solubilization of GF in the Sol–SDS matrix during the spray
drying and the dissolution. To better elucidate the roles of SDS, SDS was added to
the dissolution medium to form 0.0005% and 0.125% w/v solutions. Then, the spraydried powder without SDS (W-Sol-1:5) was dissolved in such media and its
dissolution was compared with that of W-Sol-1:5, SDS in water. Here, 0.0005%
corresponds to SDS level that would be achieved upon complete dissolution of WSol-1:5, SDS powder, while 0.125% (still below CMC) was present in the precursor
drug nanosuspensions, whose examination may reveal the impact of high SDS within
or in the neighborhood of the swollen spray-dried particles. The analysis of external
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addition of SDS to the dissolution medium vs. internal addition of SDS to the
formulation allowed us to elucidate if there is any other effect of SDS besides its
wettability enhancement. Figure 4.12 shows that adding SDS externally to the
dissolution medium improved the GF release from W-Sol-1:5 significantly and higher
SDS concentration achieved higher supersaturation, which can be explained by
wettability enhancement and redispersion of the GF nanoparticle aggregates of WSol-1:5 in the dissolution medium. On the other hand, W-Sol-1:5, SDS (SDS
internally added as part of the formulation) achieved the highest GF supersaturation

Figure 4.12 Evolution of drug release from spray-dried powders prepared using GF
suspension-based (W) feeds with 1:5 drug:polymer mass ratio and SDS and without
SDS in the formulation. Deionized water was used as the dissolution medium for the
formulation with SDS (W-Sol-1:5, SDS). For the formulation without SDS (W-Sol1:5), aqueous solution of 0.125% w/v SDS, aqueous solution of 0.0005% w/v SDS,
and deionized water were used as dissolution media. Dissolution sample size
equivalent to 100 mg GF dose (high dose, supersaturating condition in the bulk
dissolution medium).
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in water, implying that internal addition of SDS helped Sol in solubilizing GF during
the

spray-drying

and

dissolution

besides

its

favorable

effect

on

the

wetting/deaggregation of GF aggregates. Such solubilizing effect of SDS has been
reported in earlier studies on drug ASDs (Lu et al., 2014; Sjökvist et al., 1991).

4.4 Conclusions
Spray-drying of wet-milled GF suspensions with high polymer loading (1:1 to 1:5
GF:polymer mass ratio) with HPC/Sol as polymer and with/without SDS led to
formation of a special class of nanocomposites, HyNASDs, which contain drug
nanocrystals and aggregates surrounded by notable amorphous content (5%–21%)
molecularly dispersed in the polymeric matrix. All spray-dried powders had
acceptable content uniformity. XRPD–DSC–Raman spectroscopy shed light on the
nanocomposite/HyNASD formation and revealed higher GF miscibility–stronger
molecular interactions for Sol–GF than for HPC–GF. Redispersion of the HyNASD
powders indicated the critical need for wettability enhancement by SDS. The
HyNASDs with SDS exhibited fast, immediate release in non-supersaturating
dissolution condition; the ones without SDS exhibited slower GF release, whose
profile depended on polymer loading and spray-dried particle size. Under
supersaturating dissolution conditions (high GF dose), HPC-based HyNASDs
performed poorly in enhancing GF supersaturation (up to 50% even with SDS),
whereas Sol-based ones with SDS achieved fast supersaturation: up to 300% within
20 min and maintained supersaturation at 250% after 3 h. These results were
explained by higher Tg of Sol than that of HPC, higher GF–Sol miscibility, stronger
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molecular interactions between Sol–GF than HPC–GF, excellent nucleation/crystal
growth inhibition by Sol as compared to HPC as well as wettability–solubilization
enhancement by SDS. The supersaturation generation capability of HyNASDs was
largely controlled by presence of SDS either in the formulation or in the dissolution
medium, drug–polymer interactions/miscibility as well as the size of the drug
(nano)crystals in the polymeric matrix. Overall, the most striking finding from this
study is that despite having ~80% nanocrystals, Sol-based HyNASDs with SDS
provided fast drug supersaturation and maintained it at 250% unlike traditional
nanocomposites (10%–60%), which could render nanoparticle formulations more
attractive in bioavailability enhancement of poorly soluble drugs. In a forthcoming
paper, we will compare the dissolution performance of HyNASDs with ASDs having
identical formulation. Future research efforts will include investigation of the storage
stability of HyNASDs under various environmental conditions and preparation of
HyNASDs with various drug–polymer–surfactants and their comparative assessment.
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CHAPTER 5
IMPACT OF SDS ON GRISEOFULVIN RELEASE FROM SPRAY-DRIED
AMORPHOUS SOLID DISPERSIONS WITH HPC–SOLUPLUS

In Chapter 4, impact of an anionic surfactant, sodium dodecyl sulphate (SDS) was
investigated in the stabilization of GF nanosuspensions and production of HyNASDs
and

dissolution

enhancement

under

supersaturating

condition.

Significant

improvement in the drug release rate and in supersaturation generation was achieved
while using SDS in the formulation. Since the mechanism of drug release and
supersaturation generation–maintenance mechanisms are different from drug
nanocomposites and ASDs, it is important to investigate the impact of surfactant in
the production and dissolution performance of ASDs. The goal of this chapter was to
elucidate the impact of a common anionic surfactant, sodium dodecyl sulfate (SDS),
on drug release from amorphous solution dispersions (ASDs) while elucidating its
roles in wettability enhancement and recrystallization inhibition along with polymers.
To this end, hydroxypropyl cellulose (HPC) and Soluplus (Sol) were used as matrixforming polymers of the ASDs. 2.5% griseofulvin (GF, BCS Class II drug) and
HPC/Sol with 1:1, 1:3, and 1:5 GF:polymer mass ratios, along with 0.125% SDS and
without SDS, were dissolved in acetone–water and spray-dried. XRPD, DSC, and
Raman spectroscopy results suggest that Sol had stronger interactions and better
miscibility with GF than HPC and formed XRPD-amorphous GF, while HPC-based
ASDs, except the ASD with1:5 GF:HPC/SDS, had crystalline GF. SDS helped to
reduce the fraction of GF crystals in HPC-based ASDs, suggesting its role in GF
solubilization within the polymer matrix. Modified Washburn experiments revealed
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significant wettability enhancement when SDS was used along with the polymer and
better wettability enhancement by HPC (hydrophilic) than Sol (amphiphilic). Results
from in vitro dissolution tests with low (9 mg) GF dose suggest that enhanced
wettability with SDS led to faster GF release. For 100 mg GF dose (above
thermodynamic solubility), without SDS, ASDs provided limited GF supersaturation
due to poor wettability of Sol-based ASDs (max. 250%) and extensive GF
recrystallization in HPC-based ASDs (max. 50%). Microscopic imaging of a loose
ASD compact imbibed with water confirmed formation of GF crystals in HPC-based
ASDs. Incorporating even 0.83% SDS in Sol-based ASDs led to dramatic increase in
supersaturation (max. 570%), but it had no notable improvement for HPC-based
ASDs. SDS provided Sol-based ASDs with enhanced wettability and augmented Sol
in solubilizing GF, without interfering with Sol’s ability to inhibit GF
recrystallization, as confirmed by desupersaturation experiments. While elucidating
the roles of SDS, this study demonstrates the dramatic positive impact of
incorporating SDS as a minor component of ASDs unlike its common use as a carrier
for solubilization in most recent studies.

5.1 Materials and Methods
5.1.1 Materials
BP/EP grade, micronized griseofulvin (GF) purchased from Letco Medical (Decatur,
AL, USA) was used as a challenging Biopharmaceutics Classification System (BCS)
Class II drug, which is known to be a fast crystallizing drug (Baird et al. 2010). Its
aqueous solubility is ~8.9 mg/L at 25 °C and ~14.2 mg/L at 37 °C, and has a melting
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point temperature Tm of 220 °C and a glass transition temperature Tg of 89 °C (Baird
et al., 2010). Hydroxypropyl cellulose (HPC, SSL grade, Nisso America Inc., New
York, NY) is a semi-crystalline polymer with low crystallinity and amorphous
domains of very low Tg (Sarode et al., 2013) Soluplus® (Sol) is an amphiphilic graft
copolymer produced from polyvinyl caprolactam–polyvinyl acetate–polyethylene
glycol having a single glass transition temperature of 73 ± 2 °C (Terife et al., 2012).
Sodium dodecyl sulfate (SDS), an anionic surfactant, purchased from GFS
Chemicals, Inc. (Columbus, OH) was used as a surface-active agent. Acetone (ACS
reagent, ≥ 99.5%) was purchased from BDH Analytical chemicals, (VWR, GA) and
used as a solvent to prepare solution-based feed to the spray dryer
5.1.2 Preparation of Spray-Dried Powders
Organic solution-based (S:solvent) feeds of GF were fed to the spray dryer for the
preparation of drug ASDs. Table 5.1 presents the formulations used in the precursor
feeds. The drug concentration was kept constant at 2.5% (w/v) in all formulations.
The drug concentration was calculated with respect to the total volume of the solvent
mixture (acetone–water) in the solution-based feeds, which was fixed at 240 mL. A
mixture of acetone–water was purposefully selected to dissolve all components of the
formulation. 2.5% griseofulvin (GF, BCS Class II drug) and HPC/Sol with 1:1, 1:3,
and 1:5 GF:polymer mass ratios, along with 0.125% SDS (20:1 GF:SDS mass ratio)
and without SDS, were dissolved in acetone–water using a magnetic stirrer and spraydried to prepare the ASDs. The rationale for selecting of 0.125% SDS is as follows:
when fully dissolved, ASD will provide 0.0005% SDS in the dissolution medium, i.e.,
water, which is well below the critical micelle concentration of SDS (8 mM, 0.23%

167

w/v at 25 ºC) (Sharma et al., 1996). Hence, the micellar solubilization of GF by SDS
in the dissolution medium is purposefully avoided. After dissolving the drug–
polymer–surfactant into the binary solvent mixture, the solutions were sonicated for
30 min before feeding to the spray dryer.
Table 5.1 Formulations of the GF–HPC/Sol Solutions With or Without SDS Fed to
the Spray Dryer
a

ID

Formulation

S1
S2
S3
S4
S5
S6
S7
S8
S9
S10
S11
S12

S-Sol-1:5
S-Sol-1:3
S-Sol-1:1
S-Sol-1:5, SDS
S-Sol-1:3, SDS
S-Sol-1:1, SDS
S-HPC-1:5
S-HPC-1:3
S-HPC-1:1
S-HPC-1:5, SDS
S-HPC-1:3, SDS
S-HPC-1:1, SDS

GF
Polymers
b
(% w/v) (% w/v)b

SDS
(% w/v)b

Water
(mL)

Acetone
(mL)

2.5
2.5
2.5
2.5
2.5
2.5
2.5
2.5
2.5
2.5
2.5
2.5

0
0
0
0.125
0.125
0.125
0
0
0
0.125
0.125
0.125

40
40
40
40
40
40
40
40
40
40
40
40

200
200
200
200
200
200
200
200
200
200
200
200

12.5
7.5
2.5
12.5
7.5
2.5
12.5
7.5
2.5
12.5
7.5
2.5

a

S denotes solution-based feed; Sol denotes Soluplus; the ratios refer to the drug:polymer mass ratios.
% w/v with respect to the total volume (240 mL) of the solvent mixture (acetone + deionized water).
c
% w/w with respect to the total weight of the solid content.
b

Using a spray dryer (4M8-Trix, Procept, Zelzate, Belgium) having a cocurrent flow set-up, solution-based feeds were dried. The total length and the
diameter of the spray dryer are 1.59 m and 0.15 m, respectively. To ensure complete
drying, inlet temperature was selected above the boiling temperature of the respective
pure liquids. Drying air at 75 °C flowing at a rate of 0.27–0.30 m3/min were fed cocurrently at the top of the dryer column to dry the solution-based feeds. 200 g solution
of each formulation was sprayed at 2.0 g/min rate using a peristaltic pump (Make-itEZ, Creates, Zelzate, Belgium). A cyclone separator was used to separate the dried
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particles from the outlet stream into a glass jar. Atomizing air pressure of 2.0 bar, a
bi-fluidic nozzle with tip diameter of 0.6 mm, and cyclone pressure of 55–60 mbar
were selected based on prior experience (Azad et al., 2015b) and exploratory
experiments. The dried particles obtained from the collection jar were transferred into
double plastic bags and stored in a vacuum-desiccator at room temperature for further
characterization.
5.1.3 Particle Size and Morphology of the Spray-Dried Powders
The particle size of the spray-dried powders was measured by a Rodos/Helos laser
diffraction system (Sympatec, NJ, USA) based on Fraunhofer theory following the
procedure described in Li et al. (2016b). About 1 g of the powder sample was placed
on top of the sample chute of the Rodos dispersing system and the sample chute was
vibrated at a 100% setting, and 0.1 bar dispersion pressure was used to suck in the
falling powder through the sample cell of the laser diffraction system. Spray-dried
particles were placed on a glass slide and observed by Axio Scope.A1 polarized light
microscope (PLM, Carl Zeiss Microscopy GmbH, Göttingen, Germany).
5.1.4 Solid Sate Characterization and Drug–polymer Interactions
To analyze the crystallinity of the as-received GF, HPC, Sol, spray-dried powders,
and physical mixtures of GF–polymer with or w/o SDS (same formulation as stated
in Table 5.1), XRPD (PANanalytical, Westborough, MA, USA), provided with Cu Kα
radiation (λ= 1.5406 Å), was used. The samples were scanned at a rate of 0.165 s-1 for
2θ ranging from 5° to 40°. The total area under three distinct, non-overlapping peaks
of GF at characteristic diffraction angles of 13.2, 14.6, and 16.5º was calculated for

169

both the physical mixtures and the spray-dried powders using the equipment’s
HighScore Plus software, which was then used to estimate the crystallinity.
DSC of the as-received GF, Sol, HPC, and spray-dried powders was
performed using a Mettler-Toledo polymer analyzer (PolyDSC, Columbus, OH,
USA) with integrated STARe 10 software. ~6.0–7.0 mg powder sample was placed in
an aluminum pan with a hole in the lid and loaded into the DSC machine. Asreceived GF was heated at a rate of 10 °C/min from 25 °C to 250 °C. All other
samples were heated from 25 °C to 70 °C and the temperature was held for 2 min at
70 °C, then cooled back to 25 °C to remove any residual solvent in the sample. In the
final step, the samples were heated from 25 °C to 250 °C at 10 °C/min. Nitrogen gas
was used as the purge gas and protective gas at a flow rate of 50 mL/min and 150
mL/min, respectively. Thermogravimetric analysis (TGA) was performed to measure
the residual water/solvent content using a TGA/DSC1/SF Stare system (Mettler
Toledo, Inc., Columbus, OH). ~6.0–7.0 mg of each spray-dried sample was placed in
a ceramic crucible and heated from 25 °C to 150 °C at a heating rate of 10 °C/min
under nitrogen flow.
Raman spectroscopy was conducted using a Fergie Imaging Spectrometer
System (Princeton Instruments, Trenton, NJ) with a 500-mW external diode laser
processing at 785 nm wavelength. Data acquisition time for all spectra was 15 s per
scanned spectrum (100–1800 cm-1) and each spectrum acquired was averaged over
two scans. The data was presented for the range of 1550–1800 cm-1 wavenumber.

170

5.1.5 Drug Content in the Spray-Dried Powders and In Vitro Dissolution Tests
The drug content in the dried powders varied based on the drug:polymer mass ratios.
To measure the actual drug content in the spray-dried powders, an assay testing was
performed by dissolving 100 mg of the sample powders in 20 mL methanol under 30
min of sonication, followed by overnight storage to ensure complete solubilization of
the GF particles. An aliquot of 100 µL was taken from the GF solution and diluted up
to 10 mL using methanol. The absorbance of the samples was measured at 292 nm
using UV spectrophotometer (Agilent, Santa Clara, CA, USA), and the drug
concentration was calculated from a pre-established calibration curve. Six replicates
were tested for each formulation to calculate mean drug content along with the
relative standard deviation (RSD).
Drug release from the spray-dried powders and physical mixtures (PMs)
prepared by blending was determined via a Distek 2100C dissolution tester (North
Brunswick, NJ, USA), following the USP II paddle method. 1000 mL deionized
water at 37 °C was stirred at 50 rpm paddle speed during the test. Two different doses
i.e., 8.9 mg (non-supersaturating condition) and 100 mg (supersaturating condition)
were tested for the dissolution performance of the spray-dried powders. Since the
solubility of GF is 14.2 mg/L in water at 37 °C, a relatively low dose, i.e., 8.9 mg was
selected to ensure non-supersaturating condition in the dissolution medium, which
also could emulate low-dose (potent) drugs. The spray-dried powders were poured
into the dissolution medium and 4 mL samples were taken out manually at 1, 2, 5, 10,
20, 30, and 60 min. These aliquots were filtered with a 0.1 µm PVDF membrane-type
syringe filter before UV-spectroscopy measurements to minimize any confounding
effect of undissolved drug. In a separate dissolution tests, 100 mg equivalent GF was
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used to allow for supersaturation in the bulk dissolution medium, which was
conducted for 210 min with additional sampling at 120, 180, and 210 min. The
filtered samples were diluted with deionized water kept at 37 ºC at a ratio of 1 to 5
before UV measurement. Dissolved GF amount was measured by UV-vis
spectroscopy at 296 nm wavelength and calculated using a pre-established calibration
curve. Deionized water was used as blank before UV measurement, and six replicates
were performed for each sample. In this paper, relative % supersaturation is reported
based on GF concentration at 210 min and thermodynamic solubility of as-received
GF particles, unless otherwise indicated.
5.1.6 Drug Wettability Enhancement by Sol and HPC Solutions With or W/O
SDS
GF wettability by water, the dissolution medium, was investigated by analyzing the
penetration rate of aqueous polymer/SDS solutions into a packed bed of GF particles
inside a cylindrical column according to the modified Washburn method (Hołownia et
al., 2008; Washburn, 1921). An Attension Sigma 700 (Biolin Scientific, Linthicum,
MD, USA) was used to measure the mass of test liquid penetrated into the GF powder
bed as a function of time. Experimental methods were adapted from Bilgili et al. (2018)
and Li et al. (2017) (refer to Appendix D for details). In the current study, liquids and
powder refer to GF-saturated aqueous solutions of 15% Sol/HPC with 0.125% SDS–
w/o SDS, 0.125% SDS alone and as-received GF, respectively. All percentages are (%
w/w) with respective to deionized water. The aqueous solution of the stabilizers and
deionized water were saturated with griseofulvin (GF) and stirred overnight. After
overnight stirring, the saturated solutions were used for further characterization. The
apparent shear viscosity and surface tension of the liquids were measured using R/S
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Plus Rheometer (Brookfield Engineering, Middleboro, MA, USA) and Attension Sigma
700 (Biolin Scientific, Linthicum, MD, USA), respectively. The ratio of the cosine of
contact angles cosθss/cosθw was calculated using the modified Washburn equation and
used as a wetting effectiveness factor. Here, θss is the contact angle between GF and the
GF-saturated polymer/SDS solutions and θw is the contact angle between GF and GFsaturated deionized water. This ratio was used as a rough measure of the drug
wettability enhancement upon use of polymers (HPC/Sol) and SDS in water taking
water as a basis of comparison.
5.1.7 Characterization of Drug Recrystallization in the Presence of Aqueous
Medium
To elucidate GF recrystallization in the presence of water, a small portion of the spraydried powders prepared using the solution-based (S) feed (S-HPC-1:3 and S-Sol-1:3)
with and w/o SDS was gently pressed to form a loose compact, which was then
mounted onto a microscopic glass slide, and placed under the polarized light
microscope (PLM). 20 µL of deionized water was added to the sample and the PLM
images were captured at 0, 1, 2, and 5 min from the moment of water addition.

5.2 Results and Discussion
We present and discuss the properties of the spray-dried powders (Section 5.2.1),
solid state characterization of the drug and ASD formation in spray-dried powders
(Section 5.2.2), as well as in vitro drug release from the ASDs and impact of SDS–
polymer loading under non-supersaturating (Section 5.2.3) and supersaturating
dissolution conditions (Section 5.2.4).
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5.2.1 Size, Morphology, and Drug–Moisture Content of the Spray-Dried
Powders
Although the residence time in the spray dryer is short, complete drying of the feed is
expected due to the fast evaporation of the solvents from fine droplets, which
originated from atomization of the feed suspension/solution at a higher temperature
than the boiling point of the liquid at the inlet. Residual moisture content in the spraydried powders was measured by TGA based on weight loss. Weight loss of 2.0 ±
0.3% was measured with TGA for all the samples, which confirmed that most of the
solvents were removed during the spray drying. The actual (mean) drug content after
spray-drying ranged from 14.6–15.1% for 1:5 GF:polymer powders, 21.5–24.4% for
1:3 GF:polymer powders, and 42.3–44.9% for 1:1 GF:polymer powder (refer to Table
5.2). As expected, an increase in polymer loading in the feed solutions led to lower
drug content in the powders. The slight variation in the theoretical and actual drug
content can be attributed to preferential drug loss during handling, poor separation of
finer particles in the cyclone separator of the spray dryer, and presence of some
residual moisture after drying (Azad et al., 2015b; Bilgili et al., 2018). The relative
standard deviation (RSD) of drug content in all powders was less than 6.0%,
signifying pharmaceutically acceptable content uniformity. The median sizes d50 of
the spray-dried powders ranged from 10.9–22.6 µm (Table 5.2). An increase in
polymer loading led to formation of coarser particles due to increase in total solids
loading and higher viscosity of the feed (Bilgili et al., 2018; Li et al., 2018b; Poozesh
and Bilgili, 2019). Unlike this clear and strong impact of polymer loading, the impact
of SDS was weak: for a given polymer type/loading, the powders with SDS had
slightly greater median sizes than the powders without SDS, except for S:Sol-1:3.

174

The microscopic images (Figure 5.1) illustrate that spray-dried particles have
rounded–donut shapes, and their sizes are in rough agreement with the ranges
mentioned in Table 5.2.

Figure 5.1 Light microscope images of the spray-dried particles prepared using the
GF solution-based (S) feed with 1:3 GF:polymer mass ratio and 0.125% SDS/without
SDS: (a) S-HPC-1:3, (b) S-HPC-1:3, SDS, (c) S-Sol-1:3, and (d) S-Sol-1:3, SDS. All
images were taken at 50X magnification (scale bar: 20 µm).
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Table 5.2 Particle Size Statistics of the Spray-Dried Powders and Their Drug Content

ID
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S1
S2
S3
S4
S5
S6
S7
S8
S9
S10
S11
S12
a

Formulationa

Particle size statistics of the spray-dried particles
(µm)

S-Sol-1:5
S-Sol-1:3
S-Sol-1:1
S-Sol-1:5, SDS
S-Sol-1:3, SDS
S-Sol-1:1, SDS
S-HPC-1:5
S-HPC-1:3
S-HPC-1:1
S-HPC-1:5, SDS
S-HPC-1:3, SDS
S-HPC-1:1, SDS

d10±SD
7.03±0.2
6.08±0.1
3.46±0.2
6.23±0.1
4.11±0.0
5.03±0.1
6.48±0.2
5.87±0.1
5.28±0.1
7.10±0.2
6.48±0.0
7.05±0.2

d50±SD
18.3±0.2
14.3±0.0
10.9±0.1
20.8±0.1
12.3±0.0
11.0±0.1
21.5±0.4
15.4±0.3
12.7±0.2
22.6±0.2
15.8±0.6
13.0±0.9

d90±SD
38.3±0.1
32.4±0.1
21.5±0.0
40.1±0.2
33.2±0.1
20.2±0.0
42.3±0.2
33.5±0.1
30.3±1.2
40.3±0.3
31.3±1.0
26.9±0.8

S denotes solution-based feed; Sol denotes Soluplus; the ratios refer to the drug:polymer mass ratios.
% w/w with respect to the total weight of the solid content.

b
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Theoretical
drug content
(% w/w)b

Actual drug
content, RSD
(% w/w, %)b

16.7
25.0
50.0
16.5
24.7
48.8
16.7
25.0
50.0
16.5
24.7
48.8

14.8, 1.79
22.1, 1.76
44.8, 3.46
14.6, 4.45
21.5, 2.02
42.3, 2.21
15.0, 2.65
24.0, 1.51
44.9, 1.67
15.1, 3.30
24.4, 2.56
42.7, 0.73

5.2.2 Formation of Drug ASDs Upon Spray Drying
To confirm the crystalline state of the drug (GF) in the final spray-dried powders, asreceived GF (microparticles), polymers (HPC/Sol), spray-dried powders, and
corresponding physical mixtures (PM) of the spray-dried powders were analyzed
using XRPD (Figure 5.2) and DSC (Figure 5.3). Table 5.3 presents the summary of
DSC thermal events and estimated crystallinity via XRPD. X-ray diffractograms
(Figure 5.2) depict that as-received GF (microparticles) exhibited intense peak
characteristics of a crystalline material, whereas HPC/Sol exhibited halo pattern
indicating amorphous structure. The physical mixtures (PMs), prepared by blending,
exhibited peaks at the same diffraction angles as those of as-received GF, albeit with
reduced peak intensity, which can be attributed to the dilution and surface coverage
of GF microparticles with HPC/Sol/SDS. On the other hand, XRPD diffractograms of
all Sol-based spray-dried powders with and without SDS, regardless of polymer
loading, showed halo pattern instead of any characteristic peaks of GF. These halo
patterns confirm the formation of amorphous solid dispersion (ASD). Small peaks
were visible in the XRPD diffractograms of S-HPC-1:3, S-HPC-1:1, and S-HPC-1:1,
SDS powders, which had 27.7%, 11.5%, and 6.5% crystallinity, respectively (Table
5.3). Despite being largely amorphous, strictly speaking, these powders should be
referred to as solid dispersions; but, for the sake of simplicity, we call all powders
ASDs recognizing that some of them had notable crystalline content. The XRPD
results overall suggest that (i) amorphous GF was molecularly dispersed in or
solubilized by Sol matrix owing to their good miscibility even at 1:1 mass ratio
regardless of the presence/absence of SDS, (ii) GF was only partially miscible with
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Figure 5.2 X-ray diffractograms of as-received GF, HPC, Sol, physical mixtures
(PMs) of GF–HPC/Sol and the spray-dried powders prepared using the GF solutionbased (S) feed with 1:1, 1:3, and 1:5 drug:polymer mass ratios: (a) without SDS and
(b) with 0.125% SDS in the solution.

HPC, and required a high HPC loading (1:5 GF:HPC) to ensure formation of ASD;
lower HPC loading could not prevent GF recrystallization during or right after spray
drying, and (iii) SDS helped to disperse or solubilize GF in the HPC matrix, thus
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allowing ASD formation at lower HPC loading (1:3 GF:HPC ratio). However, SDS
could not prevent recrystallization when the GF:HPC mass ratio was 1:1. During
spray drying, rapid evaporation of the solvents in the spray dryer increased viscosity
instantaneously, resulting in kinetic arrest of the drug molecules in the amorphous
polymer matrices, thus forming ASD (Baghel et al., 2016). Therefore, besides drug–
polymer miscibility, fast drying kinetics in the spray dryer played a substantial role to
produce ASD from solution-based (S) feeds, even for a partially miscible (GF–HPC)
system.
The DSC thermograms in Figure 5.3 show an endothermic peak associated
with melting of as-received GF, with a Tm of 220.1 °C and ΔHf of 101.8 J/g; a glass
transition for Sol (amorphous) at 72.4 °C, and a slight endothermic event around
170–200 °C for HPC likely due to the melting of the small crystalline domain of
largely amorphous HPC (Sarode et al., 2013) (crystallinity was undetectable by
XRPD). The Tg of HPC could not be measured (in the range of –25 to 0 °C (Sarode et
al., 2013)) due to limitation of our equipment. A single Tg was observed confirming
the formation of molecular level dispersion (Luebbert et al., 2017; Wlodarski et al.,
2015) in all powders except S-HPC-1:1 with 28% GF crystallinity (see Table 5.3).
While S-Sol-1:3, SDS, S-Sol-1:5, SDS, and S-Sol-1:5 exhibited only a glass
transition, all other ASDs exhibited a glass transition followed by an exothermic
event due to re-crystallization of amorphous GF, which was followed by the melting
of the recrystallized GF (Figure 5.3a and Figure 5.3b). Recrystallization of GF from
ASDs can occur during the heating step of DSC scan because above Tg amorphous
drug molecules and amorphous polymer had higher mobility. The absence of
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recrystallization and higher temperature of recrystallization transition Trc (if it
occurred at all) in the Sol-based powders than HPC-based powders suggest better
miscibility and stronger molecular interactions between Sol–HPC than HPC–GF.

Figure 5.3 DSC thermograms of as-received GF, HPC, Sol, and the spray-dried
powders prepared using the GF solution-based (S) feed with 1:1, 1:3, and 1:5
drug:polymer mass ratios: (a) without SDS and (b) with 0.125% SDS in the solution.
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Table 5.3 Characteristic Temperatures–Enthalpy Values Obtained From DSC Thermograms and Crystallinity Estimated From
XRPD Diffractograms
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ID
S1
S2
S3
S4
S5
S6
S7
S8
S9
S10
S11
S12

Formulationa
S-Sol-1:5
S-Sol-1:3
S-Sol-1:1
S-Sol-1:5, SDS
S-Sol-1:3, SDS
S-Sol-1:1, SDS
S-HPC-1:5
S-HPC-1:3
S-HPC-1:1
S-HPC-1:5, SDS
S-HPC-1:3, SDS
S-HPC-1:1, SDS

Tg (ºC)a,b
80.6
80.4
77.7
77.4
80.0
74.6
52.9
53.2
ND
51.7
57.7
58.9

Hrc (J/g) a,b
ND
ND
–14.1
ND
ND
–9.26
–3.35
–4.36
–8.90
–2.43
–1.71
–20.0

Trc (ºC) a,b
ND
ND
131
ND
ND
127
139
122
111
130
124
109

a

Tm (ºC) a,b
ND
189
209
ND
ND
206
192
201
213
191
200
213

Hf (J/g) a,b
ND
0.64
23.2
ND
ND
25.4
6.64
13.2
34.3
5.68
10.5
40.6

Crystallinity (%)b
ND
ND
ND
ND
ND
ND
ND
11.5
27.7
ND
ND
6.5

S denotes solution-based feed, Sol denotes Soluplus; the ratios refer to the drug:polymer mass ratios. Other symbols: Tg, Trc, and Tm stand for temperature
for glass transition, recrystallization transition, and melting point, respectively, while Hrc and Hf respectively stand for recrystallization enthalpy and
fusion enthalpy.
b
ND: not detected.
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For HPC-based powders, Trc increased (recrystallization delayed to higher
temperature) and Hrc decreased when a higher polymer loading was used, which is
in line with other studies (e.g., Wlodarski et al., 2015).
GF crystals have a Tm of 220.1 °C. The powders, whose DSC thermograms
exhibited an endotherm due to melting of the existing GF crystals and/or GF crystals
formed during the heat treatment of the DSC scan, also exhibited significant melting
point depression (Figure 5.3). The significant melting point depression in drug–
polymer mixtures is an indicator of drug–polymer miscibility (Baird et al., 2012;
Newman et al., 2008). Table 5.3 indicates that higher polymer loading (lower
GF:polymer mass ratio) led to lower Tm as compared with the as-received GF
crystals, higher melting point depression, and lower ΔHf, regardless of the
presence/absence of SDS. Moreover, without exceptions, having identical
polymer/SDS composition, the spray-dried powders with Sol had either no melting
point or had a higher melting point depression and lower ΔHf than those with HPC,
which could be explained by (i) stronger molecular interactions and better miscibility
for GF–Sol than GF–HPC, (ii) higher initial amorphous content in the Sol-based
powders than in the HPC-based powders, and (iii) higher extent of drug solubilization
during the thermal treatment when the polymer loading was higher. Compared with
the clear trends regarding the impact of polymer loading for formulations
with/without SDS, the trends for SDS impact were not as strong. At the same loading
for a given polymer, the presence of SDS either led to disappearance of the melting
point or slightly higher melting point depression, which suggests that SDS appears to
help GF molecular dispersion or solubilization. These findings from DSC
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thermograms are largely in agreement with the findings from the XRPD
diffractograms regarding the impacts of GF–polymer miscibility and the impact of
polymer loading and presence of SDS on the solid state of GF.
The observed Raman spectra in Figure 5.4 for as-received GF and PMs of GF
are largely in agreement with Fourier transform Raman data of ref. (Feng et al., 2008)
and Raman data of ref. (Żarów et al., 2011) for crystalline GF. The Raman spectra of
all the spray-dried samples (Figure 5.4) show that the GF line at 1606 cm–1
disappeared, and the peaks at other characteristic frequencies shifted to new positions
that are characteristic of amorphous GF, e.g., the peak shift from 1623 to 1620 cm–1
(see Żarów et al., 2011), signifying formation of amorphous GF and molecular level
interactions between GF and polymers in the ASD. While the GF line at 1606 cm–1
disappeared in the Raman spectra of S-HPC-1:3 with and w/o SDS (Figure 5.4a and
Figure 5.4b), the shifts in other peaks were subtler than those for the Raman spectra
of S-Sol-1:3 with and w/o SDS, which could suggest stronger molecular interactions
between GF–Sol than GF–HPC.
It is suggested that if the solubility parameter difference between a drug and
polymer is <7.0 MPa1/2, they are likely to be miscible; if the difference is >10 MPa1/2,
they are considered immiscible, and if the difference is in between 7.0 and 10, they
exhibit partial miscibility (Forster et al., 2001; Greenhalgh et al., 1999). The
solubility parameters of GF, HPC, and Sol are 12.2 (Thakral and Thakral, 2013), 24.0
(Choi et al., 1994), and 19.4 (Kolter et al., 2012) MPa1/2, respectively. The solubility
parameter differences between GF–Sol and GF–HPC are 7.2 and 11.8 MPa1/2,
respectively, which suggests that GF–Sol is borderline miscible, whereas GF–HPC is
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immiscible. The solubility parameter prediction is fairly accurate for Sol–GF as
XRPD, DSC, and Raman spectroscopy results suggests GF–Sol are miscible and
molecularly interact more than GF–HPC. However, GF–HPC exhibits partial
miscibility unlike what the solubility parameters of GF–HPC suggest. As the

Figure 5.4 Raman spectra of as-received GF, physical mixtures (PMs) of GF–
HPC/Sol at 1:3 drug:polymer ratio, and the spray-dried powders prepared using the
GF solution-based (S) feed with 1:3 GF:polymer mass ratio: (a) with 0.125% SDS
and (b) without SDS in the solution.
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theoretical models behind the solubility parameter prediction are applicable for
simple molecular structures wherein van der Waals force plays a predominant role,
while for drug–polymer systems which are known to form highly directional
interactions (e.g., hydrogen bonding) or long range interactions (e.g., ionic
interaction), this approach can be erroneous (Ambike et al., 2005; Forster et al.,
2001). Indeed, the absence of diffraction peaks in XRPD in several HPC-based
powders and significant melting depression in DSC along with the Raman line shifts
suggest that HPC molecularly interacts with GF, resulting in partial miscibility unlike
the prediction from the solubility parameters.
5.2.3 Dissolution Performance of the Spray-Dried Powders Under NonSupersaturating Condition
The temporal evolution of GF release from the spray-dried powders and the PM with
the highest polymer loading (1:5 GF:polymer) containing 8.9 mg equivalent GF dose
in 1000 mL deionized water at 37 ºC was investigated. The bulk dissolution medium
will not supersaturate for this low drug dose as the GF solubility is 14.2 mg/L. We
note from Figure 5.5 that as-received (micronized) GF microparticles with d50: 9.74 ±
0.23 µm and d90: 27.4 ± 0.1 µm dissolved very slowly: <20% GF dissolved at 20 min
and <33% at 60 min. The mere blending of as-received GF particles with HPC/Sol
(1:5 GF:polymer mass ratio) with and without SDS, i.e., led to the physical mixture,
which enhanced GF release rate. This could be partly explained by the wetting
enhancement of the hydrophobic drug (GF) in the presence of dissolved HPC/Sol–
SDS (see Table 5.4) and deaggregation of the large drug aggregates present in the asreceived drug (Letchford and Burt, 2007), and partly by the higher solubility of GF in
the dissolution medium. For example, the thermodynamic solubility of the GF
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microparticles at 37 °C was measured to be 14.2 mg/L, 17.8 mg/L, and 18.3 mg/L in
the deionized water, aqueous medium of 1:3 GF:Sol with SDS, and aqueous medium
of 1:3 GF:HPC with SDS, respectively.

Figure 5.5 Evolution of drug release from as-received GF, physical mixture (PM)
with 1:5 GF:polymer mass ratio, and spray-dried powders prepared using GF
solution-based (S) feeds with 1:1, 1:3, and 1:5 drug:polymer mass ratios: (a) HPC
without SDS, (b) HPC with SDS, (c) Sol without SDS, and (d) Sol with SDS.
Dissolution sample size equivalent to 8.9 mg GF dose (low dose, non-supersaturating
condition in the bulk dissolution medium).

186

Table 5.4 Properties of Drug-Saturated Deionized Water and Aqueous Polymer–
SDS Solutions and Wetting Effectiveness Factor Determined Using the Modified
Washburn Method
Formulation

η (cP) ρ (g/mL) γ (mN/m) Slope, (g2/s)

Water
SDS
Sol
Sol–SDS
HPC
HPC–SDS

0.89
0.94
8.76
13.5
53.2
58.3

1.00
1.00
1.01
1.01
1.01
1.01

7.0×10-3
7.2×10-3
1.2×10-3
1.5×10-3
1.5×10-3
2.4×10-3

66.5
37.1
41.4
40.5
39.9
34.8

R2

cosθss/cosθw

0.990
0.975
0.989
0.991
0.998
0.999

1.00
1.94
2.65
4.65
20.9
42.1

The spray-dried powders released GF faster than the PM (except S-Sol
powders without SDS, see Figure 5.5c) owing to the presence of amorphous GF in
the former that has higher kinetic solubility than crystalline GF in the PM. The poor
wettability of S-Sol formulation hindered the dissolution of Sol and erosion of the
spray-dried particles, which in turn retarded the drug release. Inclusion of SDS in the
ASDs led to significant increase in the rate of GF release, but the increase was more
notable for the Sol-based ASDs than the HPC-based ASDs. The analysis of the
wetting effectiveness factors obtained from the modified Washburn method (Table
5.4) shed some light on this observation. Presence of SDS has almost doubled the
wetting effectiveness of the dissolved polymer in water and the rank order of
wettability enhancement is HPC–SDS > HPC > Sol–SDS > Sol > SDS, which is in
accordance with the hydrophilic nature of HPC and amphiphilic nature of Sol. Hence,
poor wettability of Sol-based ASDs was mitigated upon incorporation of SDS, which
led to significant dissolution improvement. On the other hand, HPC-based ASDs did
not significantly benefit from the incorporation of SDS as HPC is hydrophilic. The
initial fast GF release within 10 min followed by a much slower dissolution in the
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following 50 min for S-HPC-1:1 (Figure 5.5a) and S-HPC-1:1, SDS (Figure 5.5b)
could be explained by their smallest particle sizes among the S-HPC formulations
(see Table 5.1), which led to initial fast release of amorphous GF followed by the
slow dissolution of their crystalline component, i.e., 27.7% and 6.5%, respectively
(see Table 5.2).
5.2.4
Dissolution Performance
Supersaturating Condition

of

the

Spray-Dried

Powders

Under

The temporal evolution of GF release from the spray-dried powders and the PM with
the highest polymer loading (1:5 GF:polymer) containing 100 mg equivalent GF dose
in 1000 mL deionized water at 37 ºC was investigated. The bulk dissolution medium
could supersaturate for this high drug dose as the GF solubility is 14.2 mg/L. Unless
otherwise specified, all supersaturation values are relative to aqueous thermodynamic
solubility of GF and calculated at 210 min. Figure 5.6 shows that only slight
supersaturation (max. ~50%) was achieved fast upon dissolution of HPC-based
ASDs. An increase in polymer loading (lower GF:HPC mass ratio) led to slight
increase in the supersaturation attained. Similarly, presence of SDS only increased
supersaturation for the lowest HPC S-HPC-1:1; at higher polymer loadings, the effect
of SDS was not notable. A cursory look at Figure 5.7 and Figure 5.6 suggests that
Sol-based ASDs exhibited higher GF supersaturation than HPC-based ASDs, and
inclusion of SDS as a minor component of ASD had a drastic impact on the
attainment of high supersaturation fast: e.g., 430% supersaturation at 30 min for SSol-1:5, SDS, which attained 570% supersaturation at 180 min. In fact, that ASD
maintained

supersaturation

way

above
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430%

for

180

min.
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Figure 5.6 Evolution of drug release from as-received GF, physical mixture (PM) with 1:5 GF:HPC mass ratio, and spray-dried
powders prepared using GF solution-based (S) feeds with 1:1, 1:3, and 1:5 GF:HPC mass ratios: (a) HPC without SDS, (b) HPC
with SDS. Dissolution sample size equivalent to 100 mg GF dose (high dose, supersaturating condition in the bulk dissolution
medium).
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Figure 5.7 Evolution of drug release from as-received GF, physical mixture (PM) with 1:5 GF:Sol mass ratio, and spray-dried
powders prepared using GF solution-based (S) feeds with 1:1, 1:3, and 1:5 GF:Sol mass ratios: (a) Sol without SDS, (b) Sol with
SDS. Dissolution sample size equivalent to 100 mg GF dose (high dose, supersaturating condition in the bulk dissolution
medium).
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Maintaining the API in its amorphous state without precipitation during the intestinal
transit time (>180 min) would often be sufficient for achieving the necessary
bioavailability (Matsui et al., 2016).
The remarkably high GF supersaturation achieved by Sol-based ASDs as
compared with HPC-based ASDs can be explained by the higher GF solubilization in
Sol micelles, which increased with a higher Sol loading, and excellent GF
recrystallization inhibition imparted by Sol as compared with HPC. To make the
latter point more lucid, let us examine the PLM images (Figure 5.8) of loose ASD
compacts imbibed with a 20 µL deionized water droplet. The addition of water to SHPC-1:3, SDS compact (Figure 5.8a) and S-HPC-1:3 compact (Figure 5.8c) resulted
in immediate dissolution of the compact and recrystallization of amorphous GF (see
the shiny crystals in the respective images). On the other hand, for S-Sol-1:3, SDS
compact (Figure 5.8b) and S-Sol-1:3 (Figure 5.8d), the swollen ASD particles eroded
from the compact gradually released amorphous GF from the Sol matrix. The images
show spherical, swollen ASD particles. Even after 5 min of water addition, no
recrystallization of the amorphous GF observed, which implies that the phase
separation did not occur and the undissolved ASD powders stayed in the amorphous
form and facilitated the supersaturation generation of GF (Figure 5.8b and Figure
5.8c). It is inferred from these observations that due to fast and extensive
recrystallization of GF in HPC-based ASDs upon exposure to water and low
thermodynamic solubility of the GF crystals, only limited supersaturation was
achieved by HPC-based ASDs.
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Figure 5.8 PLM images of a loose compact of the spray-dried ASD particles with 1:3 drug:polymer mass ratio in 20 µL deionized
water: (a) HPC with SDS, (b) Sol with SDS, (c) HPC without SDS, and (d) Sol without SDS. The images were taken at 0 (before
adding water), 1, 2, and 5 min after the addition of deionized water addition. Except 0 min image (5X magnification, scale bar:
200 µm), which focused on the compact, all other images focused on particles that emanated from the surface, which were
captured at 20X magnification (scale bar: 50 µm).
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To gain further insights into the GF recrystallization and supersaturation
maintenance, desupersaturation experiments were performed via the solvent-shift
method. 20 mL of 5 mg/mL GF solution in acetone was mixed with 1000 mL of
aqueous solutions of 100 µg/mL, 300 µg/mL, and 500 µg/mL polymer with
0.0005%/0.125% SDS or without SDS. These concentrations and volume correspond
to the formulation of fully dissolved ASDs with 1:1, 1:3, and 1:5 GF:polymer mass
ratio, respectively, and SDS in the dissolution medium or in the initial solution fed to
the spray dryer. The addition of GF solution led to a supersaturation spike; 76–99
µg/mL GF dissolved within 2 min (see Figure 5.9). HPC with or w/o SDS could not
prevent depletion of supersaturation (desupersaturation) due to recrystallization of
GF. It appears that for HPC-based ASDs, SDS promoted nucleation (earlier
commencement of desupersaturation), but led to slower GF desupersaturation. In the
absence of polymers, SDS alone also promoted nucleation, but appeared to cause
slightly slower desupersaturation compared to the desupersaturation without any
inhibitor. Finally, Sol was able to maintain high GF supersaturation for at least 180
min with a small drop at 210 min. The presence of SDS and higher Sol led to slightly
higher supersaturation; but, these differences are small and within the experimental
errors. In the presence of 0.125% SDS alone or with 500 µg/mL Sol in the dissolution
medium, very fast nucleation and recrystallization occurred (see Figure 5.9b), which
confirms that high concertation of SDS promotes recrystallization from the
supersaturated GF solution. In summary, no adverse impact of SDS on GF
recrystallization was observed when it was used along with Sol as a minor component
(e.g., 1:3:0.05 GF:Sol:SDS). SDS promoted drug recrystallization in the presence of
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PVP-VA (Liu et al., 2016) and crystal growth in the presence of PVP (MosqueraGiraldo et al., 2014). These adverse effects could be absent partly due to low SDS
concentration in the desupersaturation and dissolution tests (SDS being a minor
component in the ASD) besides the specific interactions among GF–Sol–SDS.

Figure 5.9 GF desupersaturation curves for a supersaturated 20 mL GF–acetone
solution mixed with 1000 mL aqueous solution of 500 µg/mL, 300 µg/mL, and 100
µg/mL of HPC/Sol–SDS or w/o SDS (corresponding to 1:5, 1:3, and 1:1
drug:polymer formulations), SDS only, and deionized water without any
recrystallization inhibitor: (a) HPC, and (b) Sol. Unless otherwise indicated, 0.0005%
w/v (5 µg/mL) SDS was used for the formulation with SDS. With 500 µg/mL Sol,
both 0.0005% w/v and 0.125% w/v SDS were used. The initial concentration of GF
right after mixing was targeted at 100 µg/mL.
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It is well-established that depending on the drug–polymer miscibility and
interactions, amorphous drug may phase-separate and recrystallize upon contact of
ASDs with water in the dissolution medium (Alonzo et al., 2011; Chen et al., 2015).
Once imbibed into the ASD matrix, water acts as a plasticizing agent, enhancing the
mobility of the drug molecules by reducing the Tg of the ASD (Chen et al., 2015).
HPC-SSL has sub-ambient Tg (Sarode et al., 2013) (lower than Tg of Sol: 73 ± 2 °C)
and its ASDs have lower Tg than Sol-based ASDs (see Table 5.3). Moreover, due to
partial immiscibility of HPC with GF, its relatively weak molecular interactions with
GF as compared with Sol (miscible with GF), as well as its poor GF
nucleation/crystal growth inhibition (refer to Figure 5.9), it is no surprise that the
amorphous GF recrystallized from HPC-based ASDs during the dissolution test,
which also explains the drastically lower supersaturation generated by HPC-based
ASDs than by Sol-based ASDs.

PLM images of a loose compact of the ASD

particles in Figure 5.8 corroborated the formation of GF crystals from S-HPC-1:3
ASD upon its exposure to water, whereas no recrystallization was observed for S-Sol1:3.
To further elucidate the impact of SDS in Sol-based ASDs, S-Sol-1:5 (without
SDS) was dissolved in 1000 mL of deionized water, aqueous solution of 0.0005%
SDS solution, aqueous solution of 0.125% SDS solution. In these cases, SDS was
introduced to ASDs externally, outside the ASD particles. In S-Sol-1:5, SDS, the
SDS was in the ASD particles, whose dissolution in water would yield a 0.0005%
SDS. Figure 5.10 shows that the external addition of 0.0005% SDS significantly
improved the GF release of S-Sol-1:5, which corroborates the wettability
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enhancement mechanism. Adding 0.125% SDS led to even faster supersaturation due
to faster wettability; however, the released GF recrystallized, which is in line with the
desupersaturation test (Figure 5.9b). When too much surfactant is used either in the
ASD or in the dissolution medium, SDS molecules compete with drug molecules to
interact with Sol molecules, which interferes with the crystallization inhibiting
capability of Sol, leading to GF recrystallization (Liu et al., 2016). The fastest
supersaturation occurred when SDS was internally added or incorporated into the
ASD (S-Sol-1:5, SDS dissolution in water). It is likely that the presence of SDS in the
ASD particle led to faster wettability enhancement as the GF is already available at
the surface locally obviating the need for SDS molecules adsorbing onto ASD
microparticles from the dissolution medium. Also, the higher local SDS concentration
in the ASD particle and its boundary layer will facilitate water imbibition into Sol
matrix and its faster erosion, leading to faster release of GF. Interestingly, despite
exhbiting a much slower build-up of superstation in 0.0005% SDS solution, S-Sol-1:5
ASD (without SDS) tend to a plateau supersaturation at 210 min, which is slightly
below the supersaturation achieved by S-Sol-1:5, SDS ASD (with SDS) in water.
This finding suggests that having the SDS along with GF–Sol in the ASD led to
slightly higher kinetic solubility of GF in Sol–SDS of the ASD.
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Figure 5.10 Evolution of drug release from physical mixture (PM) with SDS and
spray-dried powders prepared using GF solution-based (S) feeds with 1:5
drug:polymer mass ratio with and without SDS in the formulation. Deionized water
was used as the medium for the formulation with SDS (S-Sol-1:5, SDS) and physical
mixture. For the formulation without SDS (S-Sol-1:5), aqueous solution of 0.125%
w/v SDS, aqueous solution of 0.0005% w/v SDS, and deionized water were used as
dissolution media. Dissolution sample size equivalent to 100 mg GF dose (high dose,
supersaturating condition in the bulk dissolution medium).

5.3 Conclusions
We have demonstrated that the use of SDS as a minor component along with a drugmiscible polymer (Sol) as major component, which provides significant solubilization
of the drug (GF) and supersaturation maintenance via recrystallization inhibition,
could boost drug supersaturation from the ASDs via mainly wettability enhancement
and some additional drug solubilization. The ASD with 1:5:0.05 GF:Sol:SDS
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composition achieved 430% GF supersaturation within 30 min and maintained it for 3
h. Unlike the use of SDS as carriers/solubilizers, the use of SDS as a minor
component dramatically improved the wettability of the ASD, without having any
deleterious impact on drug recrystallization, which is a common problem in polymer–
surfactant carrier systems. Also, the use of such low concentrations of SDS even in
high-dose applications of ASDs alleviates any concern associated with the toxicity of
anionic surfactants.
The high GF supersaturation was only possible owing to the highly favorable
properties of Sol because very limited supersaturation was achieved by HPC-based
ASDs with or without SDS. Sol-based ASDs have higher Tg owing to higher Tg of Sol
(73 ± 2 °C) than HPC-SSL; Sol has greater miscibility and stronger molecular
interactions with GF, as revealed by XRPD, DSC, and Raman spectroscopy analysis;
and it is an excellent GF recrystallization inhibitor, as suggested by the
desupersaturation experiments. The only drawback of Sol was its amphiphilic nature,
and ensuing poor wettability of the Sol-based ASDs that contain a hydrophobic drug.
Adding SDS as a minor component alleviated that problem, which enabled fast
supersaturation from Sol-based ASDs. A future study entails examining the stability
of these ASD formulations and optimizing the SDS concentration for various high
drug doses. Also, the generality of the use of anionic surfactants as a minor
component will be tested with other drug–polymer–surfactants to assess
supersaturation generation–maintenance benefits.
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CHAPTER 6
SYNERGISTIC EFFECTS OF HYDROPHILIC POLYMER–AMPHIPHILIC
POLYMER COMBINATION IN ENHANCING GRISEOFULVIN RELEASE
FROM AMORPHOUS SOLID DISPERSIONS

As discussed in Chapter 1, formulating an amorphous solid dispersion (ASD) with
high drug loading that releases drug rapidly, while generating and maintaining high
supersaturation over at least three hours is challenging. To overcome this challenge in
this study, we prepared ternary drug ASDs using a combination of a hydrophilic
polymer that provides significant wettability enhancement to drug and an amphiphilic
polymer that provides supersaturation maintenance and compared their in vitro
dissolution release to binary drug ASDs prepared using each polymer separately.
Griseofulvin (GF) was selected as a challenging, fast-crystallizing poorly soluble
drug; hydroxypropyl cellulose (HPC) and Kollidon VA64 (VA64) were the
hydrophilic polymers, while Soluplus® (Sol) was the amphiphilic polymer. In the
ASDs, GF:total polymer mass ratio was fixed at 1:3 to yield 25% GF loading. XRPD,
DSC, and Raman spectroscopy confirmed the formation of ASDs from GF–Sol, GF–
HPC, and GF–VA64 and their binary polymer combinations. Sol-based ASD
generated supersaturation very slowly and achieved 170% supersaturation in 210 min.
HPC-based ASD exhibited fast recrystallization in the matrix; whereas VA64-based
ASD achieved 220% supersaturation in 10 min followed by rapid desupersaturation
due to recrystallization in the medium. The modified Washburn experiments revealed
the significant wettability enhancement of GF by HPC/VA64 and inadequate
enhancement by Sol, which explains the rapid burst in VA64-based ASD and slow
supersaturation build-up in Sol-based ASD. Slow drying of a droplet of GF–
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polymer(s) solutions and desupersaturation experiments revealed the poor
recrystallization inhibition by the hydrophilic polymers. In most cases, combination
of Sol with HPC/VA64 led to a trade-off between rapid drug release and high
supersaturation. A strong synergistic effect emerged for the ASD with 11:1
Sol:VA64, which led to 230% supersaturation within 30 min and maintained it over
three hours. Contrary to existing literature, the inclusion of a hydrophilic polymer as a
minor component in an amphiphilic, precipitation-inhibiting polymer of a ternary
ASD exhibited optimal drug release.

6.1 Materials and Methods
6.1.1 Materials
BP/EP grade, micronized griseofulvin (GF) purchased from Letco Medical (Decatur,
AL, USA) was used as a challenging Biopharmaceutics Classification System (BCS)
Class II drug because it is a fast-crystallizing poorly soluble drug (Baird et al., 2010).
Its solubility is ~8.9 mg/L at 25 °C and ~14.2 mg/L at 37 °C, melting point Tm 220
°C, and a glass transition temperature Tg of 89 °C (Baird et al., 2010). Hydroxypropyl
cellulose (HPC, SSL grade, Nisso America Inc., New York, NY) and PVP-VA64
(Kollidon VA64) were used as the hydrophilic polymers, while Soluplus® (Sol) was
used as the amphiphilic polymer. HPC is a semi-crystalline polymer with low
crystallinity and amorphous domains of very low Tg (Sarode et al., 2013). It has been
widely used as a matrix polymer in drug nanocomposites (solid nanodispersions) that
allows for fast drug nanoparticle recovery and rapid drug release (Bhakay et al.,
2018). Kollidon VA64 (VA64) is a vinylpyrrolidone-vinyl acetate copolymer with a
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glass transition temperature of 101 °C (Kolter et al., 2012). Soluplus® (Sol, BASF,
Tarrytown, NY) is an amphiphilic graft copolymer produced from polyvinyl
caprolactam–polyvinyl acetate–polyethylene glycol having a single glass transition
temperature of 73 ± 2 °C (Terife et al., 2012). Acetone (ACS reagent, ≥ 99.5%) and
ethanol (reagent alcohol, ≥ 95%) were purchased from BDH Analytical chemicals
(VWR, GA) and used as solvent to prepare drug–polymer solutions.
6.1.2 Drug–Polymer Solution Preparation and Spray Drying
The formulations of the solution-based (S) feeds to the spray dryer are provided in
Table 6.1. The drug concentration was set at 2.5% (w/v), which was measured with
respect to the total volume (240 mL) of the solution (mixture of acetone–
water/acetone–ethanol–water), in all formulations. For both binary and tertiary ASDs,
the drug:total polymer mass ratio was kept constant at 1:3. To prepare the solutionbased (S) feed, a common solvent mixture was selected where drug, and polymers
(HPC/Sol/VA64) can be dissolved completely. A mixture of acetone–water was used
for dissolving GF–HPC/Sol, whereas a ternary solvent mixture (acetone–water–
ethanol) was used to dissolve formulations with VA64. After dissolving the drug–
polymer(s) into the solvent mixture using a magnetic stirrer, the solutions were
sonicated for 30 min to ensure complete solubilization of the solid components before
feeding to the spray dryer.
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Table 6.1 Formulations and Compositions of the Drug–Polymer Solutions (S) Used in Spray Drying Experiments
ID
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S1
S2
S3
S4
S5
S6
S7
S8
S9
S10
S11
S12
S13
S14

Formulationa
S-Sol
S-HPC
S-VA64
S-Sol-HPC-1:1
S-Sol-HPC-5:1
S-Sol-HPC-9:1
S-VA64-HPC-1:1
S-VA64-HPC-5:1
S-VA64-HPC-9:1
S-Sol-VA64-1:5
S-Sol-VA64-1:1
S-Sol-VA64-3:1
S-Sol-VA64-5:1
S-Sol-VA64-11:1

GF
(% w/v)b
2.5
2.5
2.5
2.5
2.5
2.5
2.5
2.5
2.5
2.5
2.5
2.5
2.5
2.5

Polymers (% w/v)b
HPC
Sol
7.5
7.5
3.75
3.75
1.25
6.25
0.75
6.75
3.75
1.25
0.75
1.25
3.75
5.62
6.25
6.87

a

VA64
7.5
3.75
6.25
6.75
6.25
3.75
1.88
1.25
0.63

Water
(mL)
40
40
40
40
40
40
40
40
40
40
40
40
40
40

Acetone
(mL)
200
200
140
200
200
200
140
140
140
140
140
140
140
140

Ethanol
(mL)
0
0
60
0
0
0
60
60
60
60
60
60
60
60

S denotes solution-based feed. Sol denotes Soluplus; VA64 denotes polyvinylpyrrolidone vinyl-acetate (6:4). The ratios refer to the
polymer1:polymer2 mass ratio.
b
% w/v, with respect to the total solvent volume (240 mL). All formulations had a drug:total polymer mass ratio of 1:3.
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6.2 Characterization Techniques
6.2.1 Particle Size Measurement
The particle sizes of the spray-dried powders were measured by a Rodos/Helos laser
diffraction system (Sympatec, NJ, USA) based on Fraunhofer theory following the
procedure described in Li et al. (2016b). About 1 g of the powder sample was placed
on top of the sample chute of the Rodos dispersing system and the sample chute was
vibrated at a 100% setting, and 0.1 bar dispersion pressure was used to suck in the
falling powder through the sample cell of the laser diffraction system. For further
confirmation of the particle sizes, spray-dried particles were placed on a glass slide
and observed by Axio Scope.A1 polarized light microscope (PLM, Carl Zeiss
Microscopy GmbH, Göttingen, Germany).
6.2.2 Solid State Characterization and Drug–Polymer Interactions
To analyze the crystallinity of the as-received GF, HPC, Sol, VA64, spray-dried
powders with single and binary polymers, and physical mixtures of GF–
HPC/Sol/VA64, X-ray powder diffraction (XRPD) (PANanalytical, Westborough,
MA, USA), provided with Cu Kα radiation (λ= 1.5406 Å) was used. The samples
were scanned at a rate of 0.165 s-1 for 2θ ranging from 5° to 40°. The total area under
three distinct, non-overlapping peaks of GF, if they exist, at characteristic diffraction
angles of 13.2o, 14.6o, and 16.5o was calculated for both the physical mixtures and the
spray-dried powders using the equipment’s HighScore Plus software, which was then
used to estimate the crystallinity.
Differential scanning calorimetry (DSC) of the as-received GF, Sol, HPC,
VA64, and spray-dried powders with single and binary polymers was performed
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using a Mettler-Toledo polymer analyzer (PolyDSC, Columbus, OH, USA) with
integrated STARe 10 software. ~6.0–7.0 mg powder sample was placed in an
aluminum pan with a hole in the lid and loaded into the DSC machine. As-received
GF was heated at a rate of 10 °C/min from 25 °C to 250 °C. All other samples were
heated from 25 °C to 70 °C and the temperature was held for 2 min at 70 °C, then
cooled back to 25 °C to remove any residual solvent in the sample. In the final step,
the samples were heated from 25 °C to 250 °C at 10 °C/min. Nitrogen gas was used
as the purge gas and protective gas at a flow rate of 50 mL/min and 150 mL/min,
respectively. Thermogravimetric analysis (TGA) was performed to measure the
residual water/solvent content using a TGA/DSC1/SF Stare system (Mettler Toledo,
Inc., Columbus, OH). ~6.0–7.0 mg of each spray-dried sample was placed in a
ceramic crucible and heated from 25 °C to 150 °C at a heating rate of 10 °C/min
under nitrogen flow.
Raman spectroscopy was conducted using a Fergie Imaging Spectrometer
System (Princeton Instruments, Trenton, NJ) with a 500-mW external diode laser
processing at 785 nm wavelength. Data acquisition time for all spectra was 15 s per
scanned spectrum (100–1800 cm-1) and each spectrum acquired was averaged over
two scans. The data was presented for the range of 1550–1800 cm-1 wavenumber.
6.2.3 Characterization of Drug Recrystallization
To assess the recrystallization inhibition capability of the polymer(s) qualitatively, a
droplet of 20 µL of the GF–polymer(s) solutions was put onto a hot glass slide at 75
°C and kept for drying in quiescent air. After about one min drying, the slides were
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placed under the polarized light microscope (PLM) to observe if any drug
recrystallization occurred.
6.2.4 Drug Content in the Spray-Dried Powders and In Vitro Dissolution Tests
The drug content in the dried powders varied based on the drug:polymer mass ratios.
To measure the actual drug content, an assay testing was performed by dissolving 100
mg of the sample powders in 20 mL methanol under 30 min of sonication, followed
by overnight storage to ensure complete solubilization of the drug. An aliquot of 100
µL was taken from the GF solution and diluted up to 10 mL using methanol. The
absorbance of the samples was measured at 292 nm using UV spectrophotometer
(Agilent, Santa Clara, CA, USA), and the drug concentration was calculated from a
pre-established calibration curve. Six replicates were tested for each formulation to
calculate the mean drug content along with the relative standard deviation (RSD).
Drug release from the as-received GF, various physical mixtures (PMs)
prepared by blending, and spray-dried powders was determined via a Distek 2100C
dissolution tester (North Brunswick, NJ, USA), following the USP II paddle method.
1000 mL deionized water at 37 °C was stirred at 50 rpm paddle speed. Spray-dried
powder samples containing 100 mg GF (above the thermodynamic solubility of asreceived GF particles) were weighed and added to the dissolution medium and 4 mL
samples were taken out manually at 1, 2, 5, 10, 20, 30, 60, 120, 180, and 210 min.
These aliquots were filtered with a 0.1 µm PVDF membrane-type syringe filter
before UV-spectroscopy measurements to minimize any confounding effect of the
undissolved drug clusters (Bhakay et al., 2014; Li et al., 2016b). The filtered samples
were diluted with 37 °C deionized water at a ratio of 1 to 5 before UV measurement.
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Dissolved GF amount was measured by UV spectroscopy at 296 nm wavelength and
calculated using a pre-established calibration curve. Deionized water was used as the
blank before UV measurement and six replicates of each sample were performed. In
this paper, relative % supersaturation is reported based on GF concentration at 210
min and thermodynamic solubility of as-received GF particles, unless otherwise
indicated.
6.2.5 Drug Wettability Enhancement by Single and Binary Polymer Solutions
Aqueous wettability of GF particles was investigated by analyzing the penetration
rate of drug-saturated polymer solutions into a packed bed of GF particles inside a
cylindrical column according to the Washburn method (Hołownia et al., 2008;
Washburn, 1921). Attension Sigma 700 (Biolin Scientific, Linthicum, MD, USA) setup was used to measure the mass of the liquid penetrated the GF powder bed as a
function of time. Experimental methods were adapted from Bilgili et al. (2018) and Li
et al. (2017) and the details can be found in Section E.1 of the Appendix E. In the
current study, liquids and powder refer to GF-saturated aqueous solutions of 15%
polymer (single or binary polymer) and as-received GF, respectively. All percentages
are (% w/w) with respective to deionized water. The aqueous polymer(s) solution and
deionized water were saturated with griseofulvin (GF) and stirred overnight. After
overnight stirring, the saturated solutions were used for further characterization. The
apparent shear viscosity and surface tension of the liquids were measured using R/S
Plus Rheometer (Brookfield Engineering, Middleboro, MA, USA) and Attension
Sigma 700 (Biolin Scientific, Linthicum, MD, USA), respectively. The ratio of the
cosine of contact angles cosθss/cosθw was calculated using the modified Washburn
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equation and used as a wetting effectiveness factor. Here, θss is the contact angle
between GF and the polymer(s) solutions and θw is the contact angle between GF and
deionized water. The ratio was used as a rough measure of the drug wettability
enhancement upon use of different polymer (HPC/Sol/VA64 and their combinations)
in water with respect to the GF–water wettability.
6.2.6 Drug Supersaturation Maintenance Ability of the Polymers
Drug (GF) supersaturation maintenance ability of HPC/Sol/VA64 and their
combination was examined in separate desupersaturation tests (similar to Konno et al.
(2008)) based on the solvent-shift method. A GF solution was prepared by dissolving
100 mg of as-received GF into 20 mL of acetone via sonication for 40 min. This
solution was subsequently added to a 1000 mL of pre-dissolved HPC/Sol/VA64
solution having 300 µg/mL total polymer concentrations to mimic 1:3 drug:polymer
mass ratio in the USP II paddle type dissolution tester. In the case of binary polymers,
polymer concentrations were adjusted following the formulation compositions in
Table 6.1, while keeping the total polymer concentration fixed at 300 µg/mL. The
addition resulted in 92–98 µg/mL supersaturated solution of GF initially (target: 100
µg/mL, corresponding to complete dissolution of 100 mg drug during dissolution
testing). Any subsequent desupersaturation during the following 210 min was tracked
via GF concentration measurements. The experimental conditions and concentration
measurements were identical to those in the dissolution test. All measurements were
carried out in triplicate.

207

6.3 Results and Discussion
6.3.1 Size, Morphology, and Drug–Moisture Content of the Spray-Dried
Powders
Drug–polymer solutions with single and binary polymers were dried using a spray
dryer. Despite the relatively short residence time in the spray dryer (5.0 s), the spraydried powders were completely dried, as indicated by the TGA, which shows weight
loss of ~2.0% for the samples. The extremely large surface area generated by
atomization of the feed coupled with the fast convective heat–mass transfer at high
air temperature enabled fast drying of the droplets. The slightly lower drug content as
compared with the theoretical value can be attributed to preferential drug loss during
handling, poor separation of finer particles in the cyclone separator of the spray dryer,
and presence of the residual moisture after drying (Azad et al., 2015b; Bilgili et al.,
2018). RSD values of drug content were below 6%, which signifies pharmaceutically
acceptable content uniformity. The median sizes of the spray-dried powders were
measured to be in the range of 8.69–15.4 µm (Table 6.2). The microscopic images
(Figure 6.1) illustrate that spray-dried particles have rounded–donut shapes, and their
sizes are in rough agreement with the size ranges presented in Table 6.2.
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Table 6.2
Content

Particle Size Statistics of the Spray-Dried Powders and Their Drug

ID

Formulationa

S1
S2
S3
S4
S5
S6
S7
S8
S9
S10
S11
S12
S13
S14

S-Sol
S-HPC
S-VA64
S-Sol-HPC-1:1
S-Sol-HPC-5:1
S-Sol-HPC-9:1
S-VA64-HPC-1:1
S-VA64-HPC-5:1
S-VA64-HPC-9:1
S-Sol-VA64-1:5
S-Sol-VA64-1:1
S-Sol-VA64-3:1
S-Sol-VA64-5:1
S-Sol-VA64-11:1

Size of the spray-dried powders
(µm)
d10 ± SD d50 ± SD d90 ± SD
6.08±0.1 14.3±0.0 32.4±0.1
5.87±0.1 15.4±0.3 33.5±0.1
4.21±0.1 10.3±0.2 21.3±0.2
4.01±0.0 10.9±0.0 22.7±0.0
4.52±0.1 11.2±0.1 24.3±0.6
4.21±0.0 11.5±0.0 27.7±0.1
4.35±0.0 9.90±0.5 21.6±0.7
4.11±0.1 9.34±0.2 19.7±0.2
3.27±0.1 8.69±0.1 17.4±0.1
4.40±0.0 12.1±0.1 27.3±0.1
4.61±0.1 10.2±0.2 20.6±0.1
3.71±0.1 9.76±0.3 22.8±0.2
4.58±0.0 12.0±0.0 28.9±0.1
3.47±0.1 13.0±0.1 30.9±0.2

a

Actual drug
content, RSD
(%w/w, %)b
22.1, 1.76
24.0, 1.51
22.5, 2.15
22.4, 3.85
21.7, 1.60
21.7, 3.93
22.1, 2.15
22.6, 1.76
22.3, 1.42
20.9, 1.12
21.3, 3.14
23.1, 1.22
22.8, 1.48
22.3, 2.57

S denotes solution-based feed. Sol denotes Soluplus; VA64 denotes polyvinylpyrrolidone vinylacetate (6:4). The ratios refer to the polymer1:polymer2 mass ratio.
b
% w/v, with respect to the total solvent volume (240 mL). All formulations had a drug:total
polymer mass ratio of 1:3.
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Figure 6.1 Microscope images of the spray-dried powders prepared using GF
solution-based (S) feeds with a single polymer and binary polymers with various
polymer1:polymer2 mass ratios: (a) S-HPC, (b) S-Sol, (c) S-VA64, (d) S-Sol-HPC9:1, (e) S-VA64-HPC-9:1, (f) S-Sol-VA64-1:5, (g) S-Sol-VA64-1:1, (h) S-Sol-VA645:1, and (i) S-Sol:VA64-15:1. All formulations had 1:3 drug:polymer mass ratio. The
images were taken at 50X magnification (scale bar: 20 µm).

6.3.2 Formation of Drug ASDs Upon Spray Drying
The solid state of GF in the spray-dried powders was investigated via XRPD (see
Figure 6.2) and DSC (see Figure 6.3). Table 6.3 presents the summary of DSC
thermal events and estimated crystallinity via XRPD. X-ray diffractograms depict that
as-received GF exhibited intense peak characteristics of a crystalline material,
whereas HPC/Sol/VA64 exhibited halo pattern indicating amorphous structure
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Figure 6.2 X-ray diffractograms of (a) as-received GF, HPC, Sol, VA64, and
physical mixtures (PMs) of GF–HPC/Sol/VA64; (b) spray-dried powders prepared
using the GF solution-based (S) feeds with a single polymer and binary polymers
with various polymer1:polymer2 mass ratios. All formulations had 1:3 drug:polymer
mass ratio.

(Figure 6.2a). The physical mixtures (PMs), prepared by blending, exhibited peaks at
the same diffraction angles as those of as-received GF, albeit with reduced peak
intensity (Figure 6.2a), which can be attributed to the dilution and surface coverage of
GF microparticles with HPC/Sol/VA64. XRPD diffractograms (Figure 6.2b) of the
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spray-dried powders prepared using the drug–polymer solutions showed halo pattern
instead of any characteristic diffraction peaks of GF (except S-HPC). These halo
patterns confirm that amorphous GF dispersed molecularly into the polymer matrix
forming amorphous solid dispersions (ASDs). On the other hand, the peaks in the
XRPD diffractogram of S-HPC and 11.5% crystalline GF could be explained by the
partial miscibility of GF–HPC and insufficient HPC concentration to ensure complete
dispersion of GF molecules in the polymer matrix; hence, recrystallization of GF
during spray-drying occurred.
The DSC thermograms in Figure 6.3a show an endothermic peak associated
with melting of as-received GF, with a Tm of 220.1 °C and ΔHf of 101.8 J/g; a glass
transition for Sol (amorphous) at 72.4 °C, a glass transition for VA64 (amorphous) at
102 °C and a slight endothermic event around 170–200 °C for HPC likely due to the
melting of the small crystalline domain of largely amorphous HPC (Sarode et al.,
2013) (crystallinity was undetectable by XRPD). The Tg of HPC could not be
measured (in the range of –25 to 0 °C (Sarode et al., 2013)) due to limitation of our
equipment. For the spray-dried powders prepared from the drug–polymer solutions, a
single Tg was observed for all the formulations confirming the formation of molecular
level dispersion (Luebbert et al., 2017; Wlodarski et al., 2015) (see Table 6.3). All
spray-dried powders exhibited a glass transition and a small endothermic melting
peak for GF. S-HPC had the highest value of fusion enthalpy due to presence of 12%
crystals, as measured by XRPD. The small endothermic event for all other samples
could be due to small amount of nuclei/crystals in the prepared ASDs, which could
not be detected by XRPD or crystals generated during the heat treatment of DSC.
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Figure 6.3 DSC thermograms of (a) as-received GF, HPC, Sol, and VA64; (b) spraydried powders prepared using the GF solution-based (S) feeds with a single polymer
and binary polymers with various polymer1:polymer2 mass ratios. All formulations
had 1:3 drug:polymer mass ratio.
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Table 6.3 Characteristic Temperatures–Enthalpy Values Obtained From DSC Thermograms and Crystallinity Estimated From
XRPD Diffractograms
ID
S1
S2
S3
S4
S6
S7
S9
S10
S11
S12
S13

Formulationa
S-Sol
S-HPC
S-VA64
S-Sol-HPC-1:1
S-Sol-HPC-9:1
S-VA64-HPC-1:1
S-VA64-HPC-9:1
S-Sol-VA64-1:5
S-Sol-VA64-1:1
S-Sol-VA64-3:1
S-Sol-VA64-5:1

Tg (ºC)a,b
80.4
53.2
100.4
77.6
75.1
93.7
94.1
85.9
86.1
82.8
82.7

Trc (ºC) a,b
ND
122
ND
135
ND
ND
ND
ND
ND
ND
ND

Hrc (J/g) a,b
ND
–4.36
ND
–6.38
ND
ND
ND
ND
ND
ND
ND
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a

Tm (ºC) a,b
189
201
184
195
191
187
188
185
186
186
188

Hf (J/g) a,b
0.64
13.2
0.94
7.45
4.64
2.26
1.11
1.06
1.31
0.62
0.74

Crystallinity (%)b
ND
11.5
ND
ND
ND
ND
ND
ND
ND
ND
ND

S denotes solution-based feed, Sol denotes Soluplus; the ratios refer to the polymer1:polymer2 mass ratio . Other symbols: Tg, Trc, and Tm stand for
temperature for glass transition, recrystallization transition, and melting point, respectively, while Hrc and Hf respectively stand for recrystallization
enthalpy and fusion enthalpy.
b
ND: not detected.
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However, significant depression in the melting point of the spray-dried samples
compared to the respective physical mixtures confirm the miscibility of the drug–
polymers. S-HPC and S-Sol-HPC-1:1 exhibited a glass transition followed by an
exothermic event due to the recrystallization of amorphous GF followed by the
melting of the existing crystals and/or recrystallized GF (Figure 6.3c).
Recrystallization occurred during the heating step of DSC scan because above Tg
amorphous drug molecules and amorphous polymer had higher mobility, which may
cause GF recrystallization. Since GF–HPC are partially miscible, above Tg GF
molecules can easily phase separate and recrystallize. Due to strong molecular
interactions and good miscibility of GF–Sol and GF–VA64, recrystallization event at
high temperature was not observed for the formulations with Sol, VA64, and their
combinations during the DSC scan.
The observed Raman spectra in Figure 6.4a for as-received GF and PMs of
GF are largely in agreement with Fourier transform Raman data of ref. (Feng et al.,
2008) and Raman data of ref. (Żarów et al., 2011) for crystalline GF. The Raman
spectra of all the spray-dried samples (Figure 6.4b) show that the GF line at 1606
cm-1 disappeared, and the peaks at other characteristic frequencies shifted to new
positions that are characteristic of amorphous GF, e.g., the peak shift from 1623 to
1620 cm–1 (see (Żarów et al., 2011)), signifying formation of amorphous GF and
molecular level interactions between GF and polymers in the ASD. While the GF line
at 1606 cm–1 disappeared in the Raman spectra of S-HPC (Figure 6.4b), the shifts in
other peaks were subtler than those for the Raman spectra of S-Sol and S-VA64,
which could suggest stronger molecular interactions between GF–Sol and GF–VA64
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than GF–HPC. For all the spray-dried formulations produced from binary polymers,
noticeable peaks shift also suggest stronger molecular interactions between GF–
binary polymers (Figure 6.5).

Figure 6.4 Raman spectra of (a) as-received GF, physical mixtures (PMs) of GF–
HPC, GF–Sol, and GF–VA64 at 1:3 drug:polymer mass ratio; (b) physical mixtures
(PMs) and spray-dried powders prepared using GF solution-based (S) feeds of GF–
HPC, GF–Sol, and GF–VA64 with 1:3 drug:polymer mass ratio.
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Figure 6.5 Raman spectra of (a) as-received GF, physical mixtures (PMs) of GF–
binary polymers at various polymer1:polymer2 mass ratios; (b) physical mixtures
(PMs) of GF–Sol–HPC and GF–VA64–HPC and their respective spray-dried
powders with 9:1 mass ratio of Sol:HPC and VA64:HPC, respectively; (c) physical
mixtures (PMs) of GF–Sol–VA64 and their respective spray-dried powders with 5:1
and 1:5 mass ratios of Sol:VA64. All formulations had 1:3 drug:polymer mass ratio.
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Overall, XRPD, DSC, and Raman spectroscopy results (i) confirm that the
spray-drying of drug–polymer(s) solutions produced ASDs and (ii) suggest stronger
GF–polymer interactions and miscibility for GF–Sol and GF–VA64 than GF–HPC. It
is suggested that if the solubility parameter difference between a drug and polymer is
<7.0 MPa1/2, they are likely to be miscible; if the difference is >10 MPa1/2, they are
considered immiscible; and if the difference is in between 7.0 and 10, they exhibit
partial miscibility (Forster et al., 2001; Greenhalgh et al., 1999). The solubility
parameters of GF, HPC, Sol, and VA64 are 12.2 (Thakral and Thakral, 2013), 24.0
(Choi et al., 1994), 19.4, and 19.7 (Kolter et al., 2012) MPa1/2, respectively. The
solubility parameter differences between GF–Sol and GF–VA64, and GF–HPC are
7.2, 7.5, and 11.8 MPa1/2, respectively, which suggests that GF–Sol is borderline
miscible, GF–VA64 is partially miscible, whereas GF–HPC is most likely
immiscible. While being useful, the solubility parameters do not account for all drug–
polymer interactions such as contributions from hydrogen bonding, hydrophobic
interactions, etc., and hence should be used with caution as rough estimates of drug–
polymer miscibility. The solubility parameter prediction appears to be accurate for
GF–Sol and GF–VA64 as XRPD, DSC, and Raman spectroscopy results suggests
GF–Sol and GF–VA64 are miscible and molecularly interact more than GF–HPC.
However, GF–HPC exhibits partial miscibility unlike what the solubility parameters
of GF–HPC suggest. As the theoretical models behind the solubility parameter
prediction are applicable for simple molecular structures wherein van der Waals force
plays a predominant role, while for drug–polymer systems which are known to form
highly directional interactions (e.g., hydrogen bonding) or long range interactions
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(e.g., ionic interaction), this approach can be erroneous (Baird et al., 2010; Meng et
al., 2015). Indeed, the absence of diffraction peaks in XRPD for 1:5 GF:Sol ASD (not
shown) and significant melting point depression with respect to physical mixtures
based on DSC (not shown) along with the Raman line shifts suggest that HPC
molecularly interacts with GF, resulting in partial miscibility unlike the prediction
from the solubility parameters.
6.3.3 Assessment of the Recrystallization Inhibition Capability of the Polymers
In the drug–polymer solutions, GF and polymer (s) were completely dissolved in
acetone–water/acetone–water–ethanol mixture, which allowed molecular level
interaction in the solution before spray drying. Due to fast evaporation of the solvents
in the spray dryer, viscosity increases rapidly causing entrapment of the drug
molecules in the polymer matrices, which appears to have retarded phase separation
even in the case of GF–HPC (immiscible or partially miscible) and enables the ASD
formation.
To assess the recrystallization inhibition capability of the polymers
qualitatively, we have devised a slower drying method: a single droplet of GF–
polymer (s) solution was dried on a heated glass slide at 75 ºC, i.e, the same
temperature as that of hot air in the spray-drying. However, the droplet was dried in
quiescent air, which makes external mass transfer of solvent vapor in air controlling
the evaporation rate, making drying slower compared to spray drying. This slow
drying is quite conservative regarding the crystallization inhibition capability of the
polymers as it gives ample time for dissolved drug to precipitate and form crystals.
The drying took less than 40 s, whereas the drying occurred less than ~5 s in the
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spray dryer. The PLM images in Figure 6.6 illustrate that GF crystals formed during
the slow drying of all solutions. On the other hand, the slow drying of S-Sol and SVA64 solution yielded few small crystals, whereas that of S-HPC solution yielded
significant number of long needle-shaped crystals. The extent of recrystallization was
much higher in HPC than in Sol or VA64. HPC could not inhibit the
nucleation/crystal growth of GF from the supersaturated solution as evaporation
proceeded during the spray-drying. Figure 6.6d and 6.6e show that Sol is a better
precipitation inhibitor than VA64 in the presence of HPC. An increase in Sol:VA64
mass ratio led to smaller and fewer crystals suggesting that Sol could be a good GF
crystal inhibitor. While all images in Figure 6.6 shows presence of crystals due to
slow drying, fast spray-drying did not allow much time for precipitation; thus, all
GF–polymer(s) led to ASD, except ASD with 1:3 GF:HPC mass ratio.
It is known that the phase separation and recrystallization involve diffusion
and nucleation of drug molecules, both of which require molecular mobility and can
be restricted by polymer molecules as inhibitor (Baghel et al., 2016). Strong drug–
polymer interactions can reduce the molecular mobility and delay crystallization
onset time and the extent of crystallization (Mistry et al., 2015). To gain additional
insights into the GF recrystallization inhibition capability of Sol/HPC in
supersaturated drug solutions, desupersaturation experiments were performed. In the
desupersaturation tests (Figure 6.7a), only Sol was able to maintain the GF
supersaturation for ~3 h, whereas GF concentration drastically decreased after 10 min
in the case of VA64 or HPC upon GF recrystallization. These results suggest that the
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Figure 6.6 Polarized light microscope images of a droplet of GF solution-based (S)
feed of (a) S-Sol, (b) S-HPC, (c) S-VA64, (d) S-VA64-HPC-9:1, (e) S-Sol-HPC-9:1,
(f) S-Sol-VA64-1:1, (g) S-Sol-VA64-1:5, (h) S-Sol-VA64-5:1, and (i) S-Sol-VA6415:1 after slow drying. The droplets were dried on a glass slide at room temperature.
All formulations had 1:3 drug:polymer mass ratio. The images were taken at 5X
zoom (scale bar: 200 µm).

superior GF recrystallization inhibition and supersaturation maintenance capability of
Sol over HPC and VA64 (Figure 6.7a). Excellent nucleation inhibition and
supersaturation maintenance capability of Sol was reported earlier (Guan et al.,
2019a; Guan et al., 2019b). Figure 6.7 also corroborates the fast recrystallization
tendency of GF (Baird et al., 2010) without inhibitors. Among binary polymers, Sol–
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VA64 and Sol–HPC were able to maintain the supersaturation, whereas VA64–HPC
could not maintain the supersaturation. In other words, the ASDs without Sol, as the

Figure 6.7 GF desupersaturation curves for a 20 mL GF–acetone solution mixed
with (a) 1000 mL aqueous solutions of 300 µg/mL Sol/VA64/HPC and deionized
water and (b) 1000 mL aqueous solutions of 250 µg/mL Sol–50 µg/mL VA64, 50
µg/mL Sol–250 µg/mL VA64, 150 µg/mL Sol–150 µg /mL HPC, 270 µg/mL Sol–30
µg/mL HPC, 270 µg/mL VA64–30 µg/mL HPC, and deionized water. Deionize water
has no recrystallization inhibitor. The initial concentration of GF right after mixing
was targeted at 100 µg/mL.
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crystallization inhibitor is not expected to provide or maintain a high supersaturation.
These findings suggest that having an amphiphilic polymer like Sol as the
crystallization inhibitor is a must as the rather hydrophilic polymers like VA64–HPC
do not have much inhibitory effect.
6.3.4 Dissolution Performance of the Spray-Dried Powders
The temporal evolution of GF release from the binary ASDs with single polymer and
ternary ASDs with binary polymers combinations and the PM with the binary
polymer combinations containing 100 mg equivalent GF dose in 1000 mL deionized
water at 37 ºC was investigated. The bulk dissolution medium could supersaturate for
this high drug dose as the GF solubility is 14.2 mg/L. Unless otherwise specified, all
supersaturation values are relative to aqueous thermodynamic solubility of GF and
calculated at 210 min.
Figure 6.8 shows that the GF ASDs prepared via spray-drying of the drug–
polymer solutions with single polymer enhanced the dissolution rate and extent of GF
release compared to the as-received GF. The initial drug release rate was significantly
higher for S-HPC ASD and S-VA64 ASD than S-Sol ASD. At 10 min, 220% and
40% GF supersaturation were achieved by S-VA64 and S-HPC, respectively, whereas
S-Sol could not even reach the saturation solubility (14 mg/L). These observations
can be explained by the hydrophilicity of the polymers and their relative wetting
effectiveness (see Table 6.4). The relative wetting effectiveness factor for HPC,
VA64, and Sol measured to be 20.9, 16.1, and 2.65, respectively, which is in line
with the relatively more hydrophilic nature of HPC/VA64 than Sol, based on the
functional groups of the respective groups (not shown). Therefore, in the aqueous
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dissolution medium, HPC and VA64 allowed for excellent wetting of hydrophobic
GF molecules and their ASDs exhibited rapid release of GF and the hydrophilic
polymer.

Unlike HPC/VA64, Sol does not allow for good wetting of the GF

particles, which hinders Sol/GF dissolution.

Figure 6.8 Evolution of drug release from as-received GF and spray-dried powders
prepared using solution-based (S) feeds of GF–HPC, GF–Sol, and GF–VA64 with
1:3 drug:polymer mass ratio.
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Table 6.4 Properties of Drug-Saturated Deionized Water–Aqueous Polymer
Solutions and Wetting Effectiveness Factor Determined Using the Modified
Washburn Method
Formulation

η (cP) ρ (g/mL) γ (mN/m) Slope, (g2/s) R2

Water

0.89

1

66.5

7.0×10-3

HPC

53.2

1.01

39.9

1.5×10

Sol

8.76

VA64

7.80

Sol-HPC-1:1
Sol-HPC-9:1
Sol-VA64-1:5
Sol-VA64-5:1
VA64-HPC-1:1
VA64-HPC-9:1

35.0
10.9
7.41
8.05
23.0
10.6

1.01
1.01
0.98
1.01
1.01
1.01
1.01
1.01

41.4
39.6
41.0
41.9
40.8
41.9
38.9
36.8

-3
-3

1.2×10

-3

7.8×10

-4

7.3×10

-3

2.0×10

-3

6.1×10

-3

2.9×10

-3

4.2×10

-3

7.3×10

cosθss/cosθw

0.990 1a
0.998 20.9
0.989 2.65
0.999 16.1
0.997 6.93
0.989 5.44
0.996 11.6
0.993 5.83
0.999 26.9
0.999 22.0

a

The slope of the water penetration data was used as reference for wettability enhancement by the
stabilizer solutions.

There is a drastic difference between S-HPC and S-VA64 in their GF release
(Figure 6.8): after S-VA64 achieved 220% GF supersaturation at 10 min, the GF
concentration displayed exponential decay in time due to recrystallization of the drug
in the supersaturated dissolution medium because VA64 is not a good crystallization
inhibitor (refer to Section 6.3.3 for recrystallization inhibition). On the other hand, SHPC could not provide any further supersaturation after 10 min. It is well-established
that depending on the drug–polymer miscibility and interactions, amorphous drug in
an ASD may phase-separate and recrystallize upon contact of ASDs with water in the
dissolution medium (Alonzo et al., 2011; Chen et al., 2015). Once imbibed into the
ASD matrix, water acts as a plasticizing agent, enhancing the mobility of the drug
molecules by reducing the Tg of the ASD (Chen et al., 2015). HPC-SSL has subambient Tg (Sarode et al., 2013) (lower than Tg of Sol: 73 °C and Tg of VA64: 101 °C,
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Kolter et al., 2012) and its ASDs have lower Tg than Sol-based and VA64-based
ASDs (see Table 6.3). Moreover, due to partial immiscibility of HPC with GF, its
relatively weak molecular interactions with GF as compared with Sol/VA64 (miscible
with GF), as well as its poor GF nucleation/crystal growth inhibition, it is likely that
the amorphous GF most likely crystallized in the S-HPC matrix rather than in the
dissolution medium, unlike the case for S-VA64 ASD. Interestingly, at the end of the
dissolution test (210 min), S-Sol was able to reach higher supersaturation (170%)
compared to S-VA64 (110%) and S-HPC (40%). Owing to the high Tg of Sol and its
ASD (see Table 6.3), its strong intermolecular interactions and relatively good
miscibility with GF, Sol could achieve high GF supersaturation; however, the GF
release rate from S-Sol is controlled by the relatively poor wettability, which led to
slow, monotonic build-up of supersaturation, eventually after 210 min leading to the
highest GF supersaturation in Figure 6.8.
Analysis of Figure 6.7 and Figure 6.8 and Table 6.4 overall suggests that
binary polymers Sol–VA64 in a ternary ASD could potentially complement each
other in achieving rapid drug release by VA64 and maintenance of high GF
supersaturation by Sol, which will be evaluated via dissolution tests with ternary
ASDs. Since HPC could not generate or maintain high extent of supersaturation, it
was not used as a major component in the ternary ASDs. For both VA64–HPC and
Sol–HPC combinations, 1:1, 5:1, and 9:1 VA64/Sol:HPC mass ratios were used. Due
to its unfavorable characteristics mentioned earlier, using HPC either with VA64 or
Sol did not appear to improve desirable dissolution performance (Figure 6.9a and
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Figure 6.9b). The extent of supersaturation at 210 min for all ternary ASDs with HPC
was lower than those for the binary ASDs: S-VA64 and S-Sol. Augmenting HPC with

Figure 6.9 Evolution of drug release from physical mixture (PM) of GF–binary
polymers and spray-dried powders prepared using GF–polymer solutions with a
single polymer and binary polymers with various polymer1:polymer2 mass ratios: (a)
VA64/HPC was each used as a single polymer and as binary polymers with 1:1, 5:1,
and 9:1 VA64:HPC mass ratios; (b) Sol/HPC was each used as a single polymer and
as binary polymers with 1:1, 5:1, and 9:1 Sol:HPC mass ratios. All formulations had
1:3 drug:polymer mass ratio.
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VA64 deteriorated extent of supersaturation drastically (Figure 6.9a). For the Sol–
HPC binary blends, the ternary ASDs had slightly faster initial GF release than the
S-Sol, but this benefit came at the expense of reduced extent of supersaturation at
longer times. These poor drug dissolution performance of the ternary ASDs with
HPC stems from the rapid matrix crystallization of GF caused by low Tg of HPC and
its relatively poor miscibility with GF. The detrimental impact of HPC was more
marked for its ternary ASD with VA64 than that with Sol because Sol could at least
inhibit recrystallization in the matrix to a certain extent, however, VA64 could not.
Ternary ASD of GF with Sol–VA64 exhibited desirable GF release
characteristics such as initial, rapid GF release and build-up of supersaturation and its
prolonged maintenance over 3 h when Sol was used as the major polymer component
and VA64 as the minor component, i.e., 5:1 Sol:VA64 mass ratio (Figure 6.10). At
210 min, 230% relative supersaturation was achieved from S-Sol-VA64-5:1, whereas
the relative supersaturation was 170% and 110% from S-Sol and S-VA64,
respectively. It is inferred that ternary ASD with 5:1 Sol-VA64 exhibited significant
synergistic enhancement upon combined use of an amphiphilic polymer (Sol,
crystallization inhibitor) as a major component and the hydrophilic polymer (VA64)
as a minor component. Apparently, this is contrary to the strategy proposed by Xie
and Taylor, (2016a, b) based on their work on celecoxib. In fact, following their
strategy, one would expect S-Sol-VA64-1:5 ASD to perform the best; yet, it led to the
lowest extent of supersaturation among all ASDs with Sol–VA64 (Figure 6.10).
Apparently, due to the obvious complexity of ternary ASDs, a “universal”
formulation strategy is not likely to apply to all drugs because of the specificity of
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drug–polymer1–polymer2 molecular interactions and their relative impact on
wettability, drug recrystallization inhibition within the ASD matrix and in the
dissolution medium, their diffusivities and dissolution rates relative to the drug, etc.
Although increasing Sol concentration helped to improve the extent of
supersaturation, there is a Sol:VA64 ratio after which the improvement is trivial, e.g.,
relative supersaturation 130%, 210%, 230%, and 260% was achieved at 210 min by
varying Sol:VA64 mass ratio 1:1, 3:1, 5:1, and 11:1, respectively.

Figure 6.10 Evolution of drug release from physical mixture (PM) of GF–binary
polymers and spray-dried powders prepared using GF–polymer solutions with a
single polymer and binary polymers with different Sol:VA64 mass ratios: Sol/VA64
was each used as a single polymer and as binary polymers with 1:1, 5:1, 11:1, and 1:5
Sol:VA64 mass ratios.
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6.4 Conclusions
Ternary ASDs of a poorly soluble fast crystallizing drug (GF) with binary
combinations of HPC/VA64/Sol and binary ASDs of GF with the corresponding
individual polymers, all having 1:3 GF:total polymer mass ratio, were prepared using
spray-drying. XRPD, DSC, and Raman spectroscopy confirmed the molecular
dispersion of GF in the matrices of single or binary polymers. Although binary ASDs
with single polymer showed dissolution enhancement compared to as-received GF
and physical mixtures, a desirable dissolution profile, i.e., rapid GF release
concurrently generating fast supersaturation that lasts 3 hours, was not achieved.
Despite being an excellent crystallization inhibitor, Sol did not allow for good
wettability and hence its ASD could not achieve rapid drug release. Moreover, owing
to its strong intermolecular interactions and miscibility with GF, it could generate a
high GF supersaturation, albeit slowly. VA64, on the other hand, provided excellent
wettability to the hydrophobic drug within the ASD and thus its ASD achieved fast
initial release of the drug/polymer, with a burst. However, it is a poor crystallization
inhibitor and could not sustain the initial high supersaturation. Unfortunately, having
a sub-ambient Tg with low partial miscibility with GF, HPC (SSL grade) could not
suppress the mobility of amorphous GF molecules upon contact of ASD with water,
and fast recrystallization within the ASD matrix occurred.
The dissolution profiles of the ternary ASDs of binary polymers were mostly
reflective of the deficiencies of the polymers in terms of wettability enhancement and
recrystallization inhibition in the ASD matrix and the dissolution medium. As
expected, the combination of the two hydrophilic polymers HPC–VA64 without an
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amphiphilic crystal-inhibiting polymer (Sol) led to low supersaturation, below 80%.
Being an effective crystallization inhibitor Sol compensated for HPC’s inability to
prevent recrystallization; but there was no synergistic positive impact. Any increase
in initial drug release rate upon use of HPC was nullified by lower extent of
supersaturation. Finally, based on the results regarding GF release from ternary ASDs
with Sol-VA64, we conclude that a ternary ASD of GF could exhibit synergistic
enhancement of drug release rate and its extent upon combined use of an amphiphilic
polymer (Sol, as a crystallization inhibitor) as a major component and the hydrophilic
polymer (VA64) as a minor component that provides wettability enhancement. Future
work will focus on the application of such strategy to other poorly water-soluble
drugs.
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CHAPTER 7
RELEASE OF ITRACONAZOLE FROM SPRAY-DRIED NANOCRYSTAL–
AMORPHOUS SOLID DISPERSIONS (HyNASDs) and ASDs

To elucidate the generality of the findings from the research on GF regarding
HyNASDs formation and impact of SDS in the dissolution enhancement, here
another BCS Class II drug, Itraconazole (ITZ) is selected, which has very low
aqueous solubility (0.002 µg/mL). Hydroxypropyl cellulose (HPC), Kollidon VA64
(VA64), and Soluplus® (Sol) were used as suspension stabilizers and matrix-forming
polymers. To elucidate the impact of a surfactant in on drug release from HyNASDs,
an anionic surfactant, sodium dodecyl sulfate (SDS), was selected. 2.5% wet-milled
ITZ suspensions containing 1:5 GF:polymer mass ratios, with 0.125% SDS (below
CMC) and without SDS, were spray-dried. Hydroxypropyl cellulose (HPC) and
Soluplus (Sol) were used as suspension stabilizers and matrix-forming polymers. To
prepare ASDs, ITZ–Sol/HPC/VA64 solutions having identical composition to the
nanosuspensions were spray dried. Examination of particle sizes in the milled
suspensions revealed the criticality of SDS in the synergistic stabilization of GF
nanoparticles. XRPD and DSC results suggest that nanocomposites and
nanocomposites with notable amorphous ITZ, HyNASDs, were formed upon spraydrying. For 100 mg ITZ dose (above thermodynamic solubility), up to 840% relative
supersaturation was achieved from Sol-based HyNASDs at 210 min, whereas with
SDS, this value went up to 1230%. Sol-based HyNASDs outperformed HPC and
VA64, which could be explained partly by the stronger molecular interaction between
ITZ–Sol than ITZ–HPC/VA64 and partly by the micellar solubilization by Sol as well
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as its recrystallization inhibition in the superstrated drug solutions. ITZ-Sol-ASD
generated ~2000% supersaturation, which is higher that generated by HyNASDs
(1230%).

Nonetheless,

such

high

supersaturation

from

nanoparticle-based

formulation has not been achieved in literature before. So, HyNASDs boost the
performance drug nanoparticle-based formulations and render them competitive to
ASDs. Therefore, this study demonstrates the generality of the findings in Chapter 3
and Chapter 4, by using another poorly soluble drug, ITZ and the presence of SDS in
the formulation significantly improved the extent of supersaturation in the dissolution
medium, similar to the GF-HyNASDs.

7.1 Materials and Methods
7.1.1 Materials
Itraconazole (ITZ) was used as Biopharmaceutics Classification System (BCS) Class
II drug and was purchased from Jai Radhe Sales (Ahmedabad, India). Solubility of
pure ITZ in deionized water and 0.1 N HCl are around 0.002 µg/mL and ~ 4 µg/mL,
respectively (Ghazal et al., 2009) at 37 ºC. The glass transition and melting
temperature of ITZ are reported to be 59 ºC (Zhang et al., 2016) and 171 ºC (Bilgili et
al., 2018), respectively. Hydroxypropyl cellulose (HPC, SSL grade, Nisso America
Inc., New York, NY) is a semi-crystalline polymer with low crystallinity and
amorphous domains of very low Tg. It is widely used as a stabilizer during milling
and matrix former in the nanocomposites (Azad et al., 2015b; Bhakay et al., 2014a).
Soluplus® (Sol) is an amphiphilic graft copolymer produced from polyvinyl
caprolactam–polyvinyl acetate–polyethylene glycol having a single glass transition
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temperature of 73 ± 2 °C (Terife et al., 2012). Kollidon VA64 (VA64) is a
hydrophilic polymer produced from the combination of vinylpyrrolidone (hydrophilic
in nature) and vinyl acetate (lyophilic in nature) and has a single glass transition
temperature of 101 °C (Kolter et al., 2012). Even 15% w/v aqueous solutions of all
three polymers have less than 60 cP viscosity at 25 °C, which allowed us to perform
milling and spray drying without any likely processing issues such as pressure buildup in wet media milling and nozzle clogging in spray drying. Sodium dodecyl sulfate
(SDS), an anionic surfactant with a CMC of 8.0 mM, purchased from GFS
Chemicals, Inc. (Columbus, OH) was used as a wetting agent, which also helps to
stabilize GF nanosuspensions. Dichloromethane, DCM (ACS reagent, ≥ 99.5%) was
purchased from BDH Analytical chemicals (VWR, GA) and used as the solvent to
prepare drug–polymer solutions. Wear resistant yttrium zirconia beads (Zirmil Y,
Saint Gobain ZirPro, Mountainside, NJ, USA) with a median size of 430 µm was
used as the milling media.
7.1.2 Preparation of Suspension-Based (W) and Solution-Based (S) feeds of ITZ
and Their Spray Drying
Aqueous suspension-based (W:water) feeds of ITZ prepared by wet milling were fed
to the spray dryer for the preparation of drug nanocomposites. Table 7.1 presents the
formulations used in the precursor feeds. The concentration of ITZ and SDS was kept
at 2.5% w/v and 0.125% w/v, respectively, in all suspensions. The concentration was
calculated with respect to the 240 mL suspension liquid (deionized water). ITZ
suspensions were prepared with three different polymers (HPC, Sol, and VA64) with
drug:polymer mass ratios of 1:5 to examine the impact of polymer type on ITZ
release in the dissolution tests. Finally, to investigate the impact of SDS in the
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stabilization of the milled ITZ suspensions and ITZ release during dissolution tests,
surfactant-free suspensions having the same drug:polymer mass ratios were also
prepared for comparative analysis.

Table 7.1 Formulations and Compositions of the Suspension-Based (W) Feeds Used
in Spray Drying Experiments
ID

Formulationa

W1
W2
W3
W4
W5
W6

W-Sol
W-HPC
W-VA64
W-Sol-SDS
W-HPC-SDS
W-VA64-SDS

GF
(% w/v)b
2.5
2.5
2.5
2.5
2.5
2.5

SDS
(% w/v)b
0
0
0
0.125
0.125
0.125

Polymers (% w/v)b
Sol
HPC
VA64
12.5
12.5
12.5
12.5
12.5
12.5

Water
(mL)
240
240
240
240
240
240

a

W denotes suspension-based feed; drug:polymer mass ratio was fixed at 1:5 in all the formulations;
Sol denotes Soluplus; VA64 denotes polyvinylpyrrolidone vinyl-acetate (6:4).
b
% w/v, with respect to the total solvent volume (240 mL).

In each milling experiment, a shear mixer (Fisher Scientific Laboratory
Stirrer, Catalog No. 14-503, Pittsburgh, PA) was used to disperse as-received ITZ
particles in aqueous stabilizer (HPC/Sol/VA64) solutions with and w/o SDS. The
resultant GF pre-suspensions were transferred to the holding tank of a Microcer wet
stirred media mill (WSMM) (Netzsch Fine Particle Technology, LLC, Exton, PA,
USA) having 80 mL chamber. Milling conditions were adapted from our prior work
on wet media milling (Afolabi et al., 2014; Bilgili et al., 2016; Bilgili et al., 2018). 50
mL of the milling chamber was filled with zirconia beads, and a screen with 200 µm
opening was used at the outlet of the chamber to hold the beads in the chamber. A
peristaltic pump was used to recirculate the suspension through the chamber at a rate
of 126 mL/min and the suspension was milled for 64 min at a rotor speed of 4000
rpm. A chiller (Advantage Engineering Greenwood, IN, USA) was used to maintain
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the milling chamber temperature below 35 °C throughout the milling. A portion of
each suspension was separated in a vial and stored for 7-days at 8 °C to assess the
short-term physical stability. Also, the milled suspensions were refrigerated at 8 °C
overnight before spray drying.
The formulations of the solution-based (S) feeds to the spray dryer are
provided in Table 7.2. The drug concentration was kept constant at 2.5% (w/v) in all
the formulations, which was measured with respect to the total volume of the DCM
(240 mL). ITZ solutions were prepared with three polymers (HPC, Sol, and VA64),
while keeping the drug:polymer mass ratio constant at 1:5. After dissolving the drug–
polymer into DCM using a magnetic stirrer, the solutions were sonicated for 30 min
to ensure complete solubilization of the solid components before feeding to the spray
dryer.

Table 7.2 Formulations and Compositions of the Solution-Based (S) Feeds Used in
Spray Drying Experiments
ID

Formulationa

S1
S2
S3

S-Sol
S-HPC
S-VA64

GF
(% w/v)b
2.5
2.5
2.5

Polymers (% w/v)b
Sol
HPC
VA64
12.5
12.5
12.5

DCM (mL)
240
240
240

a

S denotes solution-based feed; drug:polymer mass ratio was fixed at 1:5 in all the formulations; the
ratios refer to the polymer:polymer mass ratio; Sol denotes Soluplus; VA64 denotes
polyvinylpyrrolidone vinyl-acetate (6:4).
b
% w/v, with respect to the total solvent volume (240 mL).

7.2 Characterization Techniques
7.2.1 Particle Size Measurement
Drug particle size distributions (PSDs) in the suspensions were measured using a
laser diffraction (LS 13 320, Beckman Coulter, Miami, FL) based on Mie scattering
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theory following the procedure described in (Bilgili et al., 2016). Particle sizes were
measured at various time points: right after milling, after 1-day and 7-day storage at 8
°C in a refrigerator. During the measurement, the intensity was maintained 40–50%
while the obscuration was maintained below 8.0%. Refractive index values are 1.68
for ITZ (drug) and 1.33 for deionized water (medium). For each measurement, a 2.0
mL suspension sample was diluted with 5.0 mL of the respective stabilizer solution
and mixed using a vortex mixer (Fisher Scientific Digital Vortex Mixer, Model No:
945415, Pittsburgh, PA) at 1500 rpm for 1 min.
The particle sizes of the spray-dried powders were measured by a
Rodos/Helos laser diffraction system (Sympatec, NJ, USA) based on Fraunhofer
theory following the procedure described in (Li et al., 2016b). About 1 g of the
powder sample was placed on top of the sample chute of the Rodos dispersing system
and the sample chute was vibrated at a 100% setting, and 0.1 bar dispersion pressure
was used to suck in the falling powder through the sample cell of the laser diffraction
system.
7.2.2 Solid State Characterization and Drug –Polymer Interactions
To analyze the crystallinity of the as-received ITZ, HPC, Sol, VA64, spray-dried
powders, and physical mixtures of ITZ–polymer with or w/o SDS, X-ray powder
diffraction (XRPD) (PANanalytical, Westborough, MA, USA), provided with Cu Kα
radiation (λ= 1.5406 Å) was used. The samples were scanned at a rate of 0.165 s-1 for
2θ ranging from 5° to 40°.
Differential scanning calorimetry (DSC) of the as-received ITZ, Sol, HPC,
VA64, spray-dried powders, and physical mixtures (PM) was performed using a
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Mettler-Toledo polymer analyzer (PolyDSC, Columbus, OH, USA) with integrated
STARe 10 software. ~6.0–7.0 mg powder sample was placed in an aluminum pan
with a hole in the lid and loaded into the DSC machine. All the samples were heated
at a rate of 10 °C/min from 25 °C to 200 °C. Nitrogen gas was used as the purge gas
and protective gas at a flow rate of 50 mL/min and 150 mL/min, respectively.
Thermogravimetric analysis (TGA) was performed to measure the residual
water/solvent content using a TGA/DSC1/SF Stare system (Mettler Toledo, Inc.,
Columbus, OH). ~6.0–7.0 mg of each spray-dried sample was placed in a ceramic
crucible and heated from 25 °C to 150 °C at a heating rate of 10 °C/min under
nitrogen flow.
7.2.3 Drug Content in the Spray-Dried Powders and In Vitro Dissolution Tests
To measure the actual drug content, an assay testing was performed by dissolving 100
mg of the sample powders in 20 mL DCM under 30 min of sonication, followed by
overnight storage to ensure complete solubilization of the GF particles. An aliquot of
100 µL was taken from the ITZ solution and diluted up to 10 mL using DCM. The
absorbance of the samples was measured at 260 nm using UV spectrophotometer
(Agilent, Santa Clara, CA, USA), and the drug concentration was calculated from a
pre-established calibration curve. Six replicates were tested for each formulation to
calculate the mean drug content along with the relative standard deviation (RSD).
Drug release from the spray-dried powders and physical mixtures (PMs)
prepared by blending was determined via a Distek 2100C dissolution tester (North
Brunswick, NJ, USA), following the USP II paddle method. 1000 mL of 0.1 N HCl
solution at 37 °C was selected as the dissolution medium and stirred at 50 rpm paddle
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speed. Considering the thermodynamic aqueous solubility of ITZ in 0.1 N HCl, i.e.,
4.0 µg/mL at 37 °C (Ghazal et al., 2009), a high dose (100 mg) of ITZ would allow
for supersaturating dissolution conditions. 100 mg ITZ equivalent spray-dried
powders were poured into the dissolution medium and 4 mL samples were taken out
manually at 1, 2, 5, 10, 20, 30, 60, 120, 180, and 210 min. These aliquots were
filtered with a 0.1 µm PVDF membrane-type syringe filter before UV-spectroscopy
measurements to minimize any confounding effect of the undissolved coarse drug
aggregates (Bhakay et al., 2014a; Li et al., 2016b). The filtered samples were diluted
with 0.1 N HCl solution kept at 37 ºC at a ratio of 1 to 10 before UV measurement.
Dissolved GF amount was measured by UV-vis spectroscopy at 255 nm wavelength
and calculated using a pre-established calibration curve. 0.1 N HCl solution was used
as blank before UV measurement, and three replicates were performed for each
sample. In this chapter, relative % supersaturation is reported based on GF
concentration at 210 min and thermodynamic solubility of as-received ITZ particles,
unless otherwise indicated.
7.2.4 Drug Wettability Enhancement by Sol and HPC Solutions With or W/O
SDS
ITZ wettability was investigated by analyzing the penetration rate of stabilizer solutions
into a packed bed of ITZ particles inside a cylindrical column according to the
Washburn method (Hołownia et al., 2008; Washburn, 1921). Attension Sigma 700
(Biolin Scientific, Linthicum, MD, USA) set-up was used to measure the mass of the
liquid penetrated the ITZ powder bed as a function of time. Experimental methods were
adapted from Bilgili et al. (2018) and Li et al. (2017) and the details can be found in
Section F.1 of the Appendix F. In the current study, liquids and powder refer to
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aqueous solutions of 15% Sol/HPC/VA64 with 0.125% SDS or w/o SDS and asreceived ITZ, respectively. All percentages are (% w/w) with respective to deionized
water. The apparent shear viscosity and surface tension of the liquids were measured
using R/S Plus Rheometer (Brookfield Engineering, Middleboro, MA, USA) and
Attension Sigma 700 (Biolin Scientific, Linthicum, MD, USA), respectively. The ratio
of the cosine of contact angles cosθss/cosθw was calculated using the modified
Washburn equation and used as a wetting effectiveness factor. Here, θss is the contact
angle between ITZ and the stabilizer solutions and θw is the contact angle between ITZ
and deionized water. This ratio or its logarithmic value provides a rough measure of the
drug wettability enhancement upon use of various stabilizers in water.
7.2.5 Drug Supersaturation Maintenance Ability of the Polymers
Drug (ITZ) supersaturation maintenance ability of HPC/Sol/VA64 with or w/o SDS
was examined in separate desupersaturation tests (similar to Konno et al., 2008). A
concentrated solution of ITZ was prepared by adding 100 mg of as-received ITZ into
60 mL of methanol via sonication for 40 min. Unfortunately, 60 mL methanol did not
completely dissolve 100 mg ITZ and a turbid solution was formed. The turbid
solution was subsequently added to a 1000 mL of pre-dissolved HPC/Sol/VA64 in
aqueous solution of 0.1 N HCl solution having 500 µg/mL concentrations to maintain
1:5 drug:polymer ratios (similar to the formulations in Table 7.1 and 7.2),
respectively, with or w/o SDS in the USP II paddle type dissolution tester. The
addition resulted in 69–78 µg/mL supersaturated solution of ITZ initially. This lower
concentration of ITZ as compared with the targeted (100 µg/mL) resulted from both
incomplete dissolution of IZT in methanol and inhomogeneous mixing of methanol
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solution with the aqueous solution. Any subsequent desupersaturation during the
following 210 min was tracked via ITZ concentration measurements. The
experimental conditions and concentration measurements were identical to those in
the dissolution test. All measurements were carried out in triplicate.

7.3 Results and Discussion
7.3.1 Properties of ITZ Suspensions Prepared via Wet Stirred Media Milling
Six ITZ suspensions with HPC/Sol/VA64 with 1:5 drug:polymer mass ratios and
0.125% SDS (W4–W6) and without SDS (W1–W3) were wet media milled. Table
7.3 shows the characteristic particle sizes of the 64 min milled suspensions and after
7-day storage. As-received ITZ particles had d50: 15.5 µm and d90: 45.8 µm,
measured via Rodos/Helos laser diffraction system. After milling for 64 min, median
particle sizes d50 were in the range of 0.16–0.24 µm for W4–W6 (Sol/HPC/VA64–
SDS) and 0.21–0.80 µm for W1–W3 (Sol/HPC/VA64) formulations. Unless properly
stabilized, milled drug nanoparticles are known to form micron-sized aggregates in
aqueous suspensions (Bilgili and Afolabi, 2012; Bilgili et al., 2018). Table 7.3
suggests that only the formulations with SDS, ITZ nanosuspensions with median
sizes d50 less than 200 nm were formed (except for W-VA64-SDS, W6), and the
small changes in their d50 and d90 during the 7-day storage suggest that these
suspensions were physically stable. Among the suspensions with the three polymers,
VA64-based suspension had the coarsest particles in the presence/absence of SDS.
Also, VA64-based suspension exhibited notable size increase upon 7-day storage,
which resulted in d90 greater than 1 µm even in the presence of SDS (see Table 7.3).
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Due to their relatively neutral charge, stabilizing capability of Sol/HPC/VA64 solely
depends on their steric effects, which in turn is modulated by their adsorption onto
ITZ nanoparticle surfaces. The adsorption is dependent on free polymer concentration
in the suspension, and usually the adsorption is higher at high polymer concentrations
until a saturation point is reached (Bilgili and Afolabi, 2012; Knieke et al., 2013).

Table 7.3 Particle Size Statistics of the Milled GF Suspensions After 64 min and 7day Storage at 8 ºC
ID

Formulationa

W1
W2
W3
W4
W5
W6

W-Sol
W-HPC
W-VA64
W-Sol-SDS
W-HPC-SDS
W-VA64-SDS

After 64 min (µm)
d50 ± SD
d90 ± SD
0.26±0.0
1.85±0.1
0.21±0.0
0.32±0.0
0.80±0.1
2.19±0.1
0.16±0.0
0.25±0.0
0.18±0.0
0.25±0.0
0.24±0.0
0.45±0.0

After 7-day storage
d50 ± SD
d90 ± SD
0.37±0.0
2.16±0.2
0.23±0.0
0.35±0.0
0.96±0.1
2.18±0.2
0.18±0.0
0.25±0.0
0.18±0.0
0.25±0.0
0.27±0.0
1.81±0.1

a

W denotes solution-based feed; drug:polymer mass ratio was fixed at 1:5 in all the formulations; the
ratios refer to the polymer:polymer mass ratio; Sol denotes Soluplus; VA64 denotes Kollidon VA64.

Clearly, presence of 0.125% in the suspensions had the most dramatic effect
on the stabilization and extent of nanoparticle aggregation. HPC–SDS was reported to
have synergistic stabilizing effect on multiple BCS Class II drug nanosuspensions
during milling and storage (Bilgili et al., 2016). HPC, Sol, and VA64 imparted steric
stabilization by adsorbing on drug nanoparticles (Bilgili and Afolabi, 2012; Bilgili et
al., 2018; Yang et al., 2014), while the anionic surfactant (SDS) enhanced ITZ
wettability/deaggregation and helped to stabilize the ITZ nanosuspensions via
electrostatic repulsion. As can be seen from Table 7.4, polymers alone and polymer–
SDS combination reduce the surface tension and enhanced the ITZ wettability by
water. As indicated by the higher wetting effectiveness factor, HPC (hydrophilic
polymer) renders ITZ more wettable by water than VA64 and Sol (amphiphilic
242

polymer), and SDS enhances the wettability even further when used in combination
with both polymers. The wettability is important to deggregation of the aggregates
formed during milling, which allows for full exposure of ITZ particle surfaces for
polymer adsorption. The lower wettability of ITZ by Sol and VA64 as compared with
HPC could be another reason for the large aggregates in VA64 and Sol-based
suspensions. On the other hand, with SDS, finer suspensions were obtained with Sol
than with HPC, which suggests differing interaction between polymer–SDS. While
wettability results here helped us to explain the milling results, they should be used
with caution for interpreting the impact of polymers/surfactant on the wettability
enhancement because the dissolution medium was 0.1 N HCl whereas the modified
Washburn experiment was conducted with deionzied water as the penetrating liquid.
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Table 7.4 Properties of Deionized Water–Aqueous Stabilizer Solutions and Wetting Effectiveness Factor Determined Using the
Modified Washburn Method
Formulation

η, (cP)

Water

0.89

ρ, (g/mL)

γ, (mN/m)

Slope, (g2/s)

1

70.8

6.5×10

a

R2 (-)

cosθss/cosθw

0.995

1

0

0.996

4430

3.65

0.999

11120

4.01

0.998

8180

3.91

0.999

8310

3.92

0.999

17410

4.24

0.999

13550

4.13

log(cosθss/cosθw)

-6
-3

Sol

8.21

1.02

41.6

1.9×10
-4

HPC

54.4

1.02

40.5

7.0×10
-3

VA64

6.75

1.02

40.0

4.1×10
-3

Sol–SDS

13.3

1.01

38.6

2.0×10
-4

HPC–SDS

63.2

1.01

39.4

9.0×10
-3

VA64-SDS

8.76

1.01

38.2

4.9×10
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a

The slope of the water penetration data was used as reference for wettability enhancement by the stabilizer solution.
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7.3.2 Size, Morphology, and Drug–Moisture Content of the Spray-Dried
Powders
Despite the relatively short residence time (4 s and 5 s), the powders produced form
both suspension-based (W) and solution-based (S) feeds were completely dried, as
indicated by TGA, which shows weight loss of 2.0 ± 0.3% for the samples. The high
surface area generated by atomization of the feed coupled with the convective heat–
mass transfer at high air temperature enabled fast drying of the droplets in the drying
chamber. The mean (actual) drug content after spray-drying was close or slightly
higher than the theoretical drug content; all RSD values were below 6%: 0.49–5.23%,
which signifies pharmaceutically acceptable content uniformity (see Table 7.5). Table
7.5 shows that for a given polymer, the ITZ suspension without SDS (W1–W3) had
smaller particles than that with SDS (W4–W6) and the ITZ solution (S1–S3). The
presence of aggregated ITZ particles and the aqueous viscosity–surface tension of the
base-polymer/SDS appeared to have a joint effect on the particle size of the
suspension-based spray-dried powders. Despite an increase in base viscosity, the
presence of SDS resulted in lower surface tension (Table 7.4) and smaller ITZ
aggregates (Table 3), which could explain the smaller spray-dried particles in the
presence of SDS.
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Table 7.5
Content

Particle Size Statistics of the Spray-Dried Powders and Their Drug

ID

Formulationa

Size of the spray-dried
powders (µm)
d10±SD
d50±SD d90±SD

Theoretical
drug content
(%w/w)b

W1
W2
W3
W4
W5
W6
S1
S2
S3

W-Sol
W-HPC
W-VA64
W-Sol-SDS
W-HPC-SDS
W-VA64-SDS
S-Sol
S-HPC
S-VA64

9.65±0.1
7.33±0.1
3.20±0.1
5.20±0.0
7.93±0.1
4.21±0.0
4.20±0.0
4.90±0.1
3.27±0.1

16.7
16.7
16.7
16.5
16.5
16.5
16.7
16.7
16.7

28.8±0.0
23.0±0.3
18.7±0.2
13.5±0.0
14.7±0.1
11.5±0.0
15.8±0.5
12.3±0.2
5.1±0.1

57.9±0.1
56.4±0.1
41.5±0.2
38.2±0.0
35.9±0.6
37.7±0.1
48.6±0.7
39.7±0.2
37.6±0.1

Actual drug
content,
RSD
(%w/w, %)b
16.7, 0.49
17.2, 3.56
16.9, 4.31
16.8, 5.10
16.7, 4.37
16.9, 1.93
17.1, 2.02
16.9, 5.23
17.0, 3.41

a

S denotes solution-based feed; W denotes suspensions-based feed; drug:polymer mass ratio was fixed
at 1:5 in all the formulations; the ratios in the formulations refer to the polymer:polymer mass ratio;
Sol denotes Soluplus; VA64 denotes polyvinylpyrrolidone vinyl-acetate (6:4).
b
%w/w with respect to the total weight of the solid content.

7.3.3 Formation of Drug HyNASDs and ASDs Upon Spray Drying
Figures 7.1 and 7.2 illustrate the XRPD diffractograms of the spray-dried powders.
X-ray diffractograms depict that as-received ITZ exhibited intense peak
characteristics of a crystalline material. The physical mixtures (PMs), prepared by
blending of as-received ITZ with HPC/Sol/VA64 or HPC/Sol/VA64–SDS powders,
exhibited peaks at the same diffraction angles as those of as-received ITZ, albeit with
reduced intensity. The diffractograms of the spray-dried powders with SDS (Figure
7.1a) and without SDS (Figure 7.1b) did not remarkably differ, except for peak
intensities; they exhibit patterns similar to those of the physical mixtures. The peak
intensities of ITZ in the PMs were lower than those of the as-received ITZ powder,
which can be attributed to the dilution and surface coverage of ITZ microparticles
with HPC/Sol/VA64. Similar XRPD diffractograms to those of the PMs were
observed for the spray-dried powders produced from suspension-based feeds
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confirming that spray-drying of the milled suspensions led to formation of
nanocomposites that are crystalline in nature. Interestingly, the diffractograms of the
spray-dried powders show significant peak broadening and reduction in intensities as
compared with their respective PMs, beyond the aforementioned dilution effect of the
polymers. This peak reduction points to the possibility that wet media milling
followed by spray-drying led to reduction of crystallinity and formation of notable
amorphous ITZ (similar to the observations in Chapter 3 and Chapter 4 for GF).
However, unlike for the GF nanocomposites, the crystallinity has not been quantified
here for the ITZ nanocomposites. It is conjectured that wet media milling does not
cause any detectable amorphization of as-received ITZ, in the absence of stabilizers,
due to plasticization effect of water (Bilgili et al., 2018; Li et al., 2018b). In the
presence of high polymer loading in the suspensions here, however, amorphization of
ITZ seemed to have taken place during the spray drying. Looking at the XRPD
diffractograms (Figure 7.1a and 7.1b), the reduction in the peak intensity and peaks
broadening confirm some extent of amorphization of ITZ occurred. Taking a close
look, it is visible that the reduction in peak intensity is more pronounced for the ITZ–
Sol formulation than for the ITZ–HPC/VA64 formulations with/without SDS.
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Figure 7.1 X-ray diffractograms of as-received ITZ, physical mixtures (PMs) of GF–
HPC/Sol/VA64 and the spray-dried powders prepared using the ITZ suspensionbased (W) feed with 1:5 drug:polymer mass ratios: (a) without SDS and (b) with
0.125% SDS in the suspension.

These findings imply that (i) amorphous ITZ formed due to ITZ–polymer
molecular interactions and/or solubilization of the surface layer of nanoparticles by
the polymer during the spray-drying and (ii) Sol appears to favor the amorphization
of ITZ more than HPC and VA64, which implies stronger Sol–ITZ molecular
interactions/miscibility than HPC/VA64–ITZ. It is likely that presence of ITZ
nanoparticles and their aggregates with large surface area and higher polymer loading
(more ITZ–polymer interactions and higher ITZ solubilization in the polymer) could
have favored the formation of amorphous GF. Based on our findings and Kayaert and
Van den Mooter, 2012, it is proposed that the polymeric matrix of the spray-dried
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particles encapsulates drug nanocrystals/aggregates, surrounded by a layer of
amorphous ITZ molecularly dispersed in the polymer. Formation of amorphous
content upon drying of drug nanosuspensions was first noted by Kayaert and Van den
Mooter, 2012, albeit to a lower extent, and was regarded as “unfavorable”.
Nonetheless, the impact of such amorphous content on drug release from the
nanocomposites has not been studied at all. As the dissolution tests will reveal,
despite being crystalline in nature, these nanocomposites with relatively high polymer
loading (low drug:polymer ratio) allow for much higher supersaturation than
traditional nanocomposites, similar to the supersaturation levels observed for ASDs;
hence, we coin the term hybrid nanocrystal–ASD (HyNASD) for this special class of
nanocomposites.
XRPD diffractograms (Figure 7.2) of the spray-dried powders produced from
solution-based (S) feeds showed halo pattern instead of any characteristic diffraction
peaks of ITZ. These halo patterns confirm that amorphous ITZ dispersed molecularly
into the polymer matrix forming amorphous solid dispersions (ASDs).
Generally, it is suggested that if the solubility parameter difference between a
drug and polymer is <7.0 MPa1/2, they are likely to be miscible; if the difference is
>10 MPa1/2, they are considered immiscible (Forster et al., 2001; Greenhalgh et al.,
1999). The solubility parameters of ITZ, HPC, Sol, and VA64 are 22.6 (Kolter et al.,
2012), 24.0 (Choi et al., 1994), 19.4, and 19.7 (Kolter et al., 2012) MPa1/2,
respectively. The solubility parameter differences between ITZ–Sol and ITZ–VA64,
and ITZ–HPC are 3.2, 2.9, and 1.4 MPa1/2, respectively, which suggests that ITZ–
Sol/VA64/HPC all are miscible based on the solubility parameter difference and very
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likely to produce amorphous solid dispersions of ITZ. While being useful, the
solubility parameters do not account for all drug–polymer interactions such as
contributions from hydrogen bonding, hydrophobic interactions, etc., and hence
should be used with caution as rough estimates of drug–polymer miscibility.

Figure 7.2 X-ray diffractograms of as-received ITZ, and physical mixtures (PMs) of
GF–HPC/Sol/VA64 (a); spray-dried powders prepared using the ITZ solution-based (S)
feeds with 1:5 drug:polymer mass ratio (b).

The DSC thermograms in Figure 7.3 show an endothermic peak associated
with melting of as-received ITZ, with a melting point temperature Tm of 171 °C and a
fusion enthalpy ΔHf of 70.9 J/g; a glass transition for Sol (amorphous) at 72.4 °C, a
glass transition for VA64 (amorphous) at 102 °C and a slight endothermic event
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around 170–200 °C for HPC likely due to the melting of the small crystalline domain
of largely amorphous HPC (Sarode et al., 2013) (crystallinity was undetectable by
XRPD). The Tg of HPC could not be measured as it is in the range of –25 to 0 °C
(Sarode et al., 2013) and our DSC equipment is limited. The spray-dried powders
exhibited a melting endotherm only, corresponding to the fusion of their ITZ crystals.
The absence of any recrystallization event during the heating could suggest that the
amorphous ITZ in HyNASDs did not recrystallize due to ITZ–polymer molecular
interactions as the amorphous content was in the ASD surrounding the drug crystals.
The DSC thermograms in Figure 7.3 and the data in Table 7.6 show that
spray-drying of ITZ suspensions led to drastic melting point depression (high ΔTm),
up to 37 ºC, and reduction of ΔHf even if the values were corrected for dilution with
polymer and reduced crystallinity (not shown for brevity). Higher ΔTm and lower ΔHf
of the spray-dried powders than those of the PMs suggest that the amorphous ITZ
content of the spray-dried powders was lower. The significant melting point
depression in drug–polymer mixtures is indicator of drug–polymer miscibility (Baird
and Taylor, 2012; Newman et al., 2008). Moreover, without exceptions, having
identical polymer/SDS composition, the spray-dried powders with Sol had higher
ΔTm and lower ΔHf than those with HPC and VA64, which could be explained by (i)
stronger ITZ–Sol interactions, (ii) higher initial amorphous content in the Sol-based
spray-dried powders, and (iii) higher extent of solubilization of ITZ in the polymer
melt at high temperatures due to the thermal treatment during the DSC scan.
Compared with the clear trends regarding the impact of different polymers for
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formulations with/without SDS, the trends for SDS impact were not as strong and as
clear.

Table 7.6 Characteristic Temperatures–Enthalpy Values Obtained From DSC
Thermograms
ID
ITZ
W1
W2
W3
W4
W5
W6
S1
S2
S3

Formulationa
As-received ITZ
W-Sol
W-HPC
W-VA64
W-Sol-SDS
W-HPC-SDS
W-VA64-SDS
S-Sol
S-HPC
S-VA64

Tg (ºC)a,b
ND
ND
ND
ND
ND
ND
ND
72.3
ND
99.6

Tm (ºC) a,b
171
134
160
141
137
159
141
ND
ND
ND

Hf (J/g) a,b
70.9
1.02
6.32
3.00
1.35
4.91
5.17
ND
ND
ND

a

S denotes solution-based feed, Sol denotes Soluplus; the ratios refer to the polmer:polymer mass
ratios. Other symbols: Tg, Trc, and Tm stand for temperature for glass transition, recrystallization
transition, and melting point, respectively, while Hrc and Hf respectively stand for recrystallization
enthalpy and fusion enthalpy.
b
ND: not detected.

For the spray-dried powders prepared from the drug–polymer solutions
(Figure 7.4), a single Tg was observed for all the formulations confirming the
formation of molecular level dispersion (Luebbert et al., 2017; Wlodarski et al., 2015)
(Table 7.6). Due to strong molecular interactions and good miscibility of ITZ–Sol,
ITZ–HPC, and ITZ–VA64, recrystallization event at high temperature was not
observed for the any of the formulations during the DSC scan. However, for S-VA64
formulation, at higher temperature (around 170 ºC) there was a thermal event
observed, which might be due to phase separation of the drug and the polymer.
Overall, the XRPD and DSC results suggest that spray-drying of ITZ–polymer
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Figure 7.3 DSC thermograms of as-received ITZ, HPC, Sol, and VA64 (a); physical
mixtures (PMs), and spray-dried powders prepared using the ITZ suspension-based
(W) feed with 1:5 drug:polymer mass ratio: (b) without SDS and (c) with 0.125%
SDS in the suspension.
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nanosuspensions with/without SDS led to formation of drug HyNASDs and ITZ–
polymer solutions led to formation of ASDs. Therefore, as a general observation,
similar to Chapter 3 and Chapter 4, we note that spray-drying of a drug
nanosuspension with a lower drug:polymer mass ratio (high polymer concertation)
than typically used (see e.g., Table 1.2) and the use of a strongly miscible polymer
that interacts with the drug nanoparticles and solubilizes them during the spray drying
favor the formation of HyNASDs.

Figure 7.4 DSC thermograms of spray-dried powders prepared using the ITZ
solution-based (S) feed with 1:5 drug:polymer mass ratio.

7.3.4 Dissolution performance of the Spay-Dried Powders in Supersaturating
Condition
The temporal evolution of ITZ release from the spray-dried powders and the PM with
the highest polymer loading (1:5 ITZ:polymer) containing 100 mg equivalent ITZ
dose in 1000 mL 0.1 N HCl solution at 37 ºC was investigated. The bulk dissolution
medium could supersaturate for this high drug dose as the ITZ solubility is ~4.0
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mg/L. Unless otherwise specified, all supersaturation values are relative to aqueous
thermodynamic solubility of ITZ and calculated at 210 min.
Considering that the major shortcoming of traditional drug nanocomposites
with low polymer loading as compared with amorphous solid dispersions (ASDs) is
their limited supersaturation capability in dissolution media, the examination of drug
dissolution under supersaturating condition is critical. The most striking feature of
Figure 7.5a and 7.5b is that Sol-based HyNASDs, nanocomposites with notable
amorphous content, achieved 840% and 1230% ITZ supersaturation without SDS and
with SDS, respectively. Such high supersaturation has not been reported for drug
nanocomposites before, but for ASDs. A cursory look at Figure 7.5 also reveals some
general trends: (i) the spray-dried powder could generate ITZ superstation more than
the corresponding PM for 1:5 GF:Sol with and w/o SDS, (ii) the ITZ supersaturation
was higher for spray-dried powders with SDS than those without SDS, and (iii) Solbased formulations generated much higher supersaturation than HPC/VA64-based
formulations especially when the formulation included SDS. These results point to
the criticality of the wettability of the spray-dried powder, which is enhanced by SDS,
ITZ–polymer interaction and solubilization of the ITZ by the polymer. The smaller
ITZ nanoparticle sizes and the smaller spray-dried particle sizes in the presence of
SDS could explain why the powders with SDS released ITZ faster besides the
obvious wettability enhancement imparted by SDS (see Table 7.4).
During the dissolution test, as water wets and imbibes into the spray-dried
particles, their polymer dissolves and the particles redisperse into smaller ITZ–
polymer/SDS clusters depending on the wettability, while their amorphous ITZ
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fraction contributes to the dissolution. In the polymer/SDS-rich microenvironment of
the particles and releases clusters, ITZ could be solubilized by the polymer/SDS, and
the rate of this process depends on the cluster/particle size as well as ITZ particle size
inside these clusters as well as the drug:polymer mass ratio and presence/absence of
SDS. Unfortunately, depending on the polymer–drug miscibility and interactions,
amorphous content of the HyNASDs may phase-separate and recrystallize upon
contact with water in the dissolution medium (Alonzo et al., 2011; Chen et al., 2015)

Figure 7.5 Evolution of drug release from as-received ITZ, physical mixture (PM)
with 1:5 ITZ:Sol mass ratio, and spray-dried powders prepared using GF suspensionbased (W) feeds with 1:5 drug:polymer mass ratios: (a) with 0.125% SDS in the ITZ
suspensions and (b) without SDS. Dissolution sample size equivalent to 100 mg ITZ
dose.

because water acts as a plasticizing agent, reducing the glass transition of the ASD
component of HyNASDs and enhancing the mobility of the drug molecules (Chen et
al., 2015). Finally, the supersaturated ITZ in the dissolution medium and the released
drug nanoparticles form a metastable system, and ITZ could recrystallize on existing
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ITZ nanoparticles and cause their growth in time, which in turn could cause reduced
supersaturation. Strong drug–polymer interactions can reduce the molecular mobility
and delay recrystallization onset time and the extent of recrystallization (Mistry et al.,
2015).
With the hope of additional insights into the ITZ recrystallization inhibition
capability of Sol/HPC/VA64 with and w/o SDS in supersaturated ITZ solutions,
desupersaturation experiments were performed during which the dissolved ITZ shifts
from methanol (high solubility) to methanol–water mixture (low solubility), thus
creating supersaturation (see Figure 7.6). A peak ITZ supersaturation was attained
fast upon mixing the ITZ solution with deionized water, and it was maintained up to
~210 min with all the polymers with and w/o SDS. SDS did not in the supersaturation
maintenance is not significant compared to the polymers. In the absence of any
inhibitor, ITZ recrystallized fast and its concentration exponentially decayed to an
equilibrium concentration in 60 mL methanol–1000 mL water mixture (~21 µg/mL).
Unfortunately, methanol volume was so high to affect the solubility in the
desupersaturation experiment. Moreover, to be more predictive of the dissolution test,
0.1 N HCl rather than deionized water should have been used. Unfortunately, these
results do not discern the inhibition capability of the polymers, nor do they
confidently suggest that all polymers were good crystallization inhibitors of ITZ
because a high supersaturation that mimics the saturation level in the dissolution
vessel could not be achieved using 60 mL methanol in the desupersaturation
experiment. It appears that a better solvent than methanol for ITZ is required and that
solvent must be miscible with water and should be used at a lower solvent:antisolvent
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mass ratio to generate high supersaturation. With such a caveat in mind, it may be fair
to assert that in the presence of the polymers, ITZ recrystallization did not occur from
the solutions with the specific supersaturation levels studied here.

Figure 7.6 ITZ desupersaturation curves for a 60 mL ITZ–methanol solution mixed
with 940 mL aqueous solutions of 500 µg/mL of HPC/Sol/VA64–5 µg/mL SDS or
w/o SDS (corresponding to 1:5 drug:polymer formulations). The initial concentration
of GF right after mixing was targeted at 100 µg/mL.

A comparison of Figure 7.7a (ASDs) and Figure 7.7b (HyNASDs) indicates
that ASDs outperform HyNASDs owing to the presence of 100% amorphous ITZ in
the former. However, it is amazing to see such high supersaturation (up to 840%)
from the HyNASDs/ Figure 7.7a also shows that 1220%, 1340%, and 1980% relative
supersaturation was achieved by HPC-based, VA64-based, and Sol-based ASDs with
SDS, respectively, at 210 min. Interestingly, even after 210 min of dissolution, the
profile is still rising, which signifies that if the dissolution test was run longer than
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210 min, the extent of supersaturation would be even higher. Before an attempt is to
be made to explain these results, some caveats regarding the interpretation of
dissolution results in view of the desupersaturation and wettability results must be
mentioned. It is speculated based on the somewhat inconclusive desupersaturation
test results (refer to Figure 7.6) that all three polymers are capable of maintaining the
supersaturation in the dissolution medium. Also, since the Washburn experiments
were carried out with deionized water rather than 0.1 N HCl, relating the ITZ
wettability enhancement to the dissolution results are somewhat confounded due to
the pH effect. Since the reduced pH in the acidic media results in ionization of ITZ
(weak base), it is likely that surface properties and wettability changed with the pH. It
should also be noted that the dissolution profiles in Figure 7.7a did not plateau within
210 min; hence, longer dissolution time is needed to glean the impact of potential
recrystallization.
The solubility parameter differences suggest all polymers are miscible with
ITZ, while the melting point depression results (refer to Table 7.6) suggest the
miscibility of ITZ with Sol > VA64 > HPC. The supersaturation generation in Figure
7.7a correlated positively with the ITZ–polymer miscibility inferred from DSC. The
remarkably high ITZ supersaturation achieved by Sol-based ASDs as compared with
HPC/VA64-based ASDs can be explained by the greater miscibility with ITZ and
higher ITZ solubilization in Sol micelles in the dissolution medium. It is wellestablished that depending on the drug–polymer miscibility and interactions,
amorphous drug may phase-separate and recrystallize upon contact of ASDs with
water in the dissolution medium (Alonzo et al., 2011; Chen et al., 2015). Once
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imbibed into the ASD matrix, water acts as a plasticizing agent, enhancing the
mobility of the drug molecules by reducing the Tg of the ASD (Chen et al., 2015).
HPC-SSL has sub-ambient Tg (Srode et al., 2013) (lower than Tg of Sol: 73 ± 2 °C
and VA64: 101 ºC) and its ASDs have lower Tg (was not possible to detect) than Solbased ASDs (Table 7.6). Owing to good miscibility of ITZ–HPC, no phase separation
and recrystallization appeared in Figure 7.7a within 210 min (rising profile).

Figure 7.7 Evolution of drug release from as-received ITZ, physical mixture (PM)
with 1:5 ITZ:Sol mass ratio, and spray-dried powders prepared from: (a) ITZ
solution-based (S) feeds and (b) ITZ suspension-based (W) feeds with 1:5
drug:polymer mass ratios. Dissolution sample size equivalent to 100 mg ITZ dose.

7.4 Conclusion
Spray-drying of wet-milled ITZ suspensions with high polymer loading (1:5
ITZ:polymer mass ratio) with HPC/Sol/VA64 and with/without SDS led to formation
of a special class of nanocomposites, HyNASDs, which contain drug nanocrystals
and aggregates surrounded by notable amorphous content molecularly dispersed in
the polymeric matrix. XRPD and DSC thermogram shed light on the HyNASD
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formation and revealed miscibility of ITZ with Sol/HPC/VA64. However, the
interaction seems to be stronger in the case of ITZ–Sol than ITZ–HPC/VA64 from
XRPD and DSC results. Presence of SDS in the formulation enhanced the relative
wetting effectiveness of the polymers significantly and in the dissolution test helped
to reach higher extent of supersaturation. This higher extent of supersaturation may
be explained by the solubilizing effect of SDS, but due to the inconclusive nature of
the Washburn experiments and desupersaturation experiments in deionized water, the
roles of SDS could not be well-elucidated. Without SDS in the formulation, 480%,
430%, and 840% relative supersaturation was achieved from HPC, VA64, and Solbased formulation, respectively, at 210 min. On the other hand, presence of SDS in
the formulation resulted 720%, 470%, and 1230% relative supersaturation from HPC,
VA64, and Sol-based formulation, respectively. Therefore, the results here for ITZ
are in line with our previous observations in Chapter 2 and Chapter 3, where
significant supersaturation generation from drug nanocomposites was possible by
forming HyNASDs and presence of SDS boosted up the supersaturation level.
Although ASD formulations generated higher extent of supersaturation (up to 1980%)
than HyNASDs, 840% relative supersaturation from a largely crystalline formulation
is an interesting, novel, and impactful finding.
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CHAPTER 8
CONCLUSIONS AND FUTURE WORK
8.1 Conclusions
This thesis research has identified two major challenges in the bioavailability
enhancement of BCS Class II drugs via drug nanocomposites and amorphous solid
dispersions (ASDs): (i) the major drawback of nanocomposites is their inability to
attain high drug supersaturation during in vitro (<50% relative supersaturation) and in
vivo dissolution; (ii) formulating an amorphous solid dispersion (ASD) with high
drug loading (>20%) that releases drug rapidly, while generating and maintaining
high supersaturation over at least three hours is challenging. The goal of this thesis
was to develop a fundamental understanding of the impact of anionic surfactants–
polymers on in vitro drug release from nanocomposites and ASDs, while addressing
the aforementioned challenges. This dissertation has developed a processing–
formulation approach to produce both nanocomposites and ASDs with identical
formulation, which has allowed us to have a true head-to-head comparison of
nanocomposites and ASDs.
Spray drying of milled drug nanosuspensions with high polymer loading
(unlike traditional drug nanosuspension formulations) enabled us to produce a new
class of drug nanocomposites titled hybrid nanocrystal–ASD (HyNASD). HyNASDs
contain a notable fraction (5–22%) of amorphous drug molecularly dispersed in the
polymeric matrix that encapsulates drug nanoparticles. They generated high drug
supersaturation rapidly (~300% within 20 min) in the dissolution tests unlike
traditional

nanocomposites

(max.

50%), which could
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render nanoparticle

formulations more competitive to ASDs in bioavailability enhancement of poorly
soluble drugs. The supersaturation generation capability of HyNASDs is largely
controlled by drug–polymer interactions/miscibility as well as the size of the drug
(nano)crystals in the polymeric matrix. While HyNASDs did not generate as high
saturation as ASDs (480%), they can be rendered competitive to ASDs upon further
formulation–process optimization.
In wet media milling of drugs, various hydrophilic/amphiphilic polymers
along with an anionic surfactant provided excellent physical stability to drug
nanoparticles via electrosteric mechanisms. In the absence of the surfacatant, large
aggregates of the drug nanoparticles formed. Significant supersaturation generation
and maintenance was achieved by HyNASDs for high drug dose (100 mg). On the
other hand, the supersaturation generation capability of HyNASDs was largely
controlled by the anionic surfactant either in the formulation or in the dissolution
medium, drug–polymer interactions/miscibility as well as the size of the drug
(nano)crystals in the polymeric matrix.
Inclusion of an anionic surfactant as a minor component along with a drugmiscible polymer (major component), which can provide significant solubilization of
the drug and supersaturation maintenance via recrystallization inhibition, could boost
drug supersaturation from the ASDs via mainly wettability enhancement and some
additional drug solubilization. Unlike the use of surfactant as carriers/solubilizers, the
use of an anionic surfactant as a minor component dramatically improved the
wettability of the drug ASDs, without having any deleterious impact on drug
recrystallization, which is a common problem in polymer–surfactant carrier systems.
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Also, the use of low concentrations of an anionic surfactant even in high-dose
applications of ASDs alleviates any concern associated with the toxicity of anionic
surfactants.
Ternary ASDs of a poorly soluble fast crystallizing drug (GF) with binary
combinations of HPC/VA64/Sol and binary ASDs of GF with the corresponding
individual polymers, all having 1:3 GF:total polymer mass ratio, were prepared using
spray-drying. Although binary ASDs with single polymer showed dissolution
enhancement compared to as-received GF and physical mixtures, a desirable
dissolution profile, i.e., rapid GF release concurrently generating fast supersaturation
that lasts 3 hours, was not achieved. The dissolution profiles of the ternary ASDs of
binary polymers were mostly reflective of the deficiencies of the polymers in terms of
wettability enhancement and recrystallization inhibition in the ASD matrix and the
dissolution medium. As expected, the combination of the two hydrophilic polymers
HPC–VA64 without an amphiphilic crystal-inhibiting polymer (Sol) led to low
supersaturation, below 80%. Being an effective crystallization inhibitor, Sol
compensated for HPC’s inability to prevent recrystallization; but there was no
synergistic positive impact. Any increase in initial drug release rate upon use of HPC
was nullified by lower extent of supersaturation. Finally, based on the results
regarding GF release from ternary ASDs with Sol-VA64, we conclude that a ternary
ASD of GF could exhibit synergistic enhancement of drug release rate and its extent
upon combined use of an amphiphilic polymer (Sol, as a crystallization inhibitor) as a
major component and the hydrophilic polymer (VA64) as a minor component that
provides wettability enhancement.
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General findings from the research on GF regarding HyNASD formation and
impact of SDS were applicable to another poorly water-soluble, BCS Class II drug,
Itraconazole (ITZ) as well. Spray drying of wet media milled drug nanosuspensions
with high polymer loading led to formation of ITZ HyNASDs, which exhibited high
supersaturation, and the presence of the anionic surfactant favored the ITZ
supersaturation generation. Based on the success of the HyNASDs for two
completely different BCS Class II drugs, i.e., GF and ITZ, Figure 8.1 presents a
preliminary decision tree for the selection of nanocomposites, HyNASDs, and ASDs
for BCS Class II drugs based on the current knowledge-base generated in this thesis.
Obviously, the construction of this decision tree presumes that the physical stability
of the HyNASDs is not worse than ASDs of the same drug, and the stability aspects
of HyNASDs will be examined in future work.

Figure 8.1 A preliminary decision tree for the selection of drug nanocomposites,
HyNASDs, and ASDs based on the aqueous and dose of the drug.
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Overall, this dissertation has established a platform approach (spray-drying)
for a scientific comparison of drug nanocomposites vs. ASDs and generated the
prerequisite processing–materials knowledge and methodology needed. The
following objectives have been realized: (i) drug release from drug (GF)
nanocomposites and ASDs with identical formulation, i.e., low drug GF:polymer
(HPC/Soluplus) mass ratios (1:1 to 1:5) and an anionic surfactant (SDS), were
examined,

(2) the impact of anionic surfactant on drug release from hybrid

nanocrystal–amorphous solution dispersions (HyNASDs) has been investigated, (3)
rapidly supersaturating ternary ASDs of GF with HPC/Sol and SDS as a minor
component were prepared, and (4) GF release from ternary ASDs of GF with a
hydrophilic, wettability-enhancing polymer (HPC/PVP-VA64) as a minor component
and an amphiphilic polymer as drug precipitation inhibitor was examined, and (5) the
fundamental knowledge generated on GF was applied to another drug, itraconazole
(ITZ). While this dissertation addressed the major shortcoming of the drug
nanocomposites, i.e., limited supersaturation capability in the dissolution media
compared with ASDs, elucidated the roles/impact of anionic surfactants and binary
polymers on drug release from ASDs, there are still various areas for further research
and investigation, which are summarized below.

8.2 Future Work
8.2.1 Investigation on Storage Stability of HyNASDs vs. ASDs Under Various
Environmental Conditions
In current dissertation, we have introduced a new class of particles called Hybrid
Nanocrystals–Amorphous Solid Dispersions (HyNASDs) by spray-drying an aqueous
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GF nanosuspension with higher polymer concertation (1:1–1:5 drug:polymer mass
ratio) than conventional drug nanosuspensions, where 1:0.02–1:0.8 drug:polymer
mass ratio is used. This special class of nanoparticles has significant amount of
amorphous content (>10%), which allowed us to increase the apparent solubility of
the poorly water-soluble drugs significantly and achieve supersaturation during
dissolution. Also, significant improvement in the drug release rate was achieved by
producing ASDs of the poorly soluble drugs. Since amorphous drugs are
thermodynamically unstable in nature, they can recrystallize during storage and
dissolution. Therefore, investigation into the storage stability of HyNASDs vs. ASDs
should be conducted under various environmental (RH, T) conditions.
8.2.2 Production of HyNASDs with Various Drug–Polymer Pairs and Their
Comparative Assessment
In the current dissertation, HyNASDs of GF (griseofulvin) and ITZ (itraconazole)
were produced using HPC, Sol, and VA64, which worked as stabilizer/carrier/matrix
formers. Dissolution enhancement of a poorly soluble drug from HyNASDs requires
some extent of drug–polymer miscibility or interactions. As shown in Chapter 4, due
its good miscibility with GF and higher glass transition temperature, Sol achieved
significant supersaturation from HyNASDs, whereas due to the low glass transition
temperature and poor miscibility, HyNASDs with GF–HPC could not provide high
GF supersaturation. In Chapter 7, HyNASDs of ITZ were also produced using HPC,
Sol, and VA64, where very high extent of supersaturation was attained in the
dissolution tests. To generalize the concept of supersaturation generation from drug
nanoparticle-based formulation using HyNASDs, multiple drug–polymer pairs should
be used.
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8.2.3 Systematic Investigation of the Impact of Various Surfactants for
HyNASDs vs. ASDs
In Chapters 4, 5, and 7, the impact of an anionic surfactant, sodium dodecyl sulfate
(SDS) has been studied in the production and dissolution performance of GF and ITZ
from HyNASDs and ASDs. It was found that the inclusion of a surfactant at low
concentration in the formulation can significantly improve the stabilization of drug
nanosuspensions during milling and it has remarkable impact in the drug release rate
due to the wettability enhancement. However, the role of SDS in the HyNASDs and
ASDs was different. Investigation on various surfactants and their impact in the
production of HyNASDs/ASDs and drug release performance should be conducted
for better understanding of the roles of surfactants. This understanding can help the
formulation scientist in the selection of surfactant for the development of drug ASDs
vs. HyNASDs formulations.
8.2.4 Investigating the Impact of Various Drug Nanoparticle Sizes in the Range
of 50–1000 nm on Drug Supersaturation from HyNASDs
As shown in Chapters 3, 4, and 7, drug median particle sizes in the nanosuspensions
were less than 200 nm when SDS was included in the formulation. In the absence of
SDS, the particles were severely aggregated during milling (depending on the
stabilizers type and concertation) and the size of the particles varied up to few
microns in the final milled drug suspensions. Also, it was very evident from the
studies in Chapters 4 and 7 that the final milled particles sizes played a significant
role in the supersaturation generation besides the amorphous content of the drug in
the final spray-dried powders. Consequently, a systematic study in the impact of drug
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nanoparticles sizes in the range of 50–1000 nm will provide better understanding
about the drug particle size impact in the supersaturation generation.
8.2.5 Characterize the Thermodynamic Solubility of Crystalline Drug and
Kinetic Solubility of the Amorphous Drug in the ASD and Drug Nanoparticles
The thermodynamic solubility of the as-received crystalline drug particles in the
presence of various polymers/surfactants must be determined. Kinetic solubility of
the amorphous drug in different ASD formulation as well as drug nanoparticles must
be measured separately.
8.2.6 Detailed Characterization of HyNASDs and ASDs
Drug–polymer intermolecular interactions should be studied via FTIR spectroscopy.
Miscibility of polymer1–polymer2 in ternary ASDs should be studied by preparing
films of pure polymer1, polymer2, and their known mixtures and using such films in
FTIR spectroscopy. Modulated DSC should be used to determine glass transition
temperature more accurately.
8.2.7 Study of High Dose Effects in Drug Release from HyNASDs and ASDs
In this thesis research, only 9 mg and 100 mg drug doses were considered in the
dissolution testing. Hence, at least two other higher drug doses (200 mg and 400 mg)
should be used in dissolution testing to address the needs of pharmaceutical industry.
8.2.8 Characterization of the Dissolution/Redispersion Medium after Testing of
HyNASDs and ASDs
Characterization of particle sizes in the dissolution vessel following a dissolution
experiment with HyNASDs and ASDs could provide significant insights as to the size
of drug nanoparticles in HyNASDs. Similar information can be gleaned from
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redispersion medium following the test. Also, any residue from the dissolution or
redispersion should be characterized using polarized light microscopy, DSC, and
XRPD.
8.2.9 Development of a Decision Tree for Process–Formulation Selection
As the invention of HyNASDs has been shown the performance of drug
nanocomposites, it is likely that HyNASDs will be competitive to ASDs in the future
upon for development and optimization. While in Section 8.1 has presented a
preliminary decision tree for HyNASDs vs. ASDs, a more streamlined and robust
decision tree should be developed based on the storage stability of HyNASDs in
comparison to ASDs.
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APPENDIX A
IMPACT OF POLYMERS ON THE AGGREGATION OF WET-MILLED
ITRACONAZOLE AND THEIR DISSOLUTION FROM SPRAY-DRIED
NANOCOMPOSITES

In appendix A, detail of the modified Washburn method to measure the relative
wetting effectiveness of the stabilizer/dispersant solutions are provided. Also, to
confirm the size of the redispersed drug particles form the drug the polymeric matrix
of the drug nanocomposites, microscopic images are also shown here.
A.1 Experimental Details of the Drug Wettability Measurements
Penetration of a liquid into a packed powder bed of drug particles inside a cylindrical
column allows for measurement of the drug powder wettability, based on the
modified Washburn method (Hołownia et al., 2008; Washburn, 1921). In the current
study, liquids and powder refers to aqueous solutions of dispersants (HPC, PVP K30,
HPMC E3, SDS, HPC SL–SDS) and Itraconazole (ITZ), respectively. All percentages
are w/w with respective to deionized water. Dispersant concentrations in the solutions
were identical to those in the respective wet-milled suspensions in Table 2.1 of main
text. The apparent shear viscosity and surface tension of the solutions were measured
as described below. Then, the drug wettability was quantified based on fitting of the
experimental data on the temporal evolution of the liquid mass penetrated into the
drug powder bed by the modified Washburn equation.
A.1.1 Apparent Shear Viscosity and Surface Tension of the Dispersant Solutions
The apparent shear viscosity of the aqueous dispersant solutions was measured using
an R/S Plus Rheometer (Brookfield Engineering, Middleboro, MA, USA) with a
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water jacket assembly Lauda Eco (Lauda-Brinkmann LP, Delran, NJ, USA). A
coaxial cylinder (CC40) was used to provide a controlled shear rate on the samples
from 0 to 1000 1/s for 60 s. The temperature of the jacket was kept constant at 25 ±
0.5 °C. The raw data were analyzed using the Rheo 3000 software (Brookfield
Engineering, Middleboro, MA, USA) of the equipment to obtain the apparent shear
viscosity as a function of the shear rate. For solutions with low viscosities (< 10 cP)
such as 2.5% HPC SL, 4.5% HPC SSL, and 4.5% PVP solutions, a Kinexus Ultra
Plus Rotational Rheometer (Malvern Panalytical, Southborough, MA, USA) with
higher sensitivity/accuracy was used. 40 mm rotational parallel plates with 0.75 mm
gap were used to provide a controlled shear rate on the samples from 0 to 1000 1/s.
The viscosity value at ~100 1/s shear rate was used in the wetting effectiveness factor
calculations. The viscosities of water and the 0.2% SDS solution were taken from
Korson et al. (1969) and Kushner et al. (1952), respectively.
The surface tension of deionized water and the aforementioned solutions was
measured using Attension Sigma 700 (Biolin Scientific, Linthicum, MD, USA). The
Attention software calculates surface tension from force measurements of interaction
of a probe (Wilhelmy plate) at the boundary between air and a liquid, i.e., the
deionized water or the dispersant solution.
A.1.2 Drug Wettability with the Dispersant Solutions
Attension Sigma 700 set-up (Biolin Scientific, Linthicum, MD, USA) was used to
study the penetration of water/aforementioned dispersant solutions into a packed
powder bed of drug (ITZ) particles inside a cylindrical column and determine the
drug powder wettability, based on the Washburn method. The assembly consists of a
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sample holder in the form of a cylindrical metallic tube with small holes at the bottom
as well as a hook at the top of the cover equipped with screw threads. About 0.8 g of
ITZ powder was packed uniformly into the tube before each measurement. A filter
paper was placed at the perforated end of the sample holder to support the drug
powder sample. A petri dish containing deionized water/dispersant solution was
placed below the perforated end of the holder on the mechanical platform.
Upon contact of the sample holder with deionized water/dispersant solution,
the liquid penetrated into the drug powder bed, while Attension Sigma 700 recorded
the mass of liquid penetrated into the drug powder bed as a function of time. The
contact angle for the deionized water/dispersant solution and drug can be determined
using the modified Washburn equation, which provides a relationship between mass
2
2
of liquid penetrated and contact angle θ, i.e., M = (C  cos  )T , where T, M, η, ρ,

and γ are time after contact, mass of the liquid penetrated into the drug powder bed,
viscosity of the liquid, density of the liquid, and surface tension of the liquid,
respectively. C is a characteristic parameter of the powder sample (ITZ powder in the
current study), which could have been determined independently using a completely
wetting liquid such as hexane, heptane, etc. Since ITZ was used as the only powder
sample and C depends only on powder packing (identical packing procedure used), C
is assumed to remain invariant for various dispersant solutions and deionized water
studied. This approach allows us to eliminate C and calculate the ratio of cosθds/cosθw
as a wetting effectiveness factor, in which θds is the contact angle between ITZ and
the dispersant solution and θw is the contact angle between ITZ and deionized water.
The wettability enhancement upon use of different dispersants (polymers/surfactant)
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on the wetting of ITZ particles can be assessed by using this ratio or its logarithmic
value, taking the wettability by water as a basis of comparison.
Experimental liquid penetration data (M2 vs. T) for water and various
dispersant solutions are presented in Figure A.1. Penetration of water into ITZ bed is
extremely slow because of the highly hydrophobic (lipophilic) nature of ITZ, which
is indicated by the log-partition coefficient (logP) value of 7.3. The use of dispersant
in water increased the penetration rate (slope) markedly with respect to that of water.
The slope was obtained by fitting the linear region of liquid penetration curve. Initial
~20 s was not considered due to transient behavior, and data points that deviated from
the linear region, which may correspond to structural change in the bed, were
excluded. The modified Washburn equation fitted the data almost perfectly (R2 ≥
0.995). Using the slope, η, ρ, and γ for different dispersant solutions and water,
log(cosθds/cosθw) was calculated.

274

Figure A.1 Temporal evolution of the liquid mass penetrated into a packed bed of
as-received ITZ particles for (a) water only and (b) various dispersant solutions such
as 0.2% SDS, 2.5% HPC SL, 2.5% HPC SL–SDS, 4.5% HPC SL, 4.5% HPC SSL,
4.5% HPC L, 4.5% HPMC E3, and 4.5% PVP K30, as well as water.
A.2. Impact of the Nanocomposite Particle Size on the ITZ Release
We spray-dried the milled 4.5% HPC SL suspension (F4) using a larger nozzle tip
size (1.2 mm vs. 0.6 mm) at a lower atomization pressure (1.5 bar vs. 2 bar) as
compared with the baseline drying conditions. The so-formed nanocomposite
particles were coarser (d50: 20.7 µm and d90: 40.6 µm) than the baseline
nanocomposites (d50: 16.2 µm and d90: 32.3 µm). The dissolution profiles (Figure
A.2) suggest that despite ~30% increase in d50 and d90, (i) both the coarser and
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baseline nanocomposites exhibited fast, immediate release and (ii) there is no
statistically significant impact of the nanocomposite particle size on ITZ release (ƒ1 =
0.93 and ƒ2 = 91.8) within the particle size range studied. The differences are within
the variability of drug assay and dissolution measurements.

Figure A.2 Drug dissolution from the nanocomposites prepared via spray-drying
with different processing conditions for the same milled ITZ suspension with 4.5%
HPC SL (F4).
A.3. Optical Microscopic Images of Redispersed Nanocomposites
In the redispersion test, about 0.5 g of nanocomposites was weighed and dispersed in
30 mL of 3 g/L aqueous SDS solution inside a 60 mL beaker and stirred at 400 rpm
for 60 min with a paddle-stirrer (CAT R18, Scientific Instrument Center Limited,
Winchester, UK). ~0.5 mL aliquot of redispersed sample was taken at 2, 10 and 60
min while stirring, and particle size was measured using laser diffraction. At the same
time, a droplet of each sample was dropped on a glass slide and dried immediately
using a hot air gun (Steinel Professional, Bloomington, MN, USA). After drying,
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Axio Scope.A1 polarizing microscope (Carl Zeiss Microscopy GmbH, Göttingen,
Germany) was used to capture images of redispersed particles (Figure A3).
When redispersion was slow and incomplete, the rounded/spherical
nanocomposite particles appeared in the images even after 60 min (e.g., 2.5% HPC
SL) because the nanocomposite matrix slowly eroded or did not erode at all, keeping
the shape/morphology intact. On the other hand, fast redispersion was associated with
complete erosion of the nanocomposite matrix, leading to disappearance of the
nanocomposite particles in the images (e.g., 2.5% HPC SL–0.2% SDS). In the latter
case, ITZ nanoparticles/clusters, whose sizes are mostly below the detection limit of
the optical microscope, were released upon disappearance of the matrix. These
findings are in good agreement with the laser diffraction measurements of the
redispersed nanocomposites (see Figure 2.9 of the main text).
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Figure A.3 Optical microscope images of the nanocomposites with various
dispersants redispersed in 3 g/L SDS solution at 2 min, 10 min, and 60 min (marker
size: 20 µm).
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A.4 Difference (f1) and similarity (f2) factors for dissolution profiles of ITZ
nanocomposites
Table A.1 Difference (f1) and similarity (f2) factors for dissolution profiles of ITZ
nanocomposites with various dispersants (F1, F2, F4‒F8) as compared with that of F3
Difference and
similarity factors

Formulation ID
F1

F2

F4*

F5

F6

F7

F8

f1

68.6

71.7

3.73

48.2

24.5

44.7

41.5

f2

29.0

28.0

83.5

36.2

54.4

37.7

38.1

*This formulation had statistically similar dissolution profile to that of F3.

Table A.2 Difference (f1) and similarity (f2) factors for dissolution profiles of ITZ
nanocomposites with various dispersants (F1, F2, F4‒F8) as compared with that of F4
Difference and
similarity factors

Formulation ID
F1

F2

F3*

F5

F6

F7

F8

f1

67.4

70.6

3.88

46.2

21.4

42.5

39.2

f2

30.4

29.2

83.5

38.0

58.0

39.6

40.0

*This formulation had statistically similar dissolution profile to that of F4.
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APPENDIX B
DISSOLUTION ENHANCEMENT VIA DRUG HYBRID NANOCRYSTALS–
AMORPHOUS SOLID DISPERSIONS (HyNASDs) VS. ASDs DISSOLUTION

In appendix B, particle size statistics of the spray-dried powders before and after
redispersions is shown. To confirm the size of the redispersed drug particle,
microscopic images are also shown here.
B.1. Redispersion of the Spray-Dried Powders
Aqueous redispersion of the spray-dried powders prepared using the nanosuspensionbased (W) feeds, i.e., the HyNASD particles, was performed following a previously
established method (Bhakay et al., 2014; Li et al., 2016; Bilgili et al., 2018). About
0.5 g spray-dried powder was weighed and dispersed in 30 mL of deionized water
inside a 60 mL beaker and stirred at 500 rpm for 60 min with a paddle-stirrer (CAT
R18, Scientific Instrument Center Limited, Winchester, UK). ~1.0 mL aliquot of
redispersed sample was taken at 2, 10 and 60 min while stirring, and particle size was
measured using laser diffraction (LS 13 320, Beckman Coulter, Miami, FL). At the
same time, a droplet of each redispersed sample was dried immediately by dropping
on a preheated glass slide on a hot plate at 100 °C. After drying, Zeiss Axio Scope.A1
polarizing microscope (Carl Zeiss Microscopy GmbH, Göttingen, Germany) was
used to capture images of the redispersed particles (Figure B.2). 30 mL of deionized
water was selected purposefully so that the polymer in the sample dissolved fully,
while releasing the GF nanoparticles/clusters with minimal dissolution. Indeed, the
maximum amount of GF that can dissolve was estimated to be small (e.g., 1.1% of
GF from W-Sol-1-3).
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In general, GF nanoparticles with sizes similar to those particles in the milled
suspensions were recovered within 2 min upon redispersion of the spray-dried
powders (Figure B.1). Since the spray-dried powders contain SDS, they got wetted
fast

and

their

polymer

content

dissolved

quickly,

thus

releasing

GF

nanoparticles/clusters. The particles released are mostly below the detection limit of
the optical microscope; hence, they are barely discernible in the optical microscope
images (see Figure B.2). Overall, both the laser diffraction measurements and the
optical microscope images suggest that HyNASDs release drug nanoparticles fast
upon redispersion in water.

Figure B.1 Volume-based particle size statistics of the nanosuspension-based (W)
feeds of GF–Sol and GF–HPC before spray drying (SD) (after 1 day of milling), after
spray drying (HyNASDs), and the HyNASD particles redispersed in deionized water
at 2 min, 10 min, and 60 min: (a) Median particle size d50, and (b) 90% passing size
d90. All feeds have 2.5% w/v GF and 0.125% w/v SDS.
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Figure B.2 Optical microscope images of the HyNASD particles, prepared using the
nanosuspension-based (W) feeds, after redispersion in deionized water at 2 min, 10
min, and 60 min (marker size: 20 µm). All feeds have 2.5% w/v GF and 0.125% w/v
SDS.
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APPENDIX C
DRUG RELEASE FROM SPRAY-DRIED HYBRID NANOCRYSTAL–
AMORPHOUS SOLID DISPERSIONS (HyNASDs): IMPACT OF SDS

In appendix C, detail of the modified Washburn method to measure the relative
wetting effectiveness of the stabilizer/dispersant solutions are provided. Also, to
confirm the size of the redispersed drug particles form the drug the polymeric matrix
of the drug nanocomposites, microscopic images are also shown here.
C.1 Details of the Characterization Methods Used for Drug Wettability
Measurements
Penetration of a liquid into a packed powder bed of a drug inside a cylindrical column
allows for measurement of the drug powder wettability, based on the Washburn
method (Hołownia et al., 2008; Washburn, 1921). The method presented here was
adapted from Bilgili et al. (2018) and Li et al. (2017). In the current study, liquids and
powder refer to GF (griseofulvin)-saturated aqueous solutions of 15% Soluplus
(Sol)/HPC with 0.125% SDS or w/o SDS and GF powder, respectively. All
percentages are (% w/w) with respective to deionized water. This polymer
concentration was selected to measure the viscosity accurately in our viscometer setup instead of the maximum viscosity of 12.5% used in the stabilizer solutions. The
solutions and deionized water were saturated with griseofulvin (GF) and stirred
overnight. After overnight stirring, the saturated solutions were used for further
characterization. The apparent shear viscosity and surface tension of the solutions
were measured using R/S Plus Rheometer (Brookfield Engineering, Middleboro, MA,
USA) and Attension Sigma 700 (Biolin Scientific, Linthicum, MD, USA)
respectively, as described below; then, the drug wettability by the drug-saturated
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solutions was quantified via a wetting effectiveness factor using the modified
Washburn equation.
C.1.1 Apparent Shear Viscosity of the Solutions
The apparent shear viscosity of the GF-saturated aqueous solutions of the stabilizers
was measured using an R/S Plus Rheometer (Brookfield Engineering, Middleboro,
MA, USA) with a water jacket assembly Lauda Eco (Lauda-Brinkmann LP, Delran,
NJ, USA). A coaxial cylinder (CC40) was used to provide a controlled shear rate on
the samples and shear rate 0 to 1000 1/s for 60 s was used for all the samples. The
temperature of the jacket was kept constant at 25 ± 0.5 °C. The raw data were
analyzed using the Rheo 3000 software (Brookfield Engineering, Middleboro, MA,
USA) of the equipment to obtain the apparent shear viscosity as a function of the
shear rate. The apparent shear viscosity at ~100 1/s was used as a representative low
shear rate value. The viscosity of water was taken from Korson et al. (1969).
C.1.2 Surface Tension of the Solutions
The surface tension of the GF-saturated deionized water and the GF-saturated
aqueous solutions of the stabilizers was measured using Attension Sigma 700 (Biolin
Scientific, Linthicum, MD, USA). The Attention software calculates surface tension
from force measurements of interaction of a probe (Wilhelmy plate) at the boundary
between air and a liquid.
C.1.3 Drug Wettability with the Solutions
Attension Sigma 700 set-up (Biolin Scientific, Linthicum, MD, USA) was used to
study the penetration of GF-saturated deionized water/GF-saturated aqueous solutions
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of the stabilizers into a packed powder bed of GF inside a cylindrical column and
determine the GF wettability, based on the modified Washburn method. The
assembly consists of a sample holder in the form of a cylindrical metallic tube with
small holes at the bottom as well as a hook at the top of the cover equipped with
screw threads. About 0.8 g of GF powder was packed uniformly into the tube before
each measurement. A filter paper was placed at the perforated end of the sample
holder to support the GF powder sample. A petri dish containing deionized
water/stabilizer solution was placed below the perforated end of the holder on the
mechanical platform.
Upon contact of the sample holder with the liquid, the liquid penetrated the GF
powder bed, while Attension Sigma 700 recorded the mass M of the liquid penetrated
as a function of time T. The cosine of the contact angle θ for the GF-saturated
deionized water/GF-saturated aqueous stabilizer solution and drug can be determined
using the modified Washburn equation, which provides a relationship between liquid
, where η, ρ, and γ stand for

penetration rate and contact angle, via

viscosity of the liquid, density of the liquid, and surface tension of the liquid,
respectively. C is a characteristic parameter of the powder sample, which could have
been determined independently using a completely wetting liquid such as hexane,
heptane, etc. Since the same drug powder (GF) was used as the powder sample and C
depends only on powder packing–size, C remained invariant for different liquids
studied here. This allows us to calculate the ratio of cosθss/cosθw as a wetting
effectiveness factor from the slopes of M2 vs. T for deionized water and the stabilizer
solution. Here, θss is the contact angle between GF and the polymer–SDS stabilizer
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solution and θw is the contact angle between GF and deionized water. The wettability
enhancement upon the use of different stabilizers (polymers/surfactant) on the wetting
of GF particles can be assessed by using this ratio, taking the wettability by water as a
basis for comparison.
Experimental liquid penetration data (M2 vs. T) for various liquids are presented
in Figure C.1. The slope of the modified Washburn equation, i.e.,

, was

obtained by fitting the linear region of the liquid penetration curve. Initial ~20 s was
not considered due to transient behavior; data points that deviated from the linear
region, which may correspond to structural change in the bed, were excluded. The
modified Washburn equation fitted the data well (R2 ≥ 0.990). Using the slope for the
different stabilizer solutions and water, cosθss/cosθw was calculated. The viscosity,
surface tension, and calculated wetting effectiveness factor are reported in Table 4.3
of the main text.

286

Figure C.1 Temporal evolution of the liquid mass penetrated into a packed bed of
as-received GF particles for GF-saturated deionized (DI) water and various GFsaturated aqueous solutions of 15% HPC/Sol with 0.125% SDS and without SDS.

C.2 Optical Microscopic Images of the Spray-Dried Particles Redispersed in
Deionized Water
The redispersion test method was adapted from Bhakay et al. (2014) and Li et al.
(2016). About 0.5 g of nanocomposites was weighed and dispersed in 30 mL of
deionized water inside a 60 mL beaker and stirred at 500 rpm for 60 min with a
paddle-stirrer (CAT R18, Scientific Instrument Center Limited, Winchester, UK). 30
mL of deionized water was selected purposefully so that the polymer could dissolve
fully, while releasing the GF nanoparticles/clusters with minimal GF dissolution.
~1.0 mL aliquot of redispersed sample was taken at 2, 10 and 60 min while stirring,
and particle size was measured using laser diffraction (see Figure 4.7 and 4.8 of the
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main text). At the same time, a droplet of each redispersed sample was dried
immediately by dropping on a preheated glass slide at 100 °C using a hot plate. After
drying, Zeiss Axio Scope.A1 polarizing microscope (Carl Zeiss Microscopy GmbH,
Göttingen, Germany) was used to capture images of the redispersed particles (Figure
C.2).
Since only few images were taken per sample during the redispersion, the
microscopic imaging of the redispersion should could only provide qualitative
information. When redispersion was slow and incomplete due to poor wettability of
the spray-dried particles

as

in

most W-formulations

without SDS,

the

rounded/spherical particles with some aggregates appeared in the images even after
60 min redispersion. The matrix of such particles appears to be slowly eroded,
keeping the shape/morphology somewhat intact. On the other hand, fast redispersion
was associated with complete erosion of the spray-dried particles (W-formulations
with SDS), leading to their disappearance from the images. Note that due to inability
of the microscope to detect nanoparticles, some images do not have many particles.
The microscopic imaging of the redispersion shows that presence of SDS imparts
excellent wettability to the spray-dried particles and helped to release drug
nanoparticles faster than the particles w/o SDS. These findings are largely in good
agreement with the laser diffraction measurements presented in Figure 4.7 and 4.8 of
the main text.
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Figure C.2 Microscopic images of the spray-dried particles with 1:1, 1:3, and 1:5
GF:polymer (Sol/HPC) mass ratios having SDS and no SDS after redispersion in DI
water at 2 min, 10 min, and 60 min (marker size: 20 µm).

291

APPENDIX D
IMPACT OF SDS ON GRISEOFULVIN RELEASE FROM SPRAY-DRIED
AMORPHOUS SOLID DISPERSIONS WITH HPC–SOLUPLUS

In appendix D, detail of the modified Washburn method to measure the relative
wetting effectiveness of the stabilizer/dispersant solutions are provided.
D.1 Details of the Characterization Methods Used for Drug Wettability
Measurements
Penetration of a liquid into a packed powder bed of a drug inside a cylindrical column
allows for measurement of the drug powder wettability, based on the Washburn
method (Hołownia et al., 2008; Washburn, 1921). The method presented here was
adapted from Bilgili et al. (2018) and Li et al. (2017). In the current study, liquids and
powder refer to GF (griseofulvin)-saturated aqueous solutions of 15% Soluplus
(Sol)/HPC with 0.125% SDS or w/o SDS and GF powder, respectively. All
percentages are (% w/w) with respective to deionized water. This polymer
concentration was selected to measure the viscosity accurately in our viscometer setup instead of the maximum viscosity of 12.5% used in the solutions. The solutions
and deionized water were saturated with griseofulvin (GF) and stirred overnight.
After overnight stirring, the saturated solutions were used for further characterization.
The apparent shear viscosity and surface tension of the solutions were measured
using R/S Plus Rheometer (Brookfield Engineering, Middleboro, MA, USA) and
Attension Sigma 700 (Biolin Scientific, Linthicum, MD, USA) respectively, as
described below; then, the drug wettability by the drug-saturated solutions was
quantified via a wetting effectiveness factor using the modified Washburn equation.
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D.1.1 Apparent Shear Viscosity of the Solutions
The apparent shear viscosity of the GF-saturated aqueous solutions of the
polymer/surfactant was measured using an R/S Plus Rheometer (Brookfield
Engineering, Middleboro, MA, USA) with a water jacket assembly Lauda Eco
(Lauda-Brinkmann LP, Delran, NJ, USA). A coaxial cylinder (CC40) was used to
provide a controlled shear rate on the samples and shear rate 0 to 1000 1/s for 60 s
was used for all the samples. The temperature of the jacket was kept constant at 25 ±
0.5 °C. The raw data were analyzed using the Rheo 3000 software (Brookfield
Engineering, Middleboro, MA, USA) of the equipment to obtain the apparent shear
viscosity as a function of the shear rate. The apparent shear viscosity at ~100 1/s was
used as a representative low shear rate value. The viscosity of water was taken from
Korson et al. (1969).
D.1.2 Surface Tension of the Solutions
The surface tension of the GF-saturated deionized water and the GF-saturated aqueous
solutions of the polymer/surfactant was measured using Attension Sigma 700 (Biolin
Scientific, Linthicum, MD, USA). The Attention software calculates surface tension
from force measurements of interaction of a probe (Wilhelmy plate) at the boundary
between air and a liquid.
D.1.3 Drug Wettability with the Solutions
Attension Sigma 700 set-up (Biolin Scientific, Linthicum, MD, USA) was used to
study the penetration of GF-saturated deionized water/GF-saturated aqueous solutions
of the polymer/surfactant into a packed powder bed of GF inside a cylindrical column
and determine the GF wettability, based on the modified Washburn method. The
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assembly consists of a sample holder in the form of a cylindrical metallic tube with
small holes at the bottom as well as a hook at the top of the cover equipped with
screw threads. About 0.8 g of GF powder was packed uniformly into the tube before
each measurement. A filter paper was placed at the perforated end of the sample
holder to support the GF powder sample. A petri dish containing deionized water or
polymer/surfactant solution was placed below the perforated end of the holder on the
mechanical platform.
Upon contact of the sample holder with the liquid, the liquid penetrated the
GF powder bed, while Attension Sigma 700 recorded the mass M of the liquid
penetrated as a function of time T. The cosine of the contact angle θ for the GFsaturated deionized water/GF-saturated aqueous polymer/surfactant solution and drug
can be determined using the modified Washburn equation, which provides a
relationship between liquid penetration rate and contact angle, via , where η, ρ, and γ
stand for viscosity of the liquid, density of the liquid, and
surface tension of the liquid, respectively. C is a characteristic parameter of the
powder sample, which could have been determined independently using a completely
wetting liquid such as hexane, heptane, etc. Since the same drug powder (GF) was
used as the powder sample and C depends only on powder packing–size, C remained
invariant for different liquids studied here. This allows us to calculate the ratio of
cosθss/cosθw as a wetting effectiveness factor from the slopes of M2 vs. T for
deionized water and the polymer/surfactant solution. Here, θss is the contact angle
between GF and the polymer–surfactant solution and θw is the contact angle between
GF and deionized water. The wettability enhancement upon the use of different
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polymers/surfactant on the wetting of GF particles can be assessed by using this ratio,
taking the wettability by water as a basis for comparison.
Experimental liquid penetration data (M2 vs. T) for various liquids are
presented in Figure D.1. The slope of the modified Washburn equation, i.e.,

c 2 cos   , was obtained by fitting the linear region of the liquid penetration
curve. Initial ~20 s was not considered due to transient behavior; data points that
deviated from the linear region, which may correspond to structural change in the
bed, were excluded. The modified Washburn equation fitted the data well (R2 ≥
0.990). Using the slope for the different polymer/surfactant solutions and water,
cosθss/cosθw was calculated. The viscosity, surface tension, and calculated wetting
effectiveness factor are reported in Table 5.5 of the main text.

Figure D.1 Temporal evolution of the liquid mass penetrated into a packed bed of asreceived GF particles for GF-saturated deionized (DI) water and various GF-saturated
aqueous solutions of 15% HPC/Sol with 0.125% SDS and without SDS.
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APPENDIX E
SYNERGISTIC EFFECTS OF HYDROPHILIC POLYMER–AMPHIPHILIC
POLYMER COMBINATION IN ENHANCING GRISEOFULVIN RELEASE
FROM AMORPHOUS SOLID DISPERSIONS

In appendix E, detail of the modified Washburn method to measure the relative
wetting effectiveness of the stabilizer/dispersant solutions are provided.
E.1 Details of the Characterization Methods used for Drug Wettability
Measurements
Penetration of a liquid into a packed powder bed of a drug inside a cylindrical column
allows for measurement of the drug powder wettability, based on the Washburn
method (Hołownia et al., 2008; Washburn, 1921). The method presented here was
adapted from Bilgili et al. (2018) and Li et al. (2017). In the current study, liquids and
powder refer to GF (griseofulvin)-saturated aqueous solutions of 15% single or
binary polymers and GF powder, respectively. Single polymer includes Soluplus
(Sol)/HPC/Kollidon VA64 (VA64). In the preparation of aqueous solutions of binary
polymers, Sol–HPC were combined at 1:1 and 9:1 mass ratio, Sol–VA64 were
combined at 1:5 and 5:1 ratio, and VA64–HPC were combined at 1:1 and 9:1 ratio.
All percentages are (% w/w) with respective to deionized water. This polymer
concentration was selected to measure the viscosity accurately in our viscometer setup instead of the maximum viscosity of 7.5% used in the polymer solutions. The
solutions and deionized water were saturated with griseofulvin (GF) and stirred
overnight. After overnight stirring, the saturated solutions were used for further
characterization. The apparent shear viscosity and surface tension of the solutions
were measured using R/S Plus Rheometer (Brookfield Engineering, Middleboro, MA,
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USA) and Attension Sigma 700 (Biolin Scientific, Linthicum, MD, USA)
respectively, as described below; then, the drug wettability by the drug-saturated
solutions was quantified via a wetting effectiveness factor using the modified
Washburn equation.
E.1.1 Apparent Shear Viscosity of the Solutions
The apparent shear viscosity of the GF-saturated aqueous solutions of the polymers
was measured using an R/S Plus Rheometer (Brookfield Engineering, Middleboro,
MA, USA) with a water jacket assembly Lauda Eco (Lauda-Brinkmann LP, Delran,
NJ, USA). A coaxial cylinder (CC40) was used to provide a controlled shear rate on
the samples and shear rate 0 to 1000 1/s for 60 s was used for all the samples. The
temperature of the jacket was kept constant at 25 ± 0.5 °C. The raw data were
analyzed using the Rheo 3000 software (Brookfield Engineering, Middleboro, MA,
USA) of the equipment to obtain the apparent shear viscosity as a function of the
shear rate. The apparent shear viscosity at ~100 1/s was used as a representative low
shear rate value. The viscosity of water was taken from Korson et al. (1969).
E.1.2 Surface Tension of the Solutions
The surface tension of the GF-saturated deionized water and the GF-saturated
aqueous solutions of the polymers was measured using Attension Sigma 700 (Biolin
Scientific, Linthicum, MD, USA). The Attention software calculates surface tension
from force measurements of interaction of a probe (Wilhelmy plate) at the boundary
between air and a liquid.
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E.1.3 Drug Wettability with the Solutions
Attension Sigma 700 set-up (Biolin Scientific, Linthicum, MD, USA) was used to
study the penetration of GF-saturated deionized water/GF-saturated aqueous solutions
of the polymers into a packed powder bed of GF inside a cylindrical column and
determine the GF wettability, based on the modified Washburn method. The
assembly consists of a sample holder in the form of a cylindrical metallic tube with
small holes at the bottom as well as a hook at the top of the cover equipped with
screw threads. About 0.8 g of GF powder was packed uniformly into the tube before
each measurement. A filter paper was placed at the perforated end of the sample
holder to support the GF powder sample. A petri dish containing deionized
water/polymer solution was placed below the perforated end of the holder on the
mechanical platform.
Upon contact of the sample holder with the liquid, the liquid penetrated the
GF powder bed, while Attension Sigma 700 recorded the mass M of the liquid
penetrated as a function of time T. The cosine of the contact angle θ for the GFsaturated deionized water/GF-saturated aqueous polymer solution and drug can be
determined using the modified Washburn equation, which provides a relationship
between liquid penetration rate and contact angle, via

, where η,

ρ, and γ stand for viscosity of the liquid, density of the liquid, and surface tension of
the liquid, respectively. C is a characteristic parameter of the powder sample, which
could have been determined independently using a completely wetting liquid such as
hexane, heptane, etc. Since the same drug powder (GF) was used as the powder
sample and C depends only on powder packing–size, C remained invariant for
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different liquids studied here. This allows us to calculate the ratio of cosθss/cosθw as a
wetting effectiveness factor from the slopes of M2 vs. T for deionized water and the
polymer solution. Here, θss is the contact angle between GF and the polymer/SDS
solution and θw is the contact angle between GF and deionized water. The wettability
enhancement upon the use of different polymers on the wetting of GF particles can be
assessed by using this ratio, taking the wettability by water as a basis for comparison.
Experimental liquid penetration data (M2 vs. T) for various liquids are
presented in Figure E.1. The slope of the modified Washburn equation, i.e.,

c 2 cos   , was obtained by fitting the linear region of the liquid penetration
curve. Initial ~20 s was not considered due to transient behavior; data points that
deviated from the linear region, which may correspond to structural change in the
bed, were excluded. The modified Washburn equation fitted the data well (R2 ≥
0.990). Using the slope for various polymer solutions and water, cosθss/cosθw was
calculated. The viscosity, surface tension, and calculated wetting effectiveness factor
are reported in Table 6.4 of the main text.
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Figure E.1 Temporal evolution of the liquid mass penetrated into a packed bed of asreceived GF particles for GF-saturated deionized (DI) water and various GF-saturated
aqueous solutions of 15% HPC/Sol/VA64 (single polymer) and 15% Sol–HPC/VA64–
HPC/Sol–VA64 (binary polymer) with varied polymer1:polymer2 mass ratios.
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APPENDIX F
RELEASE OF ITRACONAZOLE FROM SPRAY-DRIED NANOCRYSTAL–
AMORPHOUS SOLID DISPERSIONS (HyNASDs) AND ASDs

In appendix F, detail of the modified Washburn method to measure the relative
wetting effectiveness of the stabilizer/dispersant solutions are provided.
F.1 Details of the Characterization Methods used for Drug Wettability
Measurements
Penetration of a liquid into a packed powder bed of a drug inside a cylindrical column
allows for measurement of the drug powder wettability, based on the Washburn
method (Hołownia et al., 2008; Washburn, 1921). The method presented here was
adapted from Bilgili et al. (2018) and Li et al. (2017). In the current study, liquids and
powder refer to aqueous solutions of 15% polymers (Soluplus (Sol)/HPC/Kollidon
VA64 (VA64)) and ITZ powder, respectively. All percentages are (% w/w) with
respective to deionized water. This polymer concentration was selected to measure
the viscosity accurately in our viscometer set-up instead of the maximum viscosity of
7.5% used in the polymer solutions. After dissolving the polymers, the solutions were
stirred overnight. After overnight stirring, the solutions were used for further
characterization. The apparent shear viscosity and surface tension of the solutions
were measured using R/S Plus Rheometer (Brookfield Engineering, Middleboro, MA,
USA) and Attension Sigma 700 (Biolin Scientific, Linthicum, MD, USA)
respectively, as described below; then, the drug wettability by the drug-saturated
solutions was quantified via a wetting effectiveness factor using the modified
Washburn equation.
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F.1.1 Apparent Shear Viscosity of the Solutions
The apparent shear viscosity of the aqueous solutions of the polymers was measured
using an R/S Plus Rheometer (Brookfield Engineering, Middleboro, MA, USA) with
a water jacket assembly Lauda Eco (Lauda-Brinkmann LP, Delran, NJ, USA). A
coaxial cylinder (CC40) was used to provide a controlled shear rate on the samples
and shear rate 0 to 1000 1/s for 60 s was used for all the samples. The temperature of
the jacket was kept constant at 25 ± 0.5 °C. The raw data were analyzed using the
Rheo 3000 software (Brookfield Engineering, Middleboro, MA, USA) of the
equipment to obtain the apparent shear viscosity as a function of the shear rate. The
apparent shear viscosity at ~100 1/s was used as a representative low shear rate value.
The viscosity of water was taken from Korson et al. (1969).
F.1.2 Surface Tension of the Solutions
The surface tension of the water and the aqueous solutions of the polymers was
measured using Attension Sigma 700 (Biolin Scientific, Linthicum, MD, USA). The
Attention software calculates surface tension from force measurements of interaction
of a probe (Wilhelmy plate) at the boundary between air and a liquid.
F.1.3 Drug Wettability with the Solutions
Attension Sigma 700 set-up (Biolin Scientific, Linthicum, MD, USA) was used to
study the penetration of deionized water/ aqueous solutions of the polymers into a
packed powder bed of ITZ inside a cylindrical column and determine the ITZ
wettability, based on the modified Washburn method. The assembly consists of a
sample holder in the form of a cylindrical metallic tube with small holes at the bottom
as well as a hook at the top of the cover equipped with screw threads. About 0.8 g of
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ITZ powder was packed uniformly into the tube before each measurement. A filter
paper was placed at the perforated end of the sample holder to support the ITZ
powder sample. A petri dish containing deionized water/polymer solution was placed
below the perforated end of the holder on the mechanical platform.
Upon contact of the sample holder with the liquid, the liquid penetrated the
ITZ powder bed, while Attension Sigma 700 recorded the mass M of the liquid
penetrated as a function of time T. The cosine of the contact angle θ for the deionized
water/ aqueous polymer solution and drug can be determined using the modified
Washburn equation, which provides a relationship between liquid penetration rate
and contact angle, via

, where η, ρ, and γ stand for viscosity of the

liquid, density of the liquid, and surface tension of the liquid, respectively. C is a
characteristic parameter of the powder sample, which could have been determined
independently using a completely wetting liquid such as hexane, heptane, etc. Since
the same drug powder (ITZ) was used as the powder sample and C depends only on
powder packing–size, C remained invariant for different liquids studied here. This
allows us to calculate the ratio of cosθss/cosθw as a wetting effectiveness factor from
the slopes of M2 vs. T for deionized water and the polymer solution. Here, θss is the
contact angle between ITZ and the polymer/SDS solution and θw is the contact angle
between ITZ and deionized water. The wettability enhancement upon the use of
different polymers on the wetting of ITZ particles can be assessed by using this ratio,
taking the wettability by water as a basis for comparison.
Experimental liquid penetration data (M2 vs. T) for various liquids are
presented in Figure F.1. The slope of the modified Washburn equation, i.e.,
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c 2 cos   , was obtained by fitting the linear region of the liquid penetration
curve. Initial ~20 s was not considered due to transient behavior; data points that
deviated from the linear region, which may correspond to structural change in the
bed, were excluded. The modified Washburn equation fitted the data well (R2 ≥
0.990). Using the slope for various polymer solutions and water, cosθss/cosθw was
calculated. The viscosity, surface tension, and calculated wetting effectiveness factor
are reported in Table 7.4 of the main text.

(a)

(b)

Figure F.1 Temporal evolution of the liquid mass penetrated into a packed bed of asreceived ITZ particles for (a) water only and (b) various aqueous solutions of 15%
HPC/Sol/VA64–0.125% SDS or w/o SDS.
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